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Preface
In spite of development in public health, medicine, and expertise, infectious diseases remain
a foremost source of illness and death globally. Characteristic of infection is the incursion of
host mechanism by infectious pathogens. The connection of pathogens with disease is a
complex process which may require long time to be understood and answered. One of the
most destructive epidemics in the last century occurred in 1918 when influenza pandemic
broke, resulting in deaths of millions in less than a year. Similarly, HIV infection is causing
continuous disaster affecting ~34 million people and causing ~13.9 million deaths. These ex‐
amples display the fright of infectious disease unpredictability and their reemergence.
Pathogens hijack the synchronized metabolic activities and use host factors as substrate for
the process of their multiplication and flourishment. Not only pathogens, but their products
like proteins and secreted toxins, damage host tissues. Infectious diseases are the outcome of
the described process; they are transmissible diseases and can jump from one host to anoth‐
er with the help of vectors; biological vectors (low vertebrates, insects, avians, etc.) or physi‐
cal vectors (air, water soil, fomites, etc). Infectious agents are microorganisms such as
viruses, bacteria, nematodes, fungi and macro parasites. Discovery of disease-causing patho‐
gens is medically and clinically important. Infectious diseases on onset display various
symptoms of illness resulting into severe from the infection, morbidity and sometimes fatali‐
ty also gets reported. Infectious diseases continue to be foundation for more risky and fatal
health threats globally, giving serious challenges to the scientific community to control, cure
and prevent them from causing diabolical effects on human race.
Majority of infectious diseases attack immune compromised hosts like infants, old aged and
sick people. They cause fatal epidemics with huge extent and severity, emergence and ree‐
mergence, reassortment and destroy economies globally. Research activities report that in‐
fectious diseases like influenza, Japanese encephalitis, measles, hepatitis, cholera, dysentery,
TB, typhoid fever, yellow fever, and malaria have been spine breaking for economy. Novel
technologies and for molecular characterization of pathogens and studying their morpholo‐
gy, genome, epidemiology, serology and advancement in vaccines development, are neces‐
sary to eradicate the pathogens effectively. These problems can be controlled only by timely
diagnosis and control measures.
The need of the hour is to efficiently combat infectious disease which requires onerous and
combinatorial efforts between individuals, researchers, analysts, drug developers and fund‐
ing agencies. Lack of specific vaccines and therapeutics increases the risk potential of infec‐
tious disease, hence the development of effective therapeutics and strategies is extremely
urgent. Disease control may be enhanced by improvements in prevention, sanitation and
hygiene. Introduction of vaccination, antibiotics, other antimicrobial medicines, technologi‐
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mergence, reassortment and destroy economies globally. Research activities report that in‐
fectious diseases like influenza, Japanese encephalitis, measles, hepatitis, cholera, dysentery,
TB, typhoid fever, yellow fever, and malaria have been spine breaking for economy. Novel
technologies and for molecular characterization of pathogens and studying their morpholo‐
gy, genome, epidemiology, serology and advancement in vaccines development, are neces‐
sary to eradicate the pathogens effectively. These problems can be controlled only by timely
diagnosis and control measures.
The need of the hour is to efficiently combat infectious disease which requires onerous and
combinatorial efforts between individuals, researchers, analysts, drug developers and fund‐
ing agencies. Lack of specific vaccines and therapeutics increases the risk potential of infec‐
tious disease, hence the development of effective therapeutics and strategies is extremely
urgent. Disease control may be enhanced by improvements in prevention, sanitation and
hygiene. Introduction of vaccination, antibiotics, other antimicrobial medicines, technologi‐
cal advances in detecting and monitoring infectious diseases like serological testing, patho‐
gen isolation and tissue culture techniques are promising and support infectious disease
surveillance and control. We need to tackle diverse challenges of the emergence of new in‐
fectious diseases, re-emergence of old diseases and outbreaks. Answering the questions
about role of infectious agents in causing acute or chronic diseases, cancers and various oth‐
er conditions is crucial.
This book covers a collection of chapters by brilliant researchers who have devoted their time
to combat against infectious diseases. This book gives a comprehensive overview of recent
trends in infectious diseases, as well as general concepts of infections, immunopathology, di‐
agnosis, treatment, epidemiology and etiology of current clinical recommendations in man‐
agement of infectious diseases, highlighting the ongoing issues, recent advances, with future
directions in diagnostic approaches and therapeutic strategies. The book focuses on various
aspects and properties of infectious diseases, whose deep understanding is very important for
safeguarding human race from more loss of resources and economies due to pathogens.
The authors and editors of the book hope that this work might increase the interest in this
field of research and that the readers will find it useful for their investigations, management
and clinical usage. Also, I would like to thank Council of Scientific and Industrial Research
(CSIR-CCMB), Director CCMB Dr CM Rao, colleagues, family, and parents who gave me a
lot of encouragement and support during the work on this book.
Shailendra K. Saxena, PhD, DCAP, FAEB,
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1. Introduction
Japanese encephalitis (JE) is among the most significant viral encephalitis in Asia, particularly
in rural and suburban areas where rice culture and pig farming coexist. It has also occurred
rarely and occasionally in northern Australia and some parts of the western pacific. JE is caused
due to infection with the JE virus (JEV), a mosquito borne flavivrus. The main JEV transmission
cycle involves Culex tritaeniorhynchus mosquitoes and similar species that lay eggs in rice
paddies and other open water resources, with pigs and aquatic birds as principal vertebrate
amplifying hosts [Han et al., 2012]. Humans are generally considered as dead-end JEV hosts
i.e. they rarely develop enough viremia to infect feeding mosquitoes. Nearly 20-30% of JE cases
are fatal and 30-50% of survivors have major neurological disorders [Bhattacharyya et al.,
2013]. JE is mostly a disease of children but other age groups may be affected [Kundu et al.,
2013; Griffiths et al., 2013; Larena et al., 2013]. In most temperate areas of Asia, JEV is transmitted
mainly during summer season, when large epidemics can occur. In the tropics and subtropics
region, transmission can occur throughout the year but often increases during the rainy season
[Campbell et al., 2011]. The first epidemic of JE was recorded in Japan in 1871. Major outbursts
have been seen in nearly every 10 years. In 1924 more than 6,000 cases were reported in a major
outbreak in Japan [Solomon et al., 2000]. The disorders caused by JEV began from Southeast
Asia and now it’s affecting people worldwide [Liu et al., 2013; Li et al., 2013]. Nearly 30 million
people are at danger of JEV infection [Saxena et al., 2003]. Though intensive care and support
are able to lower the death rate but patients continue to suffer from this disease for a long
period of time. Some effects such as learning difficulties and behavioral problems can remain
masked for several years.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Epidemiological features
JE is believed to be originated in Indonesia and Malaysia long back in mid 1500s [Weaver et
al., 1999; Sinniah et al., 1989]. JEV leads to major outbreaks in both temperate regions of Asia
like China, Japan, Korea, Philippines, Taiwan and tropical regions like Bangladesh, India, Sri
Lanka and Nepal [Bista et al., 2005]. The cases of JE are also reported in newer geographical
regions in the Torres Strait islands of Australia and in Papua New Guinea [Fig. 1]. The reason
for this wide spread of JE is unknown but it may be due to population shift or variations in
agricultural practices, animal husbandry, climate, ecology or migratory birds patterns. In India
the first case of JE was seen in 1955. JE is reported to be endemic in many parts such as Assam,
Bihar, Madhya Pradesh, Tamil Nadu, Uttar Pradesh and West Bengal.
Figure 1. Epidemiology of JE globally. The areas highlighted in red display the endemic regions affected by JE.
Trends in Infectious Diseases4
3. Viral replication and morphogenesis
JEV virion comprises of a single strand of positive-sense RNA of around 11kb, enclosed in a
nucleocapsid and surrounded by envelope made up of glycoproteins [Agrawal et al., 2013; Ye
et al., 2012]. The RNA consists of a short 5’ untranslated region (UTR), a longer 3’ UTR and a
single open reading frame between them. It encodes 3432 aminoacid polyprotein, which is
translationally and post translationally cleaved by viral and host proteases into three structural
proteins (core-C, pre-membrane-PrM and envelope-E) and seven nonstructural (NS) proteins
(NS1,NS2A,NS2B,NS3,NS4A,NS4B and NS5) [Fig 2][Yang et al., 2013].
Figure 2. Organization of the JEV genome
The C protein of 12-14 kDa in size is highly basic and fuses with the RNA to form the nucleo‐
capsid. The PrM is in close proximity with the E protein, forming a heterodimer and is believed
to act as a ‘chaperone’ to it, hindering its function until after virion release. Just before the
virion release, the PrM protein is cleaved by a protease to its mature M protein form. This
alteration contributes for the formation and activation of E protein homodimers. Researchers
suggested that the extremely conserved N glycosylation motif N15-X16-T17 in JEV PrM and its
N-glycan substituents are essential for several stages of JEV biology: PrM biogenesis, virus
release and pathogenesis. The E protein is the largest structural protein, comprising of
approximately 500 aminoacids, with up to two potential glycosylation sites. It is the main target
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for the humoral immune response and is believed to play a vital role in viral entry into host
cells [Solomon et al., 2003]. The xlink protein is involved in virus replication and regulation of
the innate immune response [Li et al., 2012; Zhang et al., 2012]. The functions of NS3 and NS4
are prominent, they code for serine protease and RNA dependent RNA polymerase (RdRp)
[Lu et al., 2013]. There is a high rate of mutation in JEV because RdRp is expected to have some
error which leads to vast alterations in genomic sequences of JEV worldwide [Saxena et al.,
2008]. Since all flaviviral NS proteins are essential for viral replication, any one of them can be
selected as target for selective inhibitors of viral replication for therapeutic intervention
[Anantpadma et al., 2011; Mastrangelo et al., 2012].
4. Pathogenesis
The development of JEV infection, beginning from its entry till reaching its site of action, the
central nervous system (CNS) is not well understood. Studies with other flaviviruses have
brought us to the belief that upon entry through mosquito bite, the virus infects dendritic cells
in the skin and is carried to the nearest draining lymph nodes, thereby initiating a round of
early immune response. But this response is not enough to counter the virus. Meanwhile the
virus spreads to secondary lymphoid organs before entering the blood circulation through the
efferent lymphatic system. During the subsequent transient viremia, peripheral organs such
as kidney, liver and spleen are known to be infected first, after which the neurotropic virus
spreads to the CNS. It is still not clear how JEV is able to escape the host’s peripheral immune
response. After the virus escapes the immune system, it crosses the Blood Brain Barrier to enter
the CNS. JEV may cross the BBB by passive transport across the endothelium, by active
replication in endothelial cells or by a ‘Trojan Horse’ mechanism in which the virus is carried
into the brain by infected inflammatory cells. Monocytes and macrophages are considered to
be the feasible carriers of the virus in the CNS as the virus can survive for a prolonged time
and effectively replicate within these cells. During the entry of infected monocytes and
macrophages through the BBB, change in the structural and functional integrity of the BBB,
leads to production of matrix metalloproteases released by endothelial cells of BBB. This
further result in deterioration of BBB stability. BBB stability. Due to the compromised func‐
tioning of the BBB, peripheral inflammatory cells are recruited to the infected brain that extends
the neuronal impairment.
JEV causes neuronal damage in the brain. However in several cases, JEV is possibly not directly
involved in the destruction of brain tissue but it may activate microglia and trigger cell-
mediated immune response. Microglial cells are the resident immune cells of the CNS and
have a crucial role in host defense against invading microorganisms. Microglial activation is
considered as an adaptive response whereby microglia release neuroprotective factors to ease
the recovery of injured neurons. They also perform phagocytosis for dying or damaged
neurons, before they lyse and release toxic agents into surrounding areas. JEV infection
activates microglia both morphologically and functionally, in vivo, which causes rise in the
level of pro-inflammatory mediators, such as IL-6, TNF-α, RANTES and MCP-1 [Thongtan et
al., 2012]. These proinflammatory mediators and cytotoxins released from activated microglia
Trends in Infectious Diseases6
are involved in inducing neuronal death that complements JE. Neuronal death by secreted
TNF is mediated by the TNF receptor-associated death domain protein (TRADD), which there
upon regulates a downstream apoptotic cascade, in neurons [Swarup et al., 2007]. During JEV
infection, nitric oxide (NO) is released by macrophages and plays a significant role in inflam‐
mation, even though NO itself is a strong antimicrobial agent, researchers have suggested that
it strongly inhibits synthesis of viral RNA, protein accumulation and virus release from
infected cells. NO production is higher in the JEV infected brain, and plays a crucial role in the
innate immunity of the host and its ability to restrict the initial stages of JEV infection in the
CNS [Saxena et al., 2000].
In addition to neuronal and microglial cells, astrocytes are also infected by JEV. Astrocytes are
known to maintain homeostasis in the CNS and support the survival and information
processing function of neurons. They respond fast to CNS infection and help regulate neuro‐
inflammation. JEV infection results in astrocyte activation, but the infection overpowers the
capacity of activated astrocytes to maintain metabolic homeostasis, resulting in an over
accumulation of toxic byproducts of metabolism that are injurious to neuronal viability.
However JEV infection triggers metabolic reprogramming by upregulating the expression of
many proteins such as IP-10, ceruloplasmin and glutamine synthase by astrocytes, involved
in the metabolic pathways vital for maintaining neuronal health. This increase is deficient to
meet the increased demand that accompanies JEV infection. Astrocytes help in the transmis‐
sion of JEV from peripheral tissues to the cerebrospinal fluid.
Disease course Incubation period Signs and symptoms
Prodromal stage 1-6 days Fever, muscle pain, headache along with vomiting. In children
gastrointestinal symptoms like nausea, vomiting, diarrhea and
abdominal pain may be prominent.
Acute encephalitic
stage
7-13 days Photophobia, hyperexcitability, focal and neurological signs,
muscular rigidity, dull, mask like face with wide unblinking eyes,
tremor, widespread hyertonia, cogwheel rigidity, other
irregularities in movement, upper motor neuron signs, cerebellar
signs and cranial nerve paralysis sometimes leading to coma
Late convalescent
stage
14-15 day onwards Fever subsides, neurological signs may improve, and eventually
either death may occur, or a long term psychoneurological
condition may persist, if patient survives.
Table 1. Duration, signs and symptoms of Japanese encephalitis
JE usually develops in patients after an incubation period of 5-15 days [Table 1]. In humans,
most JEV infections are asymptomatic, with about 1 in 300 JEV infections resulting in symp‐
toms ranging from non-specific mild fever to severe meningoencephalitis categorized by fever,
lessened consciousness, seizures and focal neurological signs. At later stages, poliomyelitis-
like flaccid paralysis and parkinsonian syndrome develop, which exhibit the standard
description of JE like dull, flat and mask-like face with wide, unblinking eyes, tremor, wide‐
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for the humoral immune response and is believed to play a vital role in viral entry into host
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are prominent, they code for serine protease and RNA dependent RNA polymerase (RdRp)
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error which leads to vast alterations in genomic sequences of JEV worldwide [Saxena et al.,
2008]. Since all flaviviral NS proteins are essential for viral replication, any one of them can be
selected as target for selective inhibitors of viral replication for therapeutic intervention
[Anantpadma et al., 2011; Mastrangelo et al., 2012].
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in the skin and is carried to the nearest draining lymph nodes, thereby initiating a round of
early immune response. But this response is not enough to counter the virus. Meanwhile the
virus spreads to secondary lymphoid organs before entering the blood circulation through the
efferent lymphatic system. During the subsequent transient viremia, peripheral organs such
as kidney, liver and spleen are known to be infected first, after which the neurotropic virus
spreads to the CNS. It is still not clear how JEV is able to escape the host’s peripheral immune
response. After the virus escapes the immune system, it crosses the Blood Brain Barrier to enter
the CNS. JEV may cross the BBB by passive transport across the endothelium, by active
replication in endothelial cells or by a ‘Trojan Horse’ mechanism in which the virus is carried
into the brain by infected inflammatory cells. Monocytes and macrophages are considered to
be the feasible carriers of the virus in the CNS as the virus can survive for a prolonged time
and effectively replicate within these cells. During the entry of infected monocytes and
macrophages through the BBB, change in the structural and functional integrity of the BBB,
leads to production of matrix metalloproteases released by endothelial cells of BBB. This
further result in deterioration of BBB stability. BBB stability. Due to the compromised func‐
tioning of the BBB, peripheral inflammatory cells are recruited to the infected brain that extends
the neuronal impairment.
JEV causes neuronal damage in the brain. However in several cases, JEV is possibly not directly
involved in the destruction of brain tissue but it may activate microglia and trigger cell-
mediated immune response. Microglial cells are the resident immune cells of the CNS and
have a crucial role in host defense against invading microorganisms. Microglial activation is
considered as an adaptive response whereby microglia release neuroprotective factors to ease
the recovery of injured neurons. They also perform phagocytosis for dying or damaged
neurons, before they lyse and release toxic agents into surrounding areas. JEV infection
activates microglia both morphologically and functionally, in vivo, which causes rise in the
level of pro-inflammatory mediators, such as IL-6, TNF-α, RANTES and MCP-1 [Thongtan et
al., 2012]. These proinflammatory mediators and cytotoxins released from activated microglia
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are involved in inducing neuronal death that complements JE. Neuronal death by secreted
TNF is mediated by the TNF receptor-associated death domain protein (TRADD), which there
upon regulates a downstream apoptotic cascade, in neurons [Swarup et al., 2007]. During JEV
infection, nitric oxide (NO) is released by macrophages and plays a significant role in inflam‐
mation, even though NO itself is a strong antimicrobial agent, researchers have suggested that
it strongly inhibits synthesis of viral RNA, protein accumulation and virus release from
infected cells. NO production is higher in the JEV infected brain, and plays a crucial role in the
innate immunity of the host and its ability to restrict the initial stages of JEV infection in the
CNS [Saxena et al., 2000].
In addition to neuronal and microglial cells, astrocytes are also infected by JEV. Astrocytes are
known to maintain homeostasis in the CNS and support the survival and information
processing function of neurons. They respond fast to CNS infection and help regulate neuro‐
inflammation. JEV infection results in astrocyte activation, but the infection overpowers the
capacity of activated astrocytes to maintain metabolic homeostasis, resulting in an over
accumulation of toxic byproducts of metabolism that are injurious to neuronal viability.
However JEV infection triggers metabolic reprogramming by upregulating the expression of
many proteins such as IP-10, ceruloplasmin and glutamine synthase by astrocytes, involved
in the metabolic pathways vital for maintaining neuronal health. This increase is deficient to
meet the increased demand that accompanies JEV infection. Astrocytes help in the transmis‐
sion of JEV from peripheral tissues to the cerebrospinal fluid.
Disease course Incubation period Signs and symptoms
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abdominal pain may be prominent.
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stage
7-13 days Photophobia, hyperexcitability, focal and neurological signs,
muscular rigidity, dull, mask like face with wide unblinking eyes,
tremor, widespread hyertonia, cogwheel rigidity, other
irregularities in movement, upper motor neuron signs, cerebellar
signs and cranial nerve paralysis sometimes leading to coma
Late convalescent
stage
14-15 day onwards Fever subsides, neurological signs may improve, and eventually
either death may occur, or a long term psychoneurological
condition may persist, if patient survives.
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spread hypertonia, cogwheel rigidity and other irregularities in movement [Dutta et al., 2010].
Paralysis of the upper body is more common than that of legs. Nearly 30% of survivors have
genuine persistent motor deficits and approximately 20% have severe cognitive and language
impairment [Mackenzie et al., 2004].
5. Transmission
The JE virus exists in a zoonotic transmission cycle between mosquitoes and pigs and/or water
birds; humans get infected only accidentally when bitten by an infected mosquito [Fig 3] and
are a dead-end host [Gould et al., 2008]. JEV has been isolated from many mosquito species in
field studies, and even though the major mosquito vectors differ in diverse geographical
regions, the most important is Culex tritaeniorhynchus. For Eastern Asia, Southern Asia and
Southeastern Asia, the chief vector is C. tritaeniorhynchus [Rao et al., 2001]. For Northern
Australia, the chief vector is C. annulirostris. From India’s outlook, there are several other
secondary vectors such as Anopheles peditaeniatus, A. subpictus, C. epidesmus, C. gelidus, C.
pseudovishnui, C. whitemorei, Mansonia uniform and M. Indiana [Borah et al., 2013]. Pigs are the
key component in the transmission cycle with respect to human infection, while egrets, herons
and other ardeid birds are significant maintenance hosts [Hecker et al., 2013; Sarkar et al.,
2013]. Of other vertebrates, horses can develop CNS infection but are a dead-end host; Other
domestic animals may also get infected, but do not show any evidence of viremia. Rodents are
refractory to infection; and amphibians, bats and reptiles can be infected experimentally and
virus can persist, but the role of these species in hibernating and maintaining the virus in the
environment is undisclosed.
There are two epidemiological forms of transmission: an endemic form in tropical areas with
virus circulation almost throughout the year, but with a wide seasonal peak probably due to
irrigation practices; and an epidemic form in more temperate areas with clear summer
seasonality [Schuh et al., 2013; Gao et al., 2013]. Subsequently, JE is mainly a rural disease, where
Cx. tritaeniorhynchus mosquitoes breed in rice paddies and pigs provide the main source of
blood meals, with the consequence of transmission cycles in close proximity to human
habitation.
6. Diagnosis
Patients with JE present many signs of acute encephalitic syndrome. There are various possible
causes of acute encephalitic syndrome; therefore laboratory confirmation is crucial for the
accurate diagnosis of JE [Table 2], which is a tough task because of very low viremia. Reverse
passive hemagglutination, immunofluorescence and staphylococcal coagglutination tests
using polyclonal or monoclonal antibodies have proved the value of antigen detection in
Cerebrospinal fluid (CSF) for rapid diagnosis of JE. Advanced methods like Immunogold silver
staining (IGSS), have been effectually used in the detection of antigen in mononuclear cells of
peripheral blood and CSF of patients. Immunohistochemistry has been used to detect viral
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antigens in the CNS. Histopathology inspection is also very obliging for clinical association
and diagnosis of JEV. Diagnosis is accordingly targeted towards the detection of antibodies in
serum and cerebrospinal fluid. Cases like cross-reactivity of antibodies to other flaviviruses
cause confusion in the diagnosis of JEV. IgM capture ELISA has been the most extensively
used diagnostic method for JE detection [Hobson-Peters et al., 2012; Palani et al., 2013;
Borthakur et al., 2013]. Currently, dipstick method, JEV-CheX and reverse transcriptase PCR
are some of the methods which are used for the early detection of JEV [Yang et al., 2013; Seo
et al., 2013; Zheng et al., 2013].
Diagnostic tool Detects
Immunogold Silver Staining (IGSS) Antigens in mononuclear cells peripheral blood and CSF
Hemagglutination test Antigens in CSF
MAC-ELISA IgM antibodies
Dipstick method, JEVCheX Antibodies
RT-PCR, RT-LAMP Universal oligonucleotide primers
Table 2. Laboratory diagnostic tools for Japanese encephalitis
Figure 3. Transmission cycle of Japanese encephalitis virus. Infected Culex mosquitoes (vectors) play the role in the
spread of JEV. Pigs are the amplifying hosts and birds (egrets) are the maintenance hosts while humans are the dead-
end hosts.
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Currently there is no therapy for JE [Saxena et al., 2009]. Presently, chemotherapy during JE is
mainly supportive and not targeted towards JEV specifically. Interferon therapy has not
proved to be a great success [Tiwari et al., 2012]. Naturally occurring compounds such as
arctigenin, a phenylpropanoid and rosmarinic acid, which is a phenolic compound found in
many Labiatae provide protection to mice against JEV GP78 by noticeably decreasing JEV
induced neuronal apoptosis, activation of microglial cells, active caspase activity and induction
of proinflammatory mediators in the brains of the infected animals.
An in vivo study has shown that minocycline reduces neuronal apoptosis, activation of
microglial cells, active caspase activity, proinflammatory mediators and viral titer on later
stages after infection. Another compound, N-methylisatin-β-thiosemicarbazone derivative is
known to inhibit JEV replication completely in vitro. Glucosidase inhibitors of the endoplasmic
reticulum such as N-nonyl-deoxynojirimycin, which block the trimming step of N-linked
glycosylation, have been shown to eliminate the production of many endoplasmic reticulum-
budding viruses, including dengue type-II and JEV. Another recent study carried out in mice
using RNA interference showed that a single intracranial organization of lentiviruses deliv‐
ering short hairpin RNA or lipid-complexed small interfering RNA (siRNA) either before or
after the viral challenge was sufficient to provide protection against lethal encephalitis. From
the study it was clear that by precise drug design of the conserved site, a single siRNA
treatment could suppress viral infection across species, thus enhancing the treatment of acute
viral infections with overlapping clinical symptoms [Ghosh et al., 2009].
8. Protection
The control of JE is based mainly on three measures: mosquito control, avoiding human
exposure and immunization. Mosquito control has failed to be an effective measure and suffers
from the lack of research into new pesticides. Avoiding complete exposure from infected
mosquitoes is not practically possible. Accordingly, immunization is the only effective method
for long-term protection. To prevent JE, it is crucial to apply a large scale vaccination for the
human population in JE prone areas [Tiwari et al., 2012]. There are many groups of vaccines
[Table 3] which are presently in use such as purified, formalin-inactivated mouse brain derived
and cell culture derived live attenuated vaccine [Lin et al., 2013]. Several vaccines are still in
different stages of development such as DNA vaccines, recombinant virus based/chimeric
vaccines [Li et al., 2013]. In most countries, the currently available vaccine for use is an
inactivated vaccine derived from mouse brain, which is manufactured in many regional
countries, but it is costly, involves three doses, needs boosting at quite frequent intervals, may
be less effective due to antigenic variation and gives rise to a number of vaccine related adverse
reactions [Yun et al., 2013].
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Vaccine Source Characteristics
(i) Formalin-inactivated mouse brain
derived
Nakayama strain
Costly, less effective and side effects are
seen
(ii) Inactivated hamster kidney cell
vaccine
Beijing strain Very less side effects are seen
(iii) Live attenuated hamster kidney
cell line vaccine
SA14-14-2 strain, China
Costly but effective and very less side
effects are seen
Table 3. Comparison of vaccine for Japanese encephalitis
There are several side effects of JE vaccination. Side effects which are mainly seen after
vaccination are redness, swelling and tenderness. Rarely systematic adverse reactions are also
seen after vaccination like headache, myalgia, abdominal pain and skin rash. Some recipients
of the vaccine had very rare major neurological side effects [Sohn et al., 2000]. To avoid some
of the adverse reactions, vero cell grown inactivated vaccines are being examined and some
of them are currently in clinical trials. Live attenuated vaccines seem to offer good hope; some
of the advantages are that these provide long lasting immunity and are very sensitive.
Currently, the only potential vaccine is the Chinese SA 14-14-2 strain [Verma et al., 2012].
Protein-protein interaction is essential for various cellular functions and impeding such
interactions using synthetic composites is a very noteworthy idea for formulation of new
pharmaceuticals [Haridas et al., 2013].
9. Conclusion
JE is a neurological disease caused by a mosquito-borne JEV. Unlike smallpox and polio, JEV
cannot be completely eradicated because of its enzootic nature of transmission. Ever since its
discovery, JEV has continued to expand its activity into new regions, while many JE vaccines
have been made commercially available in different parts of the world. Concern about its
spread has been emphasized by the recent emergence and spread of JEV in northern Australia,
making it a major concern for global public health. Currently, prevention of infection with
most arboviruses relies primarily on efforts to control vector populations by spraying repel‐
lents, wearing protective clothing and reducing breeding places.
One of the most important research areas is the development of an ideal JE vaccine: one that
is nontoxic, less expensive and more effective and that provides life-long protection with a
single dose. The development of such a vaccine will be greatly aided by a expanding our
knowledge of JEV replication and pathogenesis at the molecular level, which has now become
technically possible with the use of infectious JEV SA14-14-2 cDNA technology. This technol‐
ogy also has huge potential for developing JEV SA14-14-2 as a vaccine vector to deliver foreign
gene(s), as has already been accomplished with infectious YFV 17D cDNA technology.
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1. Introduction
Human papilloma virus (HPV) is responsible for the most common sexually transmitted
infections. It is estimated that two thirds of people who have unprotected sexual intercourse
with a HPV carrier are infected [1].
Since HPV has tropism for epithelial tissue [2-4], it can affect both skin and mucosa [3, 4]. It
causes several types of injuries, ranging from asymptomatic infection and benign warts to
invasive injuries [5]. HPV infection has been found in a wide range of anatomical sites: genital
and anal tract, urethra, upper airway, tracheobronchial mucosa, nasal paranasal cavities, and
oral cavity. HPV on oral mucosa presently afflicts 1% to 43% of the general population,
depending on the diagnosis method used [5], and may be even associated with oral malig‐
nancies [6].
The aim of this review article is to offer the academic community an updated review of HPV,
emphasizing its importance as a public health matter. This review encloses HPV epidemiology,
virology description of different oral lesions, clinical picture, oncogenesis and, diagnostic tools.
We have also reviewed current treatment choices and prophylaxis, as well as vaccines against
HPV.
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1. Introduction
Human papilloma virus (HPV) is responsible for the most common sexually transmitted
infections. It is estimated that two thirds of people who have unprotected sexual intercourse
with a HPV carrier are infected [1].
Since HPV has tropism for epithelial tissue [2-4], it can affect both skin and mucosa [3, 4]. It
causes several types of injuries, ranging from asymptomatic infection and benign warts to
invasive injuries [5]. HPV infection has been found in a wide range of anatomical sites: genital
and anal tract, urethra, upper airway, tracheobronchial mucosa, nasal paranasal cavities, and
oral cavity. HPV on oral mucosa presently afflicts 1% to 43% of the general population,
depending on the diagnosis method used [5], and may be even associated with oral malig‐
nancies [6].
The aim of this review article is to offer the academic community an updated review of HPV,
emphasizing its importance as a public health matter. This review encloses HPV epidemiology,
virology description of different oral lesions, clinical picture, oncogenesis and, diagnostic tools.
We have also reviewed current treatment choices and prophylaxis, as well as vaccines against
HPV.
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Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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2. The biology of human papillomavirus — Virion structure
HPV is a small DNA virus belonging to Papillomaviridae family [1, 2, 7, 8]. Its virion consists of
a non enveloped, singular double stranded DNA molecule [5, 8, 9], of about 7.9kb [8], involved
by a capsid, of about 55 nm in diameter [8, 9], containing only two structural proteins [8].
HPV genome presents a notable organization. It weighs 5.2x106D and contains 7.200 – 8.000
pairs of nitrogenous bases (pnb) [9]. All putative open reading frames (ORFs) are limited to
only one strand of DNA [8]. Non-coding strand probably forms a second, which bears pieces
of preserved ORFs, irrespective of localization and composition [8], Chlaudhary et al (2009)
have suggested that the basis of the HPV molecule DNA can be divided in three parts. The
first part, with 4.000 pnb, accounts for viral replication and cell transformation while the second
part, with 3.000 pnb, represents an important codification zone, since it encodes the viral
particle structural proteins. The last one, with only 1.000 pnb, contains a non-coding zone; it
is, however, fundamental, since the viral origin of replication belongs to this part [9].
2.1. Genome structure
The difference of HPV types is due to the variation of E6 and E7 sequence of nitrogenous bases.
This variation can produce either an easier to inhibit gene or a harder to inhibit one, thus
stratifying the virus oncogenic phenotype into high, intermediate and low risk types
[7].Besides its oncogenic potential, the HPV types vary according to tissue tropism and their
association with these tissues [10]. Over a 100 HPV types [7] have been identified, but only 25
(HPV - 1, 2, 3, 4, 6, 7, 10, 11, 13, 16, 18, 31, 32, 33, 35, 40, 45, 52, 55, 57, 58, 59, 69, 72, 73) were
associated with benign or malignant lesions [3, 10]. Low-risk HPV (6, 11, 38, 40, 42, 54, 55, 61,
62, 64, 67, 69, 70, 71, 72, 81, 83, 84, 89) [11] causes injuries which produce abnormal cell growth
[8]; however, they are unlikely to undergo malignant neoplastic transformation. High-risk
HPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) [11] are likely to induce
malignant neoplastic transformation [3, 11]. Recently HPV- 26, 53, 66 have been found to be
among the potentially high-risk types [12].
HPV - 6, 11 are related to condyloma acuminatum and, in children, laryngeal papilloma,
conjuntival papilloma and genital warts [13]. HPV – 16, 18, mainly, but also 31, 32 and 35 are
associated with squamous cell carcinoma [11]. Although benign forms rarely developed into
malignant, they can concurrently present with the high-risk malignant injury [9].
3. Prevalence and incidence
The American Cancer Society has estimated that more than 6 million people are infected by
HPV each year, with 3 million affecting the 15- 25 age group [14].
Asymptomatic oral and oropharynx HPV prevalence at oral cavity has not yet been established
[15], probably because different methods were used in different studies [3]. Methods have
varied in terms of size of samples, collecting procedures, test sensibility and use of PCR or PCR
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inhibitors. This may explain the huge variation in HPV detection rate: 22 to 60% or 0 to 81.1%,
depending on the methods and on the studied population [15].
Recent meta-analysis has demonstrated that HPV is an isolated risk factor for the development
of oral carcinoma [2]. Oral squamous cell carcinoma is known to be linked with both heavy
drinking and smoking and it has been related to HPV [6, 7].
3.1. Oral human papillomavirus infection
When oral mucosa is considered normal, the epithelium may serve as a container of HPV which
would be activated at some point in time and induce injury [16]. A huge number of different
oral diseases may be associated with oral HPV, but they rarely cause lesions [17]. Lesions may
range from benign warts, which are far more common, to malignant injuries [6].
3.2. Sexual and nonsexual transmission
Many studies have discussed HPV transmission, but the mechanisms involved remain
unknown. Unprotected sexual intercourse is its leading cause, particularly oral-genital sex,
when the genital mucosa is infected by the virus, which will be present both clinically and
subclinically [1, 16] in adolescent and adults. Early sexual relationships, high number of sexual
partners, parity, smoking and another sexually transmitted infection may elevate the rate of
virus infection [6, 18, 19].
Oral HPV can be transmitted by direct skin-skin contact [3] and self-inoculation [1, 4]. Upper
airway transmission has not yet been established [8].
Infant HPV is mainly transmitted at birth by infection of the maternal cervix. Thus, the
recurrent laryngeal papillomatosis seems to be acquired by such manner [19, 20]. However,
another transmission route is mother-fetus, before, during or after the child-birth [1, 4, 8] that
may be made possible by infected amniotic fluid and umbilical cord blood [21].
The transmission of HPV through fomites may also occur [22].
4. Risk and protective factors
In the social sphere, people who have yet to initiate sex life have a low probability of HPV
infection. On the other hand, people who started their sex life earlier or have a promiscuous
sexual life are more likely to have sexually transmitted infections, including HPV. In the
economical sphere, it has been found that low levels of HPV infection were strongly related
with higher income levels [4].
Early age initial sexual activity, oral sex, more than one sexual partner, not wearing condoms,
infrequent use of condoms all pose important risks to any sexually transmitted infection, such
as HPV. Homosexuals tend to have greater number of sexual partners than heterosexuals, and
as such, they should be more commonly infected than heterosexuals, but studies have yet to
confirm this trend [4, 8].
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2. The biology of human papillomavirus — Virion structure
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HPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) [11] are likely to induce
malignant neoplastic transformation [3, 11]. Recently HPV- 26, 53, 66 have been found to be
among the potentially high-risk types [12].
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varied in terms of size of samples, collecting procedures, test sensibility and use of PCR or PCR
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partners, parity, smoking and another sexually transmitted infection may elevate the rate of
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recurrent laryngeal papillomatosis seems to be acquired by such manner [19, 20]. However,
another transmission route is mother-fetus, before, during or after the child-birth [1, 4, 8] that
may be made possible by infected amniotic fluid and umbilical cord blood [21].
The transmission of HPV through fomites may also occur [22].
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In the social sphere, people who have yet to initiate sex life have a low probability of HPV
infection. On the other hand, people who started their sex life earlier or have a promiscuous
sexual life are more likely to have sexually transmitted infections, including HPV. In the
economical sphere, it has been found that low levels of HPV infection were strongly related
with higher income levels [4].
Early age initial sexual activity, oral sex, more than one sexual partner, not wearing condoms,
infrequent use of condoms all pose important risks to any sexually transmitted infection, such
as HPV. Homosexuals tend to have greater number of sexual partners than heterosexuals, and
as such, they should be more commonly infected than heterosexuals, but studies have yet to
confirm this trend [4, 8].
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Smoking may pose a lower risk for infection with high risk oral and oropharyngeal HPV than
it was previously believed probably because the oral mucosa keratinization makes it stronger
against minor traumas and consequently HPV infection. On the other hand, high levels of
alcohol consumption have been linked to a higher risk of HPV positivity, but this association
needs further research in order to be more fully established [68].
Normally, people acquire HPV during their adolescent years, or when they approach their
twenties, when they start their sexual life. An immune competent person can suppress HPV
or even eliminate it, and suppressed HPV may be kept subclinical for years [8].
Among the leading protective factors, saliva stands out. It is composed of lysozymes, lacto‐
ferrin, IgA and cytokines which seems to be the reason behind low HPV transmission through
self-inoculation, oral sex, and the virtually inexistence of transmission through kissing. It has
been suggested that regular consumption of carotenoids would contribute to make HPV
persistence less likely, and a high consumption of folic acid would reduce the risk of HPV
infection [4].
5. HPV associated oral injuries
HPV infection range from asymptomatic to visible lesions, which can be benign or malignant
[6]. The most common oral manifestations are described below:
5.1. Condyloma acuminatum
The lesion is caused by the abnormal proliferation of a squamous stratified epithelium [23].
Formerly it was believed that the only transmission route was by sexual contact, but now it is
known that there are other routes, such as self-inoculation and mother-fetus transmission [15].
However, sexual contact remains the main route of transmission (20%) [23], and people who
carry these lesions and practice oral sex have a 50% chance to acquiring oral condyloma. The
incubation period range from 3 weeks to an undetermined period of time; after that, clinic
progression will depend on cell permissiveness, virus type and host immune situation [24].
Condyloma acuminatum has tropism to tongue, lips, palate and mouth floor. Clinically, it is
described as little pinkish or whitish nodules which proliferate in papillary projections that
might be either pedicle or sessile. Outline surfaces present even more evident cauliflower
shapes than papilloma, mainly when they converge (Figure 1 – A, B).
Histologically, oral condylomata are typically papillary proliferations of squamous epithelium
with prominent acanthosis and parakeratin that line deep crypts, similar to their counterparts
in the lower genital tract. Koilocytosis is the classic diagnostic feature, consisting of cells with
perinuclear halos of various sizes and accompanied by variability in nuclear size and chro‐
maticity, as well as nuclear membrane irregularity. These features are most prominent toward
the surface of the lesion (Figure 1 – C, D) [25].
HPV presence was first determined by immunohistochemistry and later by hybridization with
75 to 85% of positivity [15]. The most involved types are 6 and 11 [5, 15, 18].
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Differential  diagnoses  include  oral  squamous  papilloma,  verruca  vulgaris,  molluscum
contagiosum, seborrheic keratosis, lichen planus and oral squamous cell carcinoma (OSCC)
[15].
Condyloma acuminatum treatment is not always necessary. For 20-30% of HPV patients,
lesions are self-limited and resolve spontaneously within six months, while for 60% of them,
lesions may regress in a year. Relapses affect 20-30% of patients undergoing treatment, and
they may reappear on the same sites or on different locations [24]. The choice of therapy is
based on a range of factors, such as lesions size, aspect, number and sites. Other factors of equal
significance include patient preference, costs, and adverse effects [23]. Commonly, lesions have
been treated by excisional surgery, but in the last years a wider choice of treatments have
become available, e.g., cryotherapy, electro cauterization and CO2 laser. Other options include
caustic agents, such as trichloroacetic acid, podophyllin and 5-flourouacil which may cause
tissue destruction [23].
Figure 1. Condyloma acuminatum. Rose-colored nodule with a cauliflower-like surface in the floor of the mouth (A;
inset – closer view). Lesion on the hard palate (B; inset – closer view). Microscopically, panoramic view of acanthosis
with papillary folds, parakeratosis and elongation of rete ridges (C, D) (HE, Objective 2.5x). Clinical images obtained
from the archives of the Stomatology Specialization at Odontoclínica Central do Exército (OCEx).
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alcohol consumption have been linked to a higher risk of HPV positivity, but this association
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twenties, when they start their sexual life. An immune competent person can suppress HPV
or even eliminate it, and suppressed HPV may be kept subclinical for years [8].
Among the leading protective factors, saliva stands out. It is composed of lysozymes, lacto‐
ferrin, IgA and cytokines which seems to be the reason behind low HPV transmission through
self-inoculation, oral sex, and the virtually inexistence of transmission through kissing. It has
been suggested that regular consumption of carotenoids would contribute to make HPV
persistence less likely, and a high consumption of folic acid would reduce the risk of HPV
infection [4].
5. HPV associated oral injuries
HPV infection range from asymptomatic to visible lesions, which can be benign or malignant
[6]. The most common oral manifestations are described below:
5.1. Condyloma acuminatum
The lesion is caused by the abnormal proliferation of a squamous stratified epithelium [23].
Formerly it was believed that the only transmission route was by sexual contact, but now it is
known that there are other routes, such as self-inoculation and mother-fetus transmission [15].
However, sexual contact remains the main route of transmission (20%) [23], and people who
carry these lesions and practice oral sex have a 50% chance to acquiring oral condyloma. The
incubation period range from 3 weeks to an undetermined period of time; after that, clinic
progression will depend on cell permissiveness, virus type and host immune situation [24].
Condyloma acuminatum has tropism to tongue, lips, palate and mouth floor. Clinically, it is
described as little pinkish or whitish nodules which proliferate in papillary projections that
might be either pedicle or sessile. Outline surfaces present even more evident cauliflower
shapes than papilloma, mainly when they converge (Figure 1 – A, B).
Histologically, oral condylomata are typically papillary proliferations of squamous epithelium
with prominent acanthosis and parakeratin that line deep crypts, similar to their counterparts
in the lower genital tract. Koilocytosis is the classic diagnostic feature, consisting of cells with
perinuclear halos of various sizes and accompanied by variability in nuclear size and chro‐
maticity, as well as nuclear membrane irregularity. These features are most prominent toward
the surface of the lesion (Figure 1 – C, D) [25].
HPV presence was first determined by immunohistochemistry and later by hybridization with
75 to 85% of positivity [15]. The most involved types are 6 and 11 [5, 15, 18].
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Differential  diagnoses  include  oral  squamous  papilloma,  verruca  vulgaris,  molluscum
contagiosum, seborrheic keratosis, lichen planus and oral squamous cell carcinoma (OSCC)
[15].
Condyloma acuminatum treatment is not always necessary. For 20-30% of HPV patients,
lesions are self-limited and resolve spontaneously within six months, while for 60% of them,
lesions may regress in a year. Relapses affect 20-30% of patients undergoing treatment, and
they may reappear on the same sites or on different locations [24]. The choice of therapy is
based on a range of factors, such as lesions size, aspect, number and sites. Other factors of equal
significance include patient preference, costs, and adverse effects [23]. Commonly, lesions have
been treated by excisional surgery, but in the last years a wider choice of treatments have
become available, e.g., cryotherapy, electro cauterization and CO2 laser. Other options include
caustic agents, such as trichloroacetic acid, podophyllin and 5-flourouacil which may cause
tissue destruction [23].
Figure 1. Condyloma acuminatum. Rose-colored nodule with a cauliflower-like surface in the floor of the mouth (A;
inset – closer view). Lesion on the hard palate (B; inset – closer view). Microscopically, panoramic view of acanthosis
with papillary folds, parakeratosis and elongation of rete ridges (C, D) (HE, Objective 2.5x). Clinical images obtained
from the archives of the Stomatology Specialization at Odontoclínica Central do Exército (OCEx).
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5.2. Verruca vulgaris (Common wart)
Verruca vulgaris, also known as common wart is one of the most common lesions affecting
mainly children [15], but seldom on oral mucosa [6].
It is usually found on lips, hard palate, gingival, and tongue dorsal surface [15], but especially
on lips and tongue [18] (Figure 2 - A, B). Differential diagnoses is made with oral squamous
papilloma and condyloma acuminatum [15, 18].
Figure 2. Verruca vulgaris. Exophytic lesion with hyperkeratotic surface, forming finger projections in the left commis‐
sure of the lip (A, circle). Lesion on the lower lip (B). Microscopically, panoramic view of acanthosis with papillary folds,
hyperortoparakeratosis and elongation of rete ridges (C; HE, Objective 4x). Koilocitosis (D; HE, Objective 20x). Clinical
images obtained from the archives of the Stomatology Specialization at Odontoclínica Central do Exército (OCEx).
Histologically, verruca vulgaris show an almost symmetrical structure, with elongated rete
ridges that are shorter at the periphery than in central area. Thin elongated connective tissue
papillae form papillomatosis. The cryptoform surface shows a conspicuous hyperkeratiniza‐
tion, predominantly composed of orthokeratin. The stratum granulosum is often pronounced,
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particularly in the grooves between the elongated connective tissue papillae. Koilocytes may
be seen. In the connective tissue, some dilated capillaries and a slight infiltration with lym‐
phocytes are usually seen (Figure 2 C, D) [26]
Immunohistochemical methods and hybridization tests showed HPV presence in 43 to 100%
of the studied lesions [15].
Most oral warts are self-limited, and resolve within 2 years. Aesthetic discomfort or bite injuries
induce patients to look for treatment. Some treatment techniques are cauterization, surgical
removal, liquid nitrogen cryotherapy, local hyperthermia, topic 5-fluoracil, CO2 laser, salicylic
acid, squaric acid, interferon and wart material implantation [18].
5.3. Oral squamous papilloma
Oral squamous papilloma (OSP) is a benign tumor that may occur in all ages, but it more
commonly affects adults between 30 and 50 years old [15]. It is mainly related to HPV 6 and
11 [15, 18]. In adults, the lesion is usually located in the oral mucosa, mostly on palate and
tongue, while in children the laryngotracheobronchial complex is a more common site [27].
OSP affects the soft palate, the lingual frenulum as well as the lower lip [15] and the uvula [27],
most often presenting as a single, small lesion smaller than 1 cm, with exophytic growth and
a wide basis or pedicle. On histopathology the pattern of epithelial proliferation repeats
features described in the previous lesions, with squamous cell acanthosis, hyperkeratosis and
a centrally disposed fibrovascular core.(Figure 3 – A, E). Koilocytosis may be present or not.
Oral squamous papilloma may be isolated or multiple-recurring, which is more likely to affect
immunosuppressed patients, such as HIV-positive patients. Multiple-recurring papilloma is
also more likely to be malignant [27] and tends to relapse more often [28]. Differential
diagnoses include exophytic carcinoma, verrucous carcinoma and condyloma acuminatum
[27]. Surgical removal is the first choice of treatment, but electrocauterization, cryosurgery and
interferon injections are other effective treatment courses [8].
5.4. Focal epithelial hyperplasia (Heck disease)
Focal epithelial hyperplasia (FEH) or Heck disease was first described in 1965 [15] and can
affect all age groups [29], but it is more common in children and adolescents (3 to 18 years) [30].
Malnutrition, poor hygiene and low social condition as well as genetic background also play
an important role [31] in lesion development.
FEH shows a benign epithelial growth and commonly affects oral mucosa, lips, tongue [18],
particularly the lower lip and more rarely the palate, floor of the mouth and oropharynx [30].
Clinically it presents as multiple papules (3 – 10 mm) [30] that tend to converge. They are
characteristically nodular, sessile, circumscribed, painless and soft masses on oral mucosa.
Color may range from pale pink to normal mucosa [15, 29- 31]. (Figure 4 – A, B). The diagnosis
is both clinical and histological [30, 32].
Microscopically it shows epithelial hyperplasia, acanthosis, mild parakeratosis and anasto‐
mosing rete ridges. Superficial layers of the epithelial tissue contain cytophatic changes
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ridges that are shorter at the periphery than in central area. Thin elongated connective tissue
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of the studied lesions [15].
Most oral warts are self-limited, and resolve within 2 years. Aesthetic discomfort or bite injuries
induce patients to look for treatment. Some treatment techniques are cauterization, surgical
removal, liquid nitrogen cryotherapy, local hyperthermia, topic 5-fluoracil, CO2 laser, salicylic
acid, squaric acid, interferon and wart material implantation [18].
5.3. Oral squamous papilloma
Oral squamous papilloma (OSP) is a benign tumor that may occur in all ages, but it more
commonly affects adults between 30 and 50 years old [15]. It is mainly related to HPV 6 and
11 [15, 18]. In adults, the lesion is usually located in the oral mucosa, mostly on palate and
tongue, while in children the laryngotracheobronchial complex is a more common site [27].
OSP affects the soft palate, the lingual frenulum as well as the lower lip [15] and the uvula [27],
most often presenting as a single, small lesion smaller than 1 cm, with exophytic growth and
a wide basis or pedicle. On histopathology the pattern of epithelial proliferation repeats
features described in the previous lesions, with squamous cell acanthosis, hyperkeratosis and
a centrally disposed fibrovascular core.(Figure 3 – A, E). Koilocytosis may be present or not.
Oral squamous papilloma may be isolated or multiple-recurring, which is more likely to affect
immunosuppressed patients, such as HIV-positive patients. Multiple-recurring papilloma is
also more likely to be malignant [27] and tends to relapse more often [28]. Differential
diagnoses include exophytic carcinoma, verrucous carcinoma and condyloma acuminatum
[27]. Surgical removal is the first choice of treatment, but electrocauterization, cryosurgery and
interferon injections are other effective treatment courses [8].
5.4. Focal epithelial hyperplasia (Heck disease)
Focal epithelial hyperplasia (FEH) or Heck disease was first described in 1965 [15] and can
affect all age groups [29], but it is more common in children and adolescents (3 to 18 years) [30].
Malnutrition, poor hygiene and low social condition as well as genetic background also play
an important role [31] in lesion development.
FEH shows a benign epithelial growth and commonly affects oral mucosa, lips, tongue [18],
particularly the lower lip and more rarely the palate, floor of the mouth and oropharynx [30].
Clinically it presents as multiple papules (3 – 10 mm) [30] that tend to converge. They are
characteristically nodular, sessile, circumscribed, painless and soft masses on oral mucosa.
Color may range from pale pink to normal mucosa [15, 29- 31]. (Figure 4 – A, B). The diagnosis
is both clinical and histological [30, 32].
Microscopically it shows epithelial hyperplasia, acanthosis, mild parakeratosis and anasto‐
mosing rete ridges. Superficial layers of the epithelial tissue contain cytophatic changes
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(koilocytosis) and apoptotic or dyskeratotic cells with an apparent mitotic appearance
(mitosoid cells) (Figure 4 – C, D) [30].
FEH has a steady association with HPV infection, and the most common types are 13 and 32
[15, 29]; they account for approximately 90% of infections [30, 32]. HPV-32 might be found in
other type of lesions, but never out of the oral region [15]. Both HPV-1 and 11 are rare and
show potential for malignancy. So far, the only malignant transformation reported has been
found with HPV-24 [32].
Differential diagnoses include condyloma, viral warts, neuroma, white sponge nevus, oral
papillomatosis, [30] and inflammatory fibrous hyperplasia.
FEH normally regresses spontaneously in a few months or years, but it can take longer [30].
Thus, treatment is often chosen to mitigate aesthetic problems or repeated bite injuries [31].
The most effective methods are surgical excision, electrocoagulation, cryotherapy [31], CO2
laser and interferon [30].
5.5. Oral lichen planus
Oral lichen planus (OLP) is a common chronic immunomediated disease [18, 33, 34] of
unknown etiology seemingly related to HPV in some lesions [18], affecting the skin and the
Figure 3. Oral squamous papilloma. Exophytic lesion with hyperkeratotic whitish surface, forming finger projections
on the dorsum of the tongue (A-B). Lesion on the inferior surface of the tongue (C). Lesion on the lower lip (D). Micro‐
scopically, panoramic view of acanthosis with papillary folds, hyperortoparakeratosis, elongation of rete ridges and a
centrally disposed fibrovascular core (E; HE, Objective 2.5x). Clinical images obtained from the archives of the Stomatol‐
ogy Specialization at Odontoclínica Central do Exército (OCEx).
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mucosa [33-, 35]. OLP prevalence ranges from 0, 5% to 4% [35] and mainly affects the female
population [33-35]. The most prevalent age is between 30 to 60 years old, although occurrence
in children and adolescents seems to be on the rise [35]. In around 15% of the cases the skin is
affected and this number increases to around 85% of cases affecting the mucosa, particularly
the oral and genital mucosa. The oral mucosa is affected in 20% to 30% of the cases. Besides
being more common, OLP is more resistant to treatment than skin OLP [34]. A possible
relationship between OLP to Hepatitis C has been hypothesized, but it has not been clearly
established.
Diagnoses depend on clinic manifestation as well as histopathology results [35]. OLP lesions
are usually bilateral and symmetric affecting areas the oral mucosa, gingiva as well as the
dorsum of the tongue and the lip mucosa (Figure 5 – A, F ).
The lesions may be single or multiple and may present in a wide range of forms- cauliflower-
like, striated or annular. Long-time evolution of a lesion is usually atrophic, and when the
lesion is located on the tongue it may cause papillae loss and modify gustation (Figure 5 – G,
F ). Extensive lesions are also more painful [35].
Figure 4. Focal Epithelial Hyperplasia. Multiple flat and coalescent papules on the lower lip mucosa (A-B). Microscopi‐
cally, panoramic view showing acanthosis and irregular elongation and anastomosis of rete ridges (C; HE, Objective
2.5x). Classic “mitosoid” figure (D; HE, Objective 40x). Clinical images obtained from the archives of the Stomatology
Specialization at Odontoclínica Central do Exército (OCEx).
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(koilocytosis) and apoptotic or dyskeratotic cells with an apparent mitotic appearance
(mitosoid cells) (Figure 4 – C, D) [30].
FEH has a steady association with HPV infection, and the most common types are 13 and 32
[15, 29]; they account for approximately 90% of infections [30, 32]. HPV-32 might be found in
other type of lesions, but never out of the oral region [15]. Both HPV-1 and 11 are rare and
show potential for malignancy. So far, the only malignant transformation reported has been
found with HPV-24 [32].
Differential diagnoses include condyloma, viral warts, neuroma, white sponge nevus, oral
papillomatosis, [30] and inflammatory fibrous hyperplasia.
FEH normally regresses spontaneously in a few months or years, but it can take longer [30].
Thus, treatment is often chosen to mitigate aesthetic problems or repeated bite injuries [31].
The most effective methods are surgical excision, electrocoagulation, cryotherapy [31], CO2
laser and interferon [30].
5.5. Oral lichen planus
Oral lichen planus (OLP) is a common chronic immunomediated disease [18, 33, 34] of
unknown etiology seemingly related to HPV in some lesions [18], affecting the skin and the
Figure 3. Oral squamous papilloma. Exophytic lesion with hyperkeratotic whitish surface, forming finger projections
on the dorsum of the tongue (A-B). Lesion on the inferior surface of the tongue (C). Lesion on the lower lip (D). Micro‐
scopically, panoramic view of acanthosis with papillary folds, hyperortoparakeratosis, elongation of rete ridges and a
centrally disposed fibrovascular core (E; HE, Objective 2.5x). Clinical images obtained from the archives of the Stomatol‐
ogy Specialization at Odontoclínica Central do Exército (OCEx).
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mucosa [33-, 35]. OLP prevalence ranges from 0, 5% to 4% [35] and mainly affects the female
population [33-35]. The most prevalent age is between 30 to 60 years old, although occurrence
in children and adolescents seems to be on the rise [35]. In around 15% of the cases the skin is
affected and this number increases to around 85% of cases affecting the mucosa, particularly
the oral and genital mucosa. The oral mucosa is affected in 20% to 30% of the cases. Besides
being more common, OLP is more resistant to treatment than skin OLP [34]. A possible
relationship between OLP to Hepatitis C has been hypothesized, but it has not been clearly
established.
Diagnoses depend on clinic manifestation as well as histopathology results [35]. OLP lesions
are usually bilateral and symmetric affecting areas the oral mucosa, gingiva as well as the
dorsum of the tongue and the lip mucosa (Figure 5 – A, F ).
The lesions may be single or multiple and may present in a wide range of forms- cauliflower-
like, striated or annular. Long-time evolution of a lesion is usually atrophic, and when the
lesion is located on the tongue it may cause papillae loss and modify gustation (Figure 5 – G,
F ). Extensive lesions are also more painful [35].
Figure 4. Focal Epithelial Hyperplasia. Multiple flat and coalescent papules on the lower lip mucosa (A-B). Microscopi‐
cally, panoramic view showing acanthosis and irregular elongation and anastomosis of rete ridges (C; HE, Objective
2.5x). Classic “mitosoid” figure (D; HE, Objective 40x). Clinical images obtained from the archives of the Stomatology
Specialization at Odontoclínica Central do Exército (OCEx).
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Figure 5. Oral lichen planus. Most prominent features are bilateral white striae in buccal mucosa, with certain symme‐
try (A-B). Gingiva may also be affected (C-D) (*) and it may show atrophic symptomatic spots surrounded by Wickham
striae (arrows). When it affects the tongue, it is not as typical (E-F) and may be confused with oral leukoplakia or
smoker’s tongue. Microscopically a strong sub epithelial lymphocytic infiltrate should be present (C; HE, Objective
10x), in association with degeneration of the basal layer (D; HE, Objective 20x) and absence of epithelial dyspla‐
sia..Clinical images obtained from the archives of the Stomatology Specialization at Odontoclínica Central do Exército
(OCEx).
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According to Silverman’s classification OLP may be presented as reticular, erosive and
atrophic forms [33]. Each form has its different clinic evolution and determines different
intensity and duration, with the possibility of evolving from one form into another [35].
On histopathology, we may find acanthosis in keratotic lesions, and atrophy in older lesions.
Two important findings are hydropic degeneration of the basal layer, as well as a strong
subepithelial lymphocytic infiltrate (Figure 5 – G, H). Those lesions that present dysplasia
should not be classified as OLP [36, 37]. Biopsy should be preferably performed on keratotic
areas, however this might be a complicated intervention when the patient has extensive oral
candidiasis [34, 35]. Some other pathologic entities may present similar histopathologic
features, such as lichenoid reaction, which is similar to lichen planus, but usually is related to
amalgam fillings or certain medicines [33, 34].
The most prevalent and commonly found HPV types are 11 and 16 [18].
The conditions that may be considered as differential diagnosis of OLP include the reticular
form which should be distinguished from systemic lupus erythematosus, candidiasis,
traumatic lesions, secondary syphilis, hairy leukoplakia and incipient OSCC. The erosive form
should be distinguished from aphthae, mucous membrane pemphigoid, pemphigus vulgaris,
drug reaction, polymorphic erythema and systemic lupus erythematosus acute lesions [35].
Malignant transformation is reported for OLP, however, a current tendency is to consider
those lesions that do not fulfill established clinical and pathologic criteria for OLP as oral
lichenoid lesions. These lesions mimic OLP and would be the ones truly at risk of becom‐
ing a OSCC [36, 37].
Treatment does not assure cure, for unknown reasons, but it does reduce symptoms, particular
when they are severe, atrophic and widespread. Unlike the asymptomatic reticular form,
erosive lesions need prompt symptomatic treatment. Oral hygiene reduces inflammatory
lesions and topic corticosteroids may be used in the form of mouth wash. Calcineurin inhibitor,
a topic immunosuppressive agent, and topic retinoid, such as imiquimod, are other treatment
options, with the latter being used together with topic corticosteroids [33-35].
5.6. Oral leukoplakia
Leukoplakia is considered a premalignant lesion or potentially malignant disorder on oral
cavity, and reported rates of development into malignancy vary widely depending on the
method of diagnosis and definition criteria used for oral leukoplakia [38]. The most common
malignant transformation is into oral squamous cell carcinoma (OSCC) [38, 39], with percen‐
tages ranging from 3 to 37% [38].
Oral leukoplakia prevalence ranges from 0, 4 to 0, 7%, and there is no variability related to
gender. However, some researchers believe that prevalence among women is higher [38].
Etiology is uncertain; however smoking along with alcohol consumption is pointed as the main
risk factors. There are possible cofactors, such as candidiasis, HPV and more recently Epstain-
Barr virus (EBV) has been associated with these lesions in imunossupressed patients [38]. EBV
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rarely affects immunocompetent people and it does not need a specific treatment [40].
Treatment should address the underlying cause of immunosuppression.
Oral leukoplakia may be located on lip vermillion, gingival, tongue and floor of mouth, and
it is on these latter regions that there is a higher risk of malignancy (around 43%) [38, 40]. Oral
leukoplakia distribution may be local or disseminated [41] (Figure 6 – A, F).
Figure 6. OL: Oral leukoplakia. OL located at lateral (A-B) and ventral tongue show higher risk for malignant transfor‐
mation. These lesions may be homogenously white (A), or associated with ulcers (B). Other common location is gingi‐
va (C-D), floor of mouth (E) and alveolar ridge (F) and a traumatic cause or association with candidiasis should be ruled
out before biopsy. Microscopically leukoplakia can demonstrate only epithelial hyperplasia with acanthosis and hyper‐
parakeratosis (G; HE, Objective 4x), without dysplasia (H; HE, Objective 20x). In this case inflammatory infiltrate was
scarce. Clinical images obtained from the archives of the Stomatology Specialization at Odontoclínica Central do Exército
(OCEx).
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Histological examination reveals a range of epithelium changes varying from innocuous
hyperplasia to dysplasia of varying degrees [18]. However, more commonly, OL presents
hyperkeratosis and epithelial hyperplasia without dysplasia [38] (Figure 6 – G, H). Depending
on the dysplasia degree, it may be classified as low, intermediate and high risk of malignancy
[38], so that severity of the dysplasia is the key standard in malignancy prediction [39].
However, diagnosis of dysplasia is rather subjective and as such it is highly dependent on the
pathologist/researcher [38, 39]. Another controversial issue is that it is virtually impossible to
accurately predict which lesion, even among those with dysplasia, will develop into a
malignant one [39]. Rather, we might get to know which lesion is more likely to become
malignant, if clinic and histological characteristics are analyzed in association [38.37]
Viral etiology is unclear. Although HPV 6, 11 and 16 have been predominantly found, and also
HPV 18, 31, 33, 35 [18, 38] in lesions, the viral etiology remains controversial. It seems that
lesions which contain HPV are less malignant than oral leukoplakia in smokers, similar to what
happens in OSCC. HPV-16 is present in 80% of the lesions, regardless of malignancy [5], and
it has already been established that type 16 is related to OSCC in nonsmoker or nondrinkers.
EBV seems to be an etiologic factor of oral leukoplakia because it appears in a great number
of malignant lesions in imunossupressed patients [38]
Differential diagnoses are leukoedema, white sponge nevus (Cannon's disease), contact
dermatitis lesions, chronic biting, nicotinic stomatitis, OSCC, oral hairy leukoplakia, verrucous
carcinoma, OLP and secondary syphilis.
There has not been any agreement as to the best treatment course, and prevention (smoking
and drinking avoidance and a diet rich in fruits and vegetables) remains the best approach. A
topical treatment based on topical bleomicyn and systemic retinoid is used as an effective short
term treatment, however there are doubts as to its long term efficacy. Invasive treatments
include cryosurgery, CO2 laser, and surgical resection. They are effective in the short run, but
lesions may relapse in the long run [38, 42]
5.7. Oral verrucous carcinoma
Oral verrucous carcinoma (OVC) is a squamous cell carcinoma (SCC) subtype [15, 43, 44], but
it shows a much more benign behavior, with well distinguished morphology and clinical
presentation. It is located on the head, neck and genitals, and more notably on the oral mucosa,
and it has low probability of metastasis [43, 44].
OVC is a rare tumor and had been described by Ackerman [15, 43, 44] in 1948 as a cancer that
involves the lips, oropharynx and laryngeal mucosa. It is also known as Ackerman’s tumor.
However, the condition has also been referred as florid oral papilomatosis, epithelioma
cuniculatum, carcinoma cuniculatum and also as Buschke-Loewestein tumor [43]. Nowadays
carcinoma cuniculatum is considered as a separated pathologic entity [45].
The etiopathogenesis of OVC is unknown, but some studies have found associations mostly
with smoking, some alcohol ingestion and infection by HPV [15, 44]. OVC related co-factors
are poor oral hygiene, OLP or the presence of leukoplakia lesions. HPV may have an important
role in tumor development and progression, but further research is necessary [44].
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HPV has been widely described as one of the causes of OVC, and the most commonly found
types are 6, 11, 16 and 18, which were identified by polymerase chain reaction (PCR), restriction
fragments analyses and DNA slot hybridization [44].
Oral verrucous carcinoma is a male disease and affects predominantly the 50-80 age group [44].
OVC is characteristically situated on the oral mucosa, gingiva, mandible alveolus crest, tongue
and lips [44].
It appears with slow exophytic growth, resulting in verrucous cauliflower lesions, with white
plaques, normally extensive and with well demarcated hyperkeratotic lesions [15, 43, 44]. It is
well circumscribed, invasive only on surface, with low probability of metastasis [43] (Fig‐
ure7 – A, C). People usually look for doctors because of the extensive rapid growth, which
scares them.
OVC histology is characterized by the presence of acanthosis and keratinization with keratin
plugging  and  clefting  [43,  44].  They  are  irregular  and  may  extend  into  cleft.  Atypia  is
minimal  and  usually  there  is  inflammatory  infiltrate  on  the  subepthelial  layer  around
epithelial invaginations which seem to compress the underlying tissue (“elephant feet”) [44]
(Figure 7 – D, E).
Figure 7. Oral verrucous carcinoma of the lip mucosa. Typical clinical presentation showing an indolor sessile nodule
with a white verrucous surface (A,B). Surgical excision was performed resulting in an excellent esthetic and functional
outcome (C). Microscopically, evident hyperkeratosis is observed, with epithelial acanthosis and invasion as pushing
borders towards the stroma (D). Minimal epithelial atypia is seen along with a strong lymphocytic infiltrate (E). Images
obtained from the archives of the Stomatology Specialization at Odontoclínica Central do Exército (OCEx).
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Main OVC differential diagnosis is verrucous hyperplasia, which is very similar, clinically and
histologicallly. Verrucous hyperplasia has in fact been regarded as an OVC precursor [43].
Other differential diagnoses are OLP, benign keratosis, chronic candidiasis, verruca vulgaris,
oral leukoplakia, reactive keratosis epithelial hyperplasia, pseudoepitheliomatous hyperpla‐
sia. It is difficult to distinguish OSCC from OVC, because they may share a similar clinical
picture and incisional biopsy excerpts may not contain atypias [44].
Besides that, tumors mainly composed of OVC may contain small areas of OSCC and behave
as one. Ideally, for definitive diagnosis the entire tumor mass with its surrounding tissue
should be excised and sent for histopathologic analysis [43].
The treatment main option is surgical resection [15, 46] that may be associated with radiother‐
apy particularly on larger lesions. Relapse rate is high when surgical resection or radiotherapy
is performed in isolation. Prognosis of OVC is better than for other types of tumor. Cytostatic
drugs, such as α- interferon (IFN), should be considered for patients who cannot undergo
surgery, but results are not superior from those obtained with surgery [46].
5.8. Oral Squamous Cell Carcinoma (OSCC)
OSCC is a worldwide problem [47], representing approximately 3% of all malignant neo‐
plasms; which means more than five thousand diagnosed cases a day [48], and more than 90%
of all oral cancers [49].
It is a condition primarily related to environmental factors [8] and lifestyle as heavy smoking
(more than a pack a day) and drinking (more than 100g a day) [47]. These two are the main
risk factors for malignant epithelial transformation. Other risk factors include compromised
immune system, poor buccal hygiene and inadequate eating habits [47, 49]. However, OSCC
may affect 15 to 20% of patients with no known risk for the condition [8].
Friedrich et al. reported a 20% to 30% HPV association with OSCC [50]. A meta-analysis
indicates that oral infection with HPV is an independent risk factor for OSCC. [51] Typically,
elderly people [47, 49] are more affected than young people. However, the incidence in young
adults is increasing. Some studies have shown that OSCC in young adults follow a different
clinical course, being more aggressive and affecting more males [47]. On the other side, other
authors have shown no difference in survival among elderly and young adults with OSCC [52].
The most commonly affected site for OSCC is the tongue, especially on inferior and lateral
surfaces (40%) [53](Figure 8 – A, F), but it can also affect buccal mucosa, lips, posterior
mandibular ridge, gingiva, hard palate and retromolar trigone [47, 49, 53, 54].
The clinical picture may vary among OSCC types. Typically they are nodular or ulcerative
lesions [15, 18], with exophytic or ulceroproliferative features [47]. At more advanced stages
lesions present an ulcerated center, not well defined with hard borders. At this point, symp‐
toms such as loss of teeth, bleeding, dysarthria, dysphagia, odynophagia and otalgy may
develop [54].Some of them, for unknown reasons, do not progress into metastasis, while others
infiltrate quickly, invading the lymph nodes [55]. Tongue and floor of the mouth tumors invade
cervical lymph nodes in up to 25% of initial stage cases [56, 57] and are often submitted to
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elective neck dissection. Cervical metastasis at diagnosis is the main indicator of a bad
prognosis [45].
Figure 8. Clinical aspect of OSCC. It may present as an exophityc nodule, ulcerated (A-B) or not (C). It can also be de‐
tected as a small induration interspersed in a white plaque (D - arrow). It may show intra osseous invasion (E), with a
strong white component, and reach distant sites (F) from the initial spot. Images obtained from the archives of the
Stomatology Specialization at Odontoclínica Central do Exército (OCEx).
Trends in Infectious Diseases32
Histologically a range of features may be present, but it is important to detect epithelial
invasion in the stroma, that may occur as islands, cords, sheets and isolated epithelial malig‐
nant cells. Keratin may be present, mostly in well and moderately differentiated tumors. There
are varying degrees of atypia, nuclear and cellular pleomorphism with aberrant and regular
mitosis (Figure 9 – A, D). Usually poorly differentiated tumors are related to recurrence [58].
Clinic and histological features are important to determine treatment, prognostic factors and
survival rates [58, 59]. There is a TNM staging scheme, for OSCC and salivary gland tumors
[60]. At the initial stages survival rates reach 80%, while at more advanced stages they decrease
to 21% [54].
Figure 9. OSCC histopathology. It is possible to observe superficial non affected oral epithelia and tumoral islands in
the stroma (A; HE, Objective 4x). A closer view of the tumoral islands with central keratin (B; HE, Objective 10x). Pleo‐
morphism and atypia are observed (C; HE, Objective 10x), as well as mitosis (*) and intercellular bridges (D; HE, Objec‐
tive 20x).
A correlation between HPV and cervical SCC of the utherus has been identified, but despite
the strong evidence of HPV presence, there is no clear-cut proof that would point to HPV as
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the strong evidence of HPV presence, there is no clear-cut proof that would point to HPV as
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an isolate SCC cause on oral cavity. Some studies argue that HPV is a mere supporting causer
[1, 61] while another study indicates that tumors positive for oncogenic types of HPV may
show better survival [62], mainly in oropharynx, where HPV positive tumors are associated
with a specific morphology (basaloid squamous cell carcinoma, a subtype of conventional
carcinoma) and positivity for p16 using immunohistochemistry [63].
HPV-16 has been found in 90% of head and neck cancers and in 50% of oropharynx [1, 18, 53,
64]. However, some authors have not found such association [64].
Potentially malignant disorders such as leukoplakia, erytroplakia, proliferative verrucous
leukoplakia and lichen planus may progress to OSCC [1] and upon biopsy, there may be
already areas of an actual OSCC [65].
Surgical resection is the treatment of choice when the lesion is placed on oral cavity while
chemoradiotherapy is used when the oropharynx is the afflicted site [22] or if it is a tumor in
a very advanced stage [66].
Surgery may impair some functions as speech, swallowing, and chewing and abruptly change
quality of life. To maintain swallowing and speech, an alternative course is ablative surgery
(microvascular free tissue), but this is not regarded to be as effective as surgical resection. In
advanced stage when metastasis is located on upper aerodigestive tract, treatment should be
multimodal, combining surgery and chemoradiotherapy [46].
Recurrent OSCC is challenging as the risk of complication is increased due to fibrosis and tissue
hipovascularization [51].
Radiotherapy may be primary, adjuvant or neoadjuvant. It is regarded as primary for unre‐
sectable tumor or for patients who cannot undergo surgery, adjuvant as a post-surgery
complementary method, and neoadjuvant when performed before surgery to facilitate tumor
resection [54].
6. HPV oncogenic potential
HPV infection may lead to cell immortalization by means of infection of the mucosa and skin
basal epithelial cells, which are the only ones that keep in the cell cycle [8, 61]. It may be by
itself a causative agent of malignant transformation or when associated with other unclear
cofactors [61]. However, some researchers have argued that HPV is not able to cause malignant
transformation, despite the studies which point to the contrary [12].
Some factors should come into play to immortalize cells: virus type, synergetic action among
physics, biological and chemical agents and genetic constitution, which are able to modify the
natural course of the disease. But if the exposed person has a favorable condition and acquires
high risk HPV it becomes easier to integrate viral DNA into human genome [61].
Oral HPV has been diagnosed in OSCC and it is believed that it has been involved in oral
carcinogenesis by transforming the keratinocytes through a mechanism involving E6 and E7
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proteins. However, the mechanisms behind immune response against high risk HPV remain
unclear [67-69].
7. HPV detection methods
The identification of various types of HPV is a recent technological advance due to the growth
impossibility in tissue cultures and research animals.
Diagnoses methods vary from simple to sophisticated ones, ranging from light microscopy to
DNA expression, with low to high sensitivity. Light microscopy and in situ hybridization are
considered low sensitivity methods because it only tests positive when there are more than 10
viral DNA copies per cell. Among the intermediate sensitivity methods we find southern blot,
do blot and reverse hybridization with a positive detection result when there is from 1 to 10
DNA copies per cell. High sensitivity methods, such as PCR, needs less than 1 viral DNA copy
per cell for microorganism detection [70].
7.1. Light microscopy
This method provides some data, even though it has low sensibility and it does not inform the
HPV type. The most common HPV induced changes are epithelial thickening, prominent
keratohyalin granules, hyperkeratosis, nuclear dysplasia, hyperchromasia, double nucleation
of superficial and intermediated cell, perinuclear cytoplasmic halos, and atypical immature
metaplasia [9].
7.2. Electron microscopy
HPV particles may be identified by electron microscopy (EM), but not the HPV type. EM can
detect the presence of virion on koilocytic and dyskeratotic cell nuclei, but it is a limited method
to investigate infection, because high risk HPV do not reproduce and as such cannot be
identified through EM [5].
7.3. Molecular methods
Molecular methods can be divided into two types: non-hybridization, such as in situ amplifi‐
cation, southern and dot blot hybridization and the amplified, such as target amplification,
signal amplification and probe amplification. Target amplification is best exemplified by PCR.
Signal amplification may be represented by hybrid technique sample. Probe amplification
which is a compound-probe is added to a probe generating signal (Ligase Chain Reaction)
according to literature [5].
7.4. In Situ Hybridization (ISH)
In situ hybridization using biotinylated probes is a common method for detecting HPV in oral
epithelium. It is practical and economical for screening for HPV in clinical pathology labora‐
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an isolate SCC cause on oral cavity. Some studies argue that HPV is a mere supporting causer
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unclear [67-69].
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DNA expression, with low to high sensitivity. Light microscopy and in situ hybridization are
considered low sensitivity methods because it only tests positive when there are more than 10
viral DNA copies per cell. Among the intermediate sensitivity methods we find southern blot,
do blot and reverse hybridization with a positive detection result when there is from 1 to 10
DNA copies per cell. High sensitivity methods, such as PCR, needs less than 1 viral DNA copy
per cell for microorganism detection [70].
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This method provides some data, even though it has low sensibility and it does not inform the
HPV type. The most common HPV induced changes are epithelial thickening, prominent
keratohyalin granules, hyperkeratosis, nuclear dysplasia, hyperchromasia, double nucleation
of superficial and intermediated cell, perinuclear cytoplasmic halos, and atypical immature
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HPV particles may be identified by electron microscopy (EM), but not the HPV type. EM can
detect the presence of virion on koilocytic and dyskeratotic cell nuclei, but it is a limited method
to investigate infection, because high risk HPV do not reproduce and as such cannot be
identified through EM [5].
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Molecular methods can be divided into two types: non-hybridization, such as in situ amplifi‐
cation, southern and dot blot hybridization and the amplified, such as target amplification,
signal amplification and probe amplification. Target amplification is best exemplified by PCR.
Signal amplification may be represented by hybrid technique sample. Probe amplification
which is a compound-probe is added to a probe generating signal (Ligase Chain Reaction)
according to literature [5].
7.4. In Situ Hybridization (ISH)
In situ hybridization using biotinylated probes is a common method for detecting HPV in oral
epithelium. It is practical and economical for screening for HPV in clinical pathology labora‐
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tories. In situ hybridization also permits direct comparison of viral DNA location with
histologic morphology [9, 71]. Although this technique is highly sensitive in cases in which
individual nuclei contain a high copy number of the target DNA, as is likely to occur in most
active infections, the method of ISH often fails to detect cases in which subgenomic fragments
of the viral DNA have been incorporated into the host genome and the infection is nonpro‐
ductive of intact viral particles. So when there is low viral DNA amount, it leads to low
sensitivity [71, 72]
7.5. Southern blot and dot blot hybridization
Southern Blot classifies and identifies new viral types. It is a labor-intensive process that
requires well trained skills and depends on a new generation of equipments. This technique
requires the total length of a DNA molecule, and offers additional information about viral
integration and subtype [70].
Dot blot is a simplified southern blot, requiring less sophisticated facilities, but it is rarely
performed because of its low sensitivity. It is often used as detection kits available on the
market [70].
7.6. Target amplification
The classic example of target amplification is PCR. This is the best subtype detection method
due to the high sensitivity [9]. It is commonly used as diagnostic tool for HPV DNA epide‐
miological investigation, but because of the high cost this method cannot be used in a routine
clinical practice. PCR has a high sensitivity and it is very effective for both malignant and pre
malignant lesions identification, and material can be collected with oral swab or wash [7, 9].
7.7. Hybrid Capture technology (HC)
Using signal amplification with microplate chemiluminescent detection, this method identifies
nucleic acid due to its high sensitivity [9]. HC is a very important tool to detect high risk HPV,
and the method has identified HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 types [9]. This
technique is able to identify 5000 viral copies per sample [73].
7.8. Probe amplification
Probe  amplification  methods  differ  from  target  amplification  in  that  the  amplification
products contain a sequence only present in the initial probes. It is used currently as an
important diagnostic application, the detection of high-risk genotypes of human papillo‐
ma viruses (HPV) [74].
7.9. Education and vaccine prophylaxis
One simple and effective prophylactic measure is patient education. It must be clear to patients
that even after treatment the virus remains on the oral mucosa, so it is imperative to maintain
good oral hygiene, condom use in all sexual relations and refrain from promiscuous sexual
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behavior. Clinical examinations have to be done periodically and smoking and chronic
alcoholism must be abolished.
It is crucial that the population in general be informed about HPV prevention as a control
strategy and early diagnosis promotion. Raising awareness of HPV through education is
essential to develop population perception about risk factors, mainly those related to sexual
activity[18]. It is also important to discourage early sexual initiation [69].
In view of the increasing figures of cervix cancer, the US Food and Drugs Administration (FDA)
approved in 2006 a vaccine against HPV [75]. There is a bivalent vaccine that contains L1
HPV-16/18 protein which generates a huge number of genotype specific antibody [75]. For
HPV 16/18 vaccine efficiency is round 96% on cervix cancer [69]. There is also a tetravalent
vaccine that works in the same way as the bivalent, but provides further immunity enclosing
HPV types 6, 11, 16, 18 [75]. Both of them use virus- like particles in their composition [9].
The vaccine(s) stimulates humoral response, but it also stimulates B cell immune memory
response, which persists for five years [69]. After a 5 years follow up, it has demonstrated 100%
of efficacy on persistent infection prevention [8].
As HPV’s physiopathology is very similar on the affected sites, whether they are the skin,
cervix, penile, anus or oral mucosa, there is no reason to doubt that the vaccine which works
well on the cervix would also prove effective for the prevention of oral mucosa lesions [75].
As HPV-16 seems to be an important risk factor for the progress of malignant lesions (because
it is found in most OSCCs), it might be possible that the vaccine would prevent or even treat
them [8].
HPV vaccine seems to be less effective on women who have already been exposed to the virus,
hence the public health focus on vaccinating girls before their first sexual relation to prevent
warts and more disaster lesions in the future [8, 9]. Some countries have promoted vaccination
for any females from 9 to 26 years who have never had sexual experience before [76]. Other
countries promote vaccination for females up to 45 years old [77]. Vaccines for men aged 11
up to 26 years old in order to prevent genital warts and anal cancer was approved in 2011 by
the US Advisory Committee on Immunization Practices [78].
HPV is as frequent in men as in women; however, it is often asymptomatic in males, what
makes them a HPV reservoir to cervix and non- cervical lesions in females, transmitted mainly
by sexual activity [69]. Current studies have been done in order to further assess the natural
history of the HPV infection in men [79, 80].
A therapeutic vaccine is under study, one which could be used as adjuvant on surgery or
radiotherapy, to clean up microscopic waste of the lesion, thus generating immune response.
In view of the potential risks of HPV and the potential benefits of the vaccine (some not yet
fully established) some researchers favor the extended use of the vaccine to all age groups of
both sexes, regardless of previous sexual practice, as a form to interrupt the transmission cycle
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integration and subtype [70].
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performed because of its low sensitivity. It is often used as detection kits available on the
market [70].
7.6. Target amplification
The classic example of target amplification is PCR. This is the best subtype detection method
due to the high sensitivity [9]. It is commonly used as diagnostic tool for HPV DNA epide‐
miological investigation, but because of the high cost this method cannot be used in a routine
clinical practice. PCR has a high sensitivity and it is very effective for both malignant and pre
malignant lesions identification, and material can be collected with oral swab or wash [7, 9].
7.7. Hybrid Capture technology (HC)
Using signal amplification with microplate chemiluminescent detection, this method identifies
nucleic acid due to its high sensitivity [9]. HC is a very important tool to detect high risk HPV,
and the method has identified HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 types [9]. This
technique is able to identify 5000 viral copies per sample [73].
7.8. Probe amplification
Probe  amplification  methods  differ  from  target  amplification  in  that  the  amplification
products contain a sequence only present in the initial probes. It is used currently as an
important diagnostic application, the detection of high-risk genotypes of human papillo‐
ma viruses (HPV) [74].
7.9. Education and vaccine prophylaxis
One simple and effective prophylactic measure is patient education. It must be clear to patients
that even after treatment the virus remains on the oral mucosa, so it is imperative to maintain
good oral hygiene, condom use in all sexual relations and refrain from promiscuous sexual
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behavior. Clinical examinations have to be done periodically and smoking and chronic
alcoholism must be abolished.
It is crucial that the population in general be informed about HPV prevention as a control
strategy and early diagnosis promotion. Raising awareness of HPV through education is
essential to develop population perception about risk factors, mainly those related to sexual
activity[18]. It is also important to discourage early sexual initiation [69].
In view of the increasing figures of cervix cancer, the US Food and Drugs Administration (FDA)
approved in 2006 a vaccine against HPV [75]. There is a bivalent vaccine that contains L1
HPV-16/18 protein which generates a huge number of genotype specific antibody [75]. For
HPV 16/18 vaccine efficiency is round 96% on cervix cancer [69]. There is also a tetravalent
vaccine that works in the same way as the bivalent, but provides further immunity enclosing
HPV types 6, 11, 16, 18 [75]. Both of them use virus- like particles in their composition [9].
The vaccine(s) stimulates humoral response, but it also stimulates B cell immune memory
response, which persists for five years [69]. After a 5 years follow up, it has demonstrated 100%
of efficacy on persistent infection prevention [8].
As HPV’s physiopathology is very similar on the affected sites, whether they are the skin,
cervix, penile, anus or oral mucosa, there is no reason to doubt that the vaccine which works
well on the cervix would also prove effective for the prevention of oral mucosa lesions [75].
As HPV-16 seems to be an important risk factor for the progress of malignant lesions (because
it is found in most OSCCs), it might be possible that the vaccine would prevent or even treat
them [8].
HPV vaccine seems to be less effective on women who have already been exposed to the virus,
hence the public health focus on vaccinating girls before their first sexual relation to prevent
warts and more disaster lesions in the future [8, 9]. Some countries have promoted vaccination
for any females from 9 to 26 years who have never had sexual experience before [76]. Other
countries promote vaccination for females up to 45 years old [77]. Vaccines for men aged 11
up to 26 years old in order to prevent genital warts and anal cancer was approved in 2011 by
the US Advisory Committee on Immunization Practices [78].
HPV is as frequent in men as in women; however, it is often asymptomatic in males, what
makes them a HPV reservoir to cervix and non- cervical lesions in females, transmitted mainly
by sexual activity [69]. Current studies have been done in order to further assess the natural
history of the HPV infection in men [79, 80].
A therapeutic vaccine is under study, one which could be used as adjuvant on surgery or
radiotherapy, to clean up microscopic waste of the lesion, thus generating immune response.
In view of the potential risks of HPV and the potential benefits of the vaccine (some not yet
fully established) some researchers favor the extended use of the vaccine to all age groups of
both sexes, regardless of previous sexual practice, as a form to interrupt the transmission cycle
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and as a preventive strategy in controlling and avoiding the risks posed by HPV, including
various types of cancer in different locations in the human body.
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1. Introduction
In 1941, the Magic Bullet Penicillin was first used clinically in an Oxfordshire constable,
Albert Alexander, but within one year Rammelkamp reported the identification of isolates
of Stphylococcus aureus, resistant to this miracle drug [1]. Within a short span of 70 years,
from discovery of Penicillin to Tigecycline, some hospital strains have developed which are
resistant to almost all available antimicrobials and the mankind is busy in writing obitu‐
ary for antimicrobials [2].
Infact, the rising trend of developing resistance to multiple antibiotics in microbes, leads to
therapeutic failure. Presently, antimicrobial resistance (AMR) is a major threat to patient care
and disease control throughout the world.
The World Health Day theme on 7th April 2011 was ‘Antimicrobial resistance and its global
spread’. World Health Organisation has raised the issue in 2011 that “Combat drug Resistance
- No action today, No cure tomorrow” [3]. Not only the Gram positive bacteria like Methicillin
Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE) etc. even the
several Gram negative bacteria of Enterobacteriaceae family e.g. E.coli, Klebsiella pneumoniae,
Enterobacter sp. etc, and Pseudomonas aeruginosa, Acinetobacter baumani, Burkholderia species etc.
also develop resistance to most of the antibiotics now a days.
Actually, the pace in which bacteria develop resistance is much higher than the rate of
development of newer antimicrobials. The antibiotic resistance is mainly developed due to
inappropriate and irrational use of antibiotics. In 2011, two new terms were coined i.e.
multidrug resistant (MDR) and Extreme drug resistant (XDR) organisms. MDR is defined as
non-susceptibility to one or more antibiotics in three or more antibiotic classes and XDR is
defined as non-susceptibility to all potentially effective antimicrobials respectively [4]. β –
lactamases are the important mechanism of drug resistance among the Gram negative bacteria.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
In 1941, the Magic Bullet Penicillin was first used clinically in an Oxfordshire constable,
Albert Alexander, but within one year Rammelkamp reported the identification of isolates
of Stphylococcus aureus, resistant to this miracle drug [1]. Within a short span of 70 years,
from discovery of Penicillin to Tigecycline, some hospital strains have developed which are
resistant to almost all available antimicrobials and the mankind is busy in writing obitu‐
ary for antimicrobials [2].
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and disease control throughout the world.
The World Health Day theme on 7th April 2011 was ‘Antimicrobial resistance and its global
spread’. World Health Organisation has raised the issue in 2011 that “Combat drug Resistance
- No action today, No cure tomorrow” [3]. Not only the Gram positive bacteria like Methicillin
Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE) etc. even the
several Gram negative bacteria of Enterobacteriaceae family e.g. E.coli, Klebsiella pneumoniae,
Enterobacter sp. etc, and Pseudomonas aeruginosa, Acinetobacter baumani, Burkholderia species etc.
also develop resistance to most of the antibiotics now a days.
Actually, the pace in which bacteria develop resistance is much higher than the rate of
development of newer antimicrobials. The antibiotic resistance is mainly developed due to
inappropriate and irrational use of antibiotics. In 2011, two new terms were coined i.e.
multidrug resistant (MDR) and Extreme drug resistant (XDR) organisms. MDR is defined as
non-susceptibility to one or more antibiotics in three or more antibiotic classes and XDR is
defined as non-susceptibility to all potentially effective antimicrobials respectively [4]. β –
lactamases are the important mechanism of drug resistance among the Gram negative bacteria.
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Though E.coli is a commensal of human or animal intestine, E.coli is the most commonly
isolated bacterial species in clinical laboratories and is incriminated in infectious diseases
involving every human tissue and organ system [5]. Theodare Escherich, a German pediatri‐
tian identified Escherichia coli in 1885 and named it ‘Bacterium coli commune’ [6]. He also
established the pathogenic role of E.coli through his studies. The nomenclature ‘Bacterium
coli’ was widely used until 1919 when Castellani and Chalmers described the genus Escherichia
[7]. The type species is Escherichia coli. Some species like E.fergusonii, E.hermanii and E.vulne‐
ris are considered opportunistic pathogens and are associated with wound infection in humans
[8]. Escherichia albertii, the sixth species associated with cases of diarrhoea in children of
Bangladesh, has been proposed by Huys et al in 2003 [9].
About 80% cases of urinary tract infection are due to E.coli [8]. It is commonly involved in Gram
negative sepsis and endotoxic shock. E.coli can cause diarrhoea, wound infections, pneumonia
in hospitalized patients and meningitis in neonates.
E.coli is the organism that is most widely studied in its various aspects. E.coli is the model
organism for studies on cell structure, growth and metabolism. It is considered to be good
vehicle for the cloning of genes from prokaryotic and eukaryotic cells and for expression of
gene products [8].
E.coli is susceptible to 97% ethylene trioxide (ETO) and 95% Hydrochlorofluorocarbon-ETO
(HCFC-ETO) respectively [10]. Chlorine 1 ppm is capable of eliminating approximately 4
log10 of E.coli O157:H7 within a minute [11]. E.coli strains causing intestinal and extra intestinal
infections, exhibits many virulence factors such as: Adhesins, O antigens, Hemolysin, Sidero‐
phore production / Iron sequestration / Aerobactin production, Cell surface hydrophobicity,
Outer membrane proteins e.g. Porins etc. Haemagglutinin, Verotoxin, Cytotoxic necrotizing
factor (CNF), Enterotoxin, Colicins, Gelatinase production, Serum resistance are other major
virulence factors of E.coli. Complete serotyping of E.coli is based on three antigen detection as
O, K & H i.e. O:K:H. If fimbrial virulence factor is present then serotype should be expressed
in terms of O:K:H:F.
A. E.coli — Role as a pathogen
They are classified into two types [12] – (a) Enterovirulent E.coli, (b) Uropathogenic E.coli
a. ENTEROVIRULENTE.coli: Adherence is one of the most important virulence mecha‐
nisms of enterovirulent E.coli.
Enterovirulent E.coli strains are classified into
Enteropathogenic E.coli (EPEC), Enterotoxigenic E.coli (ETEC), Enteroinvasive E.coli (EIEC),
Verocytotoxin – producing E.coli (VTEC), Enteroaggregative E.coli (EAEC), Diffusely adherent
E.coli (DAEC) etc.
b. UROPATHOGENICE.Coli (UPEC)
E.coli  is  the  predominant  uropathogen isolated from acute  community  acquired urinary
tract infections and is responsible for 85% of asymptomatic bacteriuria and more than 60%
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of recurrent cystitis [13]. E.coli strains involved in urinary tract infections includes O groups
1, 2, 4, 6, 7 etc.
B. Laboratory diagnosis
E.coli can be detected in the laboratory by conventional tests [5]. E.coli are Gram negative rod,
motile and on Mac Conkey’s agar form lactose fermenting nonmucoid colonies. Routine
biochemical tests done for E.coli are : Catalase test: Positive, Oxidase test: Negative, Triple
sugar iron agar test: Acid slant/Acid butt with gas, Indole test: Positive, Methyl red test:
Positive, Voges-Proskauer (VP) test: Negative, Citrate utilization test: Negative, Nitrate
reduction test: Positive, Oxidative / Fermentative test (Hugh & Leifson): Fermentative
metabolism, Lysine Decarboxylase test: Positive.
1.1. Antibiotibiotic sensitivity pattern
Intrinsic resistance is rarely seen in genus Escherichia. Susceptibility of individual strain to
different antimicrobials varies greatly, thus antibiogram is used as an epidemiological marker.
This resistance pattern is plasmid mediated. E.coli shows transferable resistance to one or
multiple drugs [14]. Recently E.coli isolated from intestinal as well as extraintestinal specimens
has become resistant to most of the routinely used antibiotics.
A. Beta - lactamases
Beta lactamases are enzymes produced by wide range of Gram negative and Gram positive
bacteria. This enzyme is responsible for resistance to β-lactam antibiotics like Penicillins,
Cephalosporins, Cephamycins and Carbapenems. The β-lactamase enzymes break the beta-
lactam ring and thus inactivate the antibacterial properties. Abraham and Chain (1940)
discovered penicillinase, first β-lactamase to be identified in E.coli before Penicillin was
introduced for clinical use [15]. The name β-lactamase was given by Pollock in 1960 [16]. First
plasmid mediated β-lactamase was ‘‘TEM’’ named after the name of first patient Temoniera
in whom the enzyme was first detected [17].
Classification of β-Lactamases can be done by -
a. Functional or Bush Jacoby Mederios classification [18]
b. Molecular or Ambler classification [19]
Ambler in 1980s classified β – lactamases into various groups and according to him, there are
three main classes as A, C and D [19]. Metallobetalactamases belong to class B which exhibits
potent hydrolyzing activity not only against Carbapenems but also to other β – lactam
antibiotics. E.coli is one of those Gram negative bacteria that has potential to develop all the
major classes of β – lactamases including Metallobetalactamases.
Determination of β-lactamase production could be done by acidometric method, iodometric
method and Chromogenic cephalosporin method using nitrocephin [20].
B. Extended spectrum beta – lactamase (ESBL)
Extended spectrum beta – lactamase (ESBL) producing strains are emerging pathogens causing
Health care associated infections (HAI) and pose great therapeutic challenge in recent years.
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Though E.coli is a commensal of human or animal intestine, E.coli is the most commonly
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in terms of O:K:H:F.
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nisms of enterovirulent E.coli.
Enterovirulent E.coli strains are classified into
Enteropathogenic E.coli (EPEC), Enterotoxigenic E.coli (ETEC), Enteroinvasive E.coli (EIEC),
Verocytotoxin – producing E.coli (VTEC), Enteroaggregative E.coli (EAEC), Diffusely adherent
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E.coli  is  the  predominant  uropathogen isolated from acute  community  acquired urinary
tract infections and is responsible for 85% of asymptomatic bacteriuria and more than 60%
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Positive, Voges-Proskauer (VP) test: Negative, Citrate utilization test: Negative, Nitrate
reduction test: Positive, Oxidative / Fermentative test (Hugh & Leifson): Fermentative
metabolism, Lysine Decarboxylase test: Positive.
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Intrinsic resistance is rarely seen in genus Escherichia. Susceptibility of individual strain to
different antimicrobials varies greatly, thus antibiogram is used as an epidemiological marker.
This resistance pattern is plasmid mediated. E.coli shows transferable resistance to one or
multiple drugs [14]. Recently E.coli isolated from intestinal as well as extraintestinal specimens
has become resistant to most of the routinely used antibiotics.
A. Beta - lactamases
Beta lactamases are enzymes produced by wide range of Gram negative and Gram positive
bacteria. This enzyme is responsible for resistance to β-lactam antibiotics like Penicillins,
Cephalosporins, Cephamycins and Carbapenems. The β-lactamase enzymes break the beta-
lactam ring and thus inactivate the antibacterial properties. Abraham and Chain (1940)
discovered penicillinase, first β-lactamase to be identified in E.coli before Penicillin was
introduced for clinical use [15]. The name β-lactamase was given by Pollock in 1960 [16]. First
plasmid mediated β-lactamase was ‘‘TEM’’ named after the name of first patient Temoniera
in whom the enzyme was first detected [17].
Classification of β-Lactamases can be done by -
a. Functional or Bush Jacoby Mederios classification [18]
b. Molecular or Ambler classification [19]
Ambler in 1980s classified β – lactamases into various groups and according to him, there are
three main classes as A, C and D [19]. Metallobetalactamases belong to class B which exhibits
potent hydrolyzing activity not only against Carbapenems but also to other β – lactam
antibiotics. E.coli is one of those Gram negative bacteria that has potential to develop all the
major classes of β – lactamases including Metallobetalactamases.
Determination of β-lactamase production could be done by acidometric method, iodometric
method and Chromogenic cephalosporin method using nitrocephin [20].
B. Extended spectrum beta – lactamase (ESBL)
Extended spectrum beta – lactamase (ESBL) producing strains are emerging pathogens causing
Health care associated infections (HAI) and pose great therapeutic challenge in recent years.
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ESBLs were first detected in Klebsiella pneumoniae in 1983 [21, 22]. ESBL are classified under
molecular AMBLer class A penicillinase having serine residue at their active site. ESBLs are
responsible for resistance to one or more β-lactam antibiotics including third generation
cephalosporins. Typically ESBLs are derived from genes for TEM-1, TEM-2 or SHV-1 by
mutations that alter the amino acid sequence around the active site of β-lactamases [23,24].
ESBLs are inhibited by β-lactam inhibitors like Clavulanic acid, Sulbactam and Tazobactam.
ESBLs are produced by Enterobacteriaceae family, Pseudomonas aeruginosa, Acinetobacter
species etc.
Detection of Extended Spectrum β-lactamase (ESBL) production:
The ESBL in E.coli is detected by two approaches: 1.Screening tests and 2.Confirmatory tests.
Screening test detect reduced susceptibility to indicator drugs. According to Clinical Labora‐
tory Standard Institute (CLSI) guidelines indicator drugs used for E.coli & Klebsiella spp. are
Cefotaxime, Ceftazidime, Ceftriaxone or Aztreonam [25]. Screening tests are not specific
because mechanism other than ESBLs may also give positive results. Therefore, positive
screening test should be followed by confirmatory tests.
Different confirmatory tests include Double disk approximation test, [26,27]. Comparison of
Minimum inhibitory concentratin (MIC) or inhibitory zone around disk in presence or absence
of β-lactamase inhibitor [28], Vitek ESBL test [29], Etest [30], three-dimentional test [31] etc.
For identification of specific ESBL different molecular detection methods can be applied like
DNA probes, PCR with oligonucleotide primers oligotyping, PCR followed by restriction
fragment length polymorphism analysis, ligase chain reaction and nucleotide sequencing etc
[32]. Commonly primers used for detecting bla genes are [33]:
CTX Forward – CGCTTTGCGATGTGCAG
Reverse - ACCGCGATATCGTTGGT
These techniques are available only in research centers and are beyond the scope of routine
Clinical Microbiology Laboratories in India considering the presence of too many different
types of ESBLs and the high cost.
C. Amp C beta-lactamase [34]
Amp C β-lactamases were first reported in 1988. Amp C β-lactamases are found either on
chromosome (inducible) or on plasmid (non-inducible). Amp C β-lactamase producing
bacteria show resistance to most of Cephalosporins including Cephamycin (Cefoxitin,
Cefotetan) except Carbapenems. But they also hydrolyze Penicillins and Aztreonem. These are
not inhibited by beta-lactam inhibitors such as Clavulanic acid, Tazobactam and Sulbactam.
Detection of AMPC β-Lactamase production: Presently, all plasmid mediated Amp C β-
lactamases have similar substrate profile to chromosomal Amp C β-lactamases. But the only
difference is chromosomal Amp C β -lactamases are inducile where as plasmid mediated Amp
C β –lactamases are uninducible [35]. Amp C β-lactamase producing strains could be detected
by disc antagonism test [36], modified three dimensional test (MTDT) [37], Amp C disc test
[38], double disk synergy test and disc potentiation test using 3-amino-phenyl-boronic acid
(APB) etc [39].
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D. Carbapenemases
These include β – lactamases which cause Carbapenem hydrolysis, with elevated Carbapenem
MICs and they belonged to molecular classes A, B and D. Molecular classes A, C and D include
the β – lactamases with serine at their active site, whereas class B β – lactamases are all
metalloenzymes which require Zn++ for their activation [40].
Molecular class A carbapenemase – Class A serine carbapenemases belong to functional
group 2f include chromosomally encoded NMC(Not Metalloenzyme Carbapenemase), IMI
(Imipenem hydrolyzing β-lactamase) and SME(Serratia marcenscens enzyme) and plasmid
mediated KPC (Klebsiella pneumoniae carbapenemase) and GES / IBC(integron borne cephalo‐
sporinase), etc [40]. All have the ability to hydrolyse Carbapenems, Cephalosporins, Penicillins
and Aztreonem and all are inhibited by Clavulanic acid and Tazobactam. The chromosomal
class A carbapenemase are infrequently found and can be induced by Imipenem and Cefoxitin.
The KPC (Klebsiella pneumoniae carbapenemase) producing strains are found in Klebsiella
pneumoniae, Enterobacter species, Salmonella species and other Enterobacteriaceae [41,42].
Class D Serine carbapenemases - The OXA (Oxacillin hydrolysing) β-lactamase with carba‐
penemase activity was detected by Patow et al in 1993 and the enzyme was purified from
Acinetobacter baumani [40]. They have been also found in Enterobacteriaceae and P.aeruginosa
and were described as penicillinase capable of hydrolyzing Oxacillin and Cloxacillin [43,44].
They are not inhibited by Clavulanic acid and EDTA and were designated as ARI-1 (Acineto‐
bacter Resistant to Imipenem) and reside on large plasmid.
Metallobetalactamases (MBL)
They belong to molecular class B β – lactamases, requiring one or more divalent cations
(Zn++) for their activation [45] and have 3 characteristics [2] –
1. Hydrolyze carbapenems
2. Resistant to clinically used β – lactamase inhibitors and
3. Inhibited by EDTA, a metal ion chelator.
The first MBL detected was chromosomally encoded and was detected in Bacillus cereus [46].
They possess a high level of resistance to all Carbapenems, Penicillins, Cephamycins, Cepha‐
losporins and beta-lactamase inhibitor combinations.
Classification of MBLs
On the basis of Imipenem and other β-lactam hydrolysis, MBLs are classified into different
subgroups as [47] –
Subgroup3a- possess broad spectrum activity; Subgroup3b – preferential avidity for carbape‐
nem; Subgroup 3c – hydrolyze carbapenems poorly compared to other β-lactam substrate.
At molecular level MBLs are classified into [48] –
Class B1 – possess key Zn co-ordinating residues of three histidines and one cystein eg. IMP,
VIM, GIM and SPM – 1,
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ESBLs were first detected in Klebsiella pneumoniae in 1983 [21, 22]. ESBL are classified under
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cephalosporins. Typically ESBLs are derived from genes for TEM-1, TEM-2 or SHV-1 by
mutations that alter the amino acid sequence around the active site of β-lactamases [23,24].
ESBLs are inhibited by β-lactam inhibitors like Clavulanic acid, Sulbactam and Tazobactam.
ESBLs are produced by Enterobacteriaceae family, Pseudomonas aeruginosa, Acinetobacter
species etc.
Detection of Extended Spectrum β-lactamase (ESBL) production:
The ESBL in E.coli is detected by two approaches: 1.Screening tests and 2.Confirmatory tests.
Screening test detect reduced susceptibility to indicator drugs. According to Clinical Labora‐
tory Standard Institute (CLSI) guidelines indicator drugs used for E.coli & Klebsiella spp. are
Cefotaxime, Ceftazidime, Ceftriaxone or Aztreonam [25]. Screening tests are not specific
because mechanism other than ESBLs may also give positive results. Therefore, positive
screening test should be followed by confirmatory tests.
Different confirmatory tests include Double disk approximation test, [26,27]. Comparison of
Minimum inhibitory concentratin (MIC) or inhibitory zone around disk in presence or absence
of β-lactamase inhibitor [28], Vitek ESBL test [29], Etest [30], three-dimentional test [31] etc.
For identification of specific ESBL different molecular detection methods can be applied like
DNA probes, PCR with oligonucleotide primers oligotyping, PCR followed by restriction
fragment length polymorphism analysis, ligase chain reaction and nucleotide sequencing etc
[32]. Commonly primers used for detecting bla genes are [33]:
CTX Forward – CGCTTTGCGATGTGCAG
Reverse - ACCGCGATATCGTTGGT
These techniques are available only in research centers and are beyond the scope of routine
Clinical Microbiology Laboratories in India considering the presence of too many different
types of ESBLs and the high cost.
C. Amp C beta-lactamase [34]
Amp C β-lactamases were first reported in 1988. Amp C β-lactamases are found either on
chromosome (inducible) or on plasmid (non-inducible). Amp C β-lactamase producing
bacteria show resistance to most of Cephalosporins including Cephamycin (Cefoxitin,
Cefotetan) except Carbapenems. But they also hydrolyze Penicillins and Aztreonem. These are
not inhibited by beta-lactam inhibitors such as Clavulanic acid, Tazobactam and Sulbactam.
Detection of AMPC β-Lactamase production: Presently, all plasmid mediated Amp C β-
lactamases have similar substrate profile to chromosomal Amp C β-lactamases. But the only
difference is chromosomal Amp C β -lactamases are inducile where as plasmid mediated Amp
C β –lactamases are uninducible [35]. Amp C β-lactamase producing strains could be detected
by disc antagonism test [36], modified three dimensional test (MTDT) [37], Amp C disc test
[38], double disk synergy test and disc potentiation test using 3-amino-phenyl-boronic acid
(APB) etc [39].
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mediated KPC (Klebsiella pneumoniae carbapenemase) and GES / IBC(integron borne cephalo‐
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class A carbapenemase are infrequently found and can be induced by Imipenem and Cefoxitin.
The KPC (Klebsiella pneumoniae carbapenemase) producing strains are found in Klebsiella
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Class D Serine carbapenemases - The OXA (Oxacillin hydrolysing) β-lactamase with carba‐
penemase activity was detected by Patow et al in 1993 and the enzyme was purified from
Acinetobacter baumani [40]. They have been also found in Enterobacteriaceae and P.aeruginosa
and were described as penicillinase capable of hydrolyzing Oxacillin and Cloxacillin [43,44].
They are not inhibited by Clavulanic acid and EDTA and were designated as ARI-1 (Acineto‐
bacter Resistant to Imipenem) and reside on large plasmid.
Metallobetalactamases (MBL)
They belong to molecular class B β – lactamases, requiring one or more divalent cations
(Zn++) for their activation [45] and have 3 characteristics [2] –
1. Hydrolyze carbapenems
2. Resistant to clinically used β – lactamase inhibitors and
3. Inhibited by EDTA, a metal ion chelator.
The first MBL detected was chromosomally encoded and was detected in Bacillus cereus [46].
They possess a high level of resistance to all Carbapenems, Penicillins, Cephamycins, Cepha‐
losporins and beta-lactamase inhibitor combinations.
Classification of MBLs
On the basis of Imipenem and other β-lactam hydrolysis, MBLs are classified into different
subgroups as [47] –
Subgroup3a- possess broad spectrum activity; Subgroup3b – preferential avidity for carbape‐
nem; Subgroup 3c – hydrolyze carbapenems poorly compared to other β-lactam substrate.
At molecular level MBLs are classified into [48] –
Class B1 – possess key Zn co-ordinating residues of three histidines and one cystein eg. IMP,
VIM, GIM and SPM – 1,
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Class B2 – possess asparagine instead of histidine at first position of principal Zn binding motif,
NXHXD. e.g. Aeromonas species and Serratia fonticola enzyme SFH – 1.
Class B3 – MBL L1 unique among all β-lactamases in being functionally represented as a
tetramer.
The numbering scheme has been recently updated to accommodate newly discovered MBLs.
MBLs are inhibited by EDTA (Ethylene diamino tetraacetic acid), 2 Mercaptoethanol, 5-
Mercaptoacetic acid, 2 Mercapto propionic acid, Copper Chloride and Ferric Chloride. MBLs
are classified mainly into two types – Chromosomally encoded and Plasmid encoded or
Acquired or Transmissible type. Usually metallobetalactamase producing strains are suscep‐
tible to Colistin or Polymyxin B. MBLs do not hydrolyze aztreonam very well, which charac‐
teristic is different than ESBLs or Class A β-lactamases [48].
The acquired MBLs are further classified into different types depending on their place of origin
as VIM (Italy or Greece), SPM (Brazil), GIM (Germany), SIM (Korea), DIM (Dutch), NDM/PCM
(New Delhi metallobetalactamases/Plasmid coded metallobetalactamases).
NDM – 1: NDM – 1 was named after New Delhi, capital of India as NDM – 1 and was first
described by Young et al in December 2009 in an individual who acquired infection in a
Hospital in India due to Carbapenam resistant Klebsiella pneumoniae strain [49].
In March 2010, researchers from Mumbai found that most of Carbapenam resistant bacteria
carried blaNDM–1 gene. The gene is carried on plasmids and is readily transferred between
different strains of bacteria by horizontal gene transfer. All these strains were resistant to most
of routinely used antibiotics like Aminoglycosides, β-lactams, Quinolones but sensitive to
Tigecycline and Colistin [50]. Recently, Espinal et al identified a new variant of NDM-1 in
Acinetobacter baumannii and designated it as NDM-2. They reported that, the clonal dissemi‐
nation of a NDM-2 producing A. baumannii was isolated in an Israeli rehabilitation ward
[51]. Recently, a new variant of the New Delhi metallo-enzyme (NDM) carbapenemase,
NDM-4 and NDM-5, was identified in E.coli from two patients both of them had a history of
hospitalization in India [52,53].
Detection of Metallo β-lactamase production
Carbapenems often used as an antibiotic of last resort for treating serious infections caused by
multi-drug resistant (MDR) organism. Reduced susceptibility to any Carbapenem can be used
as a screen for carbapenemases. Positive screening tests are to be followed by a confirmatory
test for MBL production.
Although a variety of phenotypic methods have been proposed for the detection of carbape‐
nemases, none have been recommended by CLSI. The classical Hodge [54], Modified Hodge
test (MHT) [55] are economical approach for detection and confirmation of carbapenemase
activity and Re – Modified Hodge test [56] for detection of MBL. However, the first two tests
cannot differentiate between a class A carbapenemase and MBL, making a further confirma‐
tory test necessary. Imipenem is more sensitive but less specific Carbapenem for this test
allowing detection of even OXA carbapenemases.
Trends in Infectious Diseases52
MBL detection tests involving inhibitors such as ethylene diamine tetraacetic acids (EDTA)
and 2-Mercaptopropionic acids (2-MPA) have been recommended by various workers [57].
Tris/EDTA disks can also be used in combination with a Carbapenem disk to detect Carbape‐
nem - hydrolyzing enzymes and to differentiate between class A enzymes and MBLs. MBLs
are inhibited by the Tris/EDTA disk. The inhibition of MBL can be enhanced by the addition
of chelators. Double disk synergy test (DDST) [55] and Disk potentiation tests [58] are based
on this principle. For detection of MBL many other methods used are MBL E-test using
imipenem/imipenem-EDTA [59], reduction of MIC in presence of EDTA and polymerase chain
reaction (PCR) [60].
Commonly primers used for detecting Class B metalloenzyme genes are [40]:
VIM-1 Forward – TTATGGAGCAGCAACCGATGT
Reverse - CAAAAGTCCCGCTCCAACGA
PCR is specific for gene family IMP, VIM, etc. and hence, many other specific primers can be
used for different MBL genes. The main disadvantage of PCR is that it requires tailor-made
DNA primers and cannot differentiate between variants and may not detect new variants.
E. Detection of Klebsiella pneumoniae carbapenamases (KPCs) [61]
KPCs can be mainly detected by Combined disk method using Imipenem and Imipenem with
Phenyl boronic acid, Molecular methods like PCR etc.
Recently, Carbapenem Resistant Enterobacteriaceae (CRE) pose a real threat to Medical
fraternity as the increased frequency with which Enterobacteriaceae cause infection and the
mortality associated with infection caused by CRE. Most of the studies reported newer β-
lactamases including MBL production in nonfermenters like Pseudomonas aeruginosa, Acineto‐
bacter species etc. There are very few studies that report MBL production in Enterobacteriaceae
[19]. Hence, we have conducted the study to detect newer β - lactamases producing E.coli
strains by phenotypic methods, isolated from different clinical specimens.
2. Material & methods
A total Number of 450 E.coli strains isolated from different clinical specimens like urine, stool,
blood, pus etc. were studied. The strains were characterized as E.coli according to conventional
identification tests [5]. E.coli ATCC 25922 was used as positive control for all the conventional
tests. Few recent tests were also included to identify E.coli which could reduce the number of
biochemical tests and there by cost also e.g. Motility- Indole- Lysine (MIL) medium [62],
Methylumbelliferyl- β-D- Glucuronide(MUG) MacConkey’s medium [63]. All the E.coli strains
isolated from urine samples were subcultured on Hi chrome UTI agar for direct detection of
E.coli.
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Class B2 – possess asparagine instead of histidine at first position of principal Zn binding motif,
NXHXD. e.g. Aeromonas species and Serratia fonticola enzyme SFH – 1.
Class B3 – MBL L1 unique among all β-lactamases in being functionally represented as a
tetramer.
The numbering scheme has been recently updated to accommodate newly discovered MBLs.
MBLs are inhibited by EDTA (Ethylene diamino tetraacetic acid), 2 Mercaptoethanol, 5-
Mercaptoacetic acid, 2 Mercapto propionic acid, Copper Chloride and Ferric Chloride. MBLs
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(New Delhi metallobetalactamases/Plasmid coded metallobetalactamases).
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Acinetobacter baumannii and designated it as NDM-2. They reported that, the clonal dissemi‐
nation of a NDM-2 producing A. baumannii was isolated in an Israeli rehabilitation ward
[51]. Recently, a new variant of the New Delhi metallo-enzyme (NDM) carbapenemase,
NDM-4 and NDM-5, was identified in E.coli from two patients both of them had a history of
hospitalization in India [52,53].
Detection of Metallo β-lactamase production
Carbapenems often used as an antibiotic of last resort for treating serious infections caused by
multi-drug resistant (MDR) organism. Reduced susceptibility to any Carbapenem can be used
as a screen for carbapenemases. Positive screening tests are to be followed by a confirmatory
test for MBL production.
Although a variety of phenotypic methods have been proposed for the detection of carbape‐
nemases, none have been recommended by CLSI. The classical Hodge [54], Modified Hodge
test (MHT) [55] are economical approach for detection and confirmation of carbapenemase
activity and Re – Modified Hodge test [56] for detection of MBL. However, the first two tests
cannot differentiate between a class A carbapenemase and MBL, making a further confirma‐
tory test necessary. Imipenem is more sensitive but less specific Carbapenem for this test
allowing detection of even OXA carbapenemases.
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MBL detection tests involving inhibitors such as ethylene diamine tetraacetic acids (EDTA)
and 2-Mercaptopropionic acids (2-MPA) have been recommended by various workers [57].
Tris/EDTA disks can also be used in combination with a Carbapenem disk to detect Carbape‐
nem - hydrolyzing enzymes and to differentiate between class A enzymes and MBLs. MBLs
are inhibited by the Tris/EDTA disk. The inhibition of MBL can be enhanced by the addition
of chelators. Double disk synergy test (DDST) [55] and Disk potentiation tests [58] are based
on this principle. For detection of MBL many other methods used are MBL E-test using
imipenem/imipenem-EDTA [59], reduction of MIC in presence of EDTA and polymerase chain
reaction (PCR) [60].
Commonly primers used for detecting Class B metalloenzyme genes are [40]:
VIM-1 Forward – TTATGGAGCAGCAACCGATGT
Reverse - CAAAAGTCCCGCTCCAACGA
PCR is specific for gene family IMP, VIM, etc. and hence, many other specific primers can be
used for different MBL genes. The main disadvantage of PCR is that it requires tailor-made
DNA primers and cannot differentiate between variants and may not detect new variants.
E. Detection of Klebsiella pneumoniae carbapenamases (KPCs) [61]
KPCs can be mainly detected by Combined disk method using Imipenem and Imipenem with
Phenyl boronic acid, Molecular methods like PCR etc.
Recently, Carbapenem Resistant Enterobacteriaceae (CRE) pose a real threat to Medical
fraternity as the increased frequency with which Enterobacteriaceae cause infection and the
mortality associated with infection caused by CRE. Most of the studies reported newer β-
lactamases including MBL production in nonfermenters like Pseudomonas aeruginosa, Acineto‐
bacter species etc. There are very few studies that report MBL production in Enterobacteriaceae
[19]. Hence, we have conducted the study to detect newer β - lactamases producing E.coli
strains by phenotypic methods, isolated from different clinical specimens.
2. Material & methods
A total Number of 450 E.coli strains isolated from different clinical specimens like urine, stool,
blood, pus etc. were studied. The strains were characterized as E.coli according to conventional
identification tests [5]. E.coli ATCC 25922 was used as positive control for all the conventional
tests. Few recent tests were also included to identify E.coli which could reduce the number of
biochemical tests and there by cost also e.g. Motility- Indole- Lysine (MIL) medium [62],
Methylumbelliferyl- β-D- Glucuronide(MUG) MacConkey’s medium [63]. All the E.coli strains
isolated from urine samples were subcultured on Hi chrome UTI agar for direct detection of
E.coli.
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Lysine  medium 
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2.1. Antibiotic susceptibility test
Antibiotic susceptibility test for all 450 strains of E.coli were done using Mueller Hinton(MH)
agar plate with commercially available antibiotic discs (Himedia Pvt Ltd, India) by Kirby Bauer
disc diffusion method [64] according to CLSI guidelines [65]. E.coli ATCC 25922 was used as
control.
Lawn culture of test strain (turbidity adjusted to 0.5 Mc Farland standard) was put on MH
Agar plate. The antibiotic disks were put on inoculated plate with all aseptic precaution.
Antibiotic susceptibility test was done for Aminoglycosides like Amikacin (AK-30μg),
Gentamicin (GEN-10μg), Cephalosporins like Ceftazidime (CAZ-30μg), Cefotaxime
(CTX-30μg), Fluoroquinolones like Ciprofloxacin (CIP–5μg), Monobactams like Aztreonam
(AT-30μg), Carbapenems such as Imipenem (IPM-10μg), Etrapenem (ETP-10μg) etc. For urine
sample an additional disk of Nitrofurantoin (NIT-300μg) and only for MBL producing strains,
Colistin (CL-10μg) disk were used
All 450 E.coli strains were tested for newer β-lactamases e.g. Extended Spectrum β-lactamas‐
es(ESBLs), AMPC β-lactamases Metallobetalactamases(MBLs) and Klebsiella pneumoniae
producing Carbapenemases (KPCs) [28, 30, 39, 58, 59, 61]. As Metallobetalactamases are also
found in carbapenem susceptible organisms., we have screened carbapenem sensitive strains
also for MBL production.
2.2. Detection of newer β-lactamases
2.2.1. Detection of ESBL production [28]
Combined disk method as per CLSI guideline and ESBL E-test were used for ESBL detection.
In Combined disk method, lawn cultures of test strains (turbidity adjusted to McFarland 0.5
standard) were put on MH agar plates. Ceftazidime (CAZ) 30 μg disc and Ceftazidime plus
Clavulanate (CAC) 30μg plus 10μg discs were put widely apart on that MH plate. After
overnight incubation at 370C increase in zone diameter of ≥5 mm with CAC disk as compared
to CAZ disk alone was considered positive for ESBL detection.
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In ESBL E-test, lawn culture of test strain (turbidity adjusted to McFarland 0.5 standard) was
done on a MH agar plate & ESBL E-test strip (AB Biomeriux) was placed. After overnight
incubation at 370C, MIC ratio of ceftazidime/Ceftazidime Clavulanic acid (TZ/TZL) ≥ 8 or
deformation of ellipse or phantom zone present was considered positive for ESBL production.
2.2.2. Detection of AmpC β- lactamases [39]
For, detection of Amp C β –lactamase producing strains substrate inducer combination of
Imipenem (10μg) / Ceftazidime(30 μg) disks and for confirmation disk potentiation test using
3 aminophenyl boronic acid (100 mg/ml) was used.
In Disk potentiation test, lawn culture of test strain (turbidity adjusted to McFarland 0.5
standard) was done on MH agar plate. Two ceftazidime(30μg) disks with centre to centre
distance of 30mm were placed on that MH plate. 3-aminophenylboronic acid (APB) was
dissolved in DMSO at a concentration of 100mg/ml. 10μl of this APB solution was added to
one of the ceftazidime disk. After overnight incubation at 370C, an increase in zone size of
≥5mm around the Ceftazidime - APB disc compared to Ceftazidime disc only was recorded as
a positive result for Amp C β-lactamase production.
2.2.3. Detection of both ESBL & AmpC β -lactamase producing strains [66]
As ESBL and AMPC β – lactamase can be produced by a single strain and ESBL production is
suppressed if the same strain also produces Amp C β –lactamases ,we followed the following
methods.
Lawn culture of test strain (turbidity adjusted to McFarland 0.5 standard) was done on MH
agar plate. To detect the strains producing both ESBL and AMPC β – lactamases, we used one
disk containing Ceftazidime and Clavulanic acid (CAC) and the other 02 disks containing
Ceftazidime (CAZ) only, placed widely apart. On CAC disk 10μl of 3-aminophenyl boronic
acid (3 – APB) (100mg/ml) solution was put. 3 – APB inhibit the growth of AmpC β – lactamases
and ESBL genes can be expressed whereas 10 μl of 3 – APB solution was also put on one of the
CAZ disk. The plates were incubated 370C overnight. The zone diameter of ≥ 5 mm around
CAC disk with 3 - APB compared to CAZ only was recorded as ESBL positive and increase in
zone diameter of ≥5 mm around CAZ and 3 – APB disc compared to zone diameter of CAZ
only was considered positive for AmpC β – lactamase production.
2.2.4. Detection of metallobetalactamases (MBL)
All 450 E.coli strains were screened for Carbapenemase activity by Classical Hodge test [54]
and for MBL production by Re-Modified Hodge test [56],DDST [55], DP test [58] and MBL
ETest.
Re-Modified Hodge Test (Re–MHT) [56]: All 450 E.coli strains were subjected to Re-modified
Hodge test for detection of carbapenemase activity. The broth culture of Escherichia Coli ATCC
25922 was adjusted to a turbidity of 0.5 McFarland standards and was used to put lawn culture
on MH agar plates with sterile swab. After drying, a 10μg Imipenem disc (HiMedia) was placed
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In ESBL E-test, lawn culture of test strain (turbidity adjusted to McFarland 0.5 standard) was
done on a MH agar plate & ESBL E-test strip (AB Biomeriux) was placed. After overnight
incubation at 370C, MIC ratio of ceftazidime/Ceftazidime Clavulanic acid (TZ/TZL) ≥ 8 or
deformation of ellipse or phantom zone present was considered positive for ESBL production.
2.2.2. Detection of AmpC β- lactamases [39]
For, detection of Amp C β –lactamase producing strains substrate inducer combination of
Imipenem (10μg) / Ceftazidime(30 μg) disks and for confirmation disk potentiation test using
3 aminophenyl boronic acid (100 mg/ml) was used.
In Disk potentiation test, lawn culture of test strain (turbidity adjusted to McFarland 0.5
standard) was done on MH agar plate. Two ceftazidime(30μg) disks with centre to centre
distance of 30mm were placed on that MH plate. 3-aminophenylboronic acid (APB) was
dissolved in DMSO at a concentration of 100mg/ml. 10μl of this APB solution was added to
one of the ceftazidime disk. After overnight incubation at 370C, an increase in zone size of
≥5mm around the Ceftazidime - APB disc compared to Ceftazidime disc only was recorded as
a positive result for Amp C β-lactamase production.
2.2.3. Detection of both ESBL & AmpC β -lactamase producing strains [66]
As ESBL and AMPC β – lactamase can be produced by a single strain and ESBL production is
suppressed if the same strain also produces Amp C β –lactamases ,we followed the following
methods.
Lawn culture of test strain (turbidity adjusted to McFarland 0.5 standard) was done on MH
agar plate. To detect the strains producing both ESBL and AMPC β – lactamases, we used one
disk containing Ceftazidime and Clavulanic acid (CAC) and the other 02 disks containing
Ceftazidime (CAZ) only, placed widely apart. On CAC disk 10μl of 3-aminophenyl boronic
acid (3 – APB) (100mg/ml) solution was put. 3 – APB inhibit the growth of AmpC β – lactamases
and ESBL genes can be expressed whereas 10 μl of 3 – APB solution was also put on one of the
CAZ disk. The plates were incubated 370C overnight. The zone diameter of ≥ 5 mm around
CAC disk with 3 - APB compared to CAZ only was recorded as ESBL positive and increase in
zone diameter of ≥5 mm around CAZ and 3 – APB disc compared to zone diameter of CAZ
only was considered positive for AmpC β – lactamase production.
2.2.4. Detection of metallobetalactamases (MBL)
All 450 E.coli strains were screened for Carbapenemase activity by Classical Hodge test [54]
and for MBL production by Re-Modified Hodge test [56],DDST [55], DP test [58] and MBL
ETest.
Re-Modified Hodge Test (Re–MHT) [56]: All 450 E.coli strains were subjected to Re-modified
Hodge test for detection of carbapenemase activity. The broth culture of Escherichia Coli ATCC
25922 was adjusted to a turbidity of 0.5 McFarland standards and was used to put lawn culture
on MH agar plates with sterile swab. After drying, a 10μg Imipenem disc (HiMedia) was placed
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at the centre and10 μl of 50mM zinc sulfate solution was added to Imipenem disk. Then, a test
strain of E.coli was streaked from the edge of the disk to the periphery in four different
directions. The plate was incubated overnight at 37°C. The presence of a cloverleaf shaped
zone of inhibition due to MBL production by the test strain was considered as positive Re -
Modified Hodge test (Re - MHT).
Imipenem-EDTA double disk synergy test (DDST) [55]: The IMP-EDTA double disk synergy
test was performed for detection of Metallobetalactamases. Test strains i.e. E.coli (turbidity
adjusted to 0.5 McFarland standard) were inoculated on to Mueller Hinton agar plate. After
drying, a 10μg Imipenem disk and a blank sterile filter paper disk (6mm in diameter, Whatman
filter paper no.2) were placed 10mm apart from edge to edge. 10 μl of 50mM zinc sulfate
solution was added to the 10 μg Imipenem disk. Then, 10μl of 0.5 M EDTA (Sigma, USA)
solution was applied to the blank filter paper disk. As disodium-EDTA is difficult to be
solubilised in sterile water, we had used dipotassium-EDTA which is easily soluble in sterile
water. Enhancement of the zone of inhibition towards the EDTA disk was interpreted as a
positive result.
Disk Potentiation Test (DP) [58]: The IMP-EDTA combined disk test was performed for
detection of metallobetalactamases. Test strains (turbidity adjusted to 0.5 McFarland standard )
were inoculated on to MH agar plate. Two imipenem disk (10 μg) were placed on the plate
wide apart and 10 μl of 50mM zinc sulphate solution was added to each of the imipenem disks.
Then 10μl of 0.5M EDTA solution was added to one of the disk and the plates were incubated
at 350 C for 16-18 hrs. If the increase in inhibition zone with the Imipenem and EDTA disk was
≥7 mm than the imipenem disk alone, it was considered as MBL positive.
MBL E-Test — Confirmatory test
The MBL E-test was done and interpreted using test strains and Quality control strains
according to manufacturer‘s instructions. Overnight broth culture of test strain (turbidity
adjusted to 0.5 McFarland standard) was used to inoculate MH agar plate. The MBL E-test
strip was put on that inoculated MH plate with a sterile forceps and plates were incubated at
370C for 18-20 hrs. After incubation, MIC ratio of Imipenem /Imipenem-EDTA (IP/IPI) of ≥8 or
deformations of ellipse or phantom zone indicate MBL production.
Colistin E test: All MBL producing E.coli strains were tested with Colistin E test (AB bioMer‐
ieux, Solana, Sweden). The Colistin E-test was done and interpreted using test strains and
Quality control strains according to manufacturer’s instructions.
2.2.5. Detection of Klebsiella pneumoniae carbapenemases (KPCS)
It was done by Combined disk method [61]. Lawn culture of test strain (turbidity adjusted to
0.5 Mc Farland) was put on MH agar plate and 2 Imipenem (10 μg) disks were put widely
apart. To one Imipenem disk 10 μl Phenyl boronic acid solution (400μg/disk) was put. Then
the MH agar plates were incubated at 370C overnight. After incubation, the test should be
considered positive when growth inhibitory zone around the disk containing Imipenem and
Phenyl boronic acid was ≥ 5 mm compared to zone diameter of Imipenem alone.
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2.2.6. Detection of class D enzymes
Several workers have reported that Class D enzymes i.e. OXA – 48 type are the most difficult
carbapenemase producers to be identified phenotypically [42,43]. Hence, we did not include
detection of Class D carbapenemase in our study.
3. Observation




III. OBSERVATION  
Figure 1: Incidence of MBL, ESBL & AmpC β – lactamase producing E.coli strains (n = 450) 
                                                                   
Figure 1 shows incidence of different β – lactamases e.g. MBL, ESBL, AmpC β – lactamases producing E.coli strains. Out of 450 
E.coli strains studied, 378 (84%) strains produced any of the 3 types of β – lactamases i.e. MBL, ESBL and AmpC β – 
lactamases, either alone or in combinations. Photographs of different methods used to detect newer β-lactamases phenotypically 































































Figure 1. Shows incidence of different β – lactamases e.g. MBL, ESBL, AMPC β – lactamases producing E.coli strains.
Out of 450 E.coli strains studied, 378 (84%) strains produced any of the 3 types of β – lactamases i.e. MBL, ESBL and
Amp C β –lactamases, either alone or in combinations. Photographs of different methods used to detect newer β-lac‐
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Photo 6 : Both ESBL & AmpC β- lactamase +ve 
 
Photo 7 : Classical Hodge test +ve 
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solution was added to the 10 μg Imipenem disk. Then, 10μl of 0.5 M EDTA (Sigma, USA)
solution was applied to the blank filter paper disk. As disodium-EDTA is difficult to be
solubilised in sterile water, we had used dipotassium-EDTA which is easily soluble in sterile
water. Enhancement of the zone of inhibition towards the EDTA disk was interpreted as a
positive result.
Disk Potentiation Test (DP) [58]: The IMP-EDTA combined disk test was performed for
detection of metallobetalactamases. Test strains (turbidity adjusted to 0.5 McFarland standard )
were inoculated on to MH agar plate. Two imipenem disk (10 μg) were placed on the plate
wide apart and 10 μl of 50mM zinc sulphate solution was added to each of the imipenem disks.
Then 10μl of 0.5M EDTA solution was added to one of the disk and the plates were incubated
at 350 C for 16-18 hrs. If the increase in inhibition zone with the Imipenem and EDTA disk was
≥7 mm than the imipenem disk alone, it was considered as MBL positive.
MBL E-Test — Confirmatory test
The MBL E-test was done and interpreted using test strains and Quality control strains
according to manufacturer‘s instructions. Overnight broth culture of test strain (turbidity
adjusted to 0.5 McFarland standard) was used to inoculate MH agar plate. The MBL E-test
strip was put on that inoculated MH plate with a sterile forceps and plates were incubated at
370C for 18-20 hrs. After incubation, MIC ratio of Imipenem /Imipenem-EDTA (IP/IPI) of ≥8 or
deformations of ellipse or phantom zone indicate MBL production.
Colistin E test: All MBL producing E.coli strains were tested with Colistin E test (AB bioMer‐
ieux, Solana, Sweden). The Colistin E-test was done and interpreted using test strains and
Quality control strains according to manufacturer’s instructions.
2.2.5. Detection of Klebsiella pneumoniae carbapenemases (KPCS)
It was done by Combined disk method [61]. Lawn culture of test strain (turbidity adjusted to
0.5 Mc Farland) was put on MH agar plate and 2 Imipenem (10 μg) disks were put widely
apart. To one Imipenem disk 10 μl Phenyl boronic acid solution (400μg/disk) was put. Then
the MH agar plates were incubated at 370C overnight. After incubation, the test should be
considered positive when growth inhibitory zone around the disk containing Imipenem and
Phenyl boronic acid was ≥ 5 mm compared to zone diameter of Imipenem alone.
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2.2.6. Detection of class D enzymes
Several workers have reported that Class D enzymes i.e. OXA – 48 type are the most difficult
carbapenemase producers to be identified phenotypically [42,43]. Hence, we did not include
detection of Class D carbapenemase in our study.
3. Observation




III. OBSERVATION  
Figure 1: Incidence of MBL, ESBL & AmpC β – lactamase producing E.coli strains (n = 450) 
                                                                   
Figure 1 shows incidence of different β – lactamases e.g. MBL, ESBL, AmpC β – lactamases producing E.coli strains. Out of 450 
E.coli strains studied, 378 (84%) strains produced any of the 3 types of β – lactamases i.e. MBL, ESBL and AmpC β – 
lactamases, either alone or in combinations. Photographs of different methods used to detect newer β-lactamases phenotypically 































































Figure 1. Shows incidence of different β – lactamases e.g. MBL, ESBL, AMPC β – lactamases producing E.coli strains.
Out of 450 E.coli strains studied, 378 (84%) strains produced any of the 3 types of β – lactamases i.e. MBL, ESBL and
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3.1. Detection of MBL
In photo 5 ESBL E Test positive shows MIC of Ceftazidime (TZ) 6 μg/ml and Ceftazidime
Clavulanic acid (TZL) 0.25μg/ml respectively i.e. MIC ratio of TZ/TZL is 24. Out of 378 β -
lactamase producing E.coli strains 223(59%) produced both ESBL andAmp C β –lactamases.
Out of total 51 MBL producing E.coli strains 14 (27.5%) strains produced all the three types of
β – lactamases i.e. MBL, ESBL and AMPC β – lactamases. In Photo 11 MBL E Test positive
shows MIC of Imipenem (IP) 24 μg/ml and Imipenem-EDTA (IPI) < 1μg/ml respectively i.e.
MIC ratio of IP/IPI is > 24 and also presence of Phantom zone.
All 51MBL positive E.coli strains were sensitive to Colistin with MIC range from 0.032 to
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In photo 2 ESBL E Test positive shows MIC of Ceftazidime (TZ) 6 µg/ml and Ceftazidime Clavulanic acid (TZL) 0.25µg/ml 
respectively i.e. MIC ratio of TZ/TZL is 24. Out of 378 β - lactamase producing E.coli strains 223(59%) produced both ESBL 
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and Imipenem-EDTA (IPI) < 1µg/ml respectively i.e. MIC ratio of IP/IPI is > 24 and also presence of Phantom zone.   
All 51MBL positive E.coli strains were sensitive to Colistin with MIC range from 0.032 to 0.25µg/ml and were detected by E test 
for Colistin (bioMe’rieux) (Photo 12). 
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Out of total 450 E.coli strains 218 (48.4%) were isolated from urine, 92 (20.4%) from stool, 61 from pus and wound swab, 30 
from blood, 10 from body fluids and 39 from other specimens e.g. ET tube secretions, broncho-alveolar lavage etc. 
Figure 2 shows out of total 51 MBL positive E.coli strains maximum 27(53%) strains were isolated from urine followed by 
11(21.6%) strains from pus and wound swab. Out of 27 MBL positive E.coli strains isolated from urine 12(44.4%) had history of 
catheterization and 2(7.4%) had history of instrumentation in urethra (e.g.dilatation, etc). Only 01 urine sample received from 
High Dependency Unit and that E.coli strain produced all 3 types of β – lactamases i.e. MBL, ESBL and AmpC β – lactamases. 
In our study, total 14 E.coli strains were positive for all 3 types of β – lactamases i.e. MBL, ESBL and AmpC β – lactamases ,and 
out of which 11 (78.6%) strains were isolated from urine samples which was quite alarming. No MBL producing E.coli strain 
was isolated from body fluids. Out of 92 stool samples, 5 (5.4%) were MBL producers, 15 (16.3%) were only ESBL producer 
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Figure 3 shows maximum 9/51 (17.7%) MBL producing E.coli strains were isolated from Pediatrics ward. No MBL producing 
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Pediatrics ward. No MBL producing strain was isolated from Cardiovascular & Thoracic
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10 were only Amp C β – lactamase producers.
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Figure 4 shows out of total 51 MBL producing E.coli strains, 39 (76.5%) strains were resistant to Imipenem and Etrapenem by disc 
diffusion method. The MBL producing strains of E.coli showed total resistance to Ampicillin, Gentamicin, Ciprofloxacin, Co – 
trimoxazole, Tetracycline, Ceftazidime, Cephotaxime and Cefoxitin. But all MBL positive E.coli strains (100%) were sensitive to 
Colistin. Out of total 450 E.coli strains, only 58.9% strains were sensitive to Amikacin and only 28.2% strains were sensitive to 
Ciprofloxacin. Nitrofurantoin was used for urine specimen only (n = 218) and 67.9% strains were sensitive to Nitrofurantoin. 
Amongst the 51 MBL producing E.coli strain, 12 (23.5%) strains were sensitive to Imipenem and Etrapenem by disk diffusion test. 
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detection of MBL positive strains. The sensitivity of Re - MHT was 88.2% and specificity was 99% whereas sensitivity of DDST 
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Figure 4. Antibiotic resistance pattern of MBL producing E.coli strains (n = 51)
Figure 4 shows out of total 51 MBL producing E.coli strains, 39 (76.5%) strains were resistant
to Imipenem and Etrapene  by disc diffusion method. The MBL producing strains of E.coli
showed total resistance to Ampicillin, Gentamicin, Cipr floxaci , Co – trimoxazole, T tracy‐
cline, Ceftazidime, Cephotaxime and Cefoxitin. But all MBL positive E.coli strains (100%) were
sensitive to Colist n. Out of total 450 E.coli strains, o ly 58.9% strain were sensitive to
Trends in Infectious Diseases60
Amikacin and only 28.2% strains were sensitive to Ciprofloxacin. Nitrofurantoin was used for
urine specimen only (n = 218) and 67.9% strains were sensitive to Nitrofurantoin. Amongst the
51 MBL producing E.coli strain, 12 (23.5%) strains were sensitive to Imipenem and Etrapenem
by disk diffusion test. Out of 12 Imipenem sensitive MBL producing E.coli strain, 5 (41.7%)
strains produced all 3 types of β – lactamases.
Strains Phenotypic methods
Re - MHT DDST DP
MBL + ve (n = 51)
By MBL – E test
45 46 51
MBL – ve (n = 399)
By MBL – E test
401 402 399
False negative 6 5 0
False positive 4 2 0
Sensitivity % 88.2 90.2 100
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Table 1. Performance of different phenotypic methods compared to MBL – E test in identifying MBL + ve E.coli
Table 1 shows Sensitivity, Specificity, Positive predictive value, Negative predictive value and
Efficiency calculated for Re – Modified Hodge test (Re – MHT), Double disk synergy test
(DDST) and Disk potentiation (DP) test, compared to MBL – E test in identifying MBL positive
E.coli strains. MBL – E test is considered as standard phenotypic reference method for detection
of MBL positive strains. The sensitivity of Re - MHT was 88.2% and specificity was 99%
whereas sensitivity of DDST was 90.2% and specificity was 99.5%. DP test was having
sensitivity and specificity of 100%. The efficiency of Re – MHT was 97.8%, DDST was 98.5%
and DP was 100%, when compared to MBL - E test as standard reference method.
4. Discussion
The emergence of antibiotic resistance occurs by a) spontaneous mutation and vertical gene
transfer and b) horizontal gene transfer through transformation, transduction, conjugation,
transposons (jumping genes) etc. The rapidity of development of antimicrobial resistance in
organisms, leads to selection pressure of antibiotics like 3rd generation of cephalosporin- ESBL
inhibitor combination, Monobactams and Carbapenems. Recently, Carbapenem resistant
Enterobacteriaceae (CRE) pose a real threat to Medical fraternity as the increased frequency
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Positive predictive value 91.8 95.8 100
Negative predictive value 98.5 98.8 100
Efficiency 97.8 98.5 100
Table 1. Performance of different phenotypic methods compared to MBL – E test in identifying MBL + ve E.coli
Table 1 shows Sensitivity, Specificity, Positive predictive value, Negative predictive value and
Efficiency calculated for Re – Modified Hodge test (Re – MHT), Double disk synergy test
(DDST) and Disk potentiation (DP) test, compared to MBL – E test in identifying MBL positive
E.coli strains. MBL – E test is considered as standard phenotypic reference method for detection
of MBL positive strains. The sensitivity of Re - MHT was 88.2% and specificity was 99%
whereas sensitivity of DDST was 90.2% and specificity was 99.5%. DP test was having
sensitivity and specificity of 100%. The efficiency of Re – MHT was 97.8%, DDST was 98.5%
and DP was 100%, when compared to MBL - E test as standard reference method.
4. Discussion
The emergence of antibiotic resistance occurs by a) spontaneous mutation and vertical gene
transfer and b) horizontal gene transfer through transformation, transduction, conjugation,
transposons (jumping genes) etc. The rapidity of development of antimicrobial resistance in
organisms, leads to selection pressure of antibiotics like 3rd generation of cephalosporin- ESBL
inhibitor combination, Monobactams and Carbapenems. Recently, Carbapenem resistant
Enterobacteriaceae (CRE) pose a real threat to Medical fraternity as the increased frequency
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with which Enterobacteriaceae cause infection and the mortality associated with infection
caused by CRE and ESBL producing bacteria. In mid1990, CTX-M 15 was first reported as ESBL
in India. Now, CTX-M 15 is established as globally dominant ESBL and primary cause of
acquired resistance to 3rd generation Cephalosporins in Enterobacteriaceae. Walsh TR et al in
year 2005 noted that MBL genes have spread from Pseudomonas aeruginosa to Enterobacteria‐
ceae and a clinical scenario for MBL appears to simulate the global spread of ESBL in recent
future. bla NDM-1 gene on plasmid can be readily transferred between different strains of bacteria
by horizontal genre transfer [47].
In the present study, 52(11.6%), 56(12.4%) and 342 (76%) E.coli strains were isolated from
Outpatient Departments(OPDs), Intensive Care units (ICUs) and Inpatient Departments(IPDs)
respectively. Maximum 25 (44.6%) E.coli strains were isolated from Medicine ICU (MICU) and
High dependency unit (HDU). In a previous study conducted in our laboratory in 2008, Basak
et al have already reported the incidence of ESBL producing E.coli in our hospital as 41.3% [67]
whereas 5 years after, in the present study, the incidence of ESBL producing E.coli were 68%,
out of which only 13.8% strains produced ESBL alone and other strains produced ESBL, Amp
C β-lactamases and MBL in combination. Pakzad I et al in 2011 have reported 28% of their
E.coli strains as ESBL producers [68]. Sinha et al in 2008 had reported that 40.8% of E.coli strains
were ESBL producers and 24% were AMPC β-lactamase producers [69]. 37.5% and 47.8% of
E.coli strains were reported to be Amp C β –lactamases producers in the study conducted in
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Various authors have reported MBL producing E.coli strains from 2.9% (Pandya et al from
Gujrat, India) [70], to 6.8% (Tsakris et al from Greece) [61] to 25% (Enwuru NV et al from
Nigeria) [13]. In the present study 51(11.3%) MBL producing E.coli strains were isolated. MBL
production was detected in both Imipenem resistant (39/41 i.e. 95.1%) and Imipenem sensitive
12/409 i.e. 2.9% strains also. It indicates that if only Imipenem resistant strains would have
been screened, 2.9% MBL producing strains would have been missed. But no Klebsiella
pneumoniae producing carbapenemases were detected in our present study. In 2011, Tsakris
et al reported 15.9% KPC producing E.coli in their study. Tsakris et al have also reported that
19(43.2%) E.coli strains produced Amp C β –lactamases and ESBL and 15(34%) E.coli strains
produced ESBL [61]. In another study in 2012, Gupta V et al have reported 17(68%) E.coli strains
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 Walsh et al in 2002 have reported that the MBL – E test results were in 100% agreement with the results from the 
genotypic Polymerase chain reaction (PCR) and biochemical methods [59]. They have also reported that the E test MBL strip 
IP/IPI has the ability to detect MBLs both chromosomally and plasmid mediated, in aerobic and anaerobic bacteria. This novel 
method could be used by Clinical Laboratories to monitor the emergence of the MBL [59]. 
 Omair et al in 2012, have reported that MBL – E test have been taken as a gold standard method for MBL detection 
[72]. Manoharan et al have reported that MBL - E test has taken as a phenotypic standard method for MBL detection though the 
test is expensive. Double disk synergy test (DDST) and Disk potentiation (DP) tests are economical and simple to perform but 
DDST is observer dependent while DP test is measurable with lesser chance of subjective error [45]. 
In the present study, we studied MBL positive E.coli strains by MBL E – test and compared the results of other 
phenotypic methods for MBL detection i.e. Re – Modified Hodge test (Re- MHT), Double disk synergy test (DDST) and Disk 
potentiation (DP) test.  
In figure 7, the  venndiagram showing interrelationship of Re – modified Hodge test (Re – MHT), Double disk synergy 
test (DDST) and Disk potentiation test (DP) for detection of MBL producing E.coli. 
 In the present study when results of all three phenotypic methods were compared with MBL – E test results, it was 
found that 45/51 (88.2%) MBL positive strains were positive by all three phenotypic method i.e. Re – Modified Hodge test (Re- 
MHT), Double disk synergy test (DDST) and Disk potentiation (DP) tests. 04 and 02 were false positive by Re – MHT and 
DDST methods respectively. Whereas 6/51 (11.8%) and 5/51(9.8%) were false negative by Re – MHT and DDST method 
respectively. Amongst all three phenotypic methods, DP was best correlated with MBL – E test. By DP test 51 MBL positive 
E.coli strains were detected and no false positive and false negative result was found (Sensitivity 100% and specificity 100%). 
 
V. EPIDEMIOLOGY -  
          E.coli are responsible for various infections like urinary tract infection, diarrhoea, pneumonia, bacteremia, upper 
respiratory tract infections, wound infections, osteomyelitis and neonatal meningitis[73,74].  
 The successful outcome of clinical use of 3rd generation cephalosporines unfortunately led to the increased use and 
emergence of ESBL producing Enterobacteriaceae. With the emergence of ESBL and Amp C β – lactamase production in E.coli, 
Klebsiella pneumoniae and other Enterobacteriaceae, Carbapenems were used as last resort to treat those infections. Because of 
selective pressure of Carbapenems, even carbapenemases producing Enterobacteriaceae (CRE) has emerged.  
 
Most common MBL found worldwide in Enterobacteriaceae were VIM (Verona integron encoded MBL) and IMP 
(active on imipenem). Multidrug resistant E.coli harboring New Delhi metallobetalactamase - 1 (NDM-1) isolated from a patient 
returned to Canada from India[75], was reported first in 2009. NDM -1 was also recognized among Enterobacteriaceae 32 from 
Mumbai, 13 from Varanasi and 3 from Guwahati in India and 25 isolates from eight different cities in Pakistan. These isolates 
were from cases of bacteraemia, ventilator associated pneumonia and community acquired urinary tract infections [76]. 
      NDM - 1 spread largely to different countries like Australia, Japan, Brazil, Belgium, Canada, Germany etc [77]. The 
gene encoding NDM – 1is called blaNDM – 1, located on transmissible plasmid which may include other antibiotic resistance genes also 
leading to extensive drug resistant phenotypes (so called ‘superbugs’). A recent report from ICU and wards of Sir Gangaram hospital 
Delhi, India showed 8.1% NDM – 1 positive E.coli [78]. In January 2011, the name of NDM–1 was changed to PCM (Plasmid encoding 
Carbapenem resistant metallobetalactamases)[79]. 
     Metallobatalactamases are also found in Carbapenem susceptible organisms. This hidden MBL gene can spread 
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Figure 7. Phenotypic detection of metallobetalactamase (MBL) producing E.coli strains by various methods. (n = 450)
Walsh et al in 2002 have reported that the MBL – E test results were in 100% agreement with
the results from the g notypic Polymerase chain reaction (PCR) and biochemical meth ds [59].
They have also reported that the E test MBL strip IP/IPI has the ability to detect MBLs both
chromosomally and plasmid mediated, in aerobic and anaerobic bacteria. This novel method
could be used by Clinical Laborator es to m n tor the emergence of the MBL [59].
Omair et al in 2012, have r ported that MBL – E test hav  be  taken as a gold standard met od
for MBL detection [72]. Manoharan et al have reported that MBL - E test has taken as a
phenotypic standard method for MBL detection though the test is expensive. Dou le disk
synergy test (DDST) and Disk potentiation (DP) tests are economical and simple to perform
but DDST is observer dependent while DP test is measurable with lesser chance of subjective
error [45].
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with which Enterobacteriaceae cause infection and the mortality associated with infection
caused by CRE and ESBL producing bacteria. In mid1990, CTX-M 15 was first reported as ESBL
in India. Now, CTX-M 15 is established as globally dominant ESBL and primary cause of
acquired resistance to 3rd generation Cephalosporins in Enterobacteriaceae. Walsh TR et al in
year 2005 noted that MBL genes have spread from Pseudomonas aeruginosa to Enterobacteria‐
ceae and a clinical scenario for MBL appears to simulate the global spread of ESBL in recent
future. bla NDM-1 gene on plasmid can be readily transferred between different strains of bacteria
by horizontal genre transfer [47].
In the present study, 52(11.6%), 56(12.4%) and 342 (76%) E.coli strains were isolated from
Outpatient Departments(OPDs), Intensive Care units (ICUs) and Inpatient Departments(IPDs)
respectively. Maximum 25 (44.6%) E.coli strains were isolated from Medicine ICU (MICU) and
High dependency unit (HDU). In a previous study conducted in our laboratory in 2008, Basak
et al have already reported the incidence of ESBL producing E.coli in our hospital as 41.3% [67]
whereas 5 years after, in the present study, the incidence of ESBL producing E.coli were 68%,
out of which only 13.8% strains produced ESBL alone and other strains produced ESBL, Amp
C β-lactamases and MBL in combination. Pakzad I et al in 2011 have reported 28% of their
E.coli strains as ESBL producers [68]. Sinha et al in 2008 had reported that 40.8% of E.coli strains
were ESBL producers and 24% were AMPC β-lactamase producers [69]. 37.5% and 47.8% of
E.coli strains were reported to be Amp C β –lactamases producers in the study conducted in
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Various authors have reported MBL producing E.coli strains from 2.9% (Pandya et al from
Gujrat, India) [70], to 6.8% (Tsakris et al from Greece) [61] to 25% (Enwuru NV et al from
Nigeria) [13]. In the present study 51(11.3%) MBL producing E.coli strains were isolated. MBL
production was detected in both Imipenem resistant (39/41 i.e. 95.1%) and Imipenem sensitive
12/409 i.e. 2.9% strains also. It indicates that if only Imipenem resistant strains would have
been screened, 2.9% MBL producing strains would have been missed. But no Klebsiella
pneumoniae producing carbapenemases were detected in our present study. In 2011, Tsakris
et al reported 15.9% KPC producing E.coli in their study. Tsakris et al have also reported that
19(43.2%) E.coli strains produced Amp C β –lactamases and ESBL and 15(34%) E.coli strains
produced ESBL [61]. In another study in 2012, Gupta V et al have reported 17(68%) E.coli strains
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Figure 7. Phenotypic detection of metallobetalactamase (MBL) producing E.coli strains by various methods. (n = 450)
Walsh et al in 2002 have reported that the MBL – E test results were in 100% agreement with
the results from the g notypic Polymerase chain reaction (PCR) and biochemical meth ds [59].
They have also reported that the E test MBL strip IP/IPI has the ability to detect MBLs both
chromosomally and plasmid mediated, in aerobic and anaerobic bacteria. This novel method
could be used by Clinical Laborator es to m n tor the emergence of the MBL [59].
Omair et al in 2012, have r ported that MBL – E test hav  be  taken as a gold standard met od
for MBL detection [72]. Manoharan et al have reported that MBL - E test has taken as a
phenotypic standard method for MBL detection though the test is expensive. Dou le disk
synergy test (DDST) and Disk potentiation (DP) tests are economical and simple to perform
but DDST is observer dependent while DP test is measurable with lesser chance of subjective
error [45].
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In the present study, we studied MBL positive E.coli strains by MBL E – test and compared the
results of other phenotypic methods for MBL detection i.e. Re – Modified Hodge test (Re-
MHT), Double disk synergy test (DDST) and Disk potentiation (DP) test.
In figure 7, the venndiagram showing interrelationship of Re – modified Hodge test (Re –
MHT), Double disk synergy test (DDST) and Disk potentiation test (DP) for detection of MBL
producing E.coli.
In the present study when results of all three phenotypic methods were compared with MBL
– E test results, it was found that 45/51 (88.2%) MBL positive strains were positive by all three
phenotypic method i.e. Re – Modified Hodge test (Re- MHT), Double disk synergy test (DDST)
and Disk potentiation (DP) tests. 04 and 02 were false positive by Re – MHT and DDST methods
respectively, whereas6/51 (11.8%) and 5/51(9.8%) were false negative by Re – MHT and DDST
method respectively. Amongst all three phenotypic methods, DP was best correlated with MBL
– E test. By DP test 51 MBL positive E.coli strains were detected and no false positive and false
negative result was found (Sensitivity 100% and specificity 100%).
5. Epidemiology
E.coli are responsible for various infections like urinary tract infection, diarrhoea, pneumonia,
bacteremia, upper respiratory tract infections, wound infections, osteomyelitis and neonatal
meningitis [73,74].
The successful outcome of clinical use of 3rd generation cephalosporines unfortunately led to
the increased use and emergence of ESBL producing Enterobacteriaceae. With the emergence
of ESBL and Amp C β – lactamase production in E.coli, Klebsiella pneumoniae and other
Enterobacteriaceae, Carbapenems were used as last resort to treat those infections. Because of
selective pressure of Carbapenems, even carbapenemases producing Enterobacteriaceae
(CRE) has emerged.
Most common MBL found worldwide in Enterobacteriaceae were VIM (Verona integron
encoded MBL) and IMP (active on imipenem). Multidrug resistant E.coli harboring New Delhi
metallobetalactamase - 1 (NDM-1) isolated from a patient returned to Canada from India [75],
was reported first in 2009. NDM -1 was also recognized among Enterobacteriaceae 32 from
Mumbai, 13 from Varanasi and 3 from Guwahati in India and 25 isolates from eight different
cities in Pakistan. These isolates were from cases of bacteraemia, ventilator associated pneu‐
monia and community acquired urinary tract infections [76].
NDM - 1 spread largely to different countries like Australia, Japan, Brazil, Belgium, Canada,
Germany etc [77]. The gene encoding NDM – 1is called blaNDM-1, located on transmissible
plasmid which may include other antibiotic resistance genes also leading to extensive drug
resistant phenotypes (so called ‘superbugs’). A recent report from ICU and wards of Sir
Gangaram hospital Delhi, India showed 8.1% NDM – 1 positive E.coli [78]. In January 2011,
the name of NDM–1 was changed to PCM (Plasmid encoding Carbapenem resistant metallo‐
betalactamases) [79].
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Metallobatalactamases are also found in Carbapenem susceptible organisms. This hidden MBL
gene can spread unnoticed in hospitals if isolates are reported sensitive without screening for
presence of MBL [48].
The prevalence of ESBL and Amp C beta lactamases in a single isolate reduces effectiveness
of beta – lactam and beta - lactamase inhibitor combinations while MBLs and Amp C beta–
lactamases confer resistance to carbapenems and Cephamycin. Unfortunatenly thses enzymes
usually co-exist in same isolate.
6. Prevention and control
As E.coli are one of the commonest cause of both health care and community acquired
infections, rapid identification of beta lactamase producing E.coli is crucial for appropriate
treatment and timely implementation of infection control measures in Health care set-up.
Indeed, delayed detection of ESBLs, Amp C β – lactamase and MBL producing strains, raise
the possibility of spread of these strains into the community. These issues combined with the
limited therapeutic options available to treat patient infected with these organisms, have made
CRE of epidemiological importance globally [ 80]. ESBLs and Carbapenem resistant strains
may lead to outbreaks of infection in HealthCare Set-up also.
Phenotypic methods can be useful for routine detection of ESBLs and carbapenemase pro‐
duction, among Gram negative bacteria particularly when PCR is not available.
Screening of colonisation with multidrug-resistant organisms (MDROs) upon admission to
hospitals has been advocated in patients who have already received healthcare in endemic
countries. The CDC recommends, if previously unrecognized cases are identified of being
infected with β-lactamase producing strains, a round of surveillance culture from high risk
areas i.e. ICUs or wards from where detected, should be considered in any Health Care Setup.
In addition prompt notification, must be made to infection control team members when CRE
are identified in Clinical Microbiology Laboratories.
Antimicrobial stewardship has been suggested as the most important efforts to control
multidrug resistant organisms (MDROs) [81]. It has been found to be most effective, if efforts
are directed towards an overall decrease in antimicrobial use rather than targeting a specific
antimicrobial class. Limiting use of invasive devices is another potentially important preven‐
tive mechanism for MDROs including β- lactamase producing organisms. Health care workers
(HCW) should follow hand hygiene practices while giving patient care preferably using an
alcohol based hand rubs or antimicrobial soap and water if hands are visibly soiled, and also
follow Standard precautions and Additional precautions as per the indications.
7. Conclusion
In the present study, all MBL – E test positive E.coli strains (100%) were detected by Disk
potentiation test also. MBL producing E.coli strains must be tested in both carbapenem resistant
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as well as sensitive strains by Disk potentiation method using Imipenem – EDTA. Disk
potentiation method is simple to perform and materials used are cheap, non-toxic, and easily
accessible and allowed for objective interpretation of results. It is also quite good in detecting
carbapenem sensitive MBL producing strains.
Beta-lactamase producing organisms are detected by E test, which is standard phenotypic
method and also by Polymerase chain reaction (PCR) which is a gold standard, but both are
costly and require expertise. Failure to detect these enzymes has contributed to their uncon‐
trolled spread and commonly to therapeutic failures.
Hence to conclude, for detection of ESBL, combined disk method using Ceftazidime / Cefta‐
zidime Clavulanic acid(CAZ/CAC), for detection of Amp C β-lactamases confirmatorty Disk
potentiation test using Ceftazidime / Ceftazidime - 3-aminophenylboronic acid and for
detection of Metallo β-lactamases(MBL) producing E.coli, disk potentiation test using Imipe‐
nem/Imipenem - EDTA should be done in both carbapenem sensitive as well as resistant
isolates by all Clinical Microbiology Laboratories to prevent its dissemination and also for a
good therapeutic outcome.
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1. Introduction
Although the millennium development goal to stop tuberculosis (Tb) epidemic is almost
achieved, still in 2012 there were 8.6 million new cases and 1.3 million deaths worldwide [of
which 3, 20,000 people were co-infected with HIV too (WHO 2013)]. The rate of new Tb cases
has been falling but decline rate at 2 percent per annum is still slow. Progress to handle
multidrug resistant tuberculosis (MDR Tb)-defined by resistance to rifampicin and isoniazid
(often accompanied by additional resistance), which accounts for 3.6 percent of the new and
20.2 percent of the previously treated Tb cases-is also slow (WHO 2013). Emergence of
extremely drug resistant (XDR) strains of Mycobacterium tuberculosis (M tb) which is about 9.6
percent of the MDR Tb cases (WHO 2013) is a looming threat to the programmes aimed to stop
tuberculosis. The XDR strains are resistant to isoniazid and rifampicin (first line drugs); at least
to one of the three injectable second line drugs (amikasin, kanamycin or capreomycin) and
also to any of the fluoroquinolone drugs to tuberculosis. The MDR and XDR Tb account for
much higher death rates among the incident cases.
Induction of autophagy, Vitamin D and arachidonic acid metabolites play a decisive role in
determining the susceptibility or resistance to the Mycobacterium tuberculosis infections.
Additionally, cytokine responses play a major role. Among the cytokines, important ones are
type I/ type II interferons, TNF-α and IL-1β in combination with other cytokines such as IL-4,
IL-6, IL-8, IL-10, IL-12, IL-17, IL-22 etc. (Ottenhoff TH, 2012). M tb has evolved strategies to
suppress the immune response mounted against it and even exploits host molecular pathways
for its survival benefits. Regulation of apoptosis versus necrosis by M tb or its host has emerged
as a major player in determining the survival or clearance of the pathogen. Many of these
pathways have components with opposite roles favouring either host or the pathogen. They
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has been falling but decline rate at 2 percent per annum is still slow. Progress to handle
multidrug resistant tuberculosis (MDR Tb)-defined by resistance to rifampicin and isoniazid
(often accompanied by additional resistance), which accounts for 3.6 percent of the new and
20.2 percent of the previously treated Tb cases-is also slow (WHO 2013). Emergence of
extremely drug resistant (XDR) strains of Mycobacterium tuberculosis (M tb) which is about 9.6
percent of the MDR Tb cases (WHO 2013) is a looming threat to the programmes aimed to stop
tuberculosis. The XDR strains are resistant to isoniazid and rifampicin (first line drugs); at least
to one of the three injectable second line drugs (amikasin, kanamycin or capreomycin) and
also to any of the fluoroquinolone drugs to tuberculosis. The MDR and XDR Tb account for
much higher death rates among the incident cases.
Induction of autophagy, Vitamin D and arachidonic acid metabolites play a decisive role in
determining the susceptibility or resistance to the Mycobacterium tuberculosis infections.
Additionally, cytokine responses play a major role. Among the cytokines, important ones are
type I/ type II interferons, TNF-α and IL-1β in combination with other cytokines such as IL-4,
IL-6, IL-8, IL-10, IL-12, IL-17, IL-22 etc. (Ottenhoff TH, 2012). M tb has evolved strategies to
suppress the immune response mounted against it and even exploits host molecular pathways
for its survival benefits. Regulation of apoptosis versus necrosis by M tb or its host has emerged
as a major player in determining the survival or clearance of the pathogen. Many of these
pathways have components with opposite roles favouring either host or the pathogen. They
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also are interconnected and the final outcome of the infection depends on the result of their
converging effects.
1.1. Tb epidemiology
Tb incidence is generally considered as notifications of the cases with correction for underre‐
porting and non-diagnosis. The total incidence of Tb cases in 2012 was in the range of 8.3-9.0
million globally (WHO 2013). Out of these, children account for 0.5 million cases and 3.1 million
cases were among women. According to the WHO report on tuberculosis, most of the cases
were from Asia and African regions-India (2.0-2.4 million), China (0.9-1.1 million), South Africa
(0.4-0.6 million), Indonesia and Pakistan with 0.45 million and 0.4 million cases respectively,
which is dangerously high. The report suggests that it is developing countries and specifically,
the poor who are gripped tightly by the disease and who account for the maximum number
of new cases and deaths worldwide. Awareness and access to diagnostic labs in developing
countries is still low in addition to the lack of availability of affordable treatment. The combi‐
nation of factors results in the spread of the pathogen to many people before being diagnosed.
Diagnostic methods to distinguish latent tuberculosis from active disease and treatment
options for latent Tb also are urgently required otherwise tuberculosis cannot be eradicated
completely. There is some progress in this area and newer methods to diagnose latent Tb are
being developed (Singh SB et al., 2013). In a recent study, Harari A et al. 2011, showed the
possibility of discriminating latent Tb from active disease which could not be differentiated
by a tuberculin skin test (TST) or interferon gamma release assay (IGRA). They utilized a flow-
cytometry based method and analysed the functionality of M tb specific CD4 T cells from
cohorts. Their results suggests that CD4 T cells are multifunctional and able to produce IL-2,
TNF-α and IFN-γ in latent Tb cases while they dominantly produce TNF-α (single positive)
in active disease conditions (Harari A. et al. 2011). Also since BCG is almost 100 years old with
varied efficacy, new pre-and post-exposure vaccines are needed to prevent tuberculosis.
1.2. M tb pathogenesis
The genus Mycobacterium originated millions of years ago, but the members of the M tb
complex evolved about 15,000-35,000 years back (Gutierrez MC et al., 2005). The noted
occurrence of tuberculosis in humans is from their prehistoric remains and from Egyptian
mummies dated back to 3000-2400 years (Zink AR et al., 2003). Respiratory tract is the main
route of entry of the pathogen as airborne droplets containing the bacterium reaches the lung-
a suitable site for this aerobic organism to establish infection. However other tissues and organs
viz. lymphatic system, central nervous system, pleura, liver, spleen, bones and joints are also
susceptible to infection by M tb and manifestation of the disease (Bloom BR and Small PM,
1998; Golden MP and Vikram HR, 2005). Once in the lung, alveolar macrophages engulf the
bacterium, a process facilitated by binding of the lipo-arabinomannan on the bacterial cell wall
to the mannose receptors on macrophages. Complement receptors on the macrophage surface
also take part in the process of endocytosis of opsonised M tb (Ernst JD, 1998; Kang PB et al.,
2005; Kerrigan AM and Brown GD, 2009). These interactions culminate in the release of
cytokines which stimulate the adaptive arm of the immune system and eventually leads to
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inflammatory response at the site of infection. Other cells of the innate and adaptive immune
system migrate to the infection site and try to contain the bacterium by forming a specialized
structure called granuloma.
The granuloma plays a major role in preventing the escape of the bacterium to other sites and
also creates a localized immune response. If the immune response directed against the
pathogen is capable of successfully containing it, granulomas shrink with the formation of the
caseous centres, which is the case in immune-competent individuals (Dannenberg AM Jr. and
Rook JA, 1994; Doherty TM and Andersen P, 2005). M tb is unable to replicate within the
caseous centres due to hypoxia, acidic pH and presence of the fatty acids which are toxic to
the bacterium but some organisms become dormant and persist for many years (Smith I,
2003). However, if the bacterium is able to survive by utilizing various immune evasion tactics
and is able to replicate, necrosis of the infected macrophages takes place. It leads to the
degradation of cells composing the granuloma and lipids (especially cholesterol) from the
dying cells serve as a rich source of nutrient for the bacterium (Orme IM, 2013). Subsequent
destruction of the cells leads to liquefaction within the interior of the granuloma where bacteria
lives an apparently extracellular life, probably in the form of a pellicle or biofilms (Ojha AK et
al., 2008; Orme IM, 2013) – a part of the bacterial life cycle not well perceived in the scientific
arena. At this stage, the pathogen is far from the reach of current drugs available for treating
tuberculosis and the components of the immune system modulated by the vaccine to tackle
the infection (Orme IM, 2013). The calcification process initiated inside the granuloma after
necrosis push the bacterium to the periphery and probable rupture of the membrane leads to
dissemination of the bacterium. At this point, M tb is capable of dissemination to other organs
of the body and is also released to the external environment as aerosol droplets when the host
coughs, sneezes, shouts or sings and thus is able to start a new cycle of infection.
Though a high number of people fall prey to the bacterium very often but remain asympto‐
matic unless there are perturbations in the immune status of the person. The probability of
developing active disease after getting infected is high in the initial two years but at least 5-10
percent of the people develop disease during their lifetime (Harada N, 2006; O'Garra A et al.,
2013). In this chapter some of the host molecular pathways or their components and the
signalling axes which play crucial roles in the inhibition or survival of the M tb and some of
the recent research in the area has been highlighted.
2. Interferon signalling
Type I interferons e.g. interferon-α and interferon-β are implicated in progression of the
tuberculosis. Mice with impaired type I interferon signalling are better protected from the
pathogen (Manca C et al., 2001). In-vitro studies also show that M tb infection leads to up
regulation of the genes of type I interferon signalling pathways and genes induced by them
(Remoli ME et al., 2002). On the other hand interferon-γ, a type II interferon is critically
important in protection against tuberculosis (Flynn JL et al., 1993; Trinchiari G, 2010). It plays
its role by various mechanisms including activation of macrophages, enhances functioning of
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inflammatory response at the site of infection. Other cells of the innate and adaptive immune
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CD8 T cells and through reactive nitrogen species (Flynn JL et al., 1993; Green AM et al.,
2013). Thus both types of interferons have important and opposite roles in determining the
mycobacterial pathogenesis (Teles RM et al., 2013). Berry et al., 2010, found a Tb-specific
transcriptional signature in blood which could help in discrimination between latent and active
disease and also distinguishes Tb from other infectious and inflammatory diseases. They
reported 86 gene signatures which are specific to tuberculosis. These genes are mostly
interferon inducible and consists of both type I and type II interferon signalling pathways and
could be novel targets for Tb treatment.
3. IL-1β signalling pathway in tuberculosis
IL-1β imparts immunity to tuberculosis and mice lacking in IL-1β or its receptors are suscep‐
tible to M tb infection (Mayer-Barber KD, 2010). It is an important factor in host immunity and
virulent mycobacteria suppress the IL-1β production which is regulated by type I interferons
in macrophages (Novikov A et al., 2011). IL-1β has been shown to possess bactericidal activity
in the macrophages derived from murine and humans (Jayaraman P et al., 2013). It upregulates
secretion of tumor necrosis factor (TNF) and cell surface expression of TNFR1, thus facilitates
TNF signalling which culminates in caspase-3 activation leading to growth inhibition of M tb
through apoptosis of the infected macrophage (Jayaraman P et al., 2013). They also showed
that this effect of TNF on the M tb infected macrophage is due to autocrine mode of action. In
synergy with vitamin D, IL-1β drives transcriptional expression of the antimicrobial peptide
genes such as defensin beta 4 (DEFB4), cathepsins, cathelicidins and ubiquitin derived peptides
which have M tb killing ability (Alonso S, 2007; Liu PT et al, 2009; Ottenhoff TH, 2012). Results
from the work of Liu PT et al. 2009, also suggest that the coherent action of IL-1β and vitamin
D is an integral part of the TLR2/1 signalling mediated antimicrobial activity.
IL-1β being a pro-inflammatory cytokine is under tight regulation to prevent the immune-
pathology and subsequent tissue damage during chronic infections. Mishra et al., 2013, showed
that level of this cytokine is regulated by IFN-γ induced release of nitric oxide (NO) which in
turn regulate the inflammasome NLRP3 (nucleotide binding and oligomerization domain-like
receptor family pyrin domain containing 3) during M tb infections. This regulation happens
at the stage of caspase1 mediated processing of pro-IL-1β to IL-1β and is specifically NLRP3
dependent (Mishra BB. et al., 2013).
4. Inflammasomes in tuberculosis
As briefly discussed above inflammasomes play a regulatory role in tuberculosis and imparts
protection if activated. For its survival M tb prevents the activation of inflammasomes,
caspase-1 dependent processing of pro-IL-1β and phagosome maturation through its gene
zmp1 (Master SS et al., 2008; Lazarevic V and Martinon F, 2008). It has been shown that the
production of IL-1β is dependent on the recognition of M tb by pattern recognition receptors
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(PRR) TLR2/TLR6 and NOD2 (Kleinnijenhuis J et al., 2009). TLR4, the other PRR which is
important in M tb recognition does not play major role in production of IL-1β. The immune
adaptor molecule MyD88 has a central role in the transcription of the IL-1β mRNA during M
tb infection (Kleinnijenhuis J et al., 2009).
Absence in melanoma 2 (AIM2) inflammasome is a cytosolic sensor of the DNA and recognises
DNA viruses and intracellular bacteria. Co-localisation of M tb DNA with AIM2 inflamma‐
some has been observed suggesting their direct interaction (Saiga H et al., 2012). AIM2
inflammasomes are involved in activation of macrophages and secretion of IL-1β during
infection with pathogenic strain of Mycobacterium bovis suggesting its co-operative role in host
immunity (Yang Y, 2013). AIM2 deficient mice are more susceptible to M tb infection and are
defective in production of IL-1β and IL-18 and mount poor Th1 response (Saiga H et al.,
2012). These authors also speculated on the role of AIM2 inflammasome in suppressing type
I interferons in M tb infections. NLRP3 inflammasome is implicated in the protective immune
response to M tb infection by facilitating the maturation process of IL-1β (Rathinam VA et al.,
2012). However, M tb suppresses the activation of the NLRP3 inflammasome by inducing IFN-
β, while IFN-β induces the AIM2 inflammasome which is detrimental to the pathogen
(Fernandes-Alnemri T et al., 2010; Tsuchiya K et al. 2010; Briken V et al., 2013). Thus M tb
balances the level of IFN-β such that NLRP3 inflammasome is kept suppressed and the AIM2
inflammasome is not allowed to be activated. This is done by the ESX-1 secretion system which
is dependent on the ESAT6-an RD1 region encoded protein of M tb (Shah S et al., 2013).
Activating inflammasomes, although critical for protection from M tb infection and tubercu‐
losis, also need to be regulated to prevent the tissue damage and rampant inflammation. Host
regulation of NLRP3 inflammasome is done by nitric oxide which acts as its negative regulator
during M tb infection and consequently controls the level of IL-1β (Mishra BB. et al., 2013).
5. Arachidonic acid metabolites
M tb on engulfment by macrophages tries to prevent the apoptosis of the harbouring macro‐
phage so that it can establish a niche for itself. It also promotes necrosis of the macrophages in
which it resides which help its spread to the neighbouring cells before establishment of the
adaptive immune response of the host (Divangahi M et al., 2013). Several lines of research
suggest that metabolic products of arachidonic acids such as leukotrienes, lipoxins and
eicosanoids play decisive roles by regulating innate and adaptive immunity in the mycobac‐
terial pathogenesis (Divangahi M et al., 2010). The prostaglandins and lipoxins, metabolites of
arachidonic acid, have opposite roles. While prostaglandins such as prostaglandin E2 (PGE2)
is pro-inflammatory in nature and promotes apoptosis, lipoxins inhibit it and promotes
necrosis which results in the spreading of the bacterium (Tobin DM et al., 2010). Lipoxins e.g.
Lipoxin A4 and its metabolites are anti-inflammatory in nature, repress TNF-α and stops
neutrophil recruitment to the site of infection (Tobin DM et al., 2010). The other metabolite
leukotriene B4 (LTB4) enhances level of TNF-α and thus creating a state of hyper-inflammation
which is also not a healthy state for the host. Thus, TNF-α is regulated by metabolic products
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of arachidonic acid to keep its optimum level so that M tb infection is controlled while hyper-
inflammation is also prevented.
6. Role of vitamin D
Deficiency of vitamin D is associated with higher incidence and manifestation of tuberculosis
(Nnoaham KE, 2008; Verway M et al., 2013) and its supplementation helps to overcome this
disease. Vitamin D is also able to restore the impaired secretion of TNF-α from macrophages
of HIV-positive people (Anandaiah A et al., 2013). It acts as a mediator of innate immune
response against M tb by mediating signals from toll like receptors to the activation of
antimicrobial peptides (Liu PT et al., 2006). Liu PT et al. 2006, demonstrated that TLR stimu‐
lation by M tb or lipo-polysaccharide activates vitamin D receptors and subsequent down‐
stream signalling activates transcription and translation of cathelicidin, a peptide with
antimicrobial properties and thus creating an antimicrobial state in the human macrophages.
Vitamin D has a modulatory role on the levels of cytokines specifically IL-1β and thus aid in
immunity to the pathogen (Verway M et al., 2013). It also regulates the role of NLRP3/ caspase1
inflammasome leading to regulation of the levels of IL-1β and cross talk between alveolar
epithelial cells and macrophages which is required for the synthesis and release of anti-
microbial peptides (Verway M et al., 2013).
1, 25-dihydroxyvitamin D3, the active component of vitamin D, plays a major role in induction
of autophagy during M tb infections (Yuk JM et al., 2009). This function of vitamin D3 is
performed by activation of transcription of Beclin-1 and Atg5 genes and is mediated by
cathelicidins (Yuk JM et al., 2009). Vitamin D3 also helps in the formation of autophagosomes,
autophagolysosomes and co-localization of M tb cells with them, an important step in the
killing of the bacterium (Yuk JM et al., 2009).
7. Role of foamy macrophages
After being engulfed by macrophages M tb dys-regulates its lipid metabolism which leads to
lipid accumulation within a subset of these macrophages giving them a characteristic foamy
phenotype. The lipid packed foamy macrophages have been associated with several chronic
disease conditions such as atherosclerosis and during infections with persistent intracellular
pathogens e.g. M Tb, Chlamydia and Toxoplasma (Kalayoglu MV and Byrne GI, 1998; Portugal
LR et al., 2008; Galkina E and Ley K, 2009). Triglycerides, phospholipids and cholesterol
constitute the low density lipo-proteins (LDL) and in foamy macrophages the influx and efflux
of LDLs is dys-regulated (Russell DG, et al., 2009). Cholesterol gets esterified when the
macrophage attains foamy phenotype and is retained as lipid droplets (Russell DG et al.,
2009). Recently it has been shown that triacylglycerols (TAG) of M Tb are derived from host
TAG and are imported by the bacterium for its lipid synthesis (Daniel J et al., 2011). M tb
incorporates host derived lipids directly into its own pool and the accumulation of neutral
lipids by the M tb leads to its lipid fastness (Daniel J et al., 2011).
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It is shown that pathogenic mycobacteria synthesize oxygenated mycolic acids which induce
foamy cell formation of the macrophages (Peyron P et al., 2008) but this might not hold true
under hypoxic conditions (Daniel J et al., 2011). Peyron P et al., 2008 have shown that these
lipid droplets serve as nutritional source to the pathogen and help in its non-replicative life
cycle and persistence. One recent report also suggested that mycobacterium prevents lipolysis
by interfering with the host lipid metabolic pathways, which leads to lipid accumulation inside
the macrophage (Singh V et al., 2012). These lipids serve as a source of nutrition and help the
pathogen in its dormant lifestyle. The specific presence of foamy macrophages in the necrotic
regions has been suggested that they play crucial role in necrosis and hence in spreading of
the bacterium (Peyron P et al., 2008). Although macrophages are the frontline innate immune
cells, it is clear that their foamy phenotype helps the pathogen in establishing persistent
infection and the host innate and adaptive immune response is no more able to eliminate the
pathogen once it happens. Thus the ideal way to target the pathogen is before the establishment
of the foamy phenotype of the macrophages harbouring the M Tb.
8. Role of autophagy
In addition to the above discussed mechanisms, hosts also try to clear the pathogen by inducing
autophagy-an innate defence against M tb (Kumar D et al., 2010; Jo EK, 2013). Nutrient
starvation, stress and activation of the specific cytosolic receptors induce autophagy (Ottenhoff
TH, 2012). By this process protein aggregates, damaged organelles and cytosolic pathogens
are sequestered inside the autophagosomes. The subsequent fusion of the auophagosome with
lysosomes leads to degradation of the trapped entities and this process is prominently involved
in the clearance of intracellular pathogens including mycobacteria (Gutierrez MG et al., 2004;
Alonso S, 2007; Levine B et al. 2011; Cadwell K and Philips JA, 2013). This process is carried
out by the product of autophagy related gene (Atg), Beclin 1 in combination with kinase genes
PIP3-VPS34 and the GTPase-IGRM (Deretic V. 2010). The role of autophagy is also suggested
in inflammation and related phenomenon (Castillo EF, 2012; Deretic V, 2012).
Autophagy regulates innate and adaptive immune pathways viz. antigen presentation to T
cells by macrophages and dendritic cells (Jagannath C, 2009; Ottenhoff TH, 2012) and inflam‐
matory responses (Levine B et al. 2011). Thus autophagy plays an effector function during M
tb pathogenesis, however this process itself is regulated by vitamin D. Vitamin D up regulates
autophagy and plays bridging role between innate and adaptive immune arms (Deretic V,
2005; Yuk JM et al., 2009).
9. Conclusions and future perspectives
M tb, besides evading host immune response against it also delays the onset of the adaptive
immunity (Urdahl KB et al., 2011). M tb engulfed by macrophages tries not only to prevent
apoptosis of harbouring macrophage but also promotes its necrosis which helps in spread of
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of arachidonic acid to keep its optimum level so that M tb infection is controlled while hyper-
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Trends in Infectious Diseases78
It is shown that pathogenic mycobacteria synthesize oxygenated mycolic acids which induce
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the bacterium to the neighbouring cells before establishment of the adaptive immune response
(Urdahl KB et al., 2011). Type I interferons regulate the levels of interferon-γ and production
of the IL-1β which are critical determinants of immunity to tuberculosis (Novikov A et al.,
2011). Eicosanoids play decisive roles in the fate of the infected macrophages (apoptosis versus
necrosis) by regulating the level of tumor necrosis factor. Thus, several of the host molecular
pathways converge to dictate the delicate balance between host immune response and
mycobacterial pathogenesis. We need to further understand their inter-relation and cross
regulation in greater details to tackle the mycobacterial infection appropriately. There are
intensive research and development activities in progress around the globe to tackle the
epidemic of tuberculosis. Bedaquiline-the new drug approved for treatment of the MDR
tuberculosis-was released finally in December 2012. According to WHO report on tuberculosis
2013, there are around ten drugs in various phases of clinical trials and many in the preclinical
stages (Table 1). Also there are many new TB vaccines in the various phases of clinical
development. Whether they are pre-or post-exposure vaccines and other details viz. their
immune-therapeutic potential, killed whole cell or extract etc. are nicely elaborated in the
WHO report on tuberculosis, 2013.
Lead compounds Cyclopeptides, Diarylquinoline, DprE Inhibitors, InhA inhibitor, LeuRS
inhibitor, Macrolides, Mycobacterial Gyrase inhibitors, Pyrazinamide
analogs, Riminophenazines, Ruthenium (II) complexes, Spectinamides,
Translocase-1 inhibitors
Preclinical development CPZEN-45, DC-159a, Q203, SQ609, SQ641, TBI-166
Laboratory toxicity testing PBTZ-169, TBA-354
Phase II AZD5847, Bedaquiline (TMC-207), Linezolid, PA-824, Rifapentine,
SQ-109, Sutezolid (PNU-100480)
Phase III Delamanid (OPC-67689), Gatifloxacin, Moxiflloxacin, Rifapentine
Note: Four of the drugs in phase II trials (italicized) are novel and part of the combination regimens.
Table 1. Development Pipeline for new TB drugs (WHO, 2013)
The current research is also helping us to better understand the life cycle and survival strategies
of the pathogen. Recently, work by Das B et al., 2013, suggested that M tb persists inside the
CD271+/CD45− mesenchymal stem cells in the bone marrow of tuberculosis patients. They
showed that the pathogen remains alive even after the full regimen treatment of the patients
with anti-TB drugs. The CD271+/CD45− mesenchymal stem cells express drug efflux pumps,
produce low levels of reactive oxygen species, are quiescent in nature and have self renewal
capability. This makes them an ideal place for M tb to survive for a long time. The immune-
privileged nature of the bone marrow also supports the dormant life of the pathogen and M
tb is able to live a non replicating life inside the bone marrow mesenchymal stem cells (Das B.
et al., 2013). The part of the extracellular life of M tb in the form of pellicle or biofilms inside
the liquefied granuloma and alternate hiding places has yet to be clearly elucidated. The
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growing knowledge about M tb pathogenesis should help us in targeting tuberculosis more
precisely in future.
R C Rai is financially supported by the project grant from Department of Biotechnology,
Government of India funded to Dr. KVS Rao at ICGEB, New Delhi. Author wish to thank




Immunology Group, International Centre for Genetic Engineering and Biotechnology, Aru‐
na Asaf Ali Marg, New Delhi, India
References
[1] Alonso S, Pethe K, Russell DG, Purdy GE. Lysosomal killing of Mycobacterium
mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc Natl Acad
Sci U S A. 2007 Apr 3;104(14):6031-6.
[2] Anandaiah A, Sinha S, Bole M, Sharma SK, Kumar N, Luthra K, Li X, Zhou X, Nelson
B, Han X, Tachado SD, Patel NR, Koziel H. Vitamin D rescues impaired Mycobacteri‐
um tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-sero‐
positive individuals through an enhanced Toll-like receptor signaling pathway in
vitro. Infect Immun. 2013 Jan;81(1):2-10.
[3] Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Bancher‐
eau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias
A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. An inter‐
feron-inducible neutrophil-driven blood transcriptional signature in human tubercu‐
losis. Nature. 2010 Aug 19; 466 (7309): 973-7.
[4] Bloom BR, Small PM. The evolving relation between humans and Mycobacterium tu‐
berculosis. N Engl J Med. 1998 Mar 5;338(10):677-8.
[5] Briken V, Ahlbrand SE, Shah S. Mycobacterium tuberculosis and the host cell inflam‐
masome: a complex relationship. Front Cell Infect Microbiol. 2013 Oct 9;3:62.
[6] Cadwell K, Philips JA. Autophagy meets phagocytosis. Immunity. 2013 Sep 19;39(3):
425-7.
[7] Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, Delga‐
do-Vargas M, Timmins GS, Bhattacharya D, Yang H, Hutt J, Lyons CR, Dobos KM,
Convergence of host immune mechanisms in Mycobacterium tuberculosis pathogenesis
http://dx.doi.org/10.5772/58319
81
the bacterium to the neighbouring cells before establishment of the adaptive immune response
(Urdahl KB et al., 2011). Type I interferons regulate the levels of interferon-γ and production
of the IL-1β which are critical determinants of immunity to tuberculosis (Novikov A et al.,
2011). Eicosanoids play decisive roles in the fate of the infected macrophages (apoptosis versus
necrosis) by regulating the level of tumor necrosis factor. Thus, several of the host molecular
pathways converge to dictate the delicate balance between host immune response and
mycobacterial pathogenesis. We need to further understand their inter-relation and cross
regulation in greater details to tackle the mycobacterial infection appropriately. There are
intensive research and development activities in progress around the globe to tackle the
epidemic of tuberculosis. Bedaquiline-the new drug approved for treatment of the MDR
tuberculosis-was released finally in December 2012. According to WHO report on tuberculosis
2013, there are around ten drugs in various phases of clinical trials and many in the preclinical
stages (Table 1). Also there are many new TB vaccines in the various phases of clinical
development. Whether they are pre-or post-exposure vaccines and other details viz. their
immune-therapeutic potential, killed whole cell or extract etc. are nicely elaborated in the
WHO report on tuberculosis, 2013.
Lead compounds Cyclopeptides, Diarylquinoline, DprE Inhibitors, InhA inhibitor, LeuRS
inhibitor, Macrolides, Mycobacterial Gyrase inhibitors, Pyrazinamide
analogs, Riminophenazines, Ruthenium (II) complexes, Spectinamides,
Translocase-1 inhibitors
Preclinical development CPZEN-45, DC-159a, Q203, SQ609, SQ641, TBI-166
Laboratory toxicity testing PBTZ-169, TBA-354
Phase II AZD5847, Bedaquiline (TMC-207), Linezolid, PA-824, Rifapentine,
SQ-109, Sutezolid (PNU-100480)
Phase III Delamanid (OPC-67689), Gatifloxacin, Moxiflloxacin, Rifapentine
Note: Four of the drugs in phase II trials (italicized) are novel and part of the combination regimens.
Table 1. Development Pipeline for new TB drugs (WHO, 2013)
The current research is also helping us to better understand the life cycle and survival strategies
of the pathogen. Recently, work by Das B et al., 2013, suggested that M tb persists inside the
CD271+/CD45− mesenchymal stem cells in the bone marrow of tuberculosis patients. They
showed that the pathogen remains alive even after the full regimen treatment of the patients
with anti-TB drugs. The CD271+/CD45− mesenchymal stem cells express drug efflux pumps,
produce low levels of reactive oxygen species, are quiescent in nature and have self renewal
capability. This makes them an ideal place for M tb to survive for a long time. The immune-
privileged nature of the bone marrow also supports the dormant life of the pathogen and M
tb is able to live a non replicating life inside the bone marrow mesenchymal stem cells (Das B.
et al., 2013). The part of the extracellular life of M tb in the form of pellicle or biofilms inside
the liquefied granuloma and alternate hiding places has yet to be clearly elucidated. The
Trends in Infectious Diseases80
growing knowledge about M tb pathogenesis should help us in targeting tuberculosis more
precisely in future.
R C Rai is financially supported by the project grant from Department of Biotechnology,
Government of India funded to Dr. KVS Rao at ICGEB, New Delhi. Author wish to thank




Immunology Group, International Centre for Genetic Engineering and Biotechnology, Aru‐
na Asaf Ali Marg, New Delhi, India
References
[1] Alonso S, Pethe K, Russell DG, Purdy GE. Lysosomal killing of Mycobacterium
mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc Natl Acad
Sci U S A. 2007 Apr 3;104(14):6031-6.
[2] Anandaiah A, Sinha S, Bole M, Sharma SK, Kumar N, Luthra K, Li X, Zhou X, Nelson
B, Han X, Tachado SD, Patel NR, Koziel H. Vitamin D rescues impaired Mycobacteri‐
um tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-sero‐
positive individuals through an enhanced Toll-like receptor signaling pathway in
vitro. Infect Immun. 2013 Jan;81(1):2-10.
[3] Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Bancher‐
eau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias
A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. An inter‐
feron-inducible neutrophil-driven blood transcriptional signature in human tubercu‐
losis. Nature. 2010 Aug 19; 466 (7309): 973-7.
[4] Bloom BR, Small PM. The evolving relation between humans and Mycobacterium tu‐
berculosis. N Engl J Med. 1998 Mar 5;338(10):677-8.
[5] Briken V, Ahlbrand SE, Shah S. Mycobacterium tuberculosis and the host cell inflam‐
masome: a complex relationship. Front Cell Infect Microbiol. 2013 Oct 9;3:62.
[6] Cadwell K, Philips JA. Autophagy meets phagocytosis. Immunity. 2013 Sep 19;39(3):
425-7.
[7] Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, Delga‐
do-Vargas M, Timmins GS, Bhattacharya D, Yang H, Hutt J, Lyons CR, Dobos KM,
Convergence of host immune mechanisms in Mycobacterium tuberculosis pathogenesis
http://dx.doi.org/10.5772/58319
81
Deretic V. Autophagy protects against active tuberculosis by suppressing bacterial
burden and inflammation. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3168-76.
[8] Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. Mycobacterium tubercu‐
losis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-
like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011 Jun;7(6):e1002093.
[9] Dannenberg, A. M., Jr., and J. A. Rook. 1994. Pathogenesis of pulmonary tuberculo‐
sis: an interplay of tissue-damaging and macrophage-activating immune responses.
Dual mechanisms that control bacillary multiplication, p. 459–483. In B. R. Bloom
(ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Mi‐
crobiology, Washington, D.C.
[10] Das B, Kashino SS, Pulu I, Kalita D, Swami V, Yeger H, Felsher DW, Campos-Neto A.
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant
Mycobacterium tuberculosis. Sci Transl Med. 2013 Jan 30;5(170)
[11] Deretic V. Autophagy in innate and adaptive immunity. Trends Immunol. 2005 Oct;
26(10):523-8.
[12] Deretic, V. (2010) Autophagy in infection. Curr. Opin. Cell Biol. 22, 252–262
[13] Deretic V. Autophagy as an innate immunity paradigm: expanding the scope and
repertoire of pattern recognition receptors. Curr Opin Immunol. 2012 Feb;24(1):21-31.
[14] Divangahi M, Behar SM, Remold H. Dying to live: how the death modality of the in‐
fected macrophage affects immunity to tuberculosis. Adv Exp Med Biol.
2013;783:103-20.
[15] Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid
pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol.
2010 Aug;11(8):751-8. doi: 10.1038/ni.1904. Epub 2010 Jul 11.
[16] Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent prog‐
ress. Clin Microbiol Rev. 2005 Oct;18(4):687-702.
[17] Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998
Apr;66(4):1277-81.
[18] Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCor‐
mick M, Huang L, McDermott E, Eisenlohr L, Landel CP, Alnemri ES. The AIM2 in‐
flammasome is critical for innate immunity to Francisella tularensis. Nat Immunol.
2010 May;11(5):385-93.
[19] Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role
for interferon gamma in resistance to Mycobacterium tuberculosisinfection. J Exp
Med. 1993 Dec 1;178(6):2249-54.
[20] Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu
Rev Immunol. 2009;27:165-97.
Trends in Infectious Diseases82
[21] Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physi‐
cian. 2005 Nov 1;72(9):1761-8.
[22] Green AM, Difazio R, Flynn JL. IFN-γ from CD4 T cells is essential for host survival
and enhances CD8 T cell function duringMycobacterium tuberculosis infection. J Im‐
munol. 2013 Jan 1;190(1):270-7.
[23] Gutierrez MC, Brisse S, Brosch R, Fabre M, Omaïs B, Marmiesse M, Supply P, Vin‐
cent V. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tu‐
berculosis. PLoS Pathog. 2005 Sep;1(1):e5. Epub 2005 Aug 19.
[24] Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy
is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in
infected macrophages. Cell. 2004 Dec 17;119(6):753-66.
[25] Harada N. (2006). Characteristics of a diagnostic method for tuberculosis infection
based on whole blood interferon-gamma assay. Kekkaku, 81(11): 681-6.
[26] Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calan‐
dra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA,Pantaleo G.
Dominant TNF-α+Mycobacterium tuberculosis-specific CD4+T cell responses dis‐
criminate between latentinfection and active disease. Nat Med. 2011 Mar;17(3):372-6.
[27] Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Au‐
tophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in
mouse dendritic cells. Nat Med. 2009 Mar;15(3):267-76.
[28] Jayaraman P, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG,
Behar SM. IL-1β promotes antimicrobial immunity in macrophages by regulating
TNFR signaling and caspase-3 activation. J Immunol. 2013 Apr 15;190(8):4196-204.
[29] Jo EK. Autophagy as an innate defense against mycobacteria. Pathog Dis. 2013 Mar;
67(2):108-18.
[30] Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, DesJardin LE,
Schlesinger LS. The human macrophage mannose receptor directs Mycobacterium
tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med. 2005
Oct 3;202(7):987-99.
[31] Kerrigan AM, Brown GD. C-type lectins and phagocytosis. Immunobiology. 2009 Jul;
214(7):562-75
[32] Kleinnijenhuis J, Joosten LA, van de Veerdonk FL, Savage N, van Crevel R, Kullberg
BJ, van der Ven A, Ottenhoff TH, Dinarello CA, van der Meer JW, Netea MG. Tran‐
scriptional and inflammasome-mediated pathways for the induction of IL-1beta pro‐
duction byMycobacterium tuberculosis. Eur J Immunol. 2009 Jul;39(7):1914-22.
Convergence of host immune mechanisms in Mycobacterium tuberculosis pathogenesis
http://dx.doi.org/10.5772/58319
83
Deretic V. Autophagy protects against active tuberculosis by suppressing bacterial
burden and inflammation. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3168-76.
[8] Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. Mycobacterium tubercu‐
losis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-
like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011 Jun;7(6):e1002093.
[9] Dannenberg, A. M., Jr., and J. A. Rook. 1994. Pathogenesis of pulmonary tuberculo‐
sis: an interplay of tissue-damaging and macrophage-activating immune responses.
Dual mechanisms that control bacillary multiplication, p. 459–483. In B. R. Bloom
(ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Mi‐
crobiology, Washington, D.C.
[10] Das B, Kashino SS, Pulu I, Kalita D, Swami V, Yeger H, Felsher DW, Campos-Neto A.
CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant
Mycobacterium tuberculosis. Sci Transl Med. 2013 Jan 30;5(170)
[11] Deretic V. Autophagy in innate and adaptive immunity. Trends Immunol. 2005 Oct;
26(10):523-8.
[12] Deretic, V. (2010) Autophagy in infection. Curr. Opin. Cell Biol. 22, 252–262
[13] Deretic V. Autophagy as an innate immunity paradigm: expanding the scope and
repertoire of pattern recognition receptors. Curr Opin Immunol. 2012 Feb;24(1):21-31.
[14] Divangahi M, Behar SM, Remold H. Dying to live: how the death modality of the in‐
fected macrophage affects immunity to tuberculosis. Adv Exp Med Biol.
2013;783:103-20.
[15] Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid
pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol.
2010 Aug;11(8):751-8. doi: 10.1038/ni.1904. Epub 2010 Jul 11.
[16] Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent prog‐
ress. Clin Microbiol Rev. 2005 Oct;18(4):687-702.
[17] Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998
Apr;66(4):1277-81.
[18] Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCor‐
mick M, Huang L, McDermott E, Eisenlohr L, Landel CP, Alnemri ES. The AIM2 in‐
flammasome is critical for innate immunity to Francisella tularensis. Nat Immunol.
2010 May;11(5):385-93.
[19] Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role
for interferon gamma in resistance to Mycobacterium tuberculosisinfection. J Exp
Med. 1993 Dec 1;178(6):2249-54.
[20] Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu
Rev Immunol. 2009;27:165-97.
Trends in Infectious Diseases82
[21] Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physi‐
cian. 2005 Nov 1;72(9):1761-8.
[22] Green AM, Difazio R, Flynn JL. IFN-γ from CD4 T cells is essential for host survival
and enhances CD8 T cell function duringMycobacterium tuberculosis infection. J Im‐
munol. 2013 Jan 1;190(1):270-7.
[23] Gutierrez MC, Brisse S, Brosch R, Fabre M, Omaïs B, Marmiesse M, Supply P, Vin‐
cent V. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tu‐
berculosis. PLoS Pathog. 2005 Sep;1(1):e5. Epub 2005 Aug 19.
[24] Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy
is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in
infected macrophages. Cell. 2004 Dec 17;119(6):753-66.
[25] Harada N. (2006). Characteristics of a diagnostic method for tuberculosis infection
based on whole blood interferon-gamma assay. Kekkaku, 81(11): 681-6.
[26] Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calan‐
dra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA,Pantaleo G.
Dominant TNF-α+Mycobacterium tuberculosis-specific CD4+T cell responses dis‐
criminate between latentinfection and active disease. Nat Med. 2011 Mar;17(3):372-6.
[27] Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Au‐
tophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in
mouse dendritic cells. Nat Med. 2009 Mar;15(3):267-76.
[28] Jayaraman P, Sada-Ovalle I, Nishimura T, Anderson AC, Kuchroo VK, Remold HG,
Behar SM. IL-1β promotes antimicrobial immunity in macrophages by regulating
TNFR signaling and caspase-3 activation. J Immunol. 2013 Apr 15;190(8):4196-204.
[29] Jo EK. Autophagy as an innate defense against mycobacteria. Pathog Dis. 2013 Mar;
67(2):108-18.
[30] Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, DesJardin LE,
Schlesinger LS. The human macrophage mannose receptor directs Mycobacterium
tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med. 2005
Oct 3;202(7):987-99.
[31] Kerrigan AM, Brown GD. C-type lectins and phagocytosis. Immunobiology. 2009 Jul;
214(7):562-75
[32] Kleinnijenhuis J, Joosten LA, van de Veerdonk FL, Savage N, van Crevel R, Kullberg
BJ, van der Ven A, Ottenhoff TH, Dinarello CA, van der Meer JW, Netea MG. Tran‐
scriptional and inflammasome-mediated pathways for the induction of IL-1beta pro‐
duction byMycobacterium tuberculosis. Eur J Immunol. 2009 Jul;39(7):1914-22.
Convergence of host immune mechanisms in Mycobacterium tuberculosis pathogenesis
http://dx.doi.org/10.5772/58319
83
[33] Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV. Genome-wide
analysis of the host intracellular network that regulates survival of Mycobacterium
tuberculosis. Cell, 2010 Mar 5;140(5):731-43.
[34] Lazarevic V, Martinon F. Linking inflammasome activation and phagosome matura‐
tion. Cell Host Microbe. 2008 Apr 17;3(4):199-200.
[35] Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Na‐
ture. 2011 Jan 20;469(7330):323-35.
[36] Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, Wheelwright M,
Vazirnia A, Zhang X, Steinmeyer A, Zügel U, Hollis BW, Cheng G, Modlin RL. Con‐
vergence of IL-1beta and VDR activation pathways in human TLR2/1-induced anti‐
microbial responses. PLoS One. 2009 Jun 5;4(6)
[37] Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K,
Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisen‐
berg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor
triggering of a vitamin D-mediated human antimicrobial response. Science. 2006 Mar
24;311(5768):1770-3.
[38] Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE 3rd,
Freedman VH,Kaplan G. Virulence of a Mycobacterium tuberculosis clinical isolate
in mice is determined by failure to induce Th1 type immunity and is associated with
induction of IFN-alpha /beta. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5752-7.
[39] Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, Springer B, Timmins GS, Sand‐
er P, Deretic V. Mycobacterium tuberculosis prevents inflammasome activation. Cell
Host Microbe. 2008 Apr 17;3(4):224-32.
[40] Mayer-Barber KD, Barber DL, Shenderov K, White SD, Wilson MS, Cheever A, Ku‐
gler D, Hieny S, Caspar P, Núñez G, Schlueter D, Flavell RA, Sutterwala FS,Sher A.
Caspase-1 independent IL-1beta production is critical for host resistance to mycobac‐
terium tuberculosis and does not require TLR signaling in vivo. J Immunol. 2010 Apr
1;184(7):3326-30.
[41] Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sas‐
setti CM. Nitric oxide controls the immunopathology of tuberculosis by inhibiting
NLRP3 inflammasome-dependent processing of IL-1β. Nat Immunol. 2013 Jan;14(1):
52-60.
[42] Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic
review and meta-analysis. Int J Epidemiol. 2008 Feb;37(1):113-9. doi: 10.1093/ije/
dym247.
[43] Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber
KD, Myers TG, Rabin RL, Trinchieri G, Sher A, Feng CG. Mycobacterium tuberculo‐
Trends in Infectious Diseases84
sis triggers host type I IFN signaling to regulate IL-1β production in human macro‐
phages. J Immunol. 2011 Sep 1;187(5):2540-7.
[44] O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune
response in tuberculosis. Annu Rev Immunol. 2013;31:475-527.
[45] Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, Alahari A,
Kremer L, Jacobs WR Jr, Hatfull GF. Growth of Mycobacterium tuberculosis biofilms
containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol.
2008 Jul;69(1):164-74.
[46] Orme IM. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis
(Edinb). 2013 Aug 4. doi:pii: S1472-9792(13)00142-X. 10.1016/j.tube.2013.07.004.
[47] Ottenhoff TH. New pathways of protective and pathological host defense to myco‐
bacteria. Trends Microbiol. 2012 Sep;20(9):419-28.
[48] Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile
JF, Marchou B, Cardona PJ, de Chastellier C, Altare F. Foamy macrophages from tu‐
berculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculo‐
sis persistence. PLoS Pathog. 2008 Nov;4(11):e1000204. doi: 10.1371/journal.ppat.
1000204.
[49] Portugal LR, Fernandes LR, Pietra Pedroso VS, Santiago HC, Gazzinelli RT, Alvarez-
Leite JI. Influence of low-density lipoprotein (LDL) receptor on lipid composition, in‐
flammation and parasitism during Toxoplasma gondii infection. Microbes Infect.
2008 Mar;10(3):276-84.
[50] Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, Leong
JM, Fitzgerald KA. TRIF licenses caspase-11-dependent NLRP3 inflammasome acti‐
vation by gram-negative bacteria. Cell. 2012 Aug 3;150(3):606-19.
[51] Remoli ME, Giacomini E, Lutfalla G, Dondi E, Orefici G, Battistini A, Uzé G, Pellegri‐
ni S, Coccia EM. Selective expression of type I IFN genes in human dendritic cells in‐
fected with Mycobacterium tuberculosis. J Immunol. 2002 Jul 1;169(1):366-74.
[52] Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the
progression of the human tuberculosis granuloma. Nat Immunol. 2009 Sep;10(9):
943-8.
[53] Saiga H, Kitada S, Shimada Y, Kamiyama N, Okuyama M, Makino M, Yamamoto M,
Takeda K. Critical role of AIM2 in Mycobacterium tuberculosis infection. Int Immu‐
nol. 2012 Oct;24(10):637-44. Epub 2012 Jun 13.
[54] Shah S, Bohsali A, Ahlbrand SE, Srinivasan L, Rathinam VA, Vogel SN, Fitzgerald
KA, Sutterwala FS, Briken V. Cutting edge: Mycobacterium tuberculosis but not non‐
virulent mycobacteria inhibits IFN-β and AIM2 inflammasome-dependent IL-1β pro‐
duction via its ESX-1 secretion system. J Immunol. 2013 Oct 1;191(7):3514-8
Convergence of host immune mechanisms in Mycobacterium tuberculosis pathogenesis
http://dx.doi.org/10.5772/58319
85
[33] Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV. Genome-wide
analysis of the host intracellular network that regulates survival of Mycobacterium
tuberculosis. Cell, 2010 Mar 5;140(5):731-43.
[34] Lazarevic V, Martinon F. Linking inflammasome activation and phagosome matura‐
tion. Cell Host Microbe. 2008 Apr 17;3(4):199-200.
[35] Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Na‐
ture. 2011 Jan 20;469(7330):323-35.
[36] Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, Wheelwright M,
Vazirnia A, Zhang X, Steinmeyer A, Zügel U, Hollis BW, Cheng G, Modlin RL. Con‐
vergence of IL-1beta and VDR activation pathways in human TLR2/1-induced anti‐
microbial responses. PLoS One. 2009 Jun 5;4(6)
[37] Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K,
Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisen‐
berg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor
triggering of a vitamin D-mediated human antimicrobial response. Science. 2006 Mar
24;311(5768):1770-3.
[38] Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE 3rd,
Freedman VH,Kaplan G. Virulence of a Mycobacterium tuberculosis clinical isolate
in mice is determined by failure to induce Th1 type immunity and is associated with
induction of IFN-alpha /beta. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5752-7.
[39] Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, Springer B, Timmins GS, Sand‐
er P, Deretic V. Mycobacterium tuberculosis prevents inflammasome activation. Cell
Host Microbe. 2008 Apr 17;3(4):224-32.
[40] Mayer-Barber KD, Barber DL, Shenderov K, White SD, Wilson MS, Cheever A, Ku‐
gler D, Hieny S, Caspar P, Núñez G, Schlueter D, Flavell RA, Sutterwala FS,Sher A.
Caspase-1 independent IL-1beta production is critical for host resistance to mycobac‐
terium tuberculosis and does not require TLR signaling in vivo. J Immunol. 2010 Apr
1;184(7):3326-30.
[41] Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sas‐
setti CM. Nitric oxide controls the immunopathology of tuberculosis by inhibiting
NLRP3 inflammasome-dependent processing of IL-1β. Nat Immunol. 2013 Jan;14(1):
52-60.
[42] Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic
review and meta-analysis. Int J Epidemiol. 2008 Feb;37(1):113-9. doi: 10.1093/ije/
dym247.
[43] Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber
KD, Myers TG, Rabin RL, Trinchieri G, Sher A, Feng CG. Mycobacterium tuberculo‐
Trends in Infectious Diseases84
sis triggers host type I IFN signaling to regulate IL-1β production in human macro‐
phages. J Immunol. 2011 Sep 1;187(5):2540-7.
[44] O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune
response in tuberculosis. Annu Rev Immunol. 2013;31:475-527.
[45] Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, Alahari A,
Kremer L, Jacobs WR Jr, Hatfull GF. Growth of Mycobacterium tuberculosis biofilms
containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol.
2008 Jul;69(1):164-74.
[46] Orme IM. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis
(Edinb). 2013 Aug 4. doi:pii: S1472-9792(13)00142-X. 10.1016/j.tube.2013.07.004.
[47] Ottenhoff TH. New pathways of protective and pathological host defense to myco‐
bacteria. Trends Microbiol. 2012 Sep;20(9):419-28.
[48] Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile
JF, Marchou B, Cardona PJ, de Chastellier C, Altare F. Foamy macrophages from tu‐
berculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculo‐
sis persistence. PLoS Pathog. 2008 Nov;4(11):e1000204. doi: 10.1371/journal.ppat.
1000204.
[49] Portugal LR, Fernandes LR, Pietra Pedroso VS, Santiago HC, Gazzinelli RT, Alvarez-
Leite JI. Influence of low-density lipoprotein (LDL) receptor on lipid composition, in‐
flammation and parasitism during Toxoplasma gondii infection. Microbes Infect.
2008 Mar;10(3):276-84.
[50] Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, Leong
JM, Fitzgerald KA. TRIF licenses caspase-11-dependent NLRP3 inflammasome acti‐
vation by gram-negative bacteria. Cell. 2012 Aug 3;150(3):606-19.
[51] Remoli ME, Giacomini E, Lutfalla G, Dondi E, Orefici G, Battistini A, Uzé G, Pellegri‐
ni S, Coccia EM. Selective expression of type I IFN genes in human dendritic cells in‐
fected with Mycobacterium tuberculosis. J Immunol. 2002 Jul 1;169(1):366-74.
[52] Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the
progression of the human tuberculosis granuloma. Nat Immunol. 2009 Sep;10(9):
943-8.
[53] Saiga H, Kitada S, Shimada Y, Kamiyama N, Okuyama M, Makino M, Yamamoto M,
Takeda K. Critical role of AIM2 in Mycobacterium tuberculosis infection. Int Immu‐
nol. 2012 Oct;24(10):637-44. Epub 2012 Jun 13.
[54] Shah S, Bohsali A, Ahlbrand SE, Srinivasan L, Rathinam VA, Vogel SN, Fitzgerald
KA, Sutterwala FS, Briken V. Cutting edge: Mycobacterium tuberculosis but not non‐
virulent mycobacteria inhibits IFN-β and AIM2 inflammasome-dependent IL-1β pro‐
duction via its ESX-1 secretion system. J Immunol. 2013 Oct 1;191(7):3514-8
Convergence of host immune mechanisms in Mycobacterium tuberculosis pathogenesis
http://dx.doi.org/10.5772/58319
85
[55] Singh SB, Biswas D, Rawat J, Sindhwani G, Patras A, Devrani S, Sarkar P, Mitra S,
Gupta SK. Ethnicity-tailored novel set of ESAT-6 peptides for differentiating active
and latent tuberculosis. Tuberculosis (Edinb). 2013 Nov;93(6):618-24.
[56] Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KV. Mycobacterium tuberculo‐
sis-driven targeted recalibration of macrophage lipid homeostasis promotes the
foamy phenotype. Cell Host Microbe. 2012 Nov 15;12(5):669-81.
[57] Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of
virulence. Clin Microbiol Rev. 2003 Jul;16(3):463-96.
[58] Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, Komisopoulou E,
Kelly-Scumpia K, Chun R, Iyer SS, Sarno EN, Rea TH, Hewison M, Adams JS, Pop‐
per SJ, Relman DA, Stenger S, Bloom BR, Cheng G, Modlin RL. Type I interferon sup‐
presses type II interferon-triggered human anti-mycobacterial responses. Science.
2013 Mar 22;339(6126):1448-53.
[59] Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge
S, King MC, Hawn TR, Moens CB, Ramakrishnan L. The lta4h locus modulates sus‐
ceptibility to mycobacterial infection in zebrafish and humans. Cell. 2010 Mar
5;140(5):717-30. doi: 10.1016/j.cell.2010.02.013.
[60] Trinchieri, G. Type I interferon: friend or foe? J. Exp. Med. 2010, 207: 2053–2063.
[61] Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuber‐
culosis. Mucosal Immunol. 2011 May;4(3):288-93.
[62] Verway M, Bouttier M, Wang TT, Carrier M, Calderon M, An BS, Devemy E, McIn‐
tosh F, Divangahi M, Behr MA, White JH. Vitamin D induces interleukin-1β expres‐
sion: paracrine macrophage epithelial signaling controls M. tuberculosis infection.
PLoS Pathog. 2013 Jun;9(6):e1003407.
[63] Yang Y, Zhou X, Kouadir M, Shi F, Ding T, Liu C, Liu J, Wang M, Yang L, Yin X,
Zhao D. The AIM2 inflammasome is involved in macrophage activation during in‐
fection with virulentMycobacterium bovis strain. J Infect Dis. 2013 Dec 1;208(11):
1849-58.
[64] Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo
EK. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelici‐
din. Cell Host Microbe. 2009 Sep 17;6(3):231-43
[65] World Health Organization, Global tuberculosis report 2013.
[66] Zink AR, Sola C, Reischl U, Grabner W, Rastogi N, Wolf H, Nerlich AG. Characteri‐
zation of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by
spoligotyping.
Trends in Infectious Diseases86
Section 3
Molecular Diagnostics and Stewardship for
Infectious Diseases
[55] Singh SB, Biswas D, Rawat J, Sindhwani G, Patras A, Devrani S, Sarkar P, Mitra S,
Gupta SK. Ethnicity-tailored novel set of ESAT-6 peptides for differentiating active
and latent tuberculosis. Tuberculosis (Edinb). 2013 Nov;93(6):618-24.
[56] Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KV. Mycobacterium tuberculo‐
sis-driven targeted recalibration of macrophage lipid homeostasis promotes the
foamy phenotype. Cell Host Microbe. 2012 Nov 15;12(5):669-81.
[57] Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of
virulence. Clin Microbiol Rev. 2003 Jul;16(3):463-96.
[58] Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, Komisopoulou E,
Kelly-Scumpia K, Chun R, Iyer SS, Sarno EN, Rea TH, Hewison M, Adams JS, Pop‐
per SJ, Relman DA, Stenger S, Bloom BR, Cheng G, Modlin RL. Type I interferon sup‐
presses type II interferon-triggered human anti-mycobacterial responses. Science.
2013 Mar 22;339(6126):1448-53.
[59] Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge
S, King MC, Hawn TR, Moens CB, Ramakrishnan L. The lta4h locus modulates sus‐
ceptibility to mycobacterial infection in zebrafish and humans. Cell. 2010 Mar
5;140(5):717-30. doi: 10.1016/j.cell.2010.02.013.
[60] Trinchieri, G. Type I interferon: friend or foe? J. Exp. Med. 2010, 207: 2053–2063.
[61] Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuber‐
culosis. Mucosal Immunol. 2011 May;4(3):288-93.
[62] Verway M, Bouttier M, Wang TT, Carrier M, Calderon M, An BS, Devemy E, McIn‐
tosh F, Divangahi M, Behr MA, White JH. Vitamin D induces interleukin-1β expres‐
sion: paracrine macrophage epithelial signaling controls M. tuberculosis infection.
PLoS Pathog. 2013 Jun;9(6):e1003407.
[63] Yang Y, Zhou X, Kouadir M, Shi F, Ding T, Liu C, Liu J, Wang M, Yang L, Yin X,
Zhao D. The AIM2 inflammasome is involved in macrophage activation during in‐
fection with virulentMycobacterium bovis strain. J Infect Dis. 2013 Dec 1;208(11):
1849-58.
[64] Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo
EK. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelici‐
din. Cell Host Microbe. 2009 Sep 17;6(3):231-43
[65] World Health Organization, Global tuberculosis report 2013.
[66] Zink AR, Sola C, Reischl U, Grabner W, Rastogi N, Wolf H, Nerlich AG. Characteri‐
zation of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by
spoligotyping.
Trends in Infectious Diseases86
Section 3
Molecular Diagnostics and Stewardship for
Infectious Diseases
Chapter 5
Molecular Diagnostics as an Indispensable Tool for the
Diagnosis of Infectious Diseases of Viral Origin and
Global Impact
Nora Rosas-Murrieta, Irma Herrera-Camacho,
Lourdes Millán-Pérez-Peña, Francisca Sosa-Jurado,
Gerardo Santos-López, Verónica Vallejo-Ruíz and
Julio Reyes-Leyva
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57581
1. Introduction
Infectious diseases are responsible for a considerable number of deaths in infectious in entire
world. Infectious diseases are human diseases caused by viruses, bacteria, parasites, fungi and
other microorganisms. Most of them have been controlled by vaccines or antimicrobials.
However, some of them still represent global public health problems and are being monitored
by the WHO and Center for Disease Control and Prevention. This chapter provides an
overview of the applications of molecular methods for infectious diseases caused by viruses
(intracellular obligate parasites) of global impact such as Dengue virus, Hepatitis B virus or
influenza A virus. The infectious diseases not only represent a potential danger to the life of
all human beings but also a significant investment in its detection, treatment and control of
their spread. The increase in opportunities of infection by globalization, high rates of mobility
among most countries around the world, the patient susceptibility to diseases due to genetic
variation in populations [1], the ability of the microorganisms to evade the host immune
response has forced the World Health Organization (WHO) to establish better methods of
detection, prevention and control of infectious diseases caused by viruses as influenza A virus,
coronaviruses, dengue virus, among others [2]. On the other hand, some types of cancer are
the result of chronic viral infections caused by human papillomavirus, hepatitis B and C virus.
Other infectious diseases are related to the development of neurological disorders caused by
the measles virus, or human immunodeficiency virus [3]. In the determination of the etiology
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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of such diseases has made extensive use of clinical procedures internationally validated as
methods based on viral cultures and serological assays. However, it is increasing the use of
nucleic acid tests in the diagnosis of infectious disease of viral etiology, considering that a
critical step to proper treatment and control of any virus infection is a correct diagnosis.
Diagnostic tests based on nucleic acid (NAT, nucleic acid tests) more used are the nucleic acid
sequence-based amplification (NASBA), polymerase chain reaction (PCR) or real-time PCR for
virus detection, genotyping and quantification. In addition, the automation of these techniques
decrease in test time, low contamination risk, ease of performance, speed and have lower
detection limits [4] show the relevance of their use. The detection of the infectious agent can
be done by detection of the genomic DNA, genomic ARN and the viral messenger RNA
(mRNA) using the follow techniques: Nucleic acids hybridization (Solid-phase, Liquid-phase
or in situ hybridization), amplification of the signal of nucleic acids (branched-DNA assays
and Hybrid capture assays), nucleic acid amplification (PCR, Real-Time PCR, Nested PCR,
Multiplex PCR, Transcriptional-based amplification methods coupled to qPCR or NASBA,
Strand displacement amplification), Microarrays (DNA microarrays and Multiplexed micro‐
sphere-base array) [5]. Currently there are some variants of the above techniques aimed to
screening for detection or simultaneous discrimination of various etiological agents using
multiplex PCR techniques [6], MassTag PCR, a PCR platform coupled to a mass spectrometer
which allows simultaneous detection of >20 different pathogens [7] or microarrays pathogen
detection (Virochip) [8]. The routine use of molecular techniques for the fast differential
diagnosis of viral infections is vital for a high quality care of the patient with an infectious
disease, directs the best therapeutic scheme, thus reducing the likelihood of complications, the
proper choice of antiviral drug or the best strategy for control of viral replication, reduces
resistance to antivirals and prevent the worsening of the clinical picture, the spread of the
disease and the death of the patient [9]. This chapter will present molecular techniques applied
to the diagnosis of infectious disease of viral etiology and incidence worldwide. A critical first
step to proper treatment and control of any virus infection is a correct diagnosis. Conventional
diagnostic tests for viruses it based on amplification of conserved portions of the viral genome,
detection of antibodies against to viral proteins, or replication of the virus in cell cultures.
2. Dengue virus
Dengue virus (DENV) infection is the most common arthropodborne viral disease of humans;
Aedes mosquitoes, principally Aedes aegypti, transmit this disease. According World Health
Organization DENV is an emerging infectious agent that infects with an estimated 50–100
million clinical infections occurring annually worldwide [10]. DENV belongs to the family
Flaviviridae, genus Flavivirus. DENV is a small are spherical and enveloped virus that contain
a positive strand RNA genome of approximately 10,600 nucleotides coding for three structural
proteins (capsid C, membrane, M, and the envelope, E) and seven non-structural proteins (NS1,
xlinkA, xlinkB, NS3, NS4A, NS4B, NS5) [11], (Figure 1). The envelope protein (E) plays a key
role in several important processes including receptor binding, blood cell hemagglutination,
and induction of a protective immune response, membrane fusion and virion assembly. Two
types of virions are recognized: mature extracellular virions contain M protein, while imma‐
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ture intracellular virions contain prM, which is processed proteolytically during maturation
to yield M protein. The envelope of the virus contains the viral surface proteins E and M [12,13].
Figure 1. Schematic diagram of dengue virus genome. The DENV genome of positive-sense RNA and single-stranded,
comprises approximately 10,600 nucleotides. Any region of genome can be used for genome detection by molecular
techniques.
There are 4 antigenically and genetically distinct serotypes (DENV-1,-2,-3 and-4), being the
“Asian” genotypes of DEN-2 and DEN-3 the most frequently associated with severe disease
accompanying secondary dengue infections [14]. In human, the virus can cause a spectrum of
illness, 75% of DENV infections are asymptomatic. But in persons with symptomatic DENV
infection (dengue), the illness occurs in three phases. Acute phase, with 2–7 days of fever or
self-limiting influenza-like illness (dengue fever or DF), accompanied by headache, retro-
orbital eye pain, joint pain, muscle and/or bone pain, rash, mild bleeding manifestations and
low white cell count. The critical phase of dengue which marks a 24 to 48 hours, period in
which can occur the named severe dengue associated with vascular leakage, hemorrhage
(dengue hemorrhagic fever or DHF), potentially leading to vascular shock (dengue shock
syndrome or DSS), without appropriate treatment, patients with severe dengue are at risk of
death. The convalescent phase of dengue lasts for 4-7 days [15-18]. During the past five decades,
the incidence of dengue has increased 30-fold. In 2012, dengue was the most important
mosquito-borne viral disease in the world. The emergence and spread of all four dengue
viruses (“serotypes”) from Asia to the Americas, Africa and the Eastern Mediterranean regions
represent a global pandemic threat. Because epidemics of dengue result in human suffering,
strained health services and massive economic losses, an international effort to reduce
morbidity and mortality is long overdue coordinated by WHO named Global Strategy for
Dengue Prevention and Control 2012-2020 [19]. The goal of the global strategy is to reduce the
burden of dengue by to reduce mortality and morbidity from dengue by 2020 by at least 50%
and 25% respectively. The laboratory diagnosis of dengue can detect severe cases, case
confirmation and differential diagnosis with other infectious diseases. Diagnosis of dengue is
made by detecting the infective virus, virus genome, dengue antigen or by analyzing, the
serological responses (IgM or IgG) present after infection. Serology is currently the most widely
applied in routine diagnosis [20] (Table 1). After the mosquito bites occurs an incubation period
of 4–10 days, resulting in an asymptomatic or symptomatic dengue infection. In this period,
the virus replicates and an antibody response is developed (Figure 2). The development of IgM
antibody is coincident with the disappearance of fever and viraemia. In a primary infection
(when an individual is infected for the first time with a flavivirus), viraemia develops from 1–
2 days before the onset of fever until 4–5 days after and anti-dengue IgM specific antibodies
can be detected 3−6 days after fever onset. Low levels of IgM are still detectable around one to
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of such diseases has made extensive use of clinical procedures internationally validated as
methods based on viral cultures and serological assays. However, it is increasing the use of
nucleic acid tests in the diagnosis of infectious disease of viral etiology, considering that a
critical step to proper treatment and control of any virus infection is a correct diagnosis.
Diagnostic tests based on nucleic acid (NAT, nucleic acid tests) more used are the nucleic acid
sequence-based amplification (NASBA), polymerase chain reaction (PCR) or real-time PCR for
virus detection, genotyping and quantification. In addition, the automation of these techniques
decrease in test time, low contamination risk, ease of performance, speed and have lower
detection limits [4] show the relevance of their use. The detection of the infectious agent can
be done by detection of the genomic DNA, genomic ARN and the viral messenger RNA
(mRNA) using the follow techniques: Nucleic acids hybridization (Solid-phase, Liquid-phase
or in situ hybridization), amplification of the signal of nucleic acids (branched-DNA assays
and Hybrid capture assays), nucleic acid amplification (PCR, Real-Time PCR, Nested PCR,
Multiplex PCR, Transcriptional-based amplification methods coupled to qPCR or NASBA,
Strand displacement amplification), Microarrays (DNA microarrays and Multiplexed micro‐
sphere-base array) [5]. Currently there are some variants of the above techniques aimed to
screening for detection or simultaneous discrimination of various etiological agents using
multiplex PCR techniques [6], MassTag PCR, a PCR platform coupled to a mass spectrometer
which allows simultaneous detection of >20 different pathogens [7] or microarrays pathogen
detection (Virochip) [8]. The routine use of molecular techniques for the fast differential
diagnosis of viral infections is vital for a high quality care of the patient with an infectious
disease, directs the best therapeutic scheme, thus reducing the likelihood of complications, the
proper choice of antiviral drug or the best strategy for control of viral replication, reduces
resistance to antivirals and prevent the worsening of the clinical picture, the spread of the
disease and the death of the patient [9]. This chapter will present molecular techniques applied
to the diagnosis of infectious disease of viral etiology and incidence worldwide. A critical first
step to proper treatment and control of any virus infection is a correct diagnosis. Conventional
diagnostic tests for viruses it based on amplification of conserved portions of the viral genome,
detection of antibodies against to viral proteins, or replication of the virus in cell cultures.
2. Dengue virus
Dengue virus (DENV) infection is the most common arthropodborne viral disease of humans;
Aedes mosquitoes, principally Aedes aegypti, transmit this disease. According World Health
Organization DENV is an emerging infectious agent that infects with an estimated 50–100
million clinical infections occurring annually worldwide [10]. DENV belongs to the family
Flaviviridae, genus Flavivirus. DENV is a small are spherical and enveloped virus that contain
a positive strand RNA genome of approximately 10,600 nucleotides coding for three structural
proteins (capsid C, membrane, M, and the envelope, E) and seven non-structural proteins (NS1,
xlinkA, xlinkB, NS3, NS4A, NS4B, NS5) [11], (Figure 1). The envelope protein (E) plays a key
role in several important processes including receptor binding, blood cell hemagglutination,
and induction of a protective immune response, membrane fusion and virion assembly. Two
types of virions are recognized: mature extracellular virions contain M protein, while imma‐
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ture intracellular virions contain prM, which is processed proteolytically during maturation
to yield M protein. The envelope of the virus contains the viral surface proteins E and M [12,13].
Figure 1. Schematic diagram of dengue virus genome. The DENV genome of positive-sense RNA and single-stranded,
comprises approximately 10,600 nucleotides. Any region of genome can be used for genome detection by molecular
techniques.
There are 4 antigenically and genetically distinct serotypes (DENV-1,-2,-3 and-4), being the
“Asian” genotypes of DEN-2 and DEN-3 the most frequently associated with severe disease
accompanying secondary dengue infections [14]. In human, the virus can cause a spectrum of
illness, 75% of DENV infections are asymptomatic. But in persons with symptomatic DENV
infection (dengue), the illness occurs in three phases. Acute phase, with 2–7 days of fever or
self-limiting influenza-like illness (dengue fever or DF), accompanied by headache, retro-
orbital eye pain, joint pain, muscle and/or bone pain, rash, mild bleeding manifestations and
low white cell count. The critical phase of dengue which marks a 24 to 48 hours, period in
which can occur the named severe dengue associated with vascular leakage, hemorrhage
(dengue hemorrhagic fever or DHF), potentially leading to vascular shock (dengue shock
syndrome or DSS), without appropriate treatment, patients with severe dengue are at risk of
death. The convalescent phase of dengue lasts for 4-7 days [15-18]. During the past five decades,
the incidence of dengue has increased 30-fold. In 2012, dengue was the most important
mosquito-borne viral disease in the world. The emergence and spread of all four dengue
viruses (“serotypes”) from Asia to the Americas, Africa and the Eastern Mediterranean regions
represent a global pandemic threat. Because epidemics of dengue result in human suffering,
strained health services and massive economic losses, an international effort to reduce
morbidity and mortality is long overdue coordinated by WHO named Global Strategy for
Dengue Prevention and Control 2012-2020 [19]. The goal of the global strategy is to reduce the
burden of dengue by to reduce mortality and morbidity from dengue by 2020 by at least 50%
and 25% respectively. The laboratory diagnosis of dengue can detect severe cases, case
confirmation and differential diagnosis with other infectious diseases. Diagnosis of dengue is
made by detecting the infective virus, virus genome, dengue antigen or by analyzing, the
serological responses (IgM or IgG) present after infection. Serology is currently the most widely
applied in routine diagnosis [20] (Table 1). After the mosquito bites occurs an incubation period
of 4–10 days, resulting in an asymptomatic or symptomatic dengue infection. In this period,
the virus replicates and an antibody response is developed (Figure 2). The development of IgM
antibody is coincident with the disappearance of fever and viraemia. In a primary infection
(when an individual is infected for the first time with a flavivirus), viraemia develops from 1–
2 days before the onset of fever until 4–5 days after and anti-dengue IgM specific antibodies
can be detected 3−6 days after fever onset. Low levels of IgM are still detectable around one to
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three months after fever. In addition, the primary infection is characterized by slowly increas‐
ing but low levels of dengue-specific IgG, becoming elevated at days 9−10. Low IgG levels
persist for decades, an indication of a past dengue infection. In a secondary infection, there is
a rapid and higher increase of anti-dengue specific IgG antibodies. High IgG levels remain for
30–40 days [21]. The serological tests have been used for the diagnosis of dengue infection:
hemagglutination-inhibition (HI), complement fixation (CF), neutralization test (NT), immu‐
noglobulin M (IgM) capture enzyme linked immunosorbent assay (MAC-ELISA) and indirect
immunoglobulin G ELISA. High cross-reactivity was observed with these tests. MAC-ELISA
and rapid tests are the most frequent methods for IgM detection and in the detection of IgG
are used HIA or ELISA [22-25]. Dengue non-structural protein 1 (NS1) is secreted from infected
cells and produces a very strong humoral response. NS1 is a useful early serum marker for
primary and secondary dengue infections, and is typically present between days 1–9 after onset
of clinical signs [23]. In febrile patients, the early diagnosis of dengue virus infection on based
on NS1 viral antigen [26-27]. At the end of the acute phase of infection, serology is the method
of choice for diagnosis by detection anti-DENV IgM and IgG antibodies using MAC-ELISA.
High sensitivity for NS1 antigen detection was observed by the association of MAC-ELISA
with a commercial anti-DENV IgM/IgG rapid test (PanbioH Dengue Early Rapid test) [28]. A
DENV NS1 capture assay using a test NS1 Ag Strip (BioRad Laboratories) is a valuable tool to
postmortem dengue confirmation [29]. There are several commercial kits to dengue diagnostic
such as the SD Bioline Dengue Duo device (Standard Diagnostic Inc., Korea) this test is
composed of 2 tests to detect DENV NS1 antigen (first test) and anti-DENV IgM/IgG (second
test) in serum, plasma or whole blood. With this test, still after the onset of illness, the virus
can detected in serum, plasma, circulating blood cells and other tissues for 4-5 days.
SAMPLE DIAGNOSTIC METHOD METHODOLOGY
Serological
response
Paired sera (acute serum
from 1-5 days and
second serum 15-21
days after)
IgM or IgG seroconversion ELISA
HIA
Neutralization test












(1-5 days of fever) and
necropsy tissues
Viral isolation Mosquito cell culture inoculation
Nucleic acid detection RT-PCR and real time RT-PCR
Antigen detection NS1 Ag rapid tests
NS1 Ag ELISA
Immuno-histochemistry
ELISA (Enzyme-linked immunosorbent assay). HIA (Haemagglutination inhibition assay). IgG (Immunoglubulin G). IgM
(Immunoglobulin M). NS1 Ag (Non-structural protein 1). RT-PCR (Reverse transcriptase polymerase chain reaction). In‐
formation based on Chapter 4. Laboratory Diagnosis and Diagnostic Tests. Dengue Guidelines for Diagnosis, Treat‐
ment, Prevention and Control. Geneva. TDR/World Health Organization. 2012 [21].
Table 1. Dengue diagnostic methods.
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Dengue diagnosis also relies on viral cell culture methods [30,31]. Specimens for virus isolation
should be collected early in the course of the infection, during the period of viraemia (usually
before day 5). Virus may be recovery from serum, plasma and peripheral blood mononuclear
cells. Dengue virus is heat-labile; specimens awaiting transport to the laboratory should be
kept in a refrigerator or packed in wet ice. Cell culture is the most widely used method for
dengue virus isolation usually takes several days. Four methods of viral isolation have been
routinely used for dengue viruses: intracerebral inoculation of newborn mice, inoculation on
mammalian cell cultures, intrathoracic inoculation of adult mosquitoes, and inoculation on
mosquito cell cultures [32]. The mosquito cell line C6/36 (cloned from Ae. albopictus) or AP61
(cell line from Ae. pseudoscutellaris) are the host cells of choice for isolation of virus. Indirect
fluorescent antibody staining of the infected cell culture is often regarded as the “gold
standard” in dengue diagnostics. However, it is tedious, time-consuming, and requires cell
culture. All these studies have shown that this can be a valuable approach, especially in the
early phase of infection; however, in some cases, they do not identify the viral serotype and
these assays may not be as sensitive as the detection of viral RNA by nucleic acid amplification
tests (NAAT) using reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time
RT-PCR may assume a very important role in dengue diagnosis at confirms an acute dengue
infection [33, 20, 21]. Molecular diagnosis methods are usually rapid, sensitive, and simple
when correctly standardized and can be used for serotype identification and quantification of
genome copies in human clinical samples, biopsies, autopsy tissues, or mosquitoes. NAAT
assays may identify viral RNA within 24–48 hours. Although, also be able to detect dengue
viruses up to the 10th day after the onset of the symptoms. RNA extraction from clinical
samples can be performed with the QIAamp Viral RNA kit [34], VERSANT Molecular System
SP (Siemens) or HighPureViral Nucleic Acid Kit (Roche). Several RT-PCR procedures to detect
and identify dengue serotypes in clinical specimens have been reported such as one-step, two-
step, nested RT–PCR or real time RT–PCR [35]. These PCR assays vary in the amplified gene
regions of the genome, in the detection method of RT-PCR products, and the virus typing
methods. Real-time RT-PCR assays “singleplex” or “multiplex” can identify all four serotypes
from a single sample, in a single reaction and is useful to determine viral titer in a clinical
sample. Real-Time-PCR detection and typing of DENV usually addresses to the partially
conserved 3’-UTR region of the genome. Due to the typical RNA-viral sequence variations it
is difficult to identify one particular probe to be strictly related to one type or which could be
used for a melting curve based analysis [36].
Many laboratories utilize a nested RT-PCR assay, using universal dengue primers targeting
the C/prM region of the genome for an initial reverse transcription and amplification step,
followed by a nested PCR amplification that is serotype-specific. The analysis of the amplifi‐
cation efficiencies of an in-house quantitative real time-PCR (qPCR) assay of DENV, between
the region protein-5 (NS5) versus the capsid/pre-membrane region (C-prM) and the 3'-
noncoding region (3'NC) showed that the non-structural conserved genomic region the NS5
genomic region provides the best genomic region for optimal detection and typification of
DENV in clinical samples [37]. A fragment located at the 5’-UTR region of the virus genome
was successfully used to identify and quantify distinct dengue virus strains and serotypes in
clinical samples, in sera from patients infected with dengue virus, and in the mosquito Aedes
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three months after fever. In addition, the primary infection is characterized by slowly increas‐
ing but low levels of dengue-specific IgG, becoming elevated at days 9−10. Low IgG levels
persist for decades, an indication of a past dengue infection. In a secondary infection, there is
a rapid and higher increase of anti-dengue specific IgG antibodies. High IgG levels remain for
30–40 days [21]. The serological tests have been used for the diagnosis of dengue infection:
hemagglutination-inhibition (HI), complement fixation (CF), neutralization test (NT), immu‐
noglobulin M (IgM) capture enzyme linked immunosorbent assay (MAC-ELISA) and indirect
immunoglobulin G ELISA. High cross-reactivity was observed with these tests. MAC-ELISA
and rapid tests are the most frequent methods for IgM detection and in the detection of IgG
are used HIA or ELISA [22-25]. Dengue non-structural protein 1 (NS1) is secreted from infected
cells and produces a very strong humoral response. NS1 is a useful early serum marker for
primary and secondary dengue infections, and is typically present between days 1–9 after onset
of clinical signs [23]. In febrile patients, the early diagnosis of dengue virus infection on based
on NS1 viral antigen [26-27]. At the end of the acute phase of infection, serology is the method
of choice for diagnosis by detection anti-DENV IgM and IgG antibodies using MAC-ELISA.
High sensitivity for NS1 antigen detection was observed by the association of MAC-ELISA
with a commercial anti-DENV IgM/IgG rapid test (PanbioH Dengue Early Rapid test) [28]. A
DENV NS1 capture assay using a test NS1 Ag Strip (BioRad Laboratories) is a valuable tool to
postmortem dengue confirmation [29]. There are several commercial kits to dengue diagnostic
such as the SD Bioline Dengue Duo device (Standard Diagnostic Inc., Korea) this test is
composed of 2 tests to detect DENV NS1 antigen (first test) and anti-DENV IgM/IgG (second
test) in serum, plasma or whole blood. With this test, still after the onset of illness, the virus
can detected in serum, plasma, circulating blood cells and other tissues for 4-5 days.
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ELISA (Enzyme-linked immunosorbent assay). HIA (Haemagglutination inhibition assay). IgG (Immunoglubulin G). IgM
(Immunoglobulin M). NS1 Ag (Non-structural protein 1). RT-PCR (Reverse transcriptase polymerase chain reaction). In‐
formation based on Chapter 4. Laboratory Diagnosis and Diagnostic Tests. Dengue Guidelines for Diagnosis, Treat‐
ment, Prevention and Control. Geneva. TDR/World Health Organization. 2012 [21].
Table 1. Dengue diagnostic methods.
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Dengue diagnosis also relies on viral cell culture methods [30,31]. Specimens for virus isolation
should be collected early in the course of the infection, during the period of viraemia (usually
before day 5). Virus may be recovery from serum, plasma and peripheral blood mononuclear
cells. Dengue virus is heat-labile; specimens awaiting transport to the laboratory should be
kept in a refrigerator or packed in wet ice. Cell culture is the most widely used method for
dengue virus isolation usually takes several days. Four methods of viral isolation have been
routinely used for dengue viruses: intracerebral inoculation of newborn mice, inoculation on
mammalian cell cultures, intrathoracic inoculation of adult mosquitoes, and inoculation on
mosquito cell cultures [32]. The mosquito cell line C6/36 (cloned from Ae. albopictus) or AP61
(cell line from Ae. pseudoscutellaris) are the host cells of choice for isolation of virus. Indirect
fluorescent antibody staining of the infected cell culture is often regarded as the “gold
standard” in dengue diagnostics. However, it is tedious, time-consuming, and requires cell
culture. All these studies have shown that this can be a valuable approach, especially in the
early phase of infection; however, in some cases, they do not identify the viral serotype and
these assays may not be as sensitive as the detection of viral RNA by nucleic acid amplification
tests (NAAT) using reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time
RT-PCR may assume a very important role in dengue diagnosis at confirms an acute dengue
infection [33, 20, 21]. Molecular diagnosis methods are usually rapid, sensitive, and simple
when correctly standardized and can be used for serotype identification and quantification of
genome copies in human clinical samples, biopsies, autopsy tissues, or mosquitoes. NAAT
assays may identify viral RNA within 24–48 hours. Although, also be able to detect dengue
viruses up to the 10th day after the onset of the symptoms. RNA extraction from clinical
samples can be performed with the QIAamp Viral RNA kit [34], VERSANT Molecular System
SP (Siemens) or HighPureViral Nucleic Acid Kit (Roche). Several RT-PCR procedures to detect
and identify dengue serotypes in clinical specimens have been reported such as one-step, two-
step, nested RT–PCR or real time RT–PCR [35]. These PCR assays vary in the amplified gene
regions of the genome, in the detection method of RT-PCR products, and the virus typing
methods. Real-time RT-PCR assays “singleplex” or “multiplex” can identify all four serotypes
from a single sample, in a single reaction and is useful to determine viral titer in a clinical
sample. Real-Time-PCR detection and typing of DENV usually addresses to the partially
conserved 3’-UTR region of the genome. Due to the typical RNA-viral sequence variations it
is difficult to identify one particular probe to be strictly related to one type or which could be
used for a melting curve based analysis [36].
Many laboratories utilize a nested RT-PCR assay, using universal dengue primers targeting
the C/prM region of the genome for an initial reverse transcription and amplification step,
followed by a nested PCR amplification that is serotype-specific. The analysis of the amplifi‐
cation efficiencies of an in-house quantitative real time-PCR (qPCR) assay of DENV, between
the region protein-5 (NS5) versus the capsid/pre-membrane region (C-prM) and the 3'-
noncoding region (3'NC) showed that the non-structural conserved genomic region the NS5
genomic region provides the best genomic region for optimal detection and typification of
DENV in clinical samples [37]. A fragment located at the 5’-UTR region of the virus genome
was successfully used to identify and quantify distinct dengue virus strains and serotypes in
clinical samples, in sera from patients infected with dengue virus, and in the mosquito Aedes
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aegypti, as well as to study virus replication in different cell lines using TaqMan probes [38].
A real time RT-PCR (qRT-PCR) for DENV using TaqMan Minor Groove Binding (MGB) probe
approach was development for detection and quantitation of all four serotypes using a single
probe primer set targeted against the 3'UTR of DENV. In this assay, the limit of detection was
DENV-1 (0.98 UFP/ml), DENV-2 (0.99 UFP/ml), DENV-3 (0.99 UFP/ml) and DENV-4 (0.99
UFP/ml) [39]. Other option to diagnosis to provide serotype specificity is a multiplex rRT-PCR
assay targeting the 5’ untranslated region and capsid gene of the DENV genome using
molecular beacons. This assay was linear from 7.0 to 1.0 log10 cDNA equivalents/mL for each
serotype. The limit of detection was calculated to be 0.3 cDNA equivalents/mL for DENV-1,
13.8 for DENV-2, 0.8 for DENV-3, and 12.4 for DENV-4 [40]. A technique for the multiplex
detection and typing of all DENV serotypes from clinical samples is PCR-ligase detection
reaction (LDR). In this technique, a serotype-specific PCR amplifies the regions of genes C and
E simultaneously. Then, two amplicons are targeted in a multiplex LDR, and the resultant
fluorescently labeled ligation products are detected on a universal array. The sensitivity of the
assay was 98.7%, and its specificity was 98.4%, relative to the results of real-time PCR. The
detection threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3,
and 0.7 PFU for DENV-4. The assay is specific; it does not cross-react with the other flaviviruses
tested (West Nile virus, St. Louis encephalitis virus, Japanese encephalitis virus, Kunjin virus,
Murray Valley virus, Powassan virus, and yellow fever virus). The detection limit of the assay
ranged from 0.004 to 0.7 equivalent PFU/reaction. The assay was 100 times more sensitive for
DENV-2 and DENV-1 (LOD, 0.004 and 0.017 equivalent PFU, respectively) than for the others
serotypes [41]. Detection of DENV in urine is other diagnostic method, a study by real-time
RT-PCR, reported the detection of viral genome in urine between days 6 to 16[42]. Recently,
CDC development a CDC DENV-1-4 Real-Time RT-PCR Assay, the first molecular test
Figure 2. Immune response to virus dengue. In the infection course of dengue virus, the host’s B cells produce IgM
and IgG antibodies, which are released for recognize and neutralize the dengue virus and molecules such as the den‐
gue NS1 protein with the purpose of eliminates the virus. The figure shows the viremia can detect by the amplification
of the NS1 gene by RT-PCR and the antibodies titers by ELISA. Information based on Guzman MG, et al., 2010 [25] and
WHO, Geneva, 2009 [10].
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approved by the US Food and Drug Administration (FDA) for the identification of dengue
virus serotypes 1, 2, 3 or 4 from viral RNA in serum or plasma (sodium citrate) collected during
the acute phase. The limit of detection (LoD) of assay was determined to be between 1 x 104
and 1 x 103 GCE/mL for all serotypes in both formats in serum and plasma [43]. In all reactions
by real-time RT-PCR, a positive PCR result is a definite proof of current infection and it usually
confirms the infecting serotype. However, a negative result is interpreted as "indeterminate".
Patients receiving negative results before 5 days of illness are usually asked to submit a second
serum sample for serological confirmation after the 5th day of illness. Also, it was used other
options to diagnostics dengue infection. The first is Virochip is a pan-viral microarray platform;
this assay can detect to virus of Herpesviridae, Flaviviridae, Circoviridae, Anelloviridae,
Asfarviridae, and Parvoviridae families. In other hand, for viral detection exists the option
Deep sequencing and shotgun sequencing of human clinical samples by pyrosequencing using
the Illumina GAII platform [44].
3. Influenza virus
Influenza is a highly contagious respiratory disease of humans, with propensity for seasonal
epidemics and occasional pandemics. This disease constitutes a global health issue, leading to
morbidity, mortality, and economic losses. During influenza season, influenza viruses
circulate ubiquitously in the population. Global influenza surveillance forms the primary line
of defense against the occurrence of influenza pandemics by identifying emerging influenza
virus strains that pose a potential threat [45]. Influenza affects all age groups that result from
its pulmonary complications. The virus initially infects the upper airways but can directly
extend to the lower airways in severe cases, resulting in a viral pneumonia with significant
morbidity and mortality [46, 47]. Influenza viruses belong to the Orthomyxoviridae family and
are organize into types A, B and C. Influenza types A and B are responsible for epidemics of
respiratory illness in humans and animals. The etiologic agent of influenza is the influenza
virus with negative-strand, segmented RNA genome. Influenza type A and B viruses have 8
genes that code for 10 proteins. The virion has two surface glycoproteins (hemagglutinin (HA)
and neuraminidase (NA) and the M2 protein protrude through envelop (Figure 3). Influenza
virus binds to its sialic (neuraminic) acid receptor on respiratory epithelial cells by means of
the HA protein [48]. The influenza type A viruses are sub classified into different subtypes
according to HA and NA proteins, there are 16 HA subtypes and 9 NA subtypes, all of them
have been identified and isolated from birds, humans and can affect a range of mammal
species. The influenza A subtypes that circulated extensively in humans are A(H1N1);
A(H1N2); A(H2N2); and seasonal influenza A (H3N2) [49]. Influenza A viruses (IAV) are the
cause of pandemics, which are generated by the rearrangement (reassortment) of viral RNA
segments in cells infected with two different viral strains [50].
Pandemic viruses of influenza A virus including “Spanish influenza” (H1N1 in 1918) and A/
H1N1 or A(H1N1)pdm09 (H1N1 in 2009) [51] or rarely, a novel influenza A virus infection.
For the diagnosis, the influenza tests that provide accurate and timely results are the most
recommended. The appropriate respiratory samples for influenza testing are upper respiratory
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aegypti, as well as to study virus replication in different cell lines using TaqMan probes [38].
A real time RT-PCR (qRT-PCR) for DENV using TaqMan Minor Groove Binding (MGB) probe
approach was development for detection and quantitation of all four serotypes using a single
probe primer set targeted against the 3'UTR of DENV. In this assay, the limit of detection was
DENV-1 (0.98 UFP/ml), DENV-2 (0.99 UFP/ml), DENV-3 (0.99 UFP/ml) and DENV-4 (0.99
UFP/ml) [39]. Other option to diagnosis to provide serotype specificity is a multiplex rRT-PCR
assay targeting the 5’ untranslated region and capsid gene of the DENV genome using
molecular beacons. This assay was linear from 7.0 to 1.0 log10 cDNA equivalents/mL for each
serotype. The limit of detection was calculated to be 0.3 cDNA equivalents/mL for DENV-1,
13.8 for DENV-2, 0.8 for DENV-3, and 12.4 for DENV-4 [40]. A technique for the multiplex
detection and typing of all DENV serotypes from clinical samples is PCR-ligase detection
reaction (LDR). In this technique, a serotype-specific PCR amplifies the regions of genes C and
E simultaneously. Then, two amplicons are targeted in a multiplex LDR, and the resultant
fluorescently labeled ligation products are detected on a universal array. The sensitivity of the
assay was 98.7%, and its specificity was 98.4%, relative to the results of real-time PCR. The
detection threshold was 0.017 PFU for DENV-1, 0.004 PFU for DENV-2, 0.8 PFU for DENV-3,
and 0.7 PFU for DENV-4. The assay is specific; it does not cross-react with the other flaviviruses
tested (West Nile virus, St. Louis encephalitis virus, Japanese encephalitis virus, Kunjin virus,
Murray Valley virus, Powassan virus, and yellow fever virus). The detection limit of the assay
ranged from 0.004 to 0.7 equivalent PFU/reaction. The assay was 100 times more sensitive for
DENV-2 and DENV-1 (LOD, 0.004 and 0.017 equivalent PFU, respectively) than for the others
serotypes [41]. Detection of DENV in urine is other diagnostic method, a study by real-time
RT-PCR, reported the detection of viral genome in urine between days 6 to 16[42]. Recently,
CDC development a CDC DENV-1-4 Real-Time RT-PCR Assay, the first molecular test
Figure 2. Immune response to virus dengue. In the infection course of dengue virus, the host’s B cells produce IgM
and IgG antibodies, which are released for recognize and neutralize the dengue virus and molecules such as the den‐
gue NS1 protein with the purpose of eliminates the virus. The figure shows the viremia can detect by the amplification
of the NS1 gene by RT-PCR and the antibodies titers by ELISA. Information based on Guzman MG, et al., 2010 [25] and
WHO, Geneva, 2009 [10].
Trends in Infectious Diseases94
approved by the US Food and Drug Administration (FDA) for the identification of dengue
virus serotypes 1, 2, 3 or 4 from viral RNA in serum or plasma (sodium citrate) collected during
the acute phase. The limit of detection (LoD) of assay was determined to be between 1 x 104
and 1 x 103 GCE/mL for all serotypes in both formats in serum and plasma [43]. In all reactions
by real-time RT-PCR, a positive PCR result is a definite proof of current infection and it usually
confirms the infecting serotype. However, a negative result is interpreted as "indeterminate".
Patients receiving negative results before 5 days of illness are usually asked to submit a second
serum sample for serological confirmation after the 5th day of illness. Also, it was used other
options to diagnostics dengue infection. The first is Virochip is a pan-viral microarray platform;
this assay can detect to virus of Herpesviridae, Flaviviridae, Circoviridae, Anelloviridae,
Asfarviridae, and Parvoviridae families. In other hand, for viral detection exists the option
Deep sequencing and shotgun sequencing of human clinical samples by pyrosequencing using
the Illumina GAII platform [44].
3. Influenza virus
Influenza is a highly contagious respiratory disease of humans, with propensity for seasonal
epidemics and occasional pandemics. This disease constitutes a global health issue, leading to
morbidity, mortality, and economic losses. During influenza season, influenza viruses
circulate ubiquitously in the population. Global influenza surveillance forms the primary line
of defense against the occurrence of influenza pandemics by identifying emerging influenza
virus strains that pose a potential threat [45]. Influenza affects all age groups that result from
its pulmonary complications. The virus initially infects the upper airways but can directly
extend to the lower airways in severe cases, resulting in a viral pneumonia with significant
morbidity and mortality [46, 47]. Influenza viruses belong to the Orthomyxoviridae family and
are organize into types A, B and C. Influenza types A and B are responsible for epidemics of
respiratory illness in humans and animals. The etiologic agent of influenza is the influenza
virus with negative-strand, segmented RNA genome. Influenza type A and B viruses have 8
genes that code for 10 proteins. The virion has two surface glycoproteins (hemagglutinin (HA)
and neuraminidase (NA) and the M2 protein protrude through envelop (Figure 3). Influenza
virus binds to its sialic (neuraminic) acid receptor on respiratory epithelial cells by means of
the HA protein [48]. The influenza type A viruses are sub classified into different subtypes
according to HA and NA proteins, there are 16 HA subtypes and 9 NA subtypes, all of them
have been identified and isolated from birds, humans and can affect a range of mammal
species. The influenza A subtypes that circulated extensively in humans are A(H1N1);
A(H1N2); A(H2N2); and seasonal influenza A (H3N2) [49]. Influenza A viruses (IAV) are the
cause of pandemics, which are generated by the rearrangement (reassortment) of viral RNA
segments in cells infected with two different viral strains [50].
Pandemic viruses of influenza A virus including “Spanish influenza” (H1N1 in 1918) and A/
H1N1 or A(H1N1)pdm09 (H1N1 in 2009) [51] or rarely, a novel influenza A virus infection.
For the diagnosis, the influenza tests that provide accurate and timely results are the most
recommended. The appropriate respiratory samples for influenza testing are upper respiratory
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tract specimen such as deep nostrils (nasal swab), throat (throat swab) and nasopharynx
(nasopharyngeal swab). Nasopharyngeal aspirate and bronchial aspirate are also useful.
Samples should be collected within the first 4 days of illness [52,53]. According to WHO the
diagnosis of influenza is based in enzyme-linked immunosorbent assay (ELISA), haemagglu‐
tination inhibition (HI) and neuraminidase inhibition (NI) tests, egg and cell culture inocula‐
tion, and conventional reverse transcriptase PCR (RT-PCR) and Real-Time PCR (Table 2). The
reference standards for laboratory confirmation of influenza virus infection are reverse
transcription-polymerase chain reaction (RT-PCR) or viral culture [54]. Serologic testing is
usually not recommended to detect evidence of human influenza virus infection for manage‐
ment of acute illness. However, a variety of serological tests, including the hemagglutination
inhibition (HAI) test, complement fixation and EIA are used for testing paired acute and
convalescent phase sera to detect antibody titers. The Rapid Influenza Diagnostic Tests (RIDTs)
can identify the presence of influenza A and B viral nucleoprotein antigens, the result only is
positive or negative. The RIDTs are immunoassays than provide results in 10–30 min but
exhibit decreased sensitivity (70%–90% in children and 40% to 60% in adults), compared with
RT-PCR and with viral culture. There is a potential for false negative results. Negative results
of RIDTs do not exclude influenza virus infection in patients with signs and symptoms
Figure 3. Schematic representation of influenza virus A (not drawn to scale). On the envelope viral are anchored: HA,
M2 (ion channel protein) and NA protein. Inside the virion the negative-RNA single-stranded and segmented viral ge‐
nome with ARN polymerase formed for PB1, P2 and PA. Also, there is a NEP protein.
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suggestive of influenza, follow-up testing with RT-PCR and/or viral culture should be
considered to confirm negative test results [55]. Besides, of its low sensitivity RIDTs may be
used to help with diagnostic and treatment decisions for patients in clinical settings, such as
whether to prescribe antiviral medications [45]. These tools are continuously improved, a
double-sandwich ELISA (pH1N1 ELISA), based on two monoclonal antibodies against
haemagglutinin (HA) of the pH1N1 virus has a sensitivity of 92.3% (84/91, 95% CI 84.8–96.9%),
being significantly higher than that of the BD Directigen EZ Flu A+B test (70.3%, p <0.01). In
addition, this assay can directly differentiate pandemic (H1N1) 2009 (pH1N1) virus from other
respiratory pathogens, including seasonal influenza virus [56]. A hemagglutination inhibition
assay is an extremely reliable tool for typing, subtyping and analyze the antigenic character‐
istics of influenza viral isolates if the reference antisera used contain antibodies to currently
circulating viruses [53]. An HAI test showed that the patients with influenza A H1N1 have
effective immune response [57]. The Directigen EZ Flu A+B test is a rapid chromatographic
immunoassay for the qualitative detection of influenza A and B viral antigens, it has an
accuracy of 95.5% and 96.8%, respectively. This kit has the ability to detect H5N1 isolates and
of the A/California/07/2004 strain [BD Diagnostics, Becton Dickinson and Company, 2005].
Viral culture is considering one “gold standard” for detection of infection with human
influenza viruses. Although, viral isolation is not a screening routine test in outbreaks, during
periods of low influenza activity, could performed on respiratory specimens collected from
persons with suspected influenza. Viral culture does not provide timely results (1-14 days) [58,
59]. In the influenza seasonal and in outbreaks, the viral culture is essential as a source of
virologic data about strain characteristics, such as antigenic comparison to influenza vaccine
strains and antiviral susceptibility that are important for clinicians and public health. Shell vial
centrifugation cultures have been used to shorten the time to results to 1 to 5 days, to detect
viral antigens [60]. Immunofluorescence using direct fluorescent antibody or indirect fluores‐
cent antibody staining for influenza antigen detection are used as screening tests. This test
exhibits slightly lower sensitivity and specificity than viral isolation in cell culture, but results
are obtained within hours [45]. An example is the Respiratory Screen direct immunofluores‐
cence antibody (DFA) (direct fluorescent antibody) staining of cells collected using nasophar‐
yngeal (NP) swabs or NP aspirates can detects not only influenza, but RSV, parainfluenza types
1,2,3, and adenovirus. DFA is reported within 2-3 hrs [61]. However, for detection of respira‐
tory viruses in clinical specimens, the nucleic acid tests (NATs) are fast, accurate and sensitive
test. Several nucleic acid based amplification approaches have been applied for the detection
of individual respiratory viruses including PCR, nucleic acid sequence-based amplification
(NASBA), loop mediated isothermal amplification (LAMP), and multiplex ligation-dependent
probe amplification (MLPA) [62-65]. For NATs, the nucleic acid is extracted from the samples
by using commercial kits, like QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany)
using silica gel membrane technology. KingFisher mL (ThermoFisher Scientific Inc., Worces‐
ter, MA, USA) and easyMAG (bioMérieux, Marcy l’Etoile, France) kits using magnetic beads-
based technology [66, 67]. TruTip (Akonni Biosystems, Inc., Frederick, MD, USA) use a porous
nucleic acid binding matrix embedded within a pipette tip [68]. Reverse transcriptase-PCR
(RT-PCR) or Real-time RT-PCR can be considered the other “gold standard” for detection of
influenza viruses due to its high sensitivity and specificity for detection of influenza A and B
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can identify the presence of influenza A and B viral nucleoprotein antigens, the result only is
positive or negative. The RIDTs are immunoassays than provide results in 10–30 min but
exhibit decreased sensitivity (70%–90% in children and 40% to 60% in adults), compared with
RT-PCR and with viral culture. There is a potential for false negative results. Negative results
of RIDTs do not exclude influenza virus infection in patients with signs and symptoms
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suggestive of influenza, follow-up testing with RT-PCR and/or viral culture should be
considered to confirm negative test results [55]. Besides, of its low sensitivity RIDTs may be
used to help with diagnostic and treatment decisions for patients in clinical settings, such as
whether to prescribe antiviral medications [45]. These tools are continuously improved, a
double-sandwich ELISA (pH1N1 ELISA), based on two monoclonal antibodies against
haemagglutinin (HA) of the pH1N1 virus has a sensitivity of 92.3% (84/91, 95% CI 84.8–96.9%),
being significantly higher than that of the BD Directigen EZ Flu A+B test (70.3%, p <0.01). In
addition, this assay can directly differentiate pandemic (H1N1) 2009 (pH1N1) virus from other
respiratory pathogens, including seasonal influenza virus [56]. A hemagglutination inhibition
assay is an extremely reliable tool for typing, subtyping and analyze the antigenic character‐
istics of influenza viral isolates if the reference antisera used contain antibodies to currently
circulating viruses [53]. An HAI test showed that the patients with influenza A H1N1 have
effective immune response [57]. The Directigen EZ Flu A+B test is a rapid chromatographic
immunoassay for the qualitative detection of influenza A and B viral antigens, it has an
accuracy of 95.5% and 96.8%, respectively. This kit has the ability to detect H5N1 isolates and
of the A/California/07/2004 strain [BD Diagnostics, Becton Dickinson and Company, 2005].
Viral culture is considering one “gold standard” for detection of infection with human
influenza viruses. Although, viral isolation is not a screening routine test in outbreaks, during
periods of low influenza activity, could performed on respiratory specimens collected from
persons with suspected influenza. Viral culture does not provide timely results (1-14 days) [58,
59]. In the influenza seasonal and in outbreaks, the viral culture is essential as a source of
virologic data about strain characteristics, such as antigenic comparison to influenza vaccine
strains and antiviral susceptibility that are important for clinicians and public health. Shell vial
centrifugation cultures have been used to shorten the time to results to 1 to 5 days, to detect
viral antigens [60]. Immunofluorescence using direct fluorescent antibody or indirect fluores‐
cent antibody staining for influenza antigen detection are used as screening tests. This test
exhibits slightly lower sensitivity and specificity than viral isolation in cell culture, but results
are obtained within hours [45]. An example is the Respiratory Screen direct immunofluores‐
cence antibody (DFA) (direct fluorescent antibody) staining of cells collected using nasophar‐
yngeal (NP) swabs or NP aspirates can detects not only influenza, but RSV, parainfluenza types
1,2,3, and adenovirus. DFA is reported within 2-3 hrs [61]. However, for detection of respira‐
tory viruses in clinical specimens, the nucleic acid tests (NATs) are fast, accurate and sensitive
test. Several nucleic acid based amplification approaches have been applied for the detection
of individual respiratory viruses including PCR, nucleic acid sequence-based amplification
(NASBA), loop mediated isothermal amplification (LAMP), and multiplex ligation-dependent
probe amplification (MLPA) [62-65]. For NATs, the nucleic acid is extracted from the samples
by using commercial kits, like QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany)
using silica gel membrane technology. KingFisher mL (ThermoFisher Scientific Inc., Worces‐
ter, MA, USA) and easyMAG (bioMérieux, Marcy l’Etoile, France) kits using magnetic beads-
based technology [66, 67]. TruTip (Akonni Biosystems, Inc., Frederick, MD, USA) use a porous
nucleic acid binding matrix embedded within a pipette tip [68]. Reverse transcriptase-PCR
(RT-PCR) or Real-time RT-PCR can be considered the other “gold standard” for detection of
influenza viruses due to its high sensitivity and specificity for detection of influenza A and B
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viruses. The results are available within 4–6 h after specimen submission. These molecular
tools are used as a confirmatory test. Several different gene targets have been used for
amplification such as the matrix (m) to detect all influenza A subtypes, ha to distinguish
between influenza A, B and C or between influenza A subtypes and non-structural protein
genes (nsp) [69-71]. In all eight segments of influenza A virus, the first 12 nucleotides of the 3′
terminus (Uni12) and the first 13 nucleotides of 5' terminus (Uni13) are conservative and are
the target to designed a primers pair. Detection of influenza A virus in human nasal swabs can
performed by RT-PCR with Uni12 and Uni13 primers. The coupling of RT-PCR with sequenc‐
ing analysis provides information about viral genotype [72]. Multiplex RT-PCR assays have
been widely used for detection and differentiation of a panel of respiratory viral pathogens.
FluPlex is a multiplex RT-PCR enzyme hybridization assay, capable of typing influenza viruses
and subtyping HA (H1, H2, H3, H5, H7, and H9) and NA (human N1, animal N1, N2, and N7)
with high sensitivity (10–100 copies/reaction) [73]. As the Qiagen ResPlex II multiplex RT-PCR
kit, an test with high specificity for detection of 17 viral pathogens in nasopharyngeal swab
samples such as influenza A virus (FluA), FluB, FluA 2009 pandemic A(H1N1)pdm09 and
others pathogens as parainfluenza virus 1 (PIV1), PIV2, PIV3, PIV4, respiratory syncytial virus
(RSV), human metapneumovirus (hMPV), rhinoviruses (RhV), adenoviruses (AdV), four
coronaviruses (229E, OC43, NL63 and HKU1) [74]. The TrueScience RespiFinder Identification
Panels (Applied Biosystems) is other multiplex PCR test to detect and differentiate 15 respi‐
ratory pathogens, using the multiplex ligation-dependent probe amplification (MLPA)
technology, which starts by a preamplification step, which ensures the detection of both RNA
and DNA viruses.
Follow is performed a reverse transcription, a PCR reaction, the hybridization probes to their
target regions to the PCR product. A ligation probes and the final PCR exponentially amplifies
the ligated probes with only two primers. The targets are detected through capillary electro‐
phoresis. The pathogens potentially identified are Influenza A, Influenza B, Influenza A H5N1,
Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, RSV-A, RSV-B, Corona
229E, Corona NL63, Corona OC43, Adenovirus, Rhinovirus, Bordetella pertussis, Chlamydo‐
phila pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae. MPLA shows
specificities and sensitivities of 98.2% and 100%, respectively, for influenza A virus [75]. A
successful test to detect a H5N1 virus was based on Loop-Mediated Isothermal Amplification
(LAMP) method. For other side, detection, quantification and subtyping of influenza viruses
can be performed by real-time RT-PCR (qRT-PCR). There are many papers of this technique
applied to influenza A diagnosis such as TaqMan qRT-PCR method, which detects HA and
NA genes of HPAI H5N1 virus [76]. A new generation qRT-PCR approach designated as Super
high-speed qRT-PCR (SHRT-PCR) is a version of qRT-PCR with an extremely short reaction
time (less than 20 min per run for 40 cycles) capable to detects viral RNA segments of influenza
A [77]. RealTime ready Influenza A/H1N1 Detection Set (Roche) is an assay to detect the M2
gene (M2 PCR) of a generic influenza virus A and a specific PCR targeting the HA of A/H1N1-
pdm09 (HA PCR, 2009 H1N1), to detect and quantify the 2009 H1N1 virus in clinical samples
[78]. CDC developed the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel-
Influenza A/H7 (Eurasian Lineage) assay for patients with signs and symptoms of respiratory
infection. The kit contains a dual-labeled hydrolysis probe (TaqMan). The limit of detection of
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this kit was 103.4 [79]. On April 1, 2013, an outbreak of human infections with a new avian
influenza A (H7N9) virus was first reported in China by the World Health Organization. The
diagnostics of this virus used the real time RT-PCR by TaqMan assay. Other molecular
technique to diagnosis is DNA microarray such as FluChip-55 [Sakurai & Shibasaki, 2012] used
METHOD TYPE INFLUENZA VIRUS TYPE SPECIMENS
Cell culture (Madin-Darby canine kidney
(MDCK), mink lung epithelial cell line
(Mv1Lu), rhesus monkey kidney (LLC
MK2), and buffalo green monkey kidney
(BGMK)
A and B NP swab, throat swab, NP or bronchial
wash, nasal or endotracheal aspirate,
sputum
Rapid cell culture (commercial shell vials,
single or mixed cell lines)
A and B NP swab, throat swab, NP or bronchial
wash, nasal or endotracheal aspirate,
sputum
Immunofluorescence microscopy by
direct fluorescent antibody (DFA) test or
an immunofluorescent antibody (IFA)
test, using commercial monoclonal
antibody for influenza A and B viruses; or
non commercial monoclonal antibody
specific for H1, H3 H5, H7 and H9
A and B
Identification of subtypes of A
NP swab, thrat swab, NP or bronchial wash,
NP or endotracheal aspirate, sputum
Immunospecific assay for viral antigen
detection
Rapid influenza diagnostic test (RIDT’s)





ELISA using commercially anti-human
antibody conjugates
Complement fixation
A and B Serum
Nucleic acid testing (Conventional RT-
PCR singleplex and multiplex, Multiplex
PCR, Degenerate PCR, Probe-based real-
time PCR (TaqMan), SBRY Green I-based
real-time PCR, Microarrays, NABA, LAMP,
Pyrosequencing
A and B
Identification of subtypes of A
NP swab, throat swab, NP or bronchial
wash, NP or endotracheal aspirate, sputum
Information based on Centers for Disease Control and Prevention, National Center for Immunization and Respiratory
Diseases (NCIRD). Guidance for Clinicians on the Use of Rapid Influenza Diagnostic.2011. Petric M, et al. 2006 [64];
Wang&Taubenberger, 2010 [65].
Table 2. Methods of diagnosis of influenza virus.
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viruses. The results are available within 4–6 h after specimen submission. These molecular
tools are used as a confirmatory test. Several different gene targets have been used for
amplification such as the matrix (m) to detect all influenza A subtypes, ha to distinguish
between influenza A, B and C or between influenza A subtypes and non-structural protein
genes (nsp) [69-71]. In all eight segments of influenza A virus, the first 12 nucleotides of the 3′
terminus (Uni12) and the first 13 nucleotides of 5' terminus (Uni13) are conservative and are
the target to designed a primers pair. Detection of influenza A virus in human nasal swabs can
performed by RT-PCR with Uni12 and Uni13 primers. The coupling of RT-PCR with sequenc‐
ing analysis provides information about viral genotype [72]. Multiplex RT-PCR assays have
been widely used for detection and differentiation of a panel of respiratory viral pathogens.
FluPlex is a multiplex RT-PCR enzyme hybridization assay, capable of typing influenza viruses
and subtyping HA (H1, H2, H3, H5, H7, and H9) and NA (human N1, animal N1, N2, and N7)
with high sensitivity (10–100 copies/reaction) [73]. As the Qiagen ResPlex II multiplex RT-PCR
kit, an test with high specificity for detection of 17 viral pathogens in nasopharyngeal swab
samples such as influenza A virus (FluA), FluB, FluA 2009 pandemic A(H1N1)pdm09 and
others pathogens as parainfluenza virus 1 (PIV1), PIV2, PIV3, PIV4, respiratory syncytial virus
(RSV), human metapneumovirus (hMPV), rhinoviruses (RhV), adenoviruses (AdV), four
coronaviruses (229E, OC43, NL63 and HKU1) [74]. The TrueScience RespiFinder Identification
Panels (Applied Biosystems) is other multiplex PCR test to detect and differentiate 15 respi‐
ratory pathogens, using the multiplex ligation-dependent probe amplification (MLPA)
technology, which starts by a preamplification step, which ensures the detection of both RNA
and DNA viruses.
Follow is performed a reverse transcription, a PCR reaction, the hybridization probes to their
target regions to the PCR product. A ligation probes and the final PCR exponentially amplifies
the ligated probes with only two primers. The targets are detected through capillary electro‐
phoresis. The pathogens potentially identified are Influenza A, Influenza B, Influenza A H5N1,
Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, RSV-A, RSV-B, Corona
229E, Corona NL63, Corona OC43, Adenovirus, Rhinovirus, Bordetella pertussis, Chlamydo‐
phila pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae. MPLA shows
specificities and sensitivities of 98.2% and 100%, respectively, for influenza A virus [75]. A
successful test to detect a H5N1 virus was based on Loop-Mediated Isothermal Amplification
(LAMP) method. For other side, detection, quantification and subtyping of influenza viruses
can be performed by real-time RT-PCR (qRT-PCR). There are many papers of this technique
applied to influenza A diagnosis such as TaqMan qRT-PCR method, which detects HA and
NA genes of HPAI H5N1 virus [76]. A new generation qRT-PCR approach designated as Super
high-speed qRT-PCR (SHRT-PCR) is a version of qRT-PCR with an extremely short reaction
time (less than 20 min per run for 40 cycles) capable to detects viral RNA segments of influenza
A [77]. RealTime ready Influenza A/H1N1 Detection Set (Roche) is an assay to detect the M2
gene (M2 PCR) of a generic influenza virus A and a specific PCR targeting the HA of A/H1N1-
pdm09 (HA PCR, 2009 H1N1), to detect and quantify the 2009 H1N1 virus in clinical samples
[78]. CDC developed the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel-
Influenza A/H7 (Eurasian Lineage) assay for patients with signs and symptoms of respiratory
infection. The kit contains a dual-labeled hydrolysis probe (TaqMan). The limit of detection of
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this kit was 103.4 [79]. On April 1, 2013, an outbreak of human infections with a new avian
influenza A (H7N9) virus was first reported in China by the World Health Organization. The
diagnostics of this virus used the real time RT-PCR by TaqMan assay. Other molecular
technique to diagnosis is DNA microarray such as FluChip-55 [Sakurai & Shibasaki, 2012] used
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in influenza diagnosis and others viruses such as parainfluenza, respiratory syncytial virus,
human metapneumovirus, adenovirus, rhrinoviruses, coronaviruses causes pneumonia,
which can be analyzed by multiplex PCR that assist in the discrimination of the etiologic agent
[Pavia, 2011; Mahony, 2008]. The NGEN respiratory virus analyte-specific assay (Nanogen,
San Diego, CA) detects influenza A, influenza B and others pathogens such as PIV type 1
(PIV-1), PIV-2, PIV-3, and RSV on a NanoChip 400 electronic microarray. The FilmArray
Respiratory Panel (RP) is a PCR array test (Idaho Technology, Inc., Salt Lake City, UT) that can
detect up to 21 viral and bacterial respiratory pathogens within about an hour as Adenovirus,
Bocavirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43,
Human Metapneumovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus
3, Parainfluenza virus 4, Rhinovirus/Enterovirus, Respiratory Syncytial Virus, Bordetella
pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumonia and Influenza A,
Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype H1 2009, Influenza B.
This assay is a feasible alternative to viral culture in an acute clinical setting [80]. Recently, it
was reported the method for the detection of genetic markers associated with high pathoge‐
nicity of influenza virus [81].
4. Human papillomavirus
Human papillomavirus (HPV) is a pathogen associated to development of cervical cancer,
which is the second more common cancer in women worldwide. These viruses typically infect
the skin and mucosal surfaces of humans. HPV is a non-enveloped virus with a circular and
supercoiled double-stranded DNA genome of approximately 8,000 bp long within an icosa‐
hedral coat or capsid comprised by 72 pentameric capsomers. The open reading frames (ORFs)
in the viral genome are organized in three regions: the early expression region (E), the late
region (L) and the long control region (LCR) that bears the origin of viral replication and
transcription. The E region codes for proteins related to replication (E1) and to activation or
repression of the viral DNA (E2), and the oncogenes E6, E7, E5 [82]. The L1 and L2 genes encode
the mayor and minor capsid proteins. Late genes L6 and L7 code for structural capsid proteins
which encapsidate the viral genome (Figure 4) [83]. The L1 gene is the region most conserved
between individual types and used to analyze phylogenetic relationship.
Those HPVs with L1 sequence divergence of 2–10% are known as subtypes and less than 2%,
variants. The term “genus” is used for the higher order clusters, named using the Greek
alphabet, and within genus, small clusters are referred to as species and given a number
[84-86]. There are more than 200 different types, of which approximately 100 are fully se‐
quenced and classified according to their biological niche, phylogenetic position and oncogenic
potential [87]. About 40 can infect the anogenital mucosa of humans (mucosotrophic HPVs)
[88-89]. According to their association with cervical cancer, there are low-risk HPV, which can
cause benign or low-grade cervical cell changes, genital warts, and recurrent respiratory
papillomatosis. High-risk HPV types act as carcinogens in the development of cervical cancer
and other anogenital cancers [90]. Cervical cancer is a commonly-encountered malignant
tumor in women. The surveys demonstrated that the increase of women with cervical cancer
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less than 35 years old is particularly significant. The possible causes that result in cervical
cancer to tend to occur in young include remarkable increase of HPV infection rate, especially
the high-risk HPV 16 and 18 infection closely related to cervical cancer [91]. The primary
screening and diagnostic methods have been cytology and histology. Papanicolaou (Pap)
staining is the gold standard for detecting abnormal cervical epithelial cells, using microscopic
analyses of conventional cervical smears or cell suspensions from liquid cytology medium.
The limitation of Pap smear are low specificity, is need repeat the screening at short intervals
[92]. Morphological findings from a cytology analysis determine the level of risk for develop‐
ing cervical malignancies. Cervical epithelial cells atypical or abnormal are known as “atypical
squamous cells of undetermined significance” (ASCUS). Some ASCUS signals the presence of
low-grade squamous intraepithelial lesions (LSIL). However, some ASCUS are associated with
underlying high-grade disease, including cervical intraepithelial neoplasia (CIN) [93-95]. HPV
serology is not used diagnostically. Detection of the humoral antibody response is type-specific
and first detected 6–18 months after infection. The response is weak and only between 50–60%
of patients positive to HPV DNA-positive mount a measurable antibody response [96].
Although, the role played by the humoral immune response during the HPV infection is not
very well understood; it was observed that this response is generated all throughout the
malignant process; 54%-69% of women with incident HPV 16, 6, or 18 infections had antibod‐
ies. Serum antibodies against many different viral products of HPV have been detected by
ELISA. The best characterized and most type-specific antibodies are those directed against
conformational epitopes of the L1 capsid protein assembled as VLPs (virus-like particles) such
as HPV-16 L1 VLP (virus-like particle)-based ELISA [97]. There is some high-throughput
single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-
HPV antibody titers following vaccination against HPV [98].
At present there is no “gold standard” for HPV detection. Guidelines for the management of
women with cervical neoplasia or abnormal cervical cancer screening tests indicates the
immediate colposcopy (cervical exam), cytologic follow-up, and triage by HPV DNA testing
Figure 4. Linear representation of Human Papillomavirus (HPV) genome. The circular HPV genome has approximately
7900 base pairs, in the schematic with eight overlapping reading frames. L1 is signaled as the most used genomic tar‐
get for detection of HPV.
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in influenza diagnosis and others viruses such as parainfluenza, respiratory syncytial virus,
human metapneumovirus, adenovirus, rhrinoviruses, coronaviruses causes pneumonia,
which can be analyzed by multiplex PCR that assist in the discrimination of the etiologic agent
[Pavia, 2011; Mahony, 2008]. The NGEN respiratory virus analyte-specific assay (Nanogen,
San Diego, CA) detects influenza A, influenza B and others pathogens such as PIV type 1
(PIV-1), PIV-2, PIV-3, and RSV on a NanoChip 400 electronic microarray. The FilmArray
Respiratory Panel (RP) is a PCR array test (Idaho Technology, Inc., Salt Lake City, UT) that can
detect up to 21 viral and bacterial respiratory pathogens within about an hour as Adenovirus,
Bocavirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43,
Human Metapneumovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus
3, Parainfluenza virus 4, Rhinovirus/Enterovirus, Respiratory Syncytial Virus, Bordetella
pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumonia and Influenza A,
Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype H1 2009, Influenza B.
This assay is a feasible alternative to viral culture in an acute clinical setting [80]. Recently, it
was reported the method for the detection of genetic markers associated with high pathoge‐
nicity of influenza virus [81].
4. Human papillomavirus
Human papillomavirus (HPV) is a pathogen associated to development of cervical cancer,
which is the second more common cancer in women worldwide. These viruses typically infect
the skin and mucosal surfaces of humans. HPV is a non-enveloped virus with a circular and
supercoiled double-stranded DNA genome of approximately 8,000 bp long within an icosa‐
hedral coat or capsid comprised by 72 pentameric capsomers. The open reading frames (ORFs)
in the viral genome are organized in three regions: the early expression region (E), the late
region (L) and the long control region (LCR) that bears the origin of viral replication and
transcription. The E region codes for proteins related to replication (E1) and to activation or
repression of the viral DNA (E2), and the oncogenes E6, E7, E5 [82]. The L1 and L2 genes encode
the mayor and minor capsid proteins. Late genes L6 and L7 code for structural capsid proteins
which encapsidate the viral genome (Figure 4) [83]. The L1 gene is the region most conserved
between individual types and used to analyze phylogenetic relationship.
Those HPVs with L1 sequence divergence of 2–10% are known as subtypes and less than 2%,
variants. The term “genus” is used for the higher order clusters, named using the Greek
alphabet, and within genus, small clusters are referred to as species and given a number
[84-86]. There are more than 200 different types, of which approximately 100 are fully se‐
quenced and classified according to their biological niche, phylogenetic position and oncogenic
potential [87]. About 40 can infect the anogenital mucosa of humans (mucosotrophic HPVs)
[88-89]. According to their association with cervical cancer, there are low-risk HPV, which can
cause benign or low-grade cervical cell changes, genital warts, and recurrent respiratory
papillomatosis. High-risk HPV types act as carcinogens in the development of cervical cancer
and other anogenital cancers [90]. Cervical cancer is a commonly-encountered malignant
tumor in women. The surveys demonstrated that the increase of women with cervical cancer
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less than 35 years old is particularly significant. The possible causes that result in cervical
cancer to tend to occur in young include remarkable increase of HPV infection rate, especially
the high-risk HPV 16 and 18 infection closely related to cervical cancer [91]. The primary
screening and diagnostic methods have been cytology and histology. Papanicolaou (Pap)
staining is the gold standard for detecting abnormal cervical epithelial cells, using microscopic
analyses of conventional cervical smears or cell suspensions from liquid cytology medium.
The limitation of Pap smear are low specificity, is need repeat the screening at short intervals
[92]. Morphological findings from a cytology analysis determine the level of risk for develop‐
ing cervical malignancies. Cervical epithelial cells atypical or abnormal are known as “atypical
squamous cells of undetermined significance” (ASCUS). Some ASCUS signals the presence of
low-grade squamous intraepithelial lesions (LSIL). However, some ASCUS are associated with
underlying high-grade disease, including cervical intraepithelial neoplasia (CIN) [93-95]. HPV
serology is not used diagnostically. Detection of the humoral antibody response is type-specific
and first detected 6–18 months after infection. The response is weak and only between 50–60%
of patients positive to HPV DNA-positive mount a measurable antibody response [96].
Although, the role played by the humoral immune response during the HPV infection is not
very well understood; it was observed that this response is generated all throughout the
malignant process; 54%-69% of women with incident HPV 16, 6, or 18 infections had antibod‐
ies. Serum antibodies against many different viral products of HPV have been detected by
ELISA. The best characterized and most type-specific antibodies are those directed against
conformational epitopes of the L1 capsid protein assembled as VLPs (virus-like particles) such
as HPV-16 L1 VLP (virus-like particle)-based ELISA [97]. There is some high-throughput
single-serum-dilution enzyme-linked immunoassay (ELISA) system for determining anti-
HPV antibody titers following vaccination against HPV [98].
At present there is no “gold standard” for HPV detection. Guidelines for the management of
women with cervical neoplasia or abnormal cervical cancer screening tests indicates the
immediate colposcopy (cervical exam), cytologic follow-up, and triage by HPV DNA testing
Figure 4. Linear representation of Human Papillomavirus (HPV) genome. The circular HPV genome has approximately
7900 base pairs, in the schematic with eight overlapping reading frames. L1 is signaled as the most used genomic tar‐
get for detection of HPV.
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[99]. HPV serves as paradigm for the use of NAATs due to how difficult it is to obtain the virus
via cell cultures or to develop indirect diagnosis techniques [100]. There are several molecular
techniques for HPV DNA detection (Table 3). They include DNA hybridization, PCR-RFLP,
reverse-line hybridization and hybrid capture assay. The method most commonly used is the
polymerase chain reaction (PCR). All target amplification techniques such as PCR for HPV
virus detection currently use consensus or type-specific primers group-or type-specific
conventional PCR, to amplify a broad-spectrum of HPV genotypes by targeting a conserved
region within the HPV genome [101, 102]. L1 and E1 regions are the most conserved parts of
the genome [103]. Many assays use primers targeted to the viral capsid L1 gene, which can
detect numerous HPV types [104]. There are several PCR primer sets as GP5+/6+that amplify
a 140 bp region in the L1 gene allowing the identification of 30 HPV genotypes. This method
is useful in predicting high-grade cervical intraepithelial neoplasia. The MY09/11 system
identifies high-risk HPV genotypes by amplifying a 450 bp sequence in the conserved L1
region. The MY09/11 primer set uses degenerate bases to reduce variability due to different
genotypes. The SPF10 system primers amplify a 65 bp sequence from a highly conserved region
of the viral L1 gene for the identification of 16 different genotypes of the human papillomavirus
(HPV) [105]. Commonly used L1 consensus primer sets include PGMY09/11, GP5+/6+, and
SPF10, having the ability to identify a large range of HPV types with 1 amplification [106,
107]. Hybridization on PCR products (Cervista HPV HR Test, INNO-LiPa HPV Genotyping,
Linear Array HPV Genotyping Test, Digene HPV Genotyping RH Test) [Estrade et al., 2011;
Jeney et a., 2007; Chan et a., 2012]. Linear Array HPV Genotyping Test (Roche Diagnostics,
Indianapolis, IN) is able to identify 37 types of HPV, 14 are high-risk genotypes. Linear Array
also includes PGMY primers and is a commonly used method for genotyping HPV using
Probes for multiple HPV types are fixed on a membrane strip, and the PCR product is
hybridized to the strip, followed by visual detection [108]. Other assay so used is INNO-LiPA
HPV Genotyping Extra (Innogenetics, Ghent, Belgium). This kit amplifies HPV DNA with
SPF10 primers at the L1 region. The probes are fixed to membrane strips in sequence-specific
lines and visualized as purple/brown bands. The test can detect and distinguish 24 low-and
high-risk HPV types. [INNO-LiPA HPV Genotyping Extra. Ghent, Belgium: Innogenetics;
2007. A HPV viral target to detect is the L1 gene to amplify a broad spectrum of HPV types
with a single set of degenerated primers or a cocktail of primers (Amplicor HPV Test) [Sepehr
et al., 2012] and HPV mRNA amplification against HPV E6/E7 mRNA (APTIMA HPV Assay,
NucliSENS EasyQ HPV, PreTect HPV-Proofer). Another test is the Multiplex Genotyping Kit
(Multimetrix, Heidelberg, Germany). The test is a PCR-based fluorescent bead array that can
detect 24 low-and high-risk HPV types [109]. The quadruplex quantitative PCR method
(AllGlo fluorescent probes) was established to simultaneously detect and differentiate HPV 6,
11, 16 and 18 [110]. Between the signal amplification methods are liquid-phase or in situ
hybridization as Hybrid Capture 2 HPV DNA Test for to detect 13 high-risk types (HPV 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and five low-risk types [111, 112]. Microarray on
PCR products is other molecular technique to detect influenza virus such as Infiniti HPV-HR
QUAD Assay, PapilloCheck or HybriMax for HPV genotyping [113]. PapilloCheck (Greiner
Bio-One, Monroe, NC) for HPV genotyping PapilloCheck identifies 24 types of low-and high-
risk HPV with a high specificity and sensitivity [114]. Genotyping with this method is based
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on PCR amplification of the E1 gene by a group of new E1-specific primers, followed by
hybridization to a DNA chip with immobilized HPV oligoprobes. A novel assay for molecular
diagnostics and typing application known as Sequencing Bead Array (SBA) is an alternative
method to HPV diagnosis. SBA is a digital suspension array using Next-Generation Sequenc‐
ing (NGS) that in the case of HPV could distinguish ten Human Papillomavirus (HPV)
genotypes associated with cervical cancer progression. This is a robust system capable to
identify genetic signatures or single nucleotide polymorphisms (SNPs). SBA has the potential
to change the probe-based diagnostics, and allow for a transition towards the technology by
genomic sequencing [115]. Some groups are studying other molecular factors as possible
markers of infection by HPV as a complementary diagnostics. The overexpression of the HPV
E6 and E7 genes is indicated in HPV-induced carcinogenesis, making these genes a potential
measure of virulence. Monitoring the expression levels of these genes may allow for screening
and monitoring of cancer progression [116].
MOLECULAR DIAGNOSIS
METHOD
NAME TEST GENOTYPES AND TARGET DETECTED
Real time Real Time High risk HPV test
(Abbott Molecular)
14 high risk HPV genotypes: 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68 and to partially genotype
16, 18 from other 12 high risk genotypes using L1
gene.
Cobas 4800 HPV Test
Amplification/Detection kit
(Roche Molecular Diagnostics)
HPV 16 and HPV 18 and concurrently detecting the
rest of the high risk types (31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68), using L1 gene
Hybrid capture Hybrid Capture 2 High-Risk HPV
DNA Test
High-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68 using all genome.
PCR and hybridization AMPLICOR Human
Papillomavirus Test (Roche
Molecular Diagnostics)
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68 using L1 gene.
TMA APTIMA HPV assay
(Hologic)
Qualitative detection of E6/E7 viral messenger RNA
(mRNA) from 14 high-risk types of HPV: 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Reverse hybridization Digene HPV Genotyping RH Test
(Qiagen)
Detection of HPV subtypes 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 using L1
gene.
INNO-LiPA HPV Genotyping Extra
(Innogenetics)
Detection of at least 54 HPV types using L1 gene.
Linear Array HPV Genotyping test
(Roche Molecular Diagnostics)
Linear Array detects thirty seven anogenital HPV
DNA genotypes 6, 11, 16, 18, 26, 31, 33, 35, 39, 40,
42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66,
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[99]. HPV serves as paradigm for the use of NAATs due to how difficult it is to obtain the virus
via cell cultures or to develop indirect diagnosis techniques [100]. There are several molecular
techniques for HPV DNA detection (Table 3). They include DNA hybridization, PCR-RFLP,
reverse-line hybridization and hybrid capture assay. The method most commonly used is the
polymerase chain reaction (PCR). All target amplification techniques such as PCR for HPV
virus detection currently use consensus or type-specific primers group-or type-specific
conventional PCR, to amplify a broad-spectrum of HPV genotypes by targeting a conserved
region within the HPV genome [101, 102]. L1 and E1 regions are the most conserved parts of
the genome [103]. Many assays use primers targeted to the viral capsid L1 gene, which can
detect numerous HPV types [104]. There are several PCR primer sets as GP5+/6+that amplify
a 140 bp region in the L1 gene allowing the identification of 30 HPV genotypes. This method
is useful in predicting high-grade cervical intraepithelial neoplasia. The MY09/11 system
identifies high-risk HPV genotypes by amplifying a 450 bp sequence in the conserved L1
region. The MY09/11 primer set uses degenerate bases to reduce variability due to different
genotypes. The SPF10 system primers amplify a 65 bp sequence from a highly conserved region
of the viral L1 gene for the identification of 16 different genotypes of the human papillomavirus
(HPV) [105]. Commonly used L1 consensus primer sets include PGMY09/11, GP5+/6+, and
SPF10, having the ability to identify a large range of HPV types with 1 amplification [106,
107]. Hybridization on PCR products (Cervista HPV HR Test, INNO-LiPa HPV Genotyping,
Linear Array HPV Genotyping Test, Digene HPV Genotyping RH Test) [Estrade et al., 2011;
Jeney et a., 2007; Chan et a., 2012]. Linear Array HPV Genotyping Test (Roche Diagnostics,
Indianapolis, IN) is able to identify 37 types of HPV, 14 are high-risk genotypes. Linear Array
also includes PGMY primers and is a commonly used method for genotyping HPV using
Probes for multiple HPV types are fixed on a membrane strip, and the PCR product is
hybridized to the strip, followed by visual detection [108]. Other assay so used is INNO-LiPA
HPV Genotyping Extra (Innogenetics, Ghent, Belgium). This kit amplifies HPV DNA with
SPF10 primers at the L1 region. The probes are fixed to membrane strips in sequence-specific
lines and visualized as purple/brown bands. The test can detect and distinguish 24 low-and
high-risk HPV types. [INNO-LiPA HPV Genotyping Extra. Ghent, Belgium: Innogenetics;
2007. A HPV viral target to detect is the L1 gene to amplify a broad spectrum of HPV types
with a single set of degenerated primers or a cocktail of primers (Amplicor HPV Test) [Sepehr
et al., 2012] and HPV mRNA amplification against HPV E6/E7 mRNA (APTIMA HPV Assay,
NucliSENS EasyQ HPV, PreTect HPV-Proofer). Another test is the Multiplex Genotyping Kit
(Multimetrix, Heidelberg, Germany). The test is a PCR-based fluorescent bead array that can
detect 24 low-and high-risk HPV types [109]. The quadruplex quantitative PCR method
(AllGlo fluorescent probes) was established to simultaneously detect and differentiate HPV 6,
11, 16 and 18 [110]. Between the signal amplification methods are liquid-phase or in situ
hybridization as Hybrid Capture 2 HPV DNA Test for to detect 13 high-risk types (HPV 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and five low-risk types [111, 112]. Microarray on
PCR products is other molecular technique to detect influenza virus such as Infiniti HPV-HR
QUAD Assay, PapilloCheck or HybriMax for HPV genotyping [113]. PapilloCheck (Greiner
Bio-One, Monroe, NC) for HPV genotyping PapilloCheck identifies 24 types of low-and high-
risk HPV with a high specificity and sensitivity [114]. Genotyping with this method is based
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on PCR amplification of the E1 gene by a group of new E1-specific primers, followed by
hybridization to a DNA chip with immobilized HPV oligoprobes. A novel assay for molecular
diagnostics and typing application known as Sequencing Bead Array (SBA) is an alternative
method to HPV diagnosis. SBA is a digital suspension array using Next-Generation Sequenc‐
ing (NGS) that in the case of HPV could distinguish ten Human Papillomavirus (HPV)
genotypes associated with cervical cancer progression. This is a robust system capable to
identify genetic signatures or single nucleotide polymorphisms (SNPs). SBA has the potential
to change the probe-based diagnostics, and allow for a transition towards the technology by
genomic sequencing [115]. Some groups are studying other molecular factors as possible
markers of infection by HPV as a complementary diagnostics. The overexpression of the HPV
E6 and E7 genes is indicated in HPV-induced carcinogenesis, making these genes a potential
measure of virulence. Monitoring the expression levels of these genes may allow for screening
and monitoring of cancer progression [116].
MOLECULAR DIAGNOSIS
METHOD
NAME TEST GENOTYPES AND TARGET DETECTED
Real time Real Time High risk HPV test
(Abbott Molecular)
14 high risk HPV genotypes: 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68 and to partially genotype
16, 18 from other 12 high risk genotypes using L1
gene.
Cobas 4800 HPV Test
Amplification/Detection kit
(Roche Molecular Diagnostics)
HPV 16 and HPV 18 and concurrently detecting the
rest of the high risk types (31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68), using L1 gene
Hybrid capture Hybrid Capture 2 High-Risk HPV
DNA Test
High-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68 using all genome.
PCR and hybridization AMPLICOR Human
Papillomavirus Test (Roche
Molecular Diagnostics)
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68 using L1 gene.
TMA APTIMA HPV assay
(Hologic)
Qualitative detection of E6/E7 viral messenger RNA
(mRNA) from 14 high-risk types of HPV: 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Reverse hybridization Digene HPV Genotyping RH Test
(Qiagen)
Detection of HPV subtypes 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 using L1
gene.
INNO-LiPA HPV Genotyping Extra
(Innogenetics)
Detection of at least 54 HPV types using L1 gene.
Linear Array HPV Genotyping test
(Roche Molecular Diagnostics)
Linear Array detects thirty seven anogenital HPV
DNA genotypes 6, 11, 16, 18, 26, 31, 33, 35, 39, 40,
42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66,





NAME TEST GENOTYPES AND TARGET DETECTED
67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82, 83, 84, IS39
and CP6108.
Invader chemistry Cervista HPV HR Test (Hologic) Detection of 14-type High Risk HPV genotypes: 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 using
L1 gene.
PCR-microarray PapilloCheck HPV-Screening Test
(Greiner Bio-One)
Type-specific identification of 18 high-risk(16,18,
31,33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73,




Identification of HPV 6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62,
66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89
genotypes using L1 gene.
Infiniti HPV Genotyping assay
(AutoGenomics)
Genotyping of HPV 6, 11, 16, 18, 26, 30, 31, 33, 34,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70,






Discriminates the E6/E7 mRNA between genotypes
16, 18, 31, 33 and 45.
Next-Generation assay NextGen HPV Screening Assay
and Platform (Qiagen)
15 high risk subtypes (+ types 66 and 82)
Information based on Kroupis C, et al., 2011 [90]; Arney A, et al., 2010 [100].
Table 3. Principal methods of molecular diagnosis of HPV.
Analysis of the host factor p16INK4a (p16), a cyclin-dependent kinase inhibitor could be a
molecular marker to HPV infection. The increase of p16 indicates removal of the negative
feedback control supplied by the retinoblastoma gene, pRB. When oncogenic HPV E7 proteins
bind to pRB, p16 is overexpressed and elevated, representing active expression of HPV
oncogenes [117]. The sialylation modification observed during oncogenic transformation,
tumor metastases and invasion, has been associated with enhanced sialyltransferases (STs)
transcription such as ST3Gal III, ST3Gal IV and ST6Gal I in CIN [118].
5. Viral hepatitis
Viral hepatitis is a necroinflammatory liver disease of variable severity. Persistent infection by
HBV is often associated with chronic liver disease that can lead to the development of cirrosis
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and hepatocellular carcinoma being a global public health as chronic diseases, cause of
infectious disease mortality globally, each year causing approximately 1.4 million deaths. In
addition, viral hepatitis are cause of liver cancer and the most common reason for liver
transplantation [119]. The viruses more common are Hepatitis A, Hepatitis B, and Hepatitis
C. Approximately 400 million persons living with chronic hepatitis B virus (HBV) or hepatitis
C virus infection who die from cirrhosis or liver cancer, years and decades after of their
infection [120]. Hepatitis B is caused by infection with HBV, which may lead to acute or chronic
hepatitis. HBV is the 9th leading cause of death worldwide. It causes cirrhosis, liver failure
and hepatocellular carcinoma. HBV is a small nonenveloped DNA virus that is a member of
the Hepadnaviridae family, HBV contains a 3.2-kb partially double-stranded DNA genome
with 4 open reading frames encoding 7 proteins (P/viral polymerase, S/Surface antigen
proteins/HBsAg, C/core protein, HBeAg y X/HBx protein) [121]. Eight genotypes of HBV
(designated-H) have been identified by sequence divergence of >8% over the entire genome
of HBV DNA [122]. HBV is efficiently transmitted by percutaneous or mucous membrane
exposure to infectious blood or body fluids that contain blood. Acute HBV infection can be
either asymptomatic or symptomatic. Symptoms in acute HBV infection are clinically indis‐
tinguishable from those in other acute viral hepatitis infections [123]. Diagnosis of hepatic viral
infection is carried out by studying biochemical as liver function tests, serologic assays and
histological parameters. Serological HBV diagnosis identifies virally-encoded antigens and
their corresponding antibodies in serum. Three clinical useful antigen-antibody systems have
been identified for hepatitis B: hepatitis B surface antigen (HBsAg) and antibody to HBsAg
(anti-HBs), antibody (anti-HBc IgM and anti-HBc IgG) to hepatitis B core antigen (HBcAg),
hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) [124]. B surface antigen
(HBsAg) is the first serological marker to appear during the course of HBV infection, is present
in both acute and chronic infection. The immunoassays to detect HBsAg are highly spectific
and show a sensitivity, allowing the detection of <0.15 ng/ml of HbsAg [125]. Detection of
HBsAg allowed for the first time screening of inapparently infected blood donors for a
dangerous pathogen. The simultaneous detection of antibodies against HBsAg (anti-HBs) and
HBcAg (anti-HBc) can be useful to know the evolution of disease. The presence of IgM antibody
to hepatitis B core antigen (IgM anti-HBc) is diagnostic of acute or recently acquired HBV
infection. Antibody to HBsAg (anti-HBs) is produced after a resolved infection and is the only
HBV antibody marker present after immunization. The presence of HBsAg and total anti-HBc,
with a negative test for IgM anti-HBc, indicates chronic HBV infection. The presence of anti-
HBc alone might indicate a false-positive result or acute, resolved, or chronic infection [126,
127]. Chronic HBV infection is defined by the persistence of serum HBsAg for more than 6
months [128]. Serologic assays for HBV are the mainstay diagnostic tools for HBV infection.
The clinically silent HBV infections are a strong driving force in the development of modern
virus diagnostics to analyze the HBV replication profile, HBV DNA levels and the viral protein
expression [129]. When serological testing could be inconclusive for the diagnosis of a HBV
infection (due to the presence of genetic variants of HBV), the molecular detection of HBV
DNA may help to resolve the uncertainties. The NAT assays in plasma or serum can detect to
10 copies/mL [130]. The viral genomes can be detected and quantified by polymerase chain
reaction (PCR), transcription-mediated amplification (TMA), and with signal amplification
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L1 gene.
PCR-microarray PapilloCheck HPV-Screening Test
(Greiner Bio-One)
Type-specific identification of 18 high-risk(16,18,
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Identification of HPV 6, 11, 16, 18, 26, 31, 33, 35, 39,
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Discriminates the E6/E7 mRNA between genotypes
16, 18, 31, 33 and 45.
Next-Generation assay NextGen HPV Screening Assay
and Platform (Qiagen)
15 high risk subtypes (+ types 66 and 82)
Information based on Kroupis C, et al., 2011 [90]; Arney A, et al., 2010 [100].
Table 3. Principal methods of molecular diagnosis of HPV.
Analysis of the host factor p16INK4a (p16), a cyclin-dependent kinase inhibitor could be a
molecular marker to HPV infection. The increase of p16 indicates removal of the negative
feedback control supplied by the retinoblastoma gene, pRB. When oncogenic HPV E7 proteins
bind to pRB, p16 is overexpressed and elevated, representing active expression of HPV
oncogenes [117]. The sialylation modification observed during oncogenic transformation,
tumor metastases and invasion, has been associated with enhanced sialyltransferases (STs)
transcription such as ST3Gal III, ST3Gal IV and ST6Gal I in CIN [118].
5. Viral hepatitis
Viral hepatitis is a necroinflammatory liver disease of variable severity. Persistent infection by
HBV is often associated with chronic liver disease that can lead to the development of cirrosis
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and hepatocellular carcinoma being a global public health as chronic diseases, cause of
infectious disease mortality globally, each year causing approximately 1.4 million deaths. In
addition, viral hepatitis are cause of liver cancer and the most common reason for liver
transplantation [119]. The viruses more common are Hepatitis A, Hepatitis B, and Hepatitis
C. Approximately 400 million persons living with chronic hepatitis B virus (HBV) or hepatitis
C virus infection who die from cirrhosis or liver cancer, years and decades after of their
infection [120]. Hepatitis B is caused by infection with HBV, which may lead to acute or chronic
hepatitis. HBV is the 9th leading cause of death worldwide. It causes cirrhosis, liver failure
and hepatocellular carcinoma. HBV is a small nonenveloped DNA virus that is a member of
the Hepadnaviridae family, HBV contains a 3.2-kb partially double-stranded DNA genome
with 4 open reading frames encoding 7 proteins (P/viral polymerase, S/Surface antigen
proteins/HBsAg, C/core protein, HBeAg y X/HBx protein) [121]. Eight genotypes of HBV
(designated-H) have been identified by sequence divergence of >8% over the entire genome
of HBV DNA [122]. HBV is efficiently transmitted by percutaneous or mucous membrane
exposure to infectious blood or body fluids that contain blood. Acute HBV infection can be
either asymptomatic or symptomatic. Symptoms in acute HBV infection are clinically indis‐
tinguishable from those in other acute viral hepatitis infections [123]. Diagnosis of hepatic viral
infection is carried out by studying biochemical as liver function tests, serologic assays and
histological parameters. Serological HBV diagnosis identifies virally-encoded antigens and
their corresponding antibodies in serum. Three clinical useful antigen-antibody systems have
been identified for hepatitis B: hepatitis B surface antigen (HBsAg) and antibody to HBsAg
(anti-HBs), antibody (anti-HBc IgM and anti-HBc IgG) to hepatitis B core antigen (HBcAg),
hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) [124]. B surface antigen
(HBsAg) is the first serological marker to appear during the course of HBV infection, is present
in both acute and chronic infection. The immunoassays to detect HBsAg are highly spectific
and show a sensitivity, allowing the detection of <0.15 ng/ml of HbsAg [125]. Detection of
HBsAg allowed for the first time screening of inapparently infected blood donors for a
dangerous pathogen. The simultaneous detection of antibodies against HBsAg (anti-HBs) and
HBcAg (anti-HBc) can be useful to know the evolution of disease. The presence of IgM antibody
to hepatitis B core antigen (IgM anti-HBc) is diagnostic of acute or recently acquired HBV
infection. Antibody to HBsAg (anti-HBs) is produced after a resolved infection and is the only
HBV antibody marker present after immunization. The presence of HBsAg and total anti-HBc,
with a negative test for IgM anti-HBc, indicates chronic HBV infection. The presence of anti-
HBc alone might indicate a false-positive result or acute, resolved, or chronic infection [126,
127]. Chronic HBV infection is defined by the persistence of serum HBsAg for more than 6
months [128]. Serologic assays for HBV are the mainstay diagnostic tools for HBV infection.
The clinically silent HBV infections are a strong driving force in the development of modern
virus diagnostics to analyze the HBV replication profile, HBV DNA levels and the viral protein
expression [129]. When serological testing could be inconclusive for the diagnosis of a HBV
infection (due to the presence of genetic variants of HBV), the molecular detection of HBV
DNA may help to resolve the uncertainties. The NAT assays in plasma or serum can detect to
10 copies/mL [130]. The viral genomes can be detected and quantified by polymerase chain
reaction (PCR), transcription-mediated amplification (TMA), and with signal amplification
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methods such as hybrid-capture and the branched DNA assay. Quantification of genome of
HBV can be used for diagnosing HBV infection and monitoring the effect of antiviral therapy.
HBV DNA is the earliest detectable marker in acute HBV infection and the gold standard for
the diagnosis of occult HBV infection. HBV DNA testing is particularly useful in the detection
of the early phase of acute HBV infection prior to the appearance of serum HBsAg as well as
in occult HBV infection [131, 132]. Several commercial molecular assays have been developed
for quantitation of HBV DNA. Such as COBAS Amplicor HBV Monitor, which is based on the
amplification of DNA targets by PCR with HBV-specific primers. Between the hybridizations
methods are Hybrid capture Ultrasensitive hybrid capture II and Branched DNA VERSANT
hepatitis B virus DNA 3.0. Recently developed real-time target amplification methods have
improved viral genome detection and quantification for clinical and research purposes. Real
time PCR for HBV DNA has reached an excellent level of performance with a detection limit
close to the theoretical minimum of 1 DNA molecule per reaction mix and a huge dynamic
range up to 107 or more. In 1991 the WHO introduced International Standard preparations and
an arbitrary International Unit (IU) of HBV DNA. The number of molecules per IU depends
on the assay; but typically 5 molecules correspond to one IU HBV DNA [133]. Real-Time PCR
(Real Time Abbott PCR, Smart HBVTM, Real Art HBV, COBAS AmPliprep, Cobas TaqMan
HBV, Aptima HBV Quantitative assay) [134-136]. Fosun real-time PCR HBV kit is a comercial
assay for quantitation of serum HBV DNA based on TaqMan PCR technology, which is useful
for monitoring HBV DNA levels in patients with chronic hepatitis B. The limit of the duplex
real-time PCR assay was 29.5 IU/ml, whereas the specificity was 100% for the detection of HBV
DNA [137]. A trial has been tested, a TaqMan locked nucleic acid (LNA) real-time polymerase
chain reaction (PCR) probe for the accurate quantification and detection of hepatitis B virus
(HBV) DNA in serum (plasma) [138]. The genotyping analysis of HBV can performed by real-
time PCR using (GQ-PCR) method or the direct sequencing and reverse hybridization with
INNO-LiPA HBV genotyping assay [139]. Other option to diagnostics of hepatotrophic viruses
is Real-time PCR array, useful in the rapid detection of multiple viral pathogens, between them
hepatitis B virus (HBV), hepatitis C virus (HCV) using the SYBR Green chemistry. The array
detected: 10 genome equivalents (geq)/ml of HCV, 50 geq of HBV (genotype A) [140]. Micro‐
RNAs (miRNAs) are noncoding RNAs that regulate gene expression primarily at the post-
transcriptional level by binding to mRNAs. The circulating miRNA in serum or plasma might
be a very useful biomarker for the diagnosis and prognosis of HBV-related diseases, indicating
a promising future in the treatment of HBV-related diseases [141]. Hepatitis C virus (HCV) is
a major public health problem and a leading cause of chronic liver disease. An estimated 180
million people are infected worldwide, several of these patients go on to develop chronic HCV
infection, often developing into liver cirrhosis, hepatic failure and hepatocellular carcinoma
[142]. Hepatitis C virus is a single stranded RNA, enveloped virus, belongs to the Flaviviridae
family and is the only member of the Hepacivirus genus [143]. The commercially-available
diagnostic tests are based on enzyme immunosorbent assays (EIA) for the detection of HCV-
specific antibodies and recombinant immunoblot assays (RIBA). Although, in the diagnosis of
influenza is applied the algorithm showed in figure 5 [144-146]. Testing for circulating HCV
by genomic sequence amplification (PCR and branched DNA assay) has been successfully
utilized for confirmation of serological results and the effectiveness of antiviral therapy [134,
Trends in Infectious Diseases106
147]. An alternative to HCV diagnosis is Loop-mediated isothermal amplification (LAMP)
assay for rapid detection of HCV genomic RNA [148]. The molecular HCV assays includes to
RT-PCR (AmpliScreen 2.0, Amplicor HCV 2.0, Cobas Amplicor Monitor HCV 2.0, Versant
HCV RNA, Procleix HIV/HCV assay, Procleix Ultrio assay). The methods for accurate
quantification of HCV RNA levels are key tools in the clinical management of patients. The
HCV RNA Assay by RT-PCR includes to Amplicor HCV Monitor 2.0, Cobas Amplicor Monitor
HCV 2.0, Cobas AmliPrep/Cobas TaqMan HCV, Versant HCV RNA 3.0 Quantitative assay,
LCx HCV RNA Quantitative assay, SuperQuant, Abbott RealTime [135]. To evaluate the
response to antiviral therapies is possible analyze the absence or alteration of genetic material
in clinical specimens from successfully treated patients. In situ hybridization (ISH) enables
visualization of specific nucleic acid in morphologically preserved cells and tissue sections.
The anti-sense probe detected HCV RNA, with a sensitivity and specificity of 95% and 100%,
respectively. HCV genomic RNA can be variably distributed in tissue sections and was located
primarily in the perinuclear regions in hepatocytes [149]. Viral hepatitis is one of the major
health problems worldwide. Hepatitis delta virus (HDV) is also not uncommon world-wide.
Hepatitis D virus (HDV) or delta virus is a defective virus. It requires the help of another virus
that is hepatitis B virus for its multiplication. It always occur with HBV either in the form of
co-infection or super-infection [150]. HCV, HBV, and HDV share parallel routes of transmis‐
sion due to which dual or triple viral infection can occur in a proportion of patients at the same
time. HBV and HCV are important factors in the development of liver cirrhosis (LC) and
hepatocellular carcinoma [151]. In the diagnosis of co-infections, individually each infection
(HBV, HCV and HDV) is confirmed by the presence of the serum surface antigen, hepatitis B,
C and D envelope antigen and specific antibodies to the hepatitis B, C and D core [152]. By
Deep Sequencing were readily detected at high coverage in plasma of patients with chronic
viral hepatitis B and C. Although, this protocol also is adapted to other samples such as urine,
bile, saliva and other body fluids by viral metagenomic survey [153]. For other side, other
molecular technique as the protein micro-array gives a way to diagnosis multiple viral
infections; using two viral antigens (HBsAg, HBeAg) and seven viral antibodies (HBsAb,
HBcAb, HBeAb, HCVAb, HDVAb, HEVAb, HGVAb) of human hepatitis viruses [154]. Finally,
the successful simultaneous detection of HAV, HBV and HCV was performed with the
Magicplex HepaTrio Real-time Detection test, whose sensitivity and specificity of the Hepa‐
Trio test were 93.8% and 98.2%, respectively, for detecting HBV infection, and 99.1% and
100.0%, respectively, for HCV infection [155].
6. Mumps virus
Mumps is an acute viral infection caused by a member of the Rubulavirus genus in the
Paramyxoviridae family. Mumps virus (MuV) is pleomorphic, enveloped, comprising a
nucleocapsid core with helical structure composed of the 15384 nucleotide. Nonsegmented
negative-sense RNA genome has the organization: 3′-NP-P-M-F-SH-HN-L-5′ [156]. The
molecular epidemiology of MuV is characterized by the co-existence of 10 (or more) distinct
genotypes named A-J based on the nucleotide sequence of the SH gene. MuV genotypes (C,
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a major public health problem and a leading cause of chronic liver disease. An estimated 180
million people are infected worldwide, several of these patients go on to develop chronic HCV
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by genomic sequence amplification (PCR and branched DNA assay) has been successfully
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Deep Sequencing were readily detected at high coverage in plasma of patients with chronic
viral hepatitis B and C. Although, this protocol also is adapted to other samples such as urine,
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molecular technique as the protein micro-array gives a way to diagnosis multiple viral
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the successful simultaneous detection of HAV, HBV and HCV was performed with the
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Trio test were 93.8% and 98.2%, respectively, for detecting HBV infection, and 99.1% and
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genotypes named A-J based on the nucleotide sequence of the SH gene. MuV genotypes (C,
Molecular Diagnostics as an Indispensable Tool for the Diagnosis of Infectious Diseases of…
http://dx.doi.org/10.5772/57581
107
D, H, J) and vaccine strains (Urabe Am9) have been associated with enhanced neurovirulence
[157]. MuV is known to affect the salivary glands causing parotid swelling lasting at least two
days, but may persist longer than ten days [158]. The mumps incubation period ranges from
12–25 days, but parotitis typically develops 16 to 18 days after exposure to mumps virus. The
MuV also produce an acute systemic infection involving glandular, lymphoid and nervous
tissues, leading to some important complications, the main central nervous system (CNS)
complication of mumps virus infection is aseptic meningitis (in up to 15% of cases) [159, 160,
161]. Mumps epidemics are usually caused by airborne transmission of mumps virus (MuV)
and have high morbidity in non-immunized children. Massive vaccination programs have
decreased the incidence of MuV infection worldwide. The annual incidence of mumps in the
absence of immunization was in the range of 100–1000 cases/100 000 people, outbreaks have
not been completely eliminated even in populations with high vaccination coverage [162].
Laboratory confirmation of mumps infection can be made by the detection of immunoglobulin
M (IgM) antibodies specific to mumps virus in acute-phase serum samples (gold standard for
mumps diagnosis). Mumps virus can be detected from fluid collected from the parotid duct,
other affected salivary gland ducts, the throat, from urine, and from cerebrospinal fluid (CSF).
Parotid duct swabs yield the best viral sample. With previous contact with mumps virus either
through vaccination or natural infection, serum mumps IgM test results may be negative; IgG
test results may be positive at the initial blood draw. The serologic tests available for laboratory
confirmation of mumps acute infection and confirmation of previous exposure to mumps vary
among laboratories. Tests for IgM antibody includes Enzyme Immunoassay (EIA): a highly
specific test for diagnosing acute mumps infection and Immunofluorescence assay (IFA) a test
that is relatively inexpensive and simple, but the test is particularly susceptible to interference
by high levels of mumps-specific IgG. A significant rise in IgG antibody titer, in acute-and
convalescent-phase serum specimens is a positive result of infection. The presence of mumps-
Figure 5. HCV Testing Algorithm and molecular assays.
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specific IgG, detected using a serologic assay (EIA or IFA), is considered evidence of mumps
immunity but does not predict the presence of neutralizing antibodies or protection from
mumps disease [163]. A near patient test (NPT) for the detection of mumps-specific IgM in
oral fluid specimens was developed and evaluated using 196 oral fluid specimens from
suspected cases of mumps and measles. Compared to EIA, the sensitivity, specificity, positive
and negative predictive value of the mumps IgM NPT were 79.5%, 100%, 100%, and 72.6%,
respectively. Mumps IgM NPT is rapid and simple to perform for confirmation of a clinical
diagnosis. The NPT strip is also a suitable matrix for preserving nucleic acid, enabling virus-
specific RT-PCR to be performed [164]. Standard diagnostics that detect virus or virus-specific
antibody are dependable for confirming primary mumps infection in immunologically naïve
persons, but these methods perform inconsistently for individuals with prior immune
exposure. Detection of activated mumps-specific antibody-secreting B cells (ASCs) by an
enzyme-linked immunospot (ELISPOT) assay has the potential for use as an alternative
method of diagnosis when suspect cases cannot be confirmed by detection of IgM or virus.
The mumps-specific memory B cells are detected at a much lower frequency than measles-or
rubella-specific cells, suggesting that mumps infection may not generate robust B-cell memory
[165]. Successful virus isolation by cell culture should always be confirmed by immunofluor‐
escence with a mumps-specific monoclonal antibody or by molecular techniques such as RT-
PCR, nested-PCR or real-time RT-PCR [166-168]. In patients vaccinated, pre-existing vaccine-
induced antibodies. Moreover, acute infection has to be demonstrated by direct detection of
the virus by viral isolation or genomic amplification. RT-PCR allows a diagnosis and also forms
the basis for genotype characterization by sequencing the SH gene, useful tool for mumps
surveillance, management and control, according to WHO recommendations. Virus genotyp‐
ing allows the building of a sequence database that will help to know transmission pathways
of mumps strains circulating in the world and to distinguish wild-type mumps virus from
vaccine virus [169]. Standard RT-PCR to detect the SH gene of mumps virus can be used to
detect mumps RNA in clinical samples or in infected cell culture [170]. The sequence of the
PCR product containing the coding region of the SH gene can be used to determine the viral
genotype [171]. A multiplex real-time RT-PCR test for the detection of RNA from mumps virus
in patient specimens, using primers and probes that target the mumps SH gene [172]. Several
test of real-time RT-PCR are performed with TaqMan Assay [173]. A multiplex real-time RT-
PCR assay, for rapid mumps diagnosis in a clinical setting. The assay used oligonucleotide
primers and a TaqMan probe targeting the mumps SH gene. This test showed 100% correlation
with results from viral culture. [172]. Other qRT-PCR assay is directed to the mumps virus F
gene [174]. Recently, by RT-PCR it was detect a case of corneal endothelitis following the
mumps parotitis [175].
7. Measles virus
Measles produces a highly contagious respiratory infection and may cause extensive epidem‐
ics. Measles is one of the most important causes of child morbidity and mortality. [176]. A safe
and efficacious live attenuated virus vaccine is available toward global measles control [177,
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specific IgG, detected using a serologic assay (EIA or IFA), is considered evidence of mumps
immunity but does not predict the presence of neutralizing antibodies or protection from
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the virus by viral isolation or genomic amplification. RT-PCR allows a diagnosis and also forms
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ing allows the building of a sequence database that will help to know transmission pathways
of mumps strains circulating in the world and to distinguish wild-type mumps virus from
vaccine virus [169]. Standard RT-PCR to detect the SH gene of mumps virus can be used to
detect mumps RNA in clinical samples or in infected cell culture [170]. The sequence of the
PCR product containing the coding region of the SH gene can be used to determine the viral
genotype [171]. A multiplex real-time RT-PCR test for the detection of RNA from mumps virus
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test of real-time RT-PCR are performed with TaqMan Assay [173]. A multiplex real-time RT-
PCR assay, for rapid mumps diagnosis in a clinical setting. The assay used oligonucleotide
primers and a TaqMan probe targeting the mumps SH gene. This test showed 100% correlation
with results from viral culture. [172]. Other qRT-PCR assay is directed to the mumps virus F
gene [174]. Recently, by RT-PCR it was detect a case of corneal endothelitis following the
mumps parotitis [175].
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Measles produces a highly contagious respiratory infection and may cause extensive epidem‐
ics. Measles is one of the most important causes of child morbidity and mortality. [176]. A safe
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178]. Measles vaccination is highly effective, safe and relatively cost-effective and has inter‐
rupted measles transmission in most parts of the world [179]. Despite tremendous achieve‐
ments towards global measles mortality reduction and measles elimination goals, globally, in
2010, there were 327305 measles cases reported and an estimated 139300 measles deaths) [180,
181]. Mortality is highest in children and most acute measles deaths are due to secondary
infections that result from a poorly understood measles-induced suppression of immune
responses [182]. In addition to the risks of acute infection, children under the age of 2 years
are also vulnerable to development of subacute sclerosing panencephalitis (SSPE), a progres‐
sive, uniformly fatal neurologic disease associated with persistent measles virus infection of
the nervous system, have documented high levels of antibody to measles virus [183]. Other
diseases related to measles are systemic lupus erythematosus [184] and multiple sclerosis [185].
The measles virus is a member of the Morbillivirus genus of the family Paramyxoviridae. The
virions are pleomorphic and range in size from 100 to 300 nm. The measles virus is antigenically
stable and genetic differences are few among vaccine strains. Wild-type viruses are more
variable. Several different genotypes of wild measles virus are currently circulating worldwide
and this genetic variation provides the basis for the application of molecular epidemiological
techniques to study the transmission of measles virus [186]. Laboratory confirmation of
clinically diagnosed measles was traditionally based on methods such as immunofluorescence
antibody for detection of viral antigen and haemagglutination inhibition (HI), haemolysin
inhibition, complement fixation, and plaque-reduction neutralization (PRN) for detection of
measles antibody in serum (Table 4) [187]. Currently, detection of measles-specific IgM
antibody and measles RNA by real-time RT-PCR are the most common methods for confir‐
mation of measles infection [168]. Initially laboratory confirmation of cases of measles infection
is performed by detection of measles-specific immunoglobulin M (IgM) antibodies, the test of
choice for rapid diagnosis of measles cases in a single serum specimen collected within the
first few days of rash onset, usually become detectable in serum after four days post onset of
rash (90-100% sensitivity) and decline rapidly after one month. The virus can be detected in
serum samples, blood spots, throat swab (or nasopharyngeal swab), urine and or collection of
both respiratory and urine samples that can increase the likelihood of detecting virus. [188].
Oral fluids can also be used to detect viral ribonucleic acid (RNA) [189]. The enzyme immu‐
noassay is the most commonly used method for detecting measles-specific IgM or IgG
antibodies. Both capture and indirect formats for IgM detection are available commercially.
Some tests available are LIAISON IgM measles (DiaSorin, Saluggia, Italy) a new automated
chemiluminescence immunoassay and the enzyme immunoassay (EIA) Enzygnost (Siemens,
Marburg, Germany), which have a a sensitivity of 93.7% and 98.8%, whereas the specificity
was 96.8% and 97.9%, respectively [190]. DiaSorin Liaison (Saluggia, Italy) is other option for
measles diagnosis, with a sensitivity and specificity for measles IgM of 92% and 100%
respectively [191]. Commercially, there are some test directs to simultaneous detection of
measles and rubella as Enzygnost (Siemens) and Platelia (Bio-Rad), useful for detecting IgM
against measles and rubella [192].
In acute, uncomplicated measles, there is a significant rise in measles-specific IgG antibodies
between acute-and convalescent-phase serum specimens. A positive test result for specific IgG
antibodies in a serum indicates past infection with measles virus or measles vaccination, but
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does not ensure protection from infection or re-infection. Screening the young adult population
about to enter college or the military, pregnant women, and other individuals at risk, for




Detection of IgM antibody by indirect IgM ELISA, IgM-capture
ELISA or EIA for IgM
Detection of IgG antibody by IgG ELISA
Virus neutralization test
HI
Cell culture and immunofluorescence microscopy
Using urine, nasopharyngeal swabs or blood
lymphocytes and detect to virus using specific
measles antibody
NAT analysis
measles RNA can be detected from nasopharyngeal swab, urine or
peripheral blood lymphocytes (oral fluid/ throat swabs) up to 5 days
post disease manifestation.
RT-PCR, RT-nested PCR, Real-Time RT-PCR and sequencing
Table 4. Laboratory diagnosis for measles in clinical materials.
Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of
serum IgG antibodies against measles (measles in addition to mumps, rubella, and varicella-
zoster virus, MMRV). However, a multiplex immunoassay for the simultaneous detection of
antibodies against MMRV showed be a good alternative to conventional ELISAs and suitable
for use in serosurveillance and vaccine studies [193]. An enzyme linked Immunosorbent
commercial assay is Captia Measles IgG based (Trinity, Biotech, USA). In countries where
disease prevalence is low, intensified surveillance typically implemented during and after an
importation will result in some false positive IgM results since no assay is 100% specific. So, it
is necessary to introduce other techniques of diagnosis related to ARN genome. In the Fifth
Hands-on Training on the Laboratory Diagnosis of Measles and Rubella focusing on Molecular
Detection and Sequence Analysis, in Hong Kong, China. It was exposed the need of introduce
the molecular detection of measles and rubella viruses using new real-time polymerase chain
reaction (PCR) as well as conventional PCR, quantitative real-time PCR and others molecular
techniques such as sequencing. Dr Paul Rota (Chief, Measles Virus Section, Centers for Disease
Control and Prevention USA), presented on the use of real-time and conventional RT-PCR for
case classification and molecular surveillance of measles virus. These tests can detect 10-100
copies of RNA/sample in a high throughput format and produce results within two hours. It
can help to confirm a case when serologic results are inconclusive but negative results do not
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178]. Measles vaccination is highly effective, safe and relatively cost-effective and has inter‐
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measles antibody in serum (Table 4) [187]. Currently, detection of measles-specific IgM
antibody and measles RNA by real-time RT-PCR are the most common methods for confir‐
mation of measles infection [168]. Initially laboratory confirmation of cases of measles infection
is performed by detection of measles-specific immunoglobulin M (IgM) antibodies, the test of
choice for rapid diagnosis of measles cases in a single serum specimen collected within the
first few days of rash onset, usually become detectable in serum after four days post onset of
rash (90-100% sensitivity) and decline rapidly after one month. The virus can be detected in
serum samples, blood spots, throat swab (or nasopharyngeal swab), urine and or collection of
both respiratory and urine samples that can increase the likelihood of detecting virus. [188].
Oral fluids can also be used to detect viral ribonucleic acid (RNA) [189]. The enzyme immu‐
noassay is the most commonly used method for detecting measles-specific IgM or IgG
antibodies. Both capture and indirect formats for IgM detection are available commercially.
Some tests available are LIAISON IgM measles (DiaSorin, Saluggia, Italy) a new automated
chemiluminescence immunoassay and the enzyme immunoassay (EIA) Enzygnost (Siemens,
Marburg, Germany), which have a a sensitivity of 93.7% and 98.8%, whereas the specificity
was 96.8% and 97.9%, respectively [190]. DiaSorin Liaison (Saluggia, Italy) is other option for
measles diagnosis, with a sensitivity and specificity for measles IgM of 92% and 100%
respectively [191]. Commercially, there are some test directs to simultaneous detection of
measles and rubella as Enzygnost (Siemens) and Platelia (Bio-Rad), useful for detecting IgM
against measles and rubella [192].
In acute, uncomplicated measles, there is a significant rise in measles-specific IgG antibodies
between acute-and convalescent-phase serum specimens. A positive test result for specific IgG
antibodies in a serum indicates past infection with measles virus or measles vaccination, but
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does not ensure protection from infection or re-infection. Screening the young adult population
about to enter college or the military, pregnant women, and other individuals at risk, for




Detection of IgM antibody by indirect IgM ELISA, IgM-capture
ELISA or EIA for IgM
Detection of IgG antibody by IgG ELISA
Virus neutralization test
HI
Cell culture and immunofluorescence microscopy
Using urine, nasopharyngeal swabs or blood
lymphocytes and detect to virus using specific
measles antibody
NAT analysis
measles RNA can be detected from nasopharyngeal swab, urine or
peripheral blood lymphocytes (oral fluid/ throat swabs) up to 5 days
post disease manifestation.
RT-PCR, RT-nested PCR, Real-Time RT-PCR and sequencing
Table 4. Laboratory diagnosis for measles in clinical materials.
Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of
serum IgG antibodies against measles (measles in addition to mumps, rubella, and varicella-
zoster virus, MMRV). However, a multiplex immunoassay for the simultaneous detection of
antibodies against MMRV showed be a good alternative to conventional ELISAs and suitable
for use in serosurveillance and vaccine studies [193]. An enzyme linked Immunosorbent
commercial assay is Captia Measles IgG based (Trinity, Biotech, USA). In countries where
disease prevalence is low, intensified surveillance typically implemented during and after an
importation will result in some false positive IgM results since no assay is 100% specific. So, it
is necessary to introduce other techniques of diagnosis related to ARN genome. In the Fifth
Hands-on Training on the Laboratory Diagnosis of Measles and Rubella focusing on Molecular
Detection and Sequence Analysis, in Hong Kong, China. It was exposed the need of introduce
the molecular detection of measles and rubella viruses using new real-time polymerase chain
reaction (PCR) as well as conventional PCR, quantitative real-time PCR and others molecular
techniques such as sequencing. Dr Paul Rota (Chief, Measles Virus Section, Centers for Disease
Control and Prevention USA), presented on the use of real-time and conventional RT-PCR for
case classification and molecular surveillance of measles virus. These tests can detect 10-100
copies of RNA/sample in a high throughput format and produce results within two hours. It
can help to confirm a case when serologic results are inconclusive but negative results do not
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rule out a case. These molecular tests are more sensitive than conventional (endpoint) RT-PCR.
Sequence information from the conventional PCR is required for genotype assignment and
confirmation of vaccine reactions [194].
Measles RNA can be detected (oral fluid/ throat swabs) up to 5 days post disease manifesta‐
tion. Molecular assays to measles virus includes measles H (haemagglutinin) gene real-time
PCR and hybridization [195] and nucleic acid sequence analysis of the nested N-gene PCR
amplicons (nucleocapsid) [196, 197]. A nested reverse transcriptase PCR (RT-PCR) that detected
measles virus (MV) from dried filter papers was set up using MV infected cells diluted in sterile
phosphate-buffered saline. Although, the nested RT-PCR results of low titer viruses dried onto
filter papers are not reproducible and reliable [198, 199]. Detection of RNA in PBMC by RT-
PCR is the most effective method for diagnosis of measles. A study performed in 2010, analyzed
sixty-three throat swabs, 84 peripheral blood mononuclear cell (PBMC) samples, and 85 plasma
samples were collected from 85 cases of suspected measles. The percentage of positive results
from PBMC by RT-PCR and virus isolation was 100 and 91.7%, respectively. The percentage of
positive results from throat swabs by RT-PCR and virus isolation was 91.2 and 52.8%, respec‐
tively [200]. Measles can produce congenital infections with a risk of neurological complica‐
tions in the newborn. Mother-to-child transmission of the measles virus, it has been widely
documented in the newborns either by RT-PCR in saliva or by IgM detection in blood. An early
viral  RT-PCR  detection  allows  successful  immunoglobulin  prophylaxis  in  one  newborn
avoiding the development classical or neurological clinical signs of measles infection [201].
Molecular detection of measles virus has been optimized by amplification of nucleocapsid (N)
and human RNase P mRNA for a one-step quantitative reverse transcription (qRT)-PCR [202].
The qRT-PCR for measles diagnosis can use SYBR Green or TaqMan (ABI) in real-time reverse
transcription-polymerase chain reaction (RT-PCR) assays. For the real-time RT-PCR, primer
sets are design from a region of the MV H gene of the Edmonston strain (genotype A) and a
TaqMan probe specific for the H gene of genotype D MV [203]. Currently, is possible estimate
the titer of measles, mumps and rubella (MMR) viruses by a TaqMan-based real-time reverse
transcription-polymerase chain reaction (qPCR-RT) assay optimized in infected cell culture
supernatants [204]. For genetic typing of measles virus in clinical samples is xMAP technolo‐
gy that employs specific oligonucleotide probes of genotypes D4, D6 and D7 of virus [205].
Other alternative employed for the genotype analysis of measles virus is sequencing of the 450
nucleotide of nucleoprotein gene (N450) that contributes to the genetic characterization of wild-
type measles viruses and offers data in the study of viral transmission pathways. N450 is
amplifying with the primer pair, MeV216/MeV214. It is clear that the molecular tools improve‐
ment the molecular characterization of circulating measles viruses globally and provides
enhanced quality control measures [206]. Demonstration of the usefulness of molecular tests in
the diagnosis of measles during outbreaks or epidemic peaks was reported in an outbreak in
Paris (France) in 2011. 171 oral fluid samples and 235 serum samples collected from 270 patients
were tested using a novel one-step real-time RT-PCR assay. This study showed that the detection
rate of MV-RNA by RT-PCR was 98% (100/102) for oral fluid and 95% (97/102) for serum samples.
The detection rate of MV-IgM was 85% (87/102). In addition, it was found than during the early
stage of infection, the MV-RNA viral load in serum was lower in patient’s positive than in those
negative for MV-IgG [207]. The detection and identification of the virus in cell culture may take
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several weeks. The samples should undergo virus isolation on sensitive cell lines, such as B95a
cells. Measles virus can be isolated from clinical specimens, including; throat swab, conjuncti‐
val swabs, nasopharyngeal aspirates or urine [208].
8. HIV
Acquired Immunodeficiency Syndrome (AIDS) is one of the most critically acclaimed endemic
diseases, caused by two lentiviruses HIV-1 and 2. Human immunodeficiency virus (HIV) is
the pathogen causing the acquired immunodeficiency syndrome (AIDS) [209, 210]. HIV is an
enveloped virus with tropism for CD4+lymphocytes and monocytes. HIV is classified in the
family Retroviridae, subfamily Lentivirinae, and genus Lentivirus. HIV comprising a single
stranded, positive-sense ribonucleic acid (RNA) genome of about 9.7 kilobases. From the 5'
end of genome are located the three genes that characterize retroviruses: gag-pol-env. The gag
gene codes for the internal structural proteins, the pol gene for the three viral enzymes, and
the env gene for the envelope glycoproteins. LTR (Long Terminal Repeat) sequences are found
at each extremity of the genome, containing the signals for the regulation of expression of the
viral genes. The genome also has six additional genes called "accessory" genes: vif, nef, vpr, tat,
rev and vpu (HIV-1) or vpx (HIV-2) [211]. There are two strands of HIV RNA and each strand
has a copy with nine genes, which encode 15 proteins. The RNA is surrounding by a cone -
shaped capsid which consists of approximately 2000 copies of the p24 viral protein. Surround‐
ing the capsid is the viral envelope. Each envelope subunit consists of two non-covalently
linked membrane proteins: glycoprotein (gp) 120, the outer envelope protein, and gp41, the
transmembrane protein that anchors the glycoprotein complex to the surface of the virion. The
envelope protein is the most variable component of HIV, although gp120 itself is structurally
divided into highly variable (V) and more constant (C) regions. The variability of the HIV
envelope also confers a uniquely complex antigenic diversity. The virion contains three
enzymes necessary for multiplication: reverse transcriptase (enables the viral RNA to be
transcribed into DNA), and endonuclease (enables the DNA to be integrated into the host cell,
the viral genome then becomes proviral DNA) and the protease (enables the virus to mature
at a late stage in the cycle of intracellular multiplication). The presence of two copies of the
retroviral genome in each particle promotes genetic recombination between the RNAs. This
and the high error rate of the viral reverse transcriptase leads to considerable genetic variation
in the viral progeny. AIDS is characterized by the selective targeting of the CD4+/CD8+T cells
by HIV which fatally impairs the immune system. The window period for this retrovirus is
from several weeks to few months altogether before detection of earliest antibodies in blood
serum raised against HIV [210]. HIV infection is one of the major threats to human health due
to the lack of relevant vaccine and drugs to cure AIDS. Its early diagnosis is thus important in
controlling HIV transmission. With acute HIV infection, high levels of infectious virus are
detectable in serum and genital secretions. The rate of transmission during acute HIV infection
is higher than the established HIV infection, for this reason, new HIV testing strategies need
to focus on sensitivity, especially for this highly contagious phase immediately after infection.
There are two types of virus, HIV-1 and HIV-2, which are further divided into groups and/or
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rule out a case. These molecular tests are more sensitive than conventional (endpoint) RT-PCR.
Sequence information from the conventional PCR is required for genotype assignment and
confirmation of vaccine reactions [194].
Measles RNA can be detected (oral fluid/ throat swabs) up to 5 days post disease manifesta‐
tion. Molecular assays to measles virus includes measles H (haemagglutinin) gene real-time
PCR and hybridization [195] and nucleic acid sequence analysis of the nested N-gene PCR
amplicons (nucleocapsid) [196, 197]. A nested reverse transcriptase PCR (RT-PCR) that detected
measles virus (MV) from dried filter papers was set up using MV infected cells diluted in sterile
phosphate-buffered saline. Although, the nested RT-PCR results of low titer viruses dried onto
filter papers are not reproducible and reliable [198, 199]. Detection of RNA in PBMC by RT-
PCR is the most effective method for diagnosis of measles. A study performed in 2010, analyzed
sixty-three throat swabs, 84 peripheral blood mononuclear cell (PBMC) samples, and 85 plasma
samples were collected from 85 cases of suspected measles. The percentage of positive results
from PBMC by RT-PCR and virus isolation was 100 and 91.7%, respectively. The percentage of
positive results from throat swabs by RT-PCR and virus isolation was 91.2 and 52.8%, respec‐
tively [200]. Measles can produce congenital infections with a risk of neurological complica‐
tions in the newborn. Mother-to-child transmission of the measles virus, it has been widely
documented in the newborns either by RT-PCR in saliva or by IgM detection in blood. An early
viral  RT-PCR  detection  allows  successful  immunoglobulin  prophylaxis  in  one  newborn
avoiding the development classical or neurological clinical signs of measles infection [201].
Molecular detection of measles virus has been optimized by amplification of nucleocapsid (N)
and human RNase P mRNA for a one-step quantitative reverse transcription (qRT)-PCR [202].
The qRT-PCR for measles diagnosis can use SYBR Green or TaqMan (ABI) in real-time reverse
transcription-polymerase chain reaction (RT-PCR) assays. For the real-time RT-PCR, primer
sets are design from a region of the MV H gene of the Edmonston strain (genotype A) and a
TaqMan probe specific for the H gene of genotype D MV [203]. Currently, is possible estimate
the titer of measles, mumps and rubella (MMR) viruses by a TaqMan-based real-time reverse
transcription-polymerase chain reaction (qPCR-RT) assay optimized in infected cell culture
supernatants [204]. For genetic typing of measles virus in clinical samples is xMAP technolo‐
gy that employs specific oligonucleotide probes of genotypes D4, D6 and D7 of virus [205].
Other alternative employed for the genotype analysis of measles virus is sequencing of the 450
nucleotide of nucleoprotein gene (N450) that contributes to the genetic characterization of wild-
type measles viruses and offers data in the study of viral transmission pathways. N450 is
amplifying with the primer pair, MeV216/MeV214. It is clear that the molecular tools improve‐
ment the molecular characterization of circulating measles viruses globally and provides
enhanced quality control measures [206]. Demonstration of the usefulness of molecular tests in
the diagnosis of measles during outbreaks or epidemic peaks was reported in an outbreak in
Paris (France) in 2011. 171 oral fluid samples and 235 serum samples collected from 270 patients
were tested using a novel one-step real-time RT-PCR assay. This study showed that the detection
rate of MV-RNA by RT-PCR was 98% (100/102) for oral fluid and 95% (97/102) for serum samples.
The detection rate of MV-IgM was 85% (87/102). In addition, it was found than during the early
stage of infection, the MV-RNA viral load in serum was lower in patient’s positive than in those
negative for MV-IgG [207]. The detection and identification of the virus in cell culture may take
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several weeks. The samples should undergo virus isolation on sensitive cell lines, such as B95a
cells. Measles virus can be isolated from clinical specimens, including; throat swab, conjuncti‐
val swabs, nasopharyngeal aspirates or urine [208].
8. HIV
Acquired Immunodeficiency Syndrome (AIDS) is one of the most critically acclaimed endemic
diseases, caused by two lentiviruses HIV-1 and 2. Human immunodeficiency virus (HIV) is
the pathogen causing the acquired immunodeficiency syndrome (AIDS) [209, 210]. HIV is an
enveloped virus with tropism for CD4+lymphocytes and monocytes. HIV is classified in the
family Retroviridae, subfamily Lentivirinae, and genus Lentivirus. HIV comprising a single
stranded, positive-sense ribonucleic acid (RNA) genome of about 9.7 kilobases. From the 5'
end of genome are located the three genes that characterize retroviruses: gag-pol-env. The gag
gene codes for the internal structural proteins, the pol gene for the three viral enzymes, and
the env gene for the envelope glycoproteins. LTR (Long Terminal Repeat) sequences are found
at each extremity of the genome, containing the signals for the regulation of expression of the
viral genes. The genome also has six additional genes called "accessory" genes: vif, nef, vpr, tat,
rev and vpu (HIV-1) or vpx (HIV-2) [211]. There are two strands of HIV RNA and each strand
has a copy with nine genes, which encode 15 proteins. The RNA is surrounding by a cone -
shaped capsid which consists of approximately 2000 copies of the p24 viral protein. Surround‐
ing the capsid is the viral envelope. Each envelope subunit consists of two non-covalently
linked membrane proteins: glycoprotein (gp) 120, the outer envelope protein, and gp41, the
transmembrane protein that anchors the glycoprotein complex to the surface of the virion. The
envelope protein is the most variable component of HIV, although gp120 itself is structurally
divided into highly variable (V) and more constant (C) regions. The variability of the HIV
envelope also confers a uniquely complex antigenic diversity. The virion contains three
enzymes necessary for multiplication: reverse transcriptase (enables the viral RNA to be
transcribed into DNA), and endonuclease (enables the DNA to be integrated into the host cell,
the viral genome then becomes proviral DNA) and the protease (enables the virus to mature
at a late stage in the cycle of intracellular multiplication). The presence of two copies of the
retroviral genome in each particle promotes genetic recombination between the RNAs. This
and the high error rate of the viral reverse transcriptase leads to considerable genetic variation
in the viral progeny. AIDS is characterized by the selective targeting of the CD4+/CD8+T cells
by HIV which fatally impairs the immune system. The window period for this retrovirus is
from several weeks to few months altogether before detection of earliest antibodies in blood
serum raised against HIV [210]. HIV infection is one of the major threats to human health due
to the lack of relevant vaccine and drugs to cure AIDS. Its early diagnosis is thus important in
controlling HIV transmission. With acute HIV infection, high levels of infectious virus are
detectable in serum and genital secretions. The rate of transmission during acute HIV infection
is higher than the established HIV infection, for this reason, new HIV testing strategies need
to focus on sensitivity, especially for this highly contagious phase immediately after infection.
There are two types of virus, HIV-1 and HIV-2, which are further divided into groups and/or
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subtypes. The pandemic is caused by HIV-1 group M. HIV-1 and HIV-2 have differences as
clinical progression of the disease is slower and mother-to-child transmission is less likely with
HIV-2 than with HIV-1 (maternal-fetal transmission < 2% in the absence of treatment).
Recombinant HIV strains are known as CRF (Circulating Recombinant Forms). Although
HIV-2 is also associated with AIDS, it is not transmitted as readily and, generally speaking,
progression toward immunodeficiency is much slower in individuals with an HIV-2 infection.
HIV-1 is responsible for a chronic infection that gradually develops and causes the destruction
of the body's CD4+T lymphocytes. HIV-1 is responsible for a chronic infection that gradually
causes the destruction of CD4+T lymphocytes [212]. To detect a HIV infection several tests are
used to analyze the HIV infection status of a patient, evaluate the progression of disease, and
monitor the effectiveness of antiretroviral therapy (ART). HIV infection can be diagnosed by
direct visualization of virions or electron microscopy; cultivation by lymphocyte culture;
measurement of HIV-specific serologic responses; detection of viral antigens; and detection of
viral nucleic acids [213]. For many years, laboratory diagnosis of HIV is based on the identi‐
fication of HIV antibodies using immuno-enzymatic (ELISA) tests or other immunological
techniques of equivalent sensitivity. Still considering the limitation of this approach in the
known ‘window period’ between the time of infection and the initial instance of detectable
antibody, this may last for several weeks. Primary infection is asymptomatic in more than 50%
of cases. In the remaining cases, symptoms appear two to three weeks after infection and
clinical signs usually resemble those of flu-like or mononucleosis syndromes. Plasma viraemia
levels are generally high (≥106 copies of viral genome/ml) during primary infection.
An assay useful in Multispot HIV-1/HIV-2 Rapid Test (BIO-RAD) directed to a rapid test for
detection and differentiation of HIV-1 and HIV-2 antibodies in human serum and plasma. This
test have a time of results of 10 minute and shows HIV-1 sensitivity: 100%, HIV-2 sensitivity:
100% and specificity: 99.9% [214]. BIO-RAD also has an assay know as HIV-1/HIV-2 PLUS O,
an ELISA-immuno assay utilizing recombinant proteins and synthetic peptides for the
detection of antibodies to HIV-1 (groups M and O) and/or HIV-2.
New HIV screening tests approved by the US FDA in 2010-2011 include immunoassays capable
of detecting p24 antigen and HIV antibody simultaneously. The fourth generation combo
assays could reduction the window period due to their ability to detect viral protein s in
addition to IgG and IgM class antibodies against both HIV-1 and HIV-2 [215], but the moni‐
toring of HIV disease progression is mostly accomplished by the quantitation of CD4 T cells
and viral RNA [216]. The use of combined ELISA tests called “4th generation” tests, enables
for more effective early detection of infections which are very often asymptomatic. Also, these
assays can detect acute and chronic infections. An example is the ARCHITECT HIV Ag/Ab
Combo assay (Abbott Diagnostics), which uses anti-HIV-1 p24 antibodies as reagents to detect
HIV-1 p24 antigen, thereby decreasing the window period and improving early detection of
HIV infection. The assay is useful to determine the presence of HIV-1 p24 antigen, antibodies
to HIV-1 (group M and group O), and antibodies to HIV-2 in human serum or plasma using
chemiluminescent microparticle immunoassay A technology. The test has an analytical
sensitivity of <50 pg/mL for HIV-1 p24 antigen [217]. There are others fourth-generation human
immunodeficiency virus-1 (HIV-1) screening assays as the AxSYM HIV Ag/Ab Combo (Abbott
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diagnostics, Delkenheim, Germany), Elecsys 2010 HIV Combi (Roche Diagnostics GmbH,
Mannheim, Germany) and Vidas HIV Duo Quick (Biomerieux, France). All of the assays had
sensitivities of 100% on clinical samples. The specificities of the AxSYM, ARCHITECT, Elecsys
2010 HIV Combi, and Elecsys HIV Combi PT were 99.6, 99.6, 99.0, and 99.5%, respectively
[218]. Genscreen Ultra HIV Ag-Ab is other new version of the HIV p24 antigen and antibody
combination assays [218]. The commercial ELISAs such as Vironostika HIV Ag/Ab, Enzygnost
Anti-HIV 1/2 Plus Genscreen HIV-1/2 Version 2 and INNO-LIA HIV I/II are suitable tools for
making HIV test performance accessible to people [219]. The accurate diagnosis of HIV
infection demands that to consider a positive result, at least three assays with different
antigenic base should be used, one of them, Western-Blot being mandatory for confirmation.
Confirmatory techniques which are used most frequently they are the Western Blot (WB) and
the recombinant immunoblot or immunoassay online (LIA) who have at least the same
sensitivity than ELISA and a higher specificity. Both techniques they can incorporate antigens
of HIV-2. It detects antibodies against the glycoprotein gp160 envelope, gp120 and gp41, p55,
p24 and p17 encoded-gag and p66, p51 and p311. The interpretation of the results is crucial; a
negative test is the total absence of reactivity. To assess, the positivity numerous criteria
applied, according to the Center for Disease Control (CDC) a positive result occurs with at
least 2 bands of p24, gp41, and gp160gp120 are detected. WHO recognizes a positive test with
2 bands. The ARC (American Red Cross) indicates three bands, one of each structural gene,
and the Consortium for Retrovirus Serology Standardization indicates at least one of gp120 or
gp160 and one of p24 or p31 [220, 221]. It is interpreted as an undetermined result, any reactivity
that does not meet the minimum criteria of positivity. Since, the causes of WB indeterminate
are diverse and they may correspond to early phases or advanced stages of infection associated
to severe immune impairment, or to the presence of immune complexes than can reduce the
antibodies circulating, between other causes. Detection of some band of envelope with or
without bands of gag gene, may be due to HIV infection. In these cases, is necessary performed
others confirmatory tests as LIA and sometimes complement them with the determination of
proviral DNA or viral load or p24 antigen to assess a possible primoinfeccion. In any case on
an indeterminate WB is required a new sample [222-224]. The comparison between the Ag/Ab
combo assay and RNA viral load showed that in an acute HIV infection in human gave a similar
result. HIV Combo detected 97% of infections acute. The ARCHITECT HIV Combo assay can
detect p24 Ag when RNA is above approximately 58,000 copies/mL [225]. However, the
comparison between the results of HIV RNA nucleic acid test (NAT) and 4th-generation
Ag/Ab assay (ARCHITEC HIV Ag/Ab Combo [HIV Combo] assay, Abbott Diagnostics) in 2744
HIV antibody-negative samples were identified fourteen people with acute HIV infection (HIV
antibody negative/NAT positive). The HIV Combo assay detected nine of these individuals
[226 delete these rows, from the stage word to the HIV Word [226In the 2012 HIV Diagnostics
Conference: the molecular diagnostics perspective, gives in Atlanta, GA, USA, 12–14 December
2012. The forum was foccusing in the evaluation of molecular diagnostics and their role in HIV
diagnosis. Many scientific presentations exposed the role played by RNA testing and new
developments in molecular diagnostics, including detection of total and integrated HIV-1
DNA, detection and quantification of HIV-2 RNA, and rapid formats for detection of HIV-1
RNA [227]. HIV infection monitoring is based on counting the number of CD4+lymphocytes
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subtypes. The pandemic is caused by HIV-1 group M. HIV-1 and HIV-2 have differences as
clinical progression of the disease is slower and mother-to-child transmission is less likely with
HIV-2 than with HIV-1 (maternal-fetal transmission < 2% in the absence of treatment).
Recombinant HIV strains are known as CRF (Circulating Recombinant Forms). Although
HIV-2 is also associated with AIDS, it is not transmitted as readily and, generally speaking,
progression toward immunodeficiency is much slower in individuals with an HIV-2 infection.
HIV-1 is responsible for a chronic infection that gradually develops and causes the destruction
of the body's CD4+T lymphocytes. HIV-1 is responsible for a chronic infection that gradually
causes the destruction of CD4+T lymphocytes [212]. To detect a HIV infection several tests are
used to analyze the HIV infection status of a patient, evaluate the progression of disease, and
monitor the effectiveness of antiretroviral therapy (ART). HIV infection can be diagnosed by
direct visualization of virions or electron microscopy; cultivation by lymphocyte culture;
measurement of HIV-specific serologic responses; detection of viral antigens; and detection of
viral nucleic acids [213]. For many years, laboratory diagnosis of HIV is based on the identi‐
fication of HIV antibodies using immuno-enzymatic (ELISA) tests or other immunological
techniques of equivalent sensitivity. Still considering the limitation of this approach in the
known ‘window period’ between the time of infection and the initial instance of detectable
antibody, this may last for several weeks. Primary infection is asymptomatic in more than 50%
of cases. In the remaining cases, symptoms appear two to three weeks after infection and
clinical signs usually resemble those of flu-like or mononucleosis syndromes. Plasma viraemia
levels are generally high (≥106 copies of viral genome/ml) during primary infection.
An assay useful in Multispot HIV-1/HIV-2 Rapid Test (BIO-RAD) directed to a rapid test for
detection and differentiation of HIV-1 and HIV-2 antibodies in human serum and plasma. This
test have a time of results of 10 minute and shows HIV-1 sensitivity: 100%, HIV-2 sensitivity:
100% and specificity: 99.9% [214]. BIO-RAD also has an assay know as HIV-1/HIV-2 PLUS O,
an ELISA-immuno assay utilizing recombinant proteins and synthetic peptides for the
detection of antibodies to HIV-1 (groups M and O) and/or HIV-2.
New HIV screening tests approved by the US FDA in 2010-2011 include immunoassays capable
of detecting p24 antigen and HIV antibody simultaneously. The fourth generation combo
assays could reduction the window period due to their ability to detect viral protein s in
addition to IgG and IgM class antibodies against both HIV-1 and HIV-2 [215], but the moni‐
toring of HIV disease progression is mostly accomplished by the quantitation of CD4 T cells
and viral RNA [216]. The use of combined ELISA tests called “4th generation” tests, enables
for more effective early detection of infections which are very often asymptomatic. Also, these
assays can detect acute and chronic infections. An example is the ARCHITECT HIV Ag/Ab
Combo assay (Abbott Diagnostics), which uses anti-HIV-1 p24 antibodies as reagents to detect
HIV-1 p24 antigen, thereby decreasing the window period and improving early detection of
HIV infection. The assay is useful to determine the presence of HIV-1 p24 antigen, antibodies
to HIV-1 (group M and group O), and antibodies to HIV-2 in human serum or plasma using
chemiluminescent microparticle immunoassay A technology. The test has an analytical
sensitivity of <50 pg/mL for HIV-1 p24 antigen [217]. There are others fourth-generation human
immunodeficiency virus-1 (HIV-1) screening assays as the AxSYM HIV Ag/Ab Combo (Abbott
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diagnostics, Delkenheim, Germany), Elecsys 2010 HIV Combi (Roche Diagnostics GmbH,
Mannheim, Germany) and Vidas HIV Duo Quick (Biomerieux, France). All of the assays had
sensitivities of 100% on clinical samples. The specificities of the AxSYM, ARCHITECT, Elecsys
2010 HIV Combi, and Elecsys HIV Combi PT were 99.6, 99.6, 99.0, and 99.5%, respectively
[218]. Genscreen Ultra HIV Ag-Ab is other new version of the HIV p24 antigen and antibody
combination assays [218]. The commercial ELISAs such as Vironostika HIV Ag/Ab, Enzygnost
Anti-HIV 1/2 Plus Genscreen HIV-1/2 Version 2 and INNO-LIA HIV I/II are suitable tools for
making HIV test performance accessible to people [219]. The accurate diagnosis of HIV
infection demands that to consider a positive result, at least three assays with different
antigenic base should be used, one of them, Western-Blot being mandatory for confirmation.
Confirmatory techniques which are used most frequently they are the Western Blot (WB) and
the recombinant immunoblot or immunoassay online (LIA) who have at least the same
sensitivity than ELISA and a higher specificity. Both techniques they can incorporate antigens
of HIV-2. It detects antibodies against the glycoprotein gp160 envelope, gp120 and gp41, p55,
p24 and p17 encoded-gag and p66, p51 and p311. The interpretation of the results is crucial; a
negative test is the total absence of reactivity. To assess, the positivity numerous criteria
applied, according to the Center for Disease Control (CDC) a positive result occurs with at
least 2 bands of p24, gp41, and gp160gp120 are detected. WHO recognizes a positive test with
2 bands. The ARC (American Red Cross) indicates three bands, one of each structural gene,
and the Consortium for Retrovirus Serology Standardization indicates at least one of gp120 or
gp160 and one of p24 or p31 [220, 221]. It is interpreted as an undetermined result, any reactivity
that does not meet the minimum criteria of positivity. Since, the causes of WB indeterminate
are diverse and they may correspond to early phases or advanced stages of infection associated
to severe immune impairment, or to the presence of immune complexes than can reduce the
antibodies circulating, between other causes. Detection of some band of envelope with or
without bands of gag gene, may be due to HIV infection. In these cases, is necessary performed
others confirmatory tests as LIA and sometimes complement them with the determination of
proviral DNA or viral load or p24 antigen to assess a possible primoinfeccion. In any case on
an indeterminate WB is required a new sample [222-224]. The comparison between the Ag/Ab
combo assay and RNA viral load showed that in an acute HIV infection in human gave a similar
result. HIV Combo detected 97% of infections acute. The ARCHITECT HIV Combo assay can
detect p24 Ag when RNA is above approximately 58,000 copies/mL [225]. However, the
comparison between the results of HIV RNA nucleic acid test (NAT) and 4th-generation
Ag/Ab assay (ARCHITEC HIV Ag/Ab Combo [HIV Combo] assay, Abbott Diagnostics) in 2744
HIV antibody-negative samples were identified fourteen people with acute HIV infection (HIV
antibody negative/NAT positive). The HIV Combo assay detected nine of these individuals
[226 delete these rows, from the stage word to the HIV Word [226In the 2012 HIV Diagnostics
Conference: the molecular diagnostics perspective, gives in Atlanta, GA, USA, 12–14 December
2012. The forum was foccusing in the evaluation of molecular diagnostics and their role in HIV
diagnosis. Many scientific presentations exposed the role played by RNA testing and new
developments in molecular diagnostics, including detection of total and integrated HIV-1
DNA, detection and quantification of HIV-2 RNA, and rapid formats for detection of HIV-1
RNA [227]. HIV infection monitoring is based on counting the number of CD4+lymphocytes
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and quantification of plasma viral RNA. These tests are performed every 6 months if the CD4
count is > 500/mm3 and every 3 to 4 months if the CD4 count is between 200 and 500/mm3.
Plasma viral load is measured using quantitative tests based on molecular tools: gene ampli‐
fication (PCR-polymerase chain reaction, LCR-ligase chain reaction, TMA-transcription
mediated amplification, NASBA-nucleic acid sequence based amplification) or hybridization
followed by signal amplification (bDNA-branched DNA). Most tests have sensitivity of the
order of 50-100 copies/ml. Although the new HIV diagnostic algorithm relies on RNA assays
as a supplemental test, it is not clear how accessible these assays will be for clinical laboratories.
Currently, only one HIV RNA test is approved by the US FDA for HIV diagnosis (Hologic
Gen-Probe APTIMA HIV-1 RNA Qualitative Assay) and some clinical laboratories may need
to send specimens out for RNA testing. Currently, molecular diagnosis of HIV infection is only
used as a complementary diagnosis although viral load test is used to monitor disease
progression and responsiveness to antiviral therapy. Recently, it was proposed to the first-line
HIV molecular techniques performed on a routine basis routed to the use of HIV molecular
tools for the screening of blood products, organs and tissue from human origin. Directed to
medically assisted procreation and in neonates from HIV-infected mothers [228]. In 2012 HIV
Diagnostics Conference was presented the design of a new HIV-1 proviral DNA assay capable
of detecting two copies of HIV-1 DNA in a qualitative format and quantitatively of three to
30,000 copies per ml. Since the lack a nucleic acid test for HIV-2, in this meeting was described
a novel HIV-2 RNA viral load assay based on the 5´ long terminal repeat of HIV-2, with a lower
quantification limit of 29 infectious units per ml. In addition, an assay capable of detecting
HIV-2 proviral DNA, which combines three separate amplification reactions from three
regions of the proviral genome, detected both A and B HIV-2 subtypes at between five and ten
copies of the HIV-2 proviral genome [228]. For other side, HIV-1 detection in plasma samples
with a molecular beacon-based multiplex NASBA assay of a region in the HIV-1 pol gene
showed a limit of quantification of the assay was <1000 copies/ml for HIV-1 with 98% sensi‐
tivity and 100% specificity [229]. Also, it was reported the detection and quantification of HIV-1
group O RNA in plasma by an RT-qPCR assay [230]. In addition, there are several HIV
molecular assays showed in the table 5 [231].
Routine follow-up of HIV-infected individuals includes measurement of CD4+T cell count to
evaluate the immune status, of viral load to assess virus replication directed to events of
therapeutic failure (therapeutic escape), and of changes in the viral genome to characterize
resistance to drugs and tropism. Genotype resistance testing can detect a potential viral escape
due to poor compliance with the treatment regimen, metabolic problems or the selection of
resistant mutants. In summary, the diagnosis of HIV infection is established by one of the
following methods: detecting antibodies to the virus; detecting the viral p24 antigen; detecting
viral nucleic acid; or culturing HIV.
The most widely used test is the detection of antibodies to HIV [232]. Rapid serological tests
take only 15 minutes with acceptable specificity and sensibility. But, there is the possibility of
have a negative false result with them. NATs are assays more sensitive in HIV diagnosis, but
more expensive. The expanded use of point-of-care (POC) tests to HIV testing plays an
important role in HIV prevention, both in developed and in developing countries [233]. The
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access to immediate HIV test results could improve the application of prophylactic regimens
to reduce vertical transmission when used intrapartum or postpartum [234].
The analysis of the cost-effectiveness of initial diagnosis with a rapid HIV test, to screen out
HIV-uninfected infants shows that in the comparison of DNA-PCR and rapid HIV test
approaches, the first assay identified 94.3% (91.8–94.7%) of HIV-infected infants, as compared
with 87.8% (79.4–90.5%) for the latter. Moreover, the total cost of the POC testing program was
about 40% less than that of DNA-PCR ($59 vs. $38 per infant aged 6–9 months). Assessing the
cost-effectiveness of several HIV testing as well as establishing a specific threshold of positivity
for routine testing of HIV dignosis will be critical in AIDS control [235, 236]. Despite the global
effort to control the AIDS pandemic, human immunodeficiency virus (HIV) infection continues
to spread relatively unabated in many parts of the world. As the AIDS epidemic continues is
necessary establish new strategies of prevention, treatment and molecular diagnostics assays
to discriminate "window phase" infections from those that are serologically positive. There is
opportunity to implement and evaluate the incremental diagnostic usefulness of new test
modalities that are based on sophisticated molecular diagnostic technologies and that can be
performed in settings where laboratory infrastructure is minimal [237]. Human immunodefi‐
ciency virus type 1 (HIV-1) is a highly diverse virus, a global scale, and within individual HIV-1
infected subjects [238]. The genetic variants constituting the viral population are called
haplotypes, and these haplotypes form a viral quasispecies [239]. This viral diversity is highly
METHOD AND NAME TEST
DNA/RNA qualitative assays used to diagnosis HIV
APTIMA HIV-1 RNA Qualitative assay or Procleix HIV-1/HCV Assay (Gen Probe)
RNAviral load testing used for clinical diagnosis and/or monitoring of HIV-1
COBAS AmpliPrep/TaqMan HIV-1 (Roche Molecular)
Versant HIV-1RNA (Siemens)
NucliSens HIV RNA QT (bioMérieux)
RealTime m2000 HIV-1 (Abbott Molecular)
Genotyping drug used to Antiretroviral drug resistance
TruGene HIV-1 genotyping (Siemens)
ViroSeq HIV-1 genotyping (Abbott Molecular)
HIV PRT GeneChip assay (Affymetrix)
HIV RT Line Probe assay (Innogenetics)
Phenotyping drug used to Antiretroviral drug resistance
AntiVirogram assay (Virco Lab)
Trofile (MonoGram BioSciences)
SensiTrop II HIV (Pathway Diagnostics)
Information based on Tang YW, et al. 2012 [231].
Table 5. Main molecular diagnostics methods for HIV-1.
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Currently, only one HIV RNA test is approved by the US FDA for HIV diagnosis (Hologic
Gen-Probe APTIMA HIV-1 RNA Qualitative Assay) and some clinical laboratories may need
to send specimens out for RNA testing. Currently, molecular diagnosis of HIV infection is only
used as a complementary diagnosis although viral load test is used to monitor disease
progression and responsiveness to antiviral therapy. Recently, it was proposed to the first-line
HIV molecular techniques performed on a routine basis routed to the use of HIV molecular
tools for the screening of blood products, organs and tissue from human origin. Directed to
medically assisted procreation and in neonates from HIV-infected mothers [228]. In 2012 HIV
Diagnostics Conference was presented the design of a new HIV-1 proviral DNA assay capable
of detecting two copies of HIV-1 DNA in a qualitative format and quantitatively of three to
30,000 copies per ml. Since the lack a nucleic acid test for HIV-2, in this meeting was described
a novel HIV-2 RNA viral load assay based on the 5´ long terminal repeat of HIV-2, with a lower
quantification limit of 29 infectious units per ml. In addition, an assay capable of detecting
HIV-2 proviral DNA, which combines three separate amplification reactions from three
regions of the proviral genome, detected both A and B HIV-2 subtypes at between five and ten
copies of the HIV-2 proviral genome [228]. For other side, HIV-1 detection in plasma samples
with a molecular beacon-based multiplex NASBA assay of a region in the HIV-1 pol gene
showed a limit of quantification of the assay was <1000 copies/ml for HIV-1 with 98% sensi‐
tivity and 100% specificity [229]. Also, it was reported the detection and quantification of HIV-1
group O RNA in plasma by an RT-qPCR assay [230]. In addition, there are several HIV
molecular assays showed in the table 5 [231].
Routine follow-up of HIV-infected individuals includes measurement of CD4+T cell count to
evaluate the immune status, of viral load to assess virus replication directed to events of
therapeutic failure (therapeutic escape), and of changes in the viral genome to characterize
resistance to drugs and tropism. Genotype resistance testing can detect a potential viral escape
due to poor compliance with the treatment regimen, metabolic problems or the selection of
resistant mutants. In summary, the diagnosis of HIV infection is established by one of the
following methods: detecting antibodies to the virus; detecting the viral p24 antigen; detecting
viral nucleic acid; or culturing HIV.
The most widely used test is the detection of antibodies to HIV [232]. Rapid serological tests
take only 15 minutes with acceptable specificity and sensibility. But, there is the possibility of
have a negative false result with them. NATs are assays more sensitive in HIV diagnosis, but
more expensive. The expanded use of point-of-care (POC) tests to HIV testing plays an
important role in HIV prevention, both in developed and in developing countries [233]. The
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access to immediate HIV test results could improve the application of prophylactic regimens
to reduce vertical transmission when used intrapartum or postpartum [234].
The analysis of the cost-effectiveness of initial diagnosis with a rapid HIV test, to screen out
HIV-uninfected infants shows that in the comparison of DNA-PCR and rapid HIV test
approaches, the first assay identified 94.3% (91.8–94.7%) of HIV-infected infants, as compared
with 87.8% (79.4–90.5%) for the latter. Moreover, the total cost of the POC testing program was
about 40% less than that of DNA-PCR ($59 vs. $38 per infant aged 6–9 months). Assessing the
cost-effectiveness of several HIV testing as well as establishing a specific threshold of positivity
for routine testing of HIV dignosis will be critical in AIDS control [235, 236]. Despite the global
effort to control the AIDS pandemic, human immunodeficiency virus (HIV) infection continues
to spread relatively unabated in many parts of the world. As the AIDS epidemic continues is
necessary establish new strategies of prevention, treatment and molecular diagnostics assays
to discriminate "window phase" infections from those that are serologically positive. There is
opportunity to implement and evaluate the incremental diagnostic usefulness of new test
modalities that are based on sophisticated molecular diagnostic technologies and that can be
performed in settings where laboratory infrastructure is minimal [237]. Human immunodefi‐
ciency virus type 1 (HIV-1) is a highly diverse virus, a global scale, and within individual HIV-1
infected subjects [238]. The genetic variants constituting the viral population are called
haplotypes, and these haplotypes form a viral quasispecies [239]. This viral diversity is highly
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APTIMA HIV-1 RNA Qualitative assay or Procleix HIV-1/HCV Assay (Gen Probe)
RNAviral load testing used for clinical diagnosis and/or monitoring of HIV-1
COBAS AmpliPrep/TaqMan HIV-1 (Roche Molecular)
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relevant on pathogenesis, drug resistance, and vaccine development. Currently, virus popu‐
lations can be studied much faster using next-generation sequencing (NGS) platforms. NGS
is a valuable tool for the detection and quantification of HIV-1 variants in vivo [240, 241]. As
Venet exhibited in 2004, a major evolution in the near future will be the generalization of NAT
for the diagnosis of viral etiology in patients, mostly with respiratory, CNS or hepatic diseases.
Major technical improvements have been made to avoid obstacles that still limit this general‐
ization, related to genetic variability of viruses, multiplex detection or contamination risk [242].
Real-time amplification has allowed the development of new NAT platforms and the intro‐
duction of others techniques as NGS than contributes with data that support to global
diagnostic [243].
In this chapter was presented the some methods applied to diagnosis and monitoring of an
infectious disease of viral etiology with global incidence, such as hepatitis, mumps or influenza
that have been authorized by WHO and CDC. In addition, new applications of molecular
techniques that facilitate fast identification of the etiology of an infectious disease were
presented.
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Major technical improvements have been made to avoid obstacles that still limit this general‐
ization, related to genetic variability of viruses, multiplex detection or contamination risk [242].
Real-time amplification has allowed the development of new NAT platforms and the intro‐
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1. Introduction
Antibiotic resistance among clinical isolates of Klebsiella pneumoniae, Pseudomonas aeruginosa,
Acinetobacter baumannii, Escherichia coli, Enterobacter spp and Proteus spp is causing worldwide
concern [1-5] especially when mediated by transferable genetic elements.
The role of the Clinical Microbiology Department in this regard is crucial for the isolation of
non-susceptible bacteria and the detection of the underlying mechanisms leading to their
resistant phenotype. Rapid and reliable results are of the utmost importance in order to apply
the appropriate treatment and to contain the spread of resistance determinants within hospital
settings.
In the present chapter, laboratory procedures for the detection of antibiotic resistance mecha‐
nisms will be discussed focusing mainly on those more frequently used for Gram negative
clinical isolates around the world.
2. Antibiotic resistance mechanisms among Gram negative nosocomial
pathogens
Antibiotic resistance may be intrinsic (the microorganism is by definition resistant against a
certain antibiotic) or acquired. Acquired refers to resistance that is a consequence of mutational
events or gene acquisition via horizontal gene transfer.
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Four general mechanisms leading to acquired antibiotic resistance have been described: (1)
decreased entrance of the antibiotic into the bacterial cell; (2) increased extrusion of the
antibiotic by bacterial efflux systems; (3) mutational modification of the antibiotic’s target and;
(4) production of antibiotic-inactivating enzymes. Characteristic examples for each mechanism
are presented in Table 1.
Mechanism Examples
Decreased permeability Diminished expression or loss of the OprD porin in Pseudomonas aeruginosa and
OmpK35, OmpK36 porins in Klebsiella pneumoniae [6-9]
Efflux Overexpression of MexAB-OprM and MexXY-OprM in Pseudomonas aeruginosa and
OqxAB in Klebsiella pneumoniae [10-13]
Target modification Mutations of gyrases and topoisomerases leading to fluoroquinolone resistance
[14-16]
Inactivating enzymes Production of beta-lactamases and aminoglycoside modifying enzymes [17-19]
Table 1. Examples of antibiotic resistance mechanisms.
Among the aforementioned mechanisms, the production of beta-lactamases is considered of
major importance because these enzymes are commonly transferable and inactivate multiple
beta-lactam antibiotics. Within this large enzymatic family, carbapenemases (class B metallo-
beta-lactamases (MBLs) [20] that contain zinc in their active center and class A KPC [21])
hydrolyze in vitro all or almost all beta-lactams, including carbapenems [22]. Class A extended
spectrum beta-lactamases (ESBLs) hydrolyze penicillins, monobactams and cephalosporins
whereas are inhibited by the beta-lactamase inhibitors [23,24]. Class C cephalosporinases
(AmpC) present various spectrums of cephalosporin hydrolysis but are not inhibited by the
beta-lactamase inhibitors [25]. Additionaly, AmpC enzymes may be inducible in Serratia spp,
Pseudomonas spp, Indole-positive Proteus, Citrobacter spp and Enterobacter spp (SPICE group
of bacteria) complicating the treatment of infections caused by these pathogens. Finally,
molecular class D beta-lactamases (OXA) comprise numerous enzymes with variable spec‐
trums of beta-lactam hydrolysis [26].
3. Phenotypic tests
Phenotypic tests may be used in the everyday laboratory practice in order to identify the
presence of acquired resistance mechanisms among frequently isolated nosocomial pathogens.
In the present chapter, the procedure and the interpretation of seven useful phenotypic tests
are described. Special attention has been given to the phenotypic detection of beta-lactamases
and especially those hydrolyzing carbapenems together with other beta-lactams (carbapene‐
mases).
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3.1. Double Disc Synergy Test (DDST)
The DDST is used for the detection of beta-lactamases that are inhibited by beta-lactamase
inhibitors such as clavulanic acid (Ambler class A beta-lactamases and especially ESBLs). For
SPICE organisms, cloxacillin should be incorporated in Mueller-Hinton agar during its
preparation in order to prevent any AmpC interference [27].
3.1.1. Procedure
Figure 1. Double Disc Synergy Test preparation.
Step 1: Prepare agar plates containing 200μg/ml cloxacillin (by adding 1ml solution containing
80 mg cloxacillin in 399 ml Mueller-Hinton agar at the liquid phase). Omit this step when
testing non-SPICE bacteria.
Step 2: Make a 0.5 McFarland bacterial suspension.
Step 3: Inoculate with a sterile cotton swab and place an amoxicillin/clavulanic acid disc at the
center of the plate (20 μg amoxicillin+10 μg clavulanic acid).
Step 4: Place ceftazidime, imipenem, ceftriaxone, cefotaxime, aztreonam and cefepime discs
around the central amoxicillin/clavulanic acid disc (Figure 1).
Step 5: Incubate at 37oC for 18-24h.
3.1.2. Interpretation
The DDST is considered positive when the inhibition zone of any of the antibiotics is larger
towards the clavulanic acid disc (Figure 2-lower left plate) or a ghost inhibition zone appears
between the central disc and any of the other antibiotics (Figure 2-lower right plate). This is
happening because of the ESBL’s inhibition by the clavulanic acid. In proximity to the central
disc the enzyme’s activity is blocked. Thus, the growth inhibition zone appears only towards
the clavulanic acid disc. If resistance to cephalosporins is not due to ESBL production, the test
results negative (Figure 2-upper plates).
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Figure 2. Interpretation of the DDST. (-): Negative; (+): Positive.
3.2. Imipenem-EDTA synergy test
EDTA (ethylene-diamine-tetraacetic acid) is a polyamino carboxylic acid that binds metal ions
like zinc and can inactivate the metallo-beta-lactamases. Therefore, it is used for the phenotypic
detection of MBL production in clinical isolates [28].
3.2.1. Procedure
Step 1: Soak paper discs within a 0.1 M EDTA solution.
Step 2: Make a 0.5 McFarland bacterial suspension.
Step 3: Inoculate with a sterile cotton swab and place an imipenem and a ceftazidime disc at
the center of the plate.
Step 4: Place the EDTA discs at both sides in respect to the antibiotics as shown in Figure 3.
Step 5: Incubate at 37oC for 18-24h.
Figure 3. Preparation of the imipenem-EDTA synergy test.
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3.2.2. Interpretation
The imipenem-EDTA synergy test is positive when the inhibition zone takes a characteristic
keyhole shape because of the MBL inactivation by the EDTA (Figure 4). In proximity to the
EDTA discs, the hydrolytic activity of MBLs is blocked. Consequently, imipenem and cefta‐
zidime inhibition zones may appear larger towards the EDTA discs.
3.3. Boronic acid test
Phenylboronic acid acts as an inhibitor for KPC carbapenemases and class A and C beta-
lactamases. The boronic acid test has been proposed for the phenotypic detection of KPC-
producers because it is easier to perform than the DDST and also presents less false positive
results because of the presence of ESBLs or AmpC beta-lactamases [29-31].
3.3.1. Procedure
Step 1: Make a 0.5 McFarland bacterial suspension.
Step 2: Inoculate with a sterile cotton swab and place two meropenem discs (Figure 5).
Figure 4. Interpretation of the imipenem-EDTA synergy test. (-): Negative; (+): Positive. Note that the upper left isolate
is negative for MBL production but shows positive D-test between imipenem and ceftazidime indicating for the pres‐
ence of inducible AmpC beta-lactamases (The D-test is described in paragraph 3.6).
Step 3: Add 20 μl of phenylboronic acid 20 g/L on one of the two meropenem discs.
Step 4: Incubate at 37oC for 18-24h.
3.3.2. Interpretation
In case of KPC production, the phenylboronic acid that has been added to the second mero‐
penem disc will block the hydrolytic activity of the enzyme. As a consequence, the second disc
will have a larger inhibition halo. The test is considered positive when the inhibition zone of
the meropenem+phenylboronic acid is ≥ 5mm larger than the inhibition zone of meropenem
alone (Figure 6).
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Figure 6. Interpretation of the boronic acid test. (+): Positive; (-): Negative.
3.4. Hodge test
The Hodge test is used to reveal carbapenemase production [32]. This is achieved by inocu‐
lating the study isolate together with a carbapenem-susceptible indicator strain and evaluating
the distortion of the indicator strain’s inhibition zone because of carbapenemase production
by the study isolate. Despite its usefulness, this test presents a disadvantage: it detects the
presence of carbapenemases only, without being able to discriminate between different
carbapenemase types (KPC or MBLs).
3.4.1. Procedure
Step 1: Make a 0.5 McFarland suspension of the indicator strain (for example E. coli ATCC
25922).
Figure 5. Preparation of the boronic acid test.
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Step 2: Inoculate with a sterile cotton swab and place a carbapenem disc at the center of the
plate.
Step 3: Streak 3-5 colonies of the test isolate from the center to the periphery of the plate (Figure
7).
Step 4: Incubate at 37oC for 18-24h.
Figure 7. Preparation of the Hodge test.
3.4.2. Interpretation
The presence of a distorted inhibition zone due to growth of the indicator strain toward the
carbapenem disc is interpreted as a positive result (Figure 8). This occurs due to carbapenemase
production by the study isolate. Uncertain results need to be confirmed by other tests or
molecular methods.
3.5. Combination meropenem disc test
This test is a combination of the EDTA and the boronic acid test in a single plate and has been
introduced in Greece after the emergence of Gram negative isolates co-producing KPC and
MBL carbapenemases [33-37]. The advantage of the test is that it discriminates between
carbapenem-susceptible, KPC-producing, MBL-producing and double-carbapenemase-
producing bacteria.
Phenotypic and Molecular Methods for the Detection of Antibiotic Resistance Mechanisms in…
http://dx.doi.org/10.5772/57582
145
Figure 6. Interpretation of the boronic acid test. (+): Positive; (-): Negative.
3.4. Hodge test
The Hodge test is used to reveal carbapenemase production [32]. This is achieved by inocu‐
lating the study isolate together with a carbapenem-susceptible indicator strain and evaluating
the distortion of the indicator strain’s inhibition zone because of carbapenemase production
by the study isolate. Despite its usefulness, this test presents a disadvantage: it detects the
presence of carbapenemases only, without being able to discriminate between different
carbapenemase types (KPC or MBLs).
3.4.1. Procedure
Step 1: Make a 0.5 McFarland suspension of the indicator strain (for example E. coli ATCC
25922).
Figure 5. Preparation of the boronic acid test.
Trends in Infectious Diseases144
Step 2: Inoculate with a sterile cotton swab and place a carbapenem disc at the center of the
plate.
Step 3: Streak 3-5 colonies of the test isolate from the center to the periphery of the plate (Figure
7).
Step 4: Incubate at 37oC for 18-24h.
Figure 7. Preparation of the Hodge test.
3.4.2. Interpretation
The presence of a distorted inhibition zone due to growth of the indicator strain toward the
carbapenem disc is interpreted as a positive result (Figure 8). This occurs due to carbapenemase
production by the study isolate. Uncertain results need to be confirmed by other tests or
molecular methods.
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introduced in Greece after the emergence of Gram negative isolates co-producing KPC and
MBL carbapenemases [33-37]. The advantage of the test is that it discriminates between
carbapenem-susceptible, KPC-producing, MBL-producing and double-carbapenemase-
producing bacteria.




Step 1: Make a 0.5 McFarland bacterial suspension.
Step 2: Inoculate with a sterile cotton swab and place four meropenem discs (Figure 9).
Step 3: Add 10 μl EDTA 0.1 M on the second disc, 20 μl of phenylboronic acid 20 g/L on the
third disc and 20 μl of phenylboronic acid 20 g/L+10 μl EDTA 0.1 M on the fourth disc.
Step 4: Incubate at 37oC for 18-24h.
Figure 9. Preparation of the combination meropenem disc test.
3.5.2. Interpretation
The interpretation of the combination meropenem disc test is based on the comparison
between the inhibition zones of the four meropenem discs as presented in Figure 10. If no
carbapenemase is present, the zone diameters of the discs where inhibitors have been added
Figure 8. Interpretation of the Hodge test.
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will not present significant differences (≥5mm) from the meropenem disc alone. In case of KPC
production, an increase of ≥5mm in the discs that are supplemented with boronic acid will be
observed. MBL production will become evident by an increase of ≥5mm in the discs that are
supplemented with EDTA. In case of a KPC+MBL-producer, the fourth disc will present the
larger zone diameter of all. The EDTA-supplemented and boronic acid-supplemented discs
may or may not have a ≥5mm larger zone diameter than that of the meropenem disc alone.
Figure 10. Interpretation of the combination meropenem disc test.
Recently, a novel variation of this test has been proposed [38] for surveillance cultures from
rectal swabs. The same principle is generally followed, except that each swab is initially
suspended in 1 ml sterile saline by rotating and agitating it to release the microorganisms.
Afterwards, the suspension is cultured onto McConkey agar using a different swab. This
method allows the identification and differentiation of carbapenemase-producing Enterobac‐
teriaceae (Figure 11) directly at patient admission.
Figure 11. Application of the combination meropenem disc test for the direct differentiation of carbapenemase-pro‐
ducing Enterobacteriaceae in rectal swabs.
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The D-test is used for the detection of inducible AmpC beta-lactamases [39]. An antibiotic is
used as an inducer for AmpC production (imipenem or cefoxitin) whereas others are used as
substrates (ceftazidime, cefotaxime, piperacillin/tazobactam).
3.6.1. Procedure
Step 1: Make a 0.5 McFarland bacterial suspension.
Step 2: Inoculate with a sterile cotton swab and place an imipenem disc.
Step 3: Place substrate discs (for example ceftazidime and piperacillin/tazobactam) near the
imipenem disc as shown in Figure 12.
Step 4: Incubate at 37oC for 18-24h.
Figure 12. Preparation of a D-test.
3.6.2. Interpretation
The test is positive when a D-shaped inhibition zone is observed for one of the substrate discs
(Figure 13) because of the imipenem-mediated induction of the AmpC production and the
subsequent inactivation of the substrate antibiotic by the beta-lactamase. An important
advantage of the test is that it can be easily incorporated within any routine antibiogram as
shown in Figure 14.
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3.7. CCCP test
CCCP (Carbonyl cyanide m-chlorophenyl hydrazone) is an efflux pump inhibitor that can
be added in Mueller-Hinton agar during its preparation. The test is used to detect efflux
pump overexpression that contributes to or determines carbapenem resistance in the study
isolate [40].
Figure 13. Interpretation of the D-test.
Figure 14. Incorporation of the D-test in a common antibiogram.
3.7.1. Procedure
Step 1: Prepare agar plates containing CCCP at a concentration of 12.5 μM.
Step 2: Make a 0.5 McFarland bacterial suspension.
Step 3: Inoculate with a sterile cotton swab on a CCCP-supplemented plate and in parallel on
a CCCP-free plate. For economy reasons, two isolates may be inoculated on the same plate as
shown in Figure 15.
Step 4: Place a meropenem disc on both plates for each inoculation.
Step 5: Incubate at 37oC for 18-24h.
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Figure 15. Preparation of the CCCP test.
3.7.2. Interpretation
The test is considered positive when synergy between meropenem and CCCP is observed on
the CCCP-supplemented plate (Figure 16).
Figure 16. Interpretation of the CCCP test. Isolate 1 is inoculated on the upper side and isolate 2 is inoculated on the
lower side of the plates. (+): Positive; (-): Negative.
4. Molecular methods
Genetic methods for the detection of resistance genes are based on nucleic acid hybridization
and amplification. Therefore, the knowledge of specific primers (amplification nucleotides)
and probes (labeled single-stranded ologonucleotides) is necessary in order to detect the
genetic target of interest. The technique used depends on the type of resistance that is sus‐
pected. A simple polymerase chain reaction (PCR) may be applied searching for a gene that
confers a certain level of resistance when it is expressed. This is the case for example, of genes
encoding for antibiotic-inactivating enzymes. In Tables 2 and 3, primers for the detection of
aminoglycoside or fluorquinolone resistance-conferring enzymes and beta-lactamases are
shown, respectively.
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Gene Primers (5’- 3’) Product size Reference
aac(6’)-Ia ATGAATTATCAAATTGTG 558 bp [41]
TTACTCTTTGATTAAACT
aac(6’)-Ic CTACGATTACGTCAACGGCTGC 130 bp [42]
TTGCTTCGCCCACTCCTGCACC
aac(3)-Ia ACCTACTCCCAACATCAGCC 169 bp [43]
ATATAGATCTCACTACGCGC
aac(3)-Ic GATGATCTCTACTCAAACC 472 bp [44]
TTAGGCAGCAGGTTGAGG
aac(3)-IV GTTACACCGGACCTTGGA 675 bp [45]
AACGGCATTGAGCGTCAG
aphA-3 GGGACCACCTATGATGTGGAACG 595 bp [46]
CAGGCTTGATCCCCAGTAAGTC
aph(3’)-Via ATACAGAGACCACATACAGT 235 bp [47]
GGACAATCAATAATAGCAAT
aad(2’’)-Ia ATGTTACGCAGCAGGGCAGTCG 188 bp [48]
CGTCAGATCAATATCATCGTGC
aph(3’)-IIIa GGCTAAAATGAGAATATCACCGG 523 bp [49,50]
CTTTAAAAAATCATACAGCTCGCG
ant(4’)-Ia CAAACTGCTAAATCGGTAGAAGCC 294 bp [49,50]
GGAAAGTTGACCAGACATTACGAACT
strA-strB TATCTGCGATTGGACCCTCTG 519 bp [51]
CATTGCTCATCATTTGATCGGCT
armA AGGTTGTTTCCATTTCTGAG 590 bp [52]
TCTCTTCCATTCCCTTCTCC
rmtA CTAGCGTCCATCCTTTCCTC 635 bp [53]
TTTGCTTCCATGCCCTTGCC




AAATCTGCCCGTGTCGTTGGT 343 bp [55]
GCCATACCTACGGCGATACC
gyrA (E. coli) ACGTACTAGGCAATGACTGG 190 bp [56]
AGAAGTCGCCGTCGATAGAAC
qnrA TCAGCAAGAGGATTTCTCA 627 bp [57]
GGCAGCACTATTACTCCCA
Qnr CCGTATGGATATTATTGATAAAG 661 bp [58]
CTAATCCGGCAGCACTATTA
Table 2. Primers used for the detection of aminoglycoside and quinolone resistance determinants.
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Gene Primers (5’- 3’) Product size Reference
blaSHV GGTTATGCGTTATATTCGCC 867 bp [59]
TTAGCGTTGCCAGTGCTC
blaTEM ATGAGTATTCAACATTTCCG 867 bp [59]
CTGACAGTTACCAATGCTTA
blaCTX-M CGCTTTGCGATGTGCAG 550 bp [60]
ACCGCGATATCGTTGGT
blaCTX-M-2 ATGATGACTCAGAGCATTCG 884 bp [61]
TTATTGCATCAGAAACCGTG
blaCTX-M-9 GTGACAAAGAGAGTGCAACGG 857 bp [62]
ATGATTCTCGCCGCTGAAGCC
blaCTX-M-10 GCTGATGAGCGCTTTGCG 684 bp [63]
TTACAAACCGTTGGTGACG
blaGES/IBC GTTTTGCAATGTGCTCAACG 371 bp [64]
TGCCATAGCAATAGGCGTAG
blaPER-1 ATGAATGTCATTATAAAAGC 926 bp [65]
AATTTGGGCTTAGGGCAAGAAA
blaPER-2 CGCTTCTGCTCTGCTGAT 469 bp [66]
GGCAGCTTCTTTAACGCC
blaPSE ACCGTATTGAGCCTGATTTA 321 bp [67]
ATTGAAGCCTGTGTTTGAGC
blaTLA-1 TCTCAGCGCAAATCCGCG 974 bp [68]
CTATTTCCCATCCTTAACTAG
blaVEB-1 CGACTTCCATTTCCCGATGC 643 bp [69]
GGACTCTGCAACAAATACGC
blaKPC TGTCACTGTATCGCCGTC 331 bp [70]
TATTTTTCCGAGATGGGTGAC
blaSME-1 AACGGCTTCATTTTTGTTTAG 830 bp [71]
GCTTCCGCAATAGTTTTATCA
blaIMP CTACCGCAGCAGAGTCTTTG 587 bp [72]
AACCAGTTTTGCCTTACCAT
blaIMP-1 ATGAGCAAGTTATCTGTATTC 741 bp [73]
TTAGTTGCTTGGTTTTGATGG
blaIMP-2 ATGAAGAAATTATTTGTTTTATG 741 bp [73]
TTAGTTACTTGGCTGTGATG
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Gene Primers (5’- 3’) Product size Reference
blaVIM TCTACATGACCGCGTCTGTC 748 bp [74]
TGTGCTTTGACAACGTTCGC
blaVIM-1 GTTAAAAGTTATTAGTAGTTTATTG 799 bp [73]
CTACTCGGCGACTGAGC
blaVIM-2 ATGTTCAAACTTTTGAGTAAG 801 bp [73]
CTACTCAACGACTGAGCG
blaSPM-1 CCTACAATCTAACGGCGACC 649 bp [75]
TCGCCGTGTCCAGGTATAAC
blaNDM-1 GGTTTGGCGATCTGGTTTTC 621 bp [76]
CGGAATGGCTCATCACGATC
blaOXA-1 CCAAAGACGTGGATG 540 bp [77]
GTTAAATTCGACCCCAAGTT
blaOXA-10 CGTGCTTTGTAAAAGTAGCAG 652 bp [78]
CATGATTTTGGTGGGAATGG
blaOXA-23 CCTCAGGTGTGCTGGTTATTC 513 bp [79]
CCCAACCAGTCTTTCCAAAA
blaOXA-24 TTCCCCTAACATGAATTTGT 1020 bp [80]
GTACTAATCAAAGTTGTGAA
Table 3. Primers used for the detection of beta-lactamases frequently encountered among Gram negative pathogens.
In cases in which resistance depends upon the expression level (overexpression or downre‐
gulation) of the gene, real time Reverse Transcriptase-PCR (rt RT-PCR) is used to detect not
only the presence, but also the mRNA expression of the gene. The results are consequently
confronted with the expression level of the same gene in a control strain. This technique is
useful for the study of the expression of specific porins and efflux pumps (primers and probes
for such resistance determinants in P. aeruginosa are shown in Table 4).
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Gene Primers (5’- 3’) Product size Reference
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blaSPM-1 CCTACAATCTAACGGCGACC 649 bp [75]
TCGCCGTGTCCAGGTATAAC
blaNDM-1 GGTTTGGCGATCTGGTTTTC 621 bp [76]
CGGAATGGCTCATCACGATC
blaOXA-1 CCAAAGACGTGGATG 540 bp [77]
GTTAAATTCGACCCCAAGTT
blaOXA-10 CGTGCTTTGTAAAAGTAGCAG 652 bp [78]
CATGATTTTGGTGGGAATGG
blaOXA-23 CCTCAGGTGTGCTGGTTATTC 513 bp [79]
CCCAACCAGTCTTTCCAAAA
blaOXA-24 TTCCCCTAACATGAATTTGT 1020 bp [80]
GTACTAATCAAAGTTGTGAA
Table 3. Primers used for the detection of beta-lactamases frequently encountered among Gram negative pathogens.
In cases in which resistance depends upon the expression level (overexpression or downre‐
gulation) of the gene, real time Reverse Transcriptase-PCR (rt RT-PCR) is used to detect not
only the presence, but also the mRNA expression of the gene. The results are consequently
confronted with the expression level of the same gene in a control strain. This technique is
useful for the study of the expression of specific porins and efflux pumps (primers and probes
for such resistance determinants in P. aeruginosa are shown in Table 4).
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Table 4. Primers and probes used in real-time RT PCR for the determination of the expression levels for specific
resistance mechanisms in P. aeruginosa.
Finally, sequencing [82-84] of the PCR product allows its confrontation with the already known
gene sequences that are available in genetic databases. This can lead to the detection of
mutations or to the characterization and classification of the gene within a genetic family.
5. Conclusion
There are several benefits and limitations using either phenotypic or molecular methods for
the detection of resistance mechanisms in Gram negative pathogens. Phenotypic tests require
bacteria in pure culture from a clinical sample thus needing 24-48h to obtain a final result.
Molecular techniques on the other hand, can be performed directly with clinical speciments
reducing significantly the procedure time.
The detection of low-level resistance is by definition problematic using phenotypic tests thus
interpretation problems may appear. In such cases, molecular techniques are an option for
clarifying the possible involvement of any known resistance mechanism.
Moreover, genetic detection gives a definite answer for the presence or not of specific resistance
determinants within a study isolate (a specific beta-lactamase for example) whereas this is not
possible with the phenotypic tests which provide only general information about the resistance
mechanisms involved.
Genetic assays however, present also some major limitations: (i) It is possible to screen
exclusively for known mechanisms and for one gene at the time (unless a multiplex PCR assay
[85-88] can be applied) and; (ii) their cost is high and becomes higher when screening for
multiple resistance determinants.
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Consequently, the combined and rational use of the available methodologies seems to be the
optimal solution for the cost-effective detection of resistance mechanisms in Gram negative
pathogens by the Clinical Microbiology laboratory.
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1. Introduction
Infectious diseases, particularly zoonoses, are recognized as the sources of serious problems
that affect public and animal health around the world. Emerging infectious diseases have been
reported at an unprecedented rate since the 1970s and a large proportion of these diseases are
considered to be zoonoses [1]. However, reemerging zoonoses are also affecting public health
around the world, in particular rabies, a classic zoonosis that is problematic in Africa and Asia,
while new outbreaks have occurred in areas that were previously free of this disease, such as
the islands of Flores and Bali in Indonesia [2].
Thus, research and technology development have been promoted for controlling emerging
and reemerging zoonoses in developed countries. In the case of rabies, the research and
technology developed to prevent this disease has been advancing. Rabies is a vaccine-
preventable disease, so a vaccine has been developed. The type of vaccine produced using
animal nervous tissues has been progressively replaced by safer and more immunogenic
vaccines, which are purified from cell culture supernatants. In addition, new replicative
vaccines have been developed for the oral vaccination of wildlife, which are either attenuated
rabies vaccines or recombinant vaccines where different viruses express the rabies glycopro‐
tein [3]. Moreover, user-friendly diagnostic methods have been developed, e.g., a rapid
immunochromatographic test kit and a simple enzyme-linked immunosorbent assay (ELISA)
[4,5]. Understanding the current trends in research and technology development related to
rabies control may provide a useful reference regarding the technological needs encountered
in the field of zoonoses.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Bibliometric analysis is considered to be an effective method for identifying research trends in
infectious disease control. Quantitative surveys of research articles (hereafter referred to as
article) based on bibliometric studies have been reported in the field of infectious diseases,
such as human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)
[6], tuberculosis research in India and China [7], and various forms of infectious disease
research in different regions of the world [8], Asia [9], and around the world [10]. In particular,
we have surveyed Asian and worldwide research trends, while ensuring that we avoided
underestimating the number of articles in non-English and regional journals, rather than
simply surveying journals registered in the “Infectious Disease Category” of the Science
Citation Index ExpandedTM [9,10].
Patent analysis is also considered to be an effective method for technology development trend
analysis. Patents are examined and granted by patent offices, and they are considered to be
objective indicators of technology development activities. In addition, patents have significant
advantages in terms of database availability, the variety of information included, and their
systematic classification according to standardized schemes, e.g., the international patent
classification (IPC) supports the detailed analysis of specific technological aspects. For these
reasons, patent data are used intensively for strategic technology management by companies
[11], as well as for science and technology (S&T) measurement in policy-making processes and
academic research in various fields [12]. Indeed, patent analyses have been reported in the
field of infectious diseases, such as hepatitis B vaccines [13] and influenza [14,15].
Research and technology development for rabies control is considered to be important for
future public and animal health throughout the world, as described above. However, to the
best of our knowledge, bibliometric and patent analyses of rabies have not been reported yet.
Therefore, in this chapter, we report the current trends in research and technology develop‐
ment for rabies control in the US, the EU, and Asia based on analyses of articles and patent
applications. We targeted patent applications because publication of a patent application is
invariably the earliest point when relevant technology information becomes available to the
public because it is the first set of detailed and up-to-date published information. Furthermore,
the number of patent applications in particular technological areas is considered to indicate
the volume of resources allocated [16].
The trends in research and technology development for rabies control will be summarized
using the following indicators.
• Number of articles and patent applications during each year and by each country
• Number of authors and applicants by nationality
• Number of articles by organization
• Major research areas of articles and the technical areas of patent applications
• Top 10 cited articles and patent applications
Based on this analysis, we discuss the future directions of research and technology develop‐
ment for rabies control. Moreover, we propose the development of a survey method for
zoonosis control, research and technology development.
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2. Trends in rabies research based on articles
We used a two-tiered approach to analyze research related to rabies control. First, we per‐
formed a quantitative analysis of all articles about rabies. Subsequently, we analyzed the top
10 cited articles, irrespective of whether they were related to rabies control.
2.1. Method of analysis
The Web of Science® [17] was used to survey articles about rabies, which covers over 12,000
journals worldwide, including open access journals. Using the Web of Science®, keyword and
title search of articles was performed using the terms “Rabies” OR “Lyssa” (to include virus
species related to rabies virus) NOT “Rabi” (to exclude articles in the field of optics, e.g., articles
related to “Rabi oscillations”) on June 24, 2013. The publication period of articles ranged from
January 1, 2001 to December 31, 2011.
We focused on articles and excluded reviews, proceedings papers, and other types of publi‐
cations. This is because articles are high quality because they have been peer reviewed and are
directly linked to the outputs of the latest research.
Other articles in the field of infectious diseases retrieved by the Web of Science® were also
analyzed to identify the characteristics of articles related to rabies.
2.2. Leading countries based on the number of articles
The total number of articles related to rabies published throughout the world during 2001–
2011 was 2,565. We regrouped the articles by country to identify any possible differences in
research output among countries. The US was the leading country, with the highest percentage
of total articles, i.e., 32.5% of the total (833 articles). There was a big gap for the second placed
country, France, with 10.6% of the total (273 articles). The UK, Brazil, and Germany followed
with 10.1% (258 articles), 8.6% (220 articles), and 7.2% (185 articles), respectively (Figure 1).
As shown in Table 1, the US, France, the UK, and Germany were the top four countries with
most articles related to rabies, and they were also the leading countries for all articles about
infectious diseases. However, Brazil ranked in the top five with most articles related to rabies.
This showed that rabies research was a particular focus in Brazil.
2.3. Annual changes in the number of articles
As shown in Figure 2, the total number of articles related to rabies increased during 2001–2011.
However, the US did not show a remarkable change, although it produced the highest output.
Other countries such as the UK, France, Brazil, and Germany also had stable outputs. Thus,
the overall increase in articles was considered to be attributable to other countries that were
not surveyed in this study.
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• Number of articles by organization
• Major research areas of articles and the technical areas of patent applications
• Top 10 cited articles and patent applications
Based on this analysis, we discuss the future directions of research and technology develop‐
ment for rabies control. Moreover, we propose the development of a survey method for
zoonosis control, research and technology development.
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2. Trends in rabies research based on articles
We used a two-tiered approach to analyze research related to rabies control. First, we per‐
formed a quantitative analysis of all articles about rabies. Subsequently, we analyzed the top
10 cited articles, irrespective of whether they were related to rabies control.
2.1. Method of analysis
The Web of Science® [17] was used to survey articles about rabies, which covers over 12,000
journals worldwide, including open access journals. Using the Web of Science®, keyword and
title search of articles was performed using the terms “Rabies” OR “Lyssa” (to include virus
species related to rabies virus) NOT “Rabi” (to exclude articles in the field of optics, e.g., articles
related to “Rabi oscillations”) on June 24, 2013. The publication period of articles ranged from
January 1, 2001 to December 31, 2011.
We focused on articles and excluded reviews, proceedings papers, and other types of publi‐
cations. This is because articles are high quality because they have been peer reviewed and are
directly linked to the outputs of the latest research.
Other articles in the field of infectious diseases retrieved by the Web of Science® were also
analyzed to identify the characteristics of articles related to rabies.
2.2. Leading countries based on the number of articles
The total number of articles related to rabies published throughout the world during 2001–
2011 was 2,565. We regrouped the articles by country to identify any possible differences in
research output among countries. The US was the leading country, with the highest percentage
of total articles, i.e., 32.5% of the total (833 articles). There was a big gap for the second placed
country, France, with 10.6% of the total (273 articles). The UK, Brazil, and Germany followed
with 10.1% (258 articles), 8.6% (220 articles), and 7.2% (185 articles), respectively (Figure 1).
As shown in Table 1, the US, France, the UK, and Germany were the top four countries with
most articles related to rabies, and they were also the leading countries for all articles about
infectious diseases. However, Brazil ranked in the top five with most articles related to rabies.
This showed that rabies research was a particular focus in Brazil.
2.3. Annual changes in the number of articles
As shown in Figure 2, the total number of articles related to rabies increased during 2001–2011.
However, the US did not show a remarkable change, although it produced the highest output.
Other countries such as the UK, France, Brazil, and Germany also had stable outputs. Thus,
the overall increase in articles was considered to be attributable to other countries that were
not surveyed in this study.
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Figure 1. Number of articles related to rabies by country during 2001–2011
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1 US 35,488 38.5
2 UK 9,437 10.2
3 France 7,625 8.3
4 Germany 4,908 5.3
5 Spain 4,906 5.3
Number of articles in the field of
infectious diseases
Search condition
Research field: infectious diseases
Document type: Article 
Total number of articles: 92,113 articles
Search condition
Keywords: Rabies OR Lyssa NOT Rabi
Document type: Article 
Total number of articles: 2,565 articles
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2.4. Number of articles by organization
US Centers for Disease Control and Prevention (US CDC) published most articles related to
rabies (198 articles) during 2001–2011. Institut Pasteur (France) and Thomas Jefferson Univer‐
sity (US) published the second and third highest numbers of articles (141 and 87 articles,
respectively) (Figure 3).
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2.5. Major research areas
Figure 4 shows the number of articles related to rabies for each research field, which showed
that the main field of rabies research was veterinary sciences. Research was also conducted in
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Figure 4 shows the number of articles related to rabies for each research field, which showed
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basic sciences, such as virology and immunology. It is considered that virological and













The values are the number of articles.
Figure 4. Number of articles related to rabies by research field during 2001–2011
2.6. Top 10 cited articles
Table 2 shows top 10 most cited articles related to rabies. Of these articles, two reported and
discussed methods for rabies control [18,19]. It was interesting that the two articles were based
on new research areas, i.e., agent-based modeling and economic analysis. These studies were
not categorized in the major research areas described in Section 2.5.
Three articles reported rabies virus as the delivery of a substance to the brain, i.e., a neuronal
tracer, and a vector [20–22]. This shows that research on rabies may contribute to neuroscience
research.
3. Trends in technology development related to rabies control based on
patent applications
Subsequently, we performed quantitative and qualitative analyzes of patent applications
related to rabies control, e.g., technologies related to vaccines, screening, and the diagnosis of
rabies.
3.1. Method of analysis
The survey of patent applications comprised the following four steps.
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Rank Cited
number
Title Author(s) Journal Volume, Page, Year Contribution  to rabies 
control
1 400 Pattern-oriented modeling of agent-based 
complex systems: Lessons from ecology
Grimm, V. 
et al.,
SCIENCE 310, 987–991, 2005 Yes (rabies prevalence 
simulation )
2 377 Transvascular delivery of small interfering 
RNA to the central nervous system
Kumar, P. et al., NATURE 448, 39–43, 2007 No (usage of viral peptide 
as delivery to the brain)
3 339 Cerebellar loops with motor cortex and 
prefrontal cortex of a nonhuman primate
Kelly, R.M. et al., JOURNAL OF 
NEUROSCIENCE
23, 8432–8444, 2003 No (usage of virus as 
neuronal tracer)
4 314 Efficacy of RTS,S/ASO2 malaria vaccine 
against Plasmodium falciparum infection in 
semi-immune adult men in The Gambia: a 
randomised trial
Bojang, K.A. et al., LANCET 358, 1927–1934, 2001 No (usage of rabies vaccine 
as a control of malaria 
vaccine)
5 288 Re-evaluating the burden of rabies in Africa 
and Asia
Knobel, D.L. et al., BULLETIN OF THE 
WORLD HEALTH 
ORGANIZATION 
83, 360–368, 2005 Yes (study to quantify 
public health and economic 
burden)
6 261 Small world effect in an epidemiological mode Kuperman, M. et al., PHYSICAL REVIEW 
LETTERS
86, 2909–2912, 2001 No (epidemiological model 
based on the structure of a 
population)
7 249 Cannabinoid-based drugs as anti-
inflammatory therapeutics
Klein, T.W. NATURE REVIEWS 
IMMUNOLOGY
5, 400–411, 2005 No (therapeutic usefulness 
of these drugs in chronic 
inflammatory diseases)
8 239 Diseases of humans and their domestic 
mammals: pathogen characteristics, host range 
and the risk of emergence
Cleaveland, S. et al., PHILOSOPHICAL 
TRANSACTIONS OF 
THE ROYAL SOCIETY 
OF LONDON SERIES 
B-BIOLOGICAL 
SCIENCES
356, 991–999, 2001 Indirectly yes (database 
analysis of multihost
pathogens)
9 214 Rabies virus glycoprotein pseudotyping of 
lentiviral vectors enables retrograde axonal 
transport and access to the nervous system 
after peripheral delivery
Mazarakis, N,D. et al., HUMAN 
MOLECULAR 
GENETICS
10, 2109–2121, 2001 No (usage of virus protein 
as a virus vector)
10 208 Population biology of multihost pathogens Woolhouse, M.E.J. 
et al.,
SCIENCE 292, 1109–1112, 2001 Indirectly yes (database 
analysis of multihost
pathogens)
Table 2. Top 10 cited articles related to rabies during 2001–2011
3.1.1. Step 1-Collection of data sources for patent applications
The Derwent Patent Index® (DWPI) and the Derwent Patent Citation Index® (DPCI) [23,24]
were used to survey patent applications related to rabies control using the search strategy
described belo .
DWPI is one of the largest and most user-friendly patent databases in the world, which contains
over 21.85 million patent families that cover over 45.2 million patent documents. It includes
coverage of over 47 worldwide patent authorities with enhanced patent titles and abstracts
prepared by subject experts to facilitate the survey of patent documents. Additionally the
DWPI assembles all of the patent documents relating to an invention into a single database
record as a "patent family". A single "patent family" is a set of either patent applications or
publications taken in multiple countries to protect a single invention by a common inventor(s)
[25]. DPCI provides patent citation information from 10 organizations, including the EPO and
the WIPO.
To survey the number of applicants by nationality, we used the FAMPAT® [26], which is a
comprehensive worldwide patent family database. We used the FAMPAT® because the DWPI
does not include the nationalities of applicants.
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comprehensive worldwide patent family database. We used the FAMPAT® because the DWPI
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3.1.2. Step 2-Screening and selection of patent applications
Using the DWPI, we surveyed Asian, US, and European patent applications related to rabies
control by patent family, as well as patent applications filed under the International Patent
Cooperation Treaty [27] for 2001–2011 (the year when priority was claimed based on the patent
application) on December 21, 2012. In this study, one should note that the data of ”patent
applications” represented the data of ”patent families” assembled uniquely by the DWPI. The
countries targeted for analysis are shown in Table 3 and they were selected based on our
previous study, i.e., the countries that published more infectious disease research articles than
other countries [10].
We screened patent applications using search formulae 1–7 as shown in Table 3, which were
based on keywords and the IPC. Patent applications were selected that contained the keywords
in the titles or abstracts and that belonged to the IPC categories. To ensure the complete capture
of all relevant patent applications, we used “Rabies” and inflected forms of the keywords such
as “Rabic” and “Rabid”, and “Lyssa.” We also used the IPC categories that included antigens,
antibodies, amino acids, chemical compounds, and anti-infectives related to the Rhabdoviri‐
dae family or RNA viruses, which include the rabies virus and lyssaviruses.
After screening the patent applications, we selected patent applications related to rabies
control. We reviewed all the abstracts and claims for patent applications to identify applica‐
tions related to the prevention and diagnosis of rabies.
We primarily focused on patent applications that claimed technologies for preventive and
diagnostic uses related to rabies genes and proteins, but we also included applications related
to technologies for producing vaccine adjuvants and for stabilization, as well as other pertinent
items within the search scope. For example, a patent application was included that claimed a
recombinant adenovirus as a rabies vaccine carrier. However, we excluded patent applications
related to research and therapeutic tools for other diseases, e.g., the synthesis of rabies virus
proteins for human neurodegenerative disorder therapy and the development of a rabies virus
vector for expressing other viral proteins.
3.1.3. Step 3-Analysis of patent applications
The patent applications selected in Step 2 were analyzed with respect to the following items;
patenting activity (the number of patent applications per application year and for each country,
and the number of applicants by nationality), major technical areas of patent applications, and
the most cited patent applications. We used citation analysis as an indicator of important
technological progress, upon which many later patents may rely [28].
3.2. Total number of patent applications
The screening of patent applications related to rabies control retrieved 354 candidates. The
candidates included keywords related to rabies in the titles or abstracts and belonged to the
IPC categories A61K-039/205, C07K-014/145, A61P-031/12, A61P-031/14, or G01N-033/569
(Table 3). Subsequently, we selected 237 of 354 patent applications by reviewing all the
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abstracts and claims to identify patent applications related to rabies control. The following
analysis was based on results, which included 237 patent applications.
3.3. Annual change in the number of patent applications by country
We regrouped the patent applications and applicants for each country to identify possible
differences in technology development among various countries. The numbers of PCT
applications and applications in each country were stable during 2001–2011, except in China
where the number increased relatively. The US had the most patent applications until 2007,
but was overtaken by China in 2008. We found that China had a remarkable increase in patent





1 PRD = 2001:2011 11,315,347 Priority year
2 (US OR EP OR GB OR DE OR ES OR
FR OR IT OR NL OR JP OR CN OR KR
OR IN)/PC
20,081,126 Country or patent administration office (the US, the
European Patent Office, the UK, Germany, Spain,
France, Italy, the Netherlands, Japan, China, Korea, and
India)
3 (RABIES OR RABIC OR RABID OR
LYSSA)/TI/AB/EAB
1,317 Keywords related to rabies
4 (A61K-039/205 OR
C07K-014/145)/IC
601 IPC for medical preparations containing antigens or
antibodies against Rhabdoviridae (A61K-039/205) or
peptides with more than 20 amino acids from
Rhabdoviridae (C07K-014/145)
5 (A61P-031/12 OR A61P-031/14)/IC 25,706 IPC for the specific therapeutic activity of chemical
compounds or medicinal preparations for
antiinfectives (A61P-031/12) or RNA viruses
(A61P-031/14)
6 (G01N-033/569)/IC 11,177 IPC for investigating or analyzing materials by
determining the chemical or physical properties of
micro-organisms
7 1 AND 2 AND 3 AND
(4 OR 5 OR 6)
354 Targeted patent applications
IPC: International Patent Classification
*The number of patent applications was calculated by patent family. In some cases, a patent family contains a number
of relevant patent applications.
Table 3. Table 3 Search formula and the number of patent applications retrieved
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Figure 5. Number of patent applications related to rabies control by country during 2001–2011
The number of patent applications was calculated by patent family. In some cases, a patent
family contains a number of relevant patent applications. US: United States, CN: China, WO:
PCT, EP: European Patent Office, JP: Japan, IN: India, KR: Korea, DE: Germany, ES: Spain, GB:
UK, FR: France, IT: Italy, NL: the Netherlands
3.4. Number of patent applicants by country
The US had the most applicants, but was overtaken by China in 2008–2009. China had a
remarkable increase in applicants after 2003, while it decreased temporarily in 2006. Germany,
Japan, and France had ≤5 patent applications per year during 2001–2011 (Figure 6).
3.5. Major technological fields of patent applications
The technological types of 237 patent applications related to rabies control were determined
in the contexts of prevention, diagnosis, and treatment. As shown in Table 4, the patent
applications were classified into seven technological fields: recombinant virus, protein,
peptide, organic active ingredient, natural product, fabrication method, and mutant. Patent
applications related to recombinant viruses were the most frequent and they primarily claimed
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uses for the prevention and treatment of rabies. Patent applications related to organic active
ingredients used for treatments, fabrication methods for prevention (primarily vaccines), and
natural products and Chinese herbal extracts for treatment were more frequent than other
patent applications. Patent applications related to natural products and Chinese herbal extracts
were primarily from China.
The number of patent applications was calculated by patent family. In some cases, a patent
belonged to two or more technology fields, so the total number of applications exceeded 237.
3.6. Top 10 most cited patent applications
Table 5 shows the top 10 most cited patent applications related to rabies. All the patent
applications were related to diagnostic or therapeutic methods for rabies, such as immuno‐
conjugates (US 5332567, WO200454622), a vaccine carrier (US 6019978), and a monoclonal
antibody production system (WO200476677). It was interesting that all the patent applications
were applicable to various pathogens, such as bacteria, viruses, and mycoplasma, whereas
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Figure 5. Number of patent applications related to rabies control by country during 2001–2011
The number of patent applications was calculated by patent family. In some cases, a patent
family contains a number of relevant patent applications. US: United States, CN: China, WO:
PCT, EP: European Patent Office, JP: Japan, IN: India, KR: Korea, DE: Germany, ES: Spain, GB:
UK, FR: France, IT: Italy, NL: the Netherlands
3.4. Number of patent applicants by country
The US had the most applicants, but was overtaken by China in 2008–2009. China had a
remarkable increase in applicants after 2003, while it decreased temporarily in 2006. Germany,
Japan, and France had ≤5 patent applications per year during 2001–2011 (Figure 6).
3.5. Major technological fields of patent applications
The technological types of 237 patent applications related to rabies control were determined
in the contexts of prevention, diagnosis, and treatment. As shown in Table 4, the patent
applications were classified into seven technological fields: recombinant virus, protein,
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applications related to recombinant viruses were the most frequent and they primarily claimed
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uses for the prevention and treatment of rabies. Patent applications related to organic active
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PHARMACEUTICALS 
Stably tethered structures of defined compositions with 
multiple functions or binding specificities
Yes (useful for treating subjects infected with various 
pathogens including rabies virus)
6 32 US6019978 WISTAR INSTITUTE 




Replication-defective adenovirus human type 5 
recombinant as a vaccine carrier
Yes (more efficacious method in comparison with the 
currently used vaccinia rabies vaccine)
7 31 WO9800166 RHONE MERIEUX Recombinant canine adenovirus (CAV) containing 
exogenous DNA 
Yes (vector for cloning heterologous DNA encodes 
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Vaccine delivery system Yes (useful for the diagnosis of viral diseases including 
rabies)
9 29 WO200775270 IBC 
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Multivalent immunoglobulin-based bioactive assemblies Yes (useful for treating  infection with various 
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MCCALL JOHN 
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linkage 
Yes (useful for therapeutic conjugates against  
pathogens including rabies virus)
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recombinant as a rabies vaccine carrier)
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Protein (e.g. chimeric rabies G protein ) 18 13 15 0
Peptide (e.g. antigenic peptide of rabies virus) 10 8 14 0
Organic active ingredient (e.g. 
organophosphorous compound for producing 
medicaments for therapeutic treatment of 
infections caused by virus )
17 2 36 0
Natural product,  Chinese herbal extract (e.g. 
red bean-derived antiviral agent)
9 0 24 2
Fabrication method (e.g. preparation method of 
rabies vaccine)
31 7 15 8
Mutant (e.g. attenuated recombinant rabies 
virus mutant for live vaccines)
10 1 5 0
Other 10 14 5 2
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4. General overview of research and technology development related to
rabies control based on bibliometric and patent analyses
Our bibliometric and patent analyses using the Web of Science®, DWPI, and DPCI highlighted
five main features of the trends in research and technology development related to rabies
control during 2001–2011.
4.1. Research and technology developments related to rabies control were diverse and
polyspecific
Given that the major research areas were veterinary sciences, virology, and immunology
(Figure 4), and that the two most cited articles related to rabies control belonged to interdis‐
ciplinary research regions, i.e., agent-based modeling and economic analysis (Table 2), it is
apparent that rabies research has diversified from classical to novel research areas. In partic‐
ular, new research is prospective and aims to accelerate the development of domestic and
international management frameworks for rabies.
However, the methods used for rabies diagnosis and vaccine development are progressing if
we take patent US 5332567 and US 6019978 as examples of the top 10 most cited patent
applications (Table 5). These methods were characterized as being applicable to various other
pathogens and were polyspecific. Given that current rabies vaccines aim to introduce new
functions, e.g., animal rabies vaccines combined with other antigens [3], these polyspecific
methods would contribute to further vaccine development.
4.2. Gap between research and technology development for rabies control
We found that the number of articles related to rabies increased throughout the world, but the
number of patent applications directed at rabies control was stable according to PCT and in
each country. Given that only two of the top 10 most cited articles were directly related to
rabies control, as shown in Table 2, and that none of the top 10 patent applications were
specifically for rabies control, as shown in Table 5, it was not clear whether the articles were
directly linked to the patent applications for rabies. Thus, it is not necessarily that research on
rabies leads to technological developments related to rabies control.
4.3. The US, France, and the UK are the leading countries for rabies research
The survey demonstrated that the US led rabies research because it had the highest percentage
of total articles related to rabies, i.e., 32.5% of the total. France ranked second (10.6%) but there
was a big difference compared with the US. These two countries and the UK were also the top
three producers of articles in the area of infectious diseases (Table 1). Four of the top five
organizations that published articles related to rabies were also in these three countries. These
results showed that the US, France, and the UK were the undisputed leaders in research on
rabies and all infectious diseases.
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five main features of the trends in research and technology development related to rabies
control during 2001–2011.
4.1. Research and technology developments related to rabies control were diverse and
polyspecific
Given that the major research areas were veterinary sciences, virology, and immunology
(Figure 4), and that the two most cited articles related to rabies control belonged to interdis‐
ciplinary research regions, i.e., agent-based modeling and economic analysis (Table 2), it is
apparent that rabies research has diversified from classical to novel research areas. In partic‐
ular, new research is prospective and aims to accelerate the development of domestic and
international management frameworks for rabies.
However, the methods used for rabies diagnosis and vaccine development are progressing if
we take patent US 5332567 and US 6019978 as examples of the top 10 most cited patent
applications (Table 5). These methods were characterized as being applicable to various other
pathogens and were polyspecific. Given that current rabies vaccines aim to introduce new
functions, e.g., animal rabies vaccines combined with other antigens [3], these polyspecific
methods would contribute to further vaccine development.
4.2. Gap between research and technology development for rabies control
We found that the number of articles related to rabies increased throughout the world, but the
number of patent applications directed at rabies control was stable according to PCT and in
each country. Given that only two of the top 10 most cited articles were directly related to
rabies control, as shown in Table 2, and that none of the top 10 patent applications were
specifically for rabies control, as shown in Table 5, it was not clear whether the articles were
directly linked to the patent applications for rabies. Thus, it is not necessarily that research on
rabies leads to technological developments related to rabies control.
4.3. The US, France, and the UK are the leading countries for rabies research
The survey demonstrated that the US led rabies research because it had the highest percentage
of total articles related to rabies, i.e., 32.5% of the total. France ranked second (10.6%) but there
was a big difference compared with the US. These two countries and the UK were also the top
three producers of articles in the area of infectious diseases (Table 1). Four of the top five
organizations that published articles related to rabies were also in these three countries. These
results showed that the US, France, and the UK were the undisputed leaders in research on
rabies and all infectious diseases.
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4.4. Brazil was a particularly productive country for rabies research
Like the US, France, and the UK, Brazil was considered to be a productive country for rabies
research because it published the fourth highest number of articles (Table 1). The Universidade
de Sao Paulo was ranked fourth among the top five organizations (Figure 3) and it played a
leading role in rabies research in Brazil.
Brazil may have a high level of rabies research because this country has initiated nationwide
public campaigns to vaccinate dogs and cats against rabies, which have demanded studies to
assess the antibody levels in vaccinated animals [29]. Moreover, research on rabies control has
been active because the population has a serious risk of infection given the close relationships
between these potential zoonosis-transmitting animals and humans [29].
4.5. Development of patent applications for rabies control in China
China exhibited a remarkable increase in patent applications (Figure 5). It was significant that
China overtook the US with respect to the number of patent applications after 2007. From a
technological perspective, patent applications related to natural products and Chinese herbal
extracts increased greatly, as described in section 3.5.
The Chinese statistics showed that 1,633,000 patent applications (the total number of invention
patents, design patents, and utility models) were filed with the State Intellectual Property
Office (SIPO) by 2011, with a greater than threefold increase during 2005 alone [30]. This
remarkable increase in the overall volume of patent applications in China may be attributable
to the subsidization policy specified by the China Elements of Strategy for Intellectural
Property Right, which facilitated the creation, application, protection, and management of
intellectual property rights in 2008. Thus, the notable increase in overall patent applications
after the change in China’s policy may have led to the increased number of patent applications
related to rabies control.
5. Conclusion
This chapter describes the trends in research and technology development related to rabies
control during 2001–2011, which illustrate the measures introduced to control zoonoses. We
found that the research and technology development activities differed among countries,
which were characterized as diverse and polyspecific. The methods used for rabies diagnosis
and vaccine development were found to be progressing.
The highly cited research on agent-based modeling and economic impact analysis shows that
new interdisciplinary studies of rabies are being conducted. These studies are aimed to
accelerate the development of domestic and international management frameworks for rabies.
This bibliometric and patent analysis did not demonstrate that articles (indicators of research
outputs) were closely linked to patent applications (indicators of technology development).
Our method aimed to measure science linkage to analyze the effects of science and research
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on technology development. Science linkage is an indicator of technological innovation, which
is based on calculating the number of non-patent references such as articles, which are an
indicator of the degree of science related to patents, i.e., the number of articles cited per patent
[31]. There are technological limitations to science linkage, but many studies have aimed to
measure the linkage of patents filed in the US and Europe [31]. From this perspective, meas‐
uring science linkage may be a challenge during future surveys of the trends in research and
technology development related to rabies control. This challenge will also apply to zoonoses
in general.
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1. Introduction
Epidemiology is considered as the study of causes of occurrence and transmission of diseases
in human population. It deals with the properties of epidemics in the equilibrium or long-time
steady state. It involves prediction and monitoring of the spread of both naturally occurring
infection and infection caused by bioterrorism, within a population based on the data regard‐
ing course of infection in a single isolated individual. It enables identification of measures for
improving the health of the community as a whole. Epidemics can pass through the population
at an extremely fast rate, may persist for a long time at low levels, may show cyclic patterns
or there may be sudden flare-ups. Therefore, meaningful data collection and data interpreta‐
tion are the essential components of epidemiology. These data can be exploited to identify
trends, make general predictions and assess shortcomings of those predictions. Such predic‐
tion can be highly erroneous unless derived mathematically and here lies the utility of
mathematical modeling. Moreover, age, clinical status and socio-economic status of the
patient, environmental condition, demographic data, meta-population structure, geographical
location etc are of great relevance to the disease occurrence, prevalence, persistence and
ultimately eradication from a heterogeneous population.
For an in-depth and complete understanding of the unpredictable behavior and pattern of
transmission of infectious diseases, both in time and space, epidemiological modeling proves
to be a very powerful tool. It enables the epidemiologist to think rigorously and frame policies
for protection and treatment of the unaffected and affected population respectively from the
invasion by the pathogen. The use of mathematical model in the study of infectious diseases
is being envisaged as an insightful alternative to ethically challenging, expensive and at times,
practically impossible in vivo and in vitro detailed experimentation and subsequent compli‐
cated interpretation. There are instances when the models and the experimental data exist in
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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a symbiotic relationship and improve our quantitative understanding of the infection dynam‐
ics. These models are used to hypothetically disrupt or neutralize genes and simulate infections
within a few seconds. Latent infections that can be maintained for decades in a host can be
mathematically reactivated to determine the effect on an outbreak. Sometimes, the concept of
modeling has been enriched by introduction of an idea from a related field of science as in the
case of HIV quasi-species model inspired by molecular quasi-species model in chemistry [1].
Interpretation of variables associated with mathematical modeling helps in estimation of
parameters of biological significance and deduction of concepts not directly perceptible from
the data. These concepts prove invaluable in giving rise to the observed patterns as also
unearthing the complexities underlying the infection. Concept-building, as derived from the
framework of mathematical model, gives lead-time to the medical fraternity and the govern‐
ment policy-makers in designing and implementing timely intervention measures for preven‐
tion and control of spread of a communicable disease.
Daniel Bernoulli is regarded as the father of epidemiological modeling since he investigated
the influence of variolation on life expectancy as early as 1760. One of the fundamental
principles of epidemiology, the threshold theorem was established by Kermack and McKen‐
drick in 1927 to establish the dynamics of bubonic plague. Disease persistence in large host
population was determined by Barlett.
2. Basis of infectious disease
Spread of an infectious disease depends on several factors like factors related to the pathogen,
environmental factors, population factors and finally, social structure and behavior of the
contagion. Natural birth and death rates of the population are independent of the pathogen.
The rate of transmission may differ in different age groups where incubation period may vary.
Type and mode of contact or incidence function and immunity duration are known to govern
the spread. Geographical location and seasonality are other factors affecting the spread of an
infection [2-4].
Complete understanding of infectious diseases requires knowledge of the various processes
involved in host-parasite interactions. The two most important processes in these interactions
are the epidemiological process associated with disease transmission within the population
and immunological process involved in the disease dynamics within the host. Modeling of
host-pathogen interactions helps in identification of key factors that may have a major impact
on the outcome of an infection. In dynamic models of viral diseases, epidemiological modeling
is based on the interaction between the susceptible and infected classes of the population and
within-host dynamics is usually overlooked [5]. In any viral or bacterial infection, one of the
key determinants of the disease progression within the host is the immunological status which
is governed by dynamic interaction between different groups of cells and various signaling
molecules [1].
Some of the terminologies associated with infectious disease are (a) infectivity or secondary
attack rate, which is defined as the ratio of number infected and number exposed, (b) patho‐
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genicity or illness rate, which is expressed as the ratio of number with symptoms and number
infected and lastly, (c) virulence which may be written as the ratio of number of severe/fatal
cases and total number of cases. For example, chicken pox and measles are characterized by
high infectivity, high pathogenicity and low virulence whereas, smallpox is recognized by high
levels of all the three variables and tuberculosis is found to possess low infectivity, low
pathogenicity and high degree of virulence.
3. Categories of infectious diseases
The etiological agents of micro-parasitic infections are viruses, bacteria, protozoa or prions, all
of which are usually unicellular and of microscopic size and can reproduce very fast. High
degree of prevalence of this class of infections among the children worldwide is a matter of
great concern to the parents, school authorities and the government. They include measles,
rubella, chickenpox, mumps, whooping cough etc. Usual route of transmission is by direct
contact through air-borne droplets. These diseases are characterized by high infectivity, short
disease generation length and low mean age at infection, on one hand and lifelong acquired
immunity following recovery on the other hand.
Macroparasitic infections, caused by parasites, visible to the naked eye (e.g. helminthes,
arthropods) are characterized by short duration of immunity following recovery. The number
of parasites per host is a critical factor in epidemiology of this category of infections [6].
Microparasitic or macroparasitic infections can occur by either direct or indirect transmission.
Usually microparasitic infections are transmitted by direct contact between two individuals
as in the case of influenza, HIV, measles etc. The pathogen cannot survive outside the host
body. Macroparasites, on the other hand, are indirectly transmitted and they spend a part of
their lifecycle outside the host system, freely in the environment. There is a third category of
diseases or vector-borne diseases where the causative organism is passed from primary host
to the vector and from vector to another primary host as found in case of malaria, filariasis,
sleeping sickness etc. [7].
Variation in the characteristics of the infectious agent is manifested as difference in traits and
thus arises the need of different dynamics.
4. Mathematical model
Mathematical models help in generating and clarifying hypotheses, assessing quantitative
conjectures, finding answers to specific questions, determining sensitivities to changes in
parameter values and estimating parameters from data in absence and presence of preventive
and therapeutic interventions. Therefore, according to input-output approach, mathematical
model may be viewed as a system where the facts about the disease serve as the inputs and
prediction about the number of infected and uninfected people over time is regarded as the
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output. A model is usually expressed in terms of variables which are related to experimentally
measurable quantities.
A mathematical model helps in establishment of links between sets of epidemiological data
through well-understood mathematical relationships. This is facilitated only through a
thorough understanding of various factors associated with the disease like, incubation,
transmission and mortality and also factors associated with the vector. Models may also help
to characterize and integrate the cellular network and molecular data operating within the
different compartments of the host immunity system for disease progression. At a mechanistic
level, they help in finding answers to several biological questions which cannot be addressed
experimentally. Different conceptual qualitative results and threshold values of paramount
importance like basic reproduction ratio, contact numbers, replacement numbers and herd
immunity, are derived from mathematical models, since the quantity and diversity of available
data is limited. Conditions for local and global stability of various equilibria, relationships
among these stability conditions and endemicity are also derived from the epidemiological
models. Prediction and recommendations for control of an epidemic outbreak are therefore,
the most important outcomes of mathematical modeling of a communicable disease and then
they are known as decision models. These models facilitate economic evaluation of different
courses of action for mitigation of a particular infection and finally help in selection of optimal
control measure [8].
Spatio-temporal progression and temporal development of communicable diseases can be
explained by compartmental, agent-based or contact network-based model. In the compart‐
mental model, the host population is divided into different states or compartments, depending
on the level of infection in them. Rates of transfer e.g. transmission rate, removal rate between
compartments are expressed as derivatives of the sizes of the compartments with respect to
time and are assumed to be constant. Ordinary differential equations form the basic framework
of compartmental models. In agent-based model, the region of interaction of people in a
population is considered as a system of software agents interacting in time and space. It is a
high fidelity model and involves complex parameterization and extensive computation.
Modern concepts of network theory are employed in dissecting the transmission dynamics
within heterogeneous population in a contact network model. Social networking among the
individuals influence the possibility, extent and speed of epidemic spreading. This model is
intermediate between compartmental model and agent-based model. In this model, the
pathogen and the social network within the population are closely intertwined and represent‐
ed by a node for each individual. The framework of contact network highly depends on the
mode of transmission of the disease [2], [9].
Accuracy, transparency and flexibility are the key elements which should be balanced to
develop a mathematical model of high quality. For development of any type of mathematical
model, mathematical modelers formulate a set of equations by feeding into them various type
of factors like the length of time one is ill, the length of time one can infect others, the level of
contagiousness of the disease, the number of uninfected individuals who can contract the
disease, human behavior and any such known component of disease dynamics. Once a model
with biological significance and relevance has been formulated, the model can be fitted to the
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experimental data to obtain estimates for the kinetic parameters associated with the system,
which are otherwise difficult to obtain experimentally.
Qualitative fitting of the data enables deeper understanding of the disease dynamics and
quantitative fitting helps in designing and implementing control measures [7]. Apart from
constructing a set of equations, data fitting and estimation of parameters, mathematical model
also uses some graphical tools for characterization of dynamical systems. Phase plane techni‐
que like, linearization approximation is a graphical tool used to analyze the system dynamics
of one state variable as a function of another state variable. In such plot, time dimension is not
present but the trajectory of the dynamics is shown by arrows. The second technique is
bifurcation diagram reserved for visualization of relatively complex dynamics. Bifurcation
diagram is a summary of the asymptomatic dynamics of a dynamical system as a function of
a bifurcation parameter [6].
5. Compartmental mathematical models
These models can be either Susceptible-Infectious-Recovered (SIR), Susceptible-Infectious-
Recovered-Susceptible (SIRS), Susceptible-Exposed-Infectious-Recovered (SEIR), Susceptible-
Infected (SI) or Susceptible-Infectious-Susceptible (SIS). Number of compartments in the
model depend on the disease being studied and the objective of the study. In this approach,
the progress of the disease is defined in terms of level of pathogen within the host.
5.1. SIR model
Number or density of individuals in each stage of infection is more important than the load of
the pathogen per person in modeling of microparasitic infections. In the SIR model in order to
emulate epidemics, population is classified as Susceptible, currently Infectious and Recovered.
The total size of the host population is the summation of the three classes. When an individual
is concerned, he is assumed to exist in either of the three states. Susceptible means that the
individual has never had the disease and is susceptible to contraction of the disease by an
infected individual, at random from the population. The mode of transmission of infection
depends on the type of the pathogen. Depending on the relative magnitude of the latent period
of the infection, the infected host can infect others and then it becomes Infectious. The total
time spent in the infected state by an individual is a geometric random variable. When the
infectious agent is removed from the system of the infected class or death occurs, they become
Recovered with immunity and will never be infected again. In case of a dead individual, he
cannot get infected or cannot infect anybody and thus is equivalent to a recovered individual
with acquired immunity. Then, it can be assumed that the number of infected individuals tends
to decrease towards zero and finally disappears from the network permanently. In the study
of disease dynamics, six distinct and well-defined events can be assumed to occur : birth, death
of a susceptible individual, death of an infected individual, death of a recovered individual,
infection and recovery. Epidemic data supports the assumption that the per capita rate at which
a given susceptible individual becomes infected is proportional to the prevalence of infection
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diagram is a summary of the asymptomatic dynamics of a dynamical system as a function of
a bifurcation parameter [6].
5. Compartmental mathematical models
These models can be either Susceptible-Infectious-Recovered (SIR), Susceptible-Infectious-
Recovered-Susceptible (SIRS), Susceptible-Exposed-Infectious-Recovered (SEIR), Susceptible-
Infected (SI) or Susceptible-Infectious-Susceptible (SIS). Number of compartments in the
model depend on the disease being studied and the objective of the study. In this approach,
the progress of the disease is defined in terms of level of pathogen within the host.
5.1. SIR model
Number or density of individuals in each stage of infection is more important than the load of
the pathogen per person in modeling of microparasitic infections. In the SIR model in order to
emulate epidemics, population is classified as Susceptible, currently Infectious and Recovered.
The total size of the host population is the summation of the three classes. When an individual
is concerned, he is assumed to exist in either of the three states. Susceptible means that the
individual has never had the disease and is susceptible to contraction of the disease by an
infected individual, at random from the population. The mode of transmission of infection
depends on the type of the pathogen. Depending on the relative magnitude of the latent period
of the infection, the infected host can infect others and then it becomes Infectious. The total
time spent in the infected state by an individual is a geometric random variable. When the
infectious agent is removed from the system of the infected class or death occurs, they become
Recovered with immunity and will never be infected again. In case of a dead individual, he
cannot get infected or cannot infect anybody and thus is equivalent to a recovered individual
with acquired immunity. Then, it can be assumed that the number of infected individuals tends
to decrease towards zero and finally disappears from the network permanently. In the study
of disease dynamics, six distinct and well-defined events can be assumed to occur : birth, death
of a susceptible individual, death of an infected individual, death of a recovered individual,
infection and recovery. Epidemic data supports the assumption that the per capita rate at which
a given susceptible individual becomes infected is proportional to the prevalence of infection
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in the population. Therefore, according to SIR model, number of cases increases exponentially
initially till there has been a sufficient decrease in the proportion of susceptible when the
growth rate slows; this process goes on until the epidemic can no longer be maintained and
the number of cases goes below a threshold level resulting in disease eradication. Human
behavior can affect the disease dynamics in an individual as also in the whole population
because it may influence the disease state of an individual, rate of infection or recovery rate
and the contact network structure. Therefore, behavioral responses should be considered as
an integral part of the study of dynamics of infectious diseases. An intriguing feature of
childhood microparasitic infections is that the children are born in the susceptible category as
there is no vertical transmission. Birth rate and vaccination affect the recruitment to the
susceptible compartment. Moreover, in case of common cold, there is no permanent removal
state because the individual enters the susceptible class soon after recovery. This widely used
model is applicable for diseases which are contracted by an individual only once in its lifetime
and either acquired lifelong immunity develops or death occurs as in case of measles, mumps,
SARS, influenza. An important drawback of the model is that it ignores the random effects,
specially at early stages of infection, when the number of both susceptible and infected classes
is low. This model is unable to describe the spatial aspects of the spread of the disease.
Moreover, in this modeling approach it is assumed that each individual has the same amount
of contacts as every other individual. Therefore, if the rate of contact varies during course of
infection, it cannot be appropriately included in the simple SIR model. Precision in prediction
can be improved by incorporating realistic contact patterns or by using modeling approaches
possessing higher fidelity.
The SIR model can also be expressed by a stochastic version where the future course of the
infection is independent of the past, if present is known completely [2], [6], [9-10].
5.2. SIRS
This model assumes that after recovery, the person becomes susceptible again as immunity
wanes, i.e. recovered individuals possess short-term immunity [4], [14].
5.3. SEIR
It is an extended SIR model where a new compartment or state is added. It is known as Exposed
or E which is positioned between the susceptible and infectious compartments. The Exposed
individual is infected but not infectious, i.e. the disease remains in latent state [15].This concept
can also be explained on the basis of the level of pathogen within the host and immunological
status of the host. When the host is susceptible, it indicates that no pathogen is present and
only a low level of non-specific immunity exists within the host. As soon as the susceptible
encounters an infectious individual, he becomes infected. The pathogen increases in number
and the infected host may not show any signs of infection and thus he enters the Exposed
compartment. As soon as the pathogen burden is sufficiently high, the Exposed host becomes
Infectious and disease is transmitted to another susceptible individual. When the Infectious
individual can no longer transmit infection as the pathogen is cleared from his immunity
system, he belongs to the Recovered category. The class distinction between Exposed-
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Infectious and Infectious-Recovered is not very distinct because of variability in responses
between different individuals and variability in pathogen levels over the infectious period [7].
5.4. SI model
This modeling approach is unrealistic in case of animal or human infections because here it is
assumed that an infected individual remains in this state forever. Hence, the ultimate conse‐
quence of the presence of one infected individual in the population is the infection of the entire
population. In the early stages of an infection, when the count of infected cases is low, the SI
and SIR models behave in a similar fashion as there is limited number of recovered individuals.
5.5. SIS model
In this model, individuals run stochastically through the cycle of Susceptible-Infected –
Susceptible. Thus, here exist only two states because the infected individual, after recovery,
again becomes susceptible to infection. Removal due to death or acquired immunization is not
considered. Therefore, the number of infected individuals increases up to a stationary non-
zero constant value as observed in case of sexually transmitted diseases [10]. The renewed
susceptibility of an individual is due to vast antigenic variation associated with gonorrhea and
other similar sexually transmitted diseases [7]. This model is based on assumptions like,
different contagion probabilities between different pairs of people, probabilistic recovery from
the disease and multiple stages of infection, with varying disease properties [9].
6. Deterministic and Stochastic approach to mathematical modeling
If the objective of the study is to model disease propagation in a large population, with
continuous variations of population sizes, deterministic model is the most appropriate one.
Such model indicates same output or same fate of individuals subjected to same possible events
with identical probabilities [6]. For a given set of parameter values, the deterministic model
has one solution which can be fitted to data using various methods. The most common method
minimizes the sum of squares of differences between observed data and model prediction.
Natural and biological discrete events of random occurrence in a small population cannot be
explained by deterministic and continuous modeling and here comes the utility of stochastic
modeling. Stochastic models capture the randomness of birth and death rates associated with
disease dynamics and also the variability among disease strains. The earliest stages of an
infection are stochastic. This occurs because encounter with a pathogen may either lead to an
infection or elimination from the system. Stochasticity decreases as the number of cases
increases. Emergent behaviors that have neither been defined nor expected are simulated in
this modeling approach. Probability distributions associated with such systems are typically
memory-less. If the objective of modeling of disease dynamics is to establish the conditions for
disease eradication, or if irregular epidemics are to be modeled, stochastic model is the choice.
Stochasticity can induce chance extinctions of the disease and it introduces variances and co-
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in the population. Therefore, according to SIR model, number of cases increases exponentially
initially till there has been a sufficient decrease in the proportion of susceptible when the
growth rate slows; this process goes on until the epidemic can no longer be maintained and
the number of cases goes below a threshold level resulting in disease eradication. Human
behavior can affect the disease dynamics in an individual as also in the whole population
because it may influence the disease state of an individual, rate of infection or recovery rate
and the contact network structure. Therefore, behavioral responses should be considered as
an integral part of the study of dynamics of infectious diseases. An intriguing feature of
childhood microparasitic infections is that the children are born in the susceptible category as
there is no vertical transmission. Birth rate and vaccination affect the recruitment to the
susceptible compartment. Moreover, in case of common cold, there is no permanent removal
state because the individual enters the susceptible class soon after recovery. This widely used
model is applicable for diseases which are contracted by an individual only once in its lifetime
and either acquired lifelong immunity develops or death occurs as in case of measles, mumps,
SARS, influenza. An important drawback of the model is that it ignores the random effects,
specially at early stages of infection, when the number of both susceptible and infected classes
is low. This model is unable to describe the spatial aspects of the spread of the disease.
Moreover, in this modeling approach it is assumed that each individual has the same amount
of contacts as every other individual. Therefore, if the rate of contact varies during course of
infection, it cannot be appropriately included in the simple SIR model. Precision in prediction
can be improved by incorporating realistic contact patterns or by using modeling approaches
possessing higher fidelity.
The SIR model can also be expressed by a stochastic version where the future course of the
infection is independent of the past, if present is known completely [2], [6], [9-10].
5.2. SIRS
This model assumes that after recovery, the person becomes susceptible again as immunity
wanes, i.e. recovered individuals possess short-term immunity [4], [14].
5.3. SEIR
It is an extended SIR model where a new compartment or state is added. It is known as Exposed
or E which is positioned between the susceptible and infectious compartments. The Exposed
individual is infected but not infectious, i.e. the disease remains in latent state [15].This concept
can also be explained on the basis of the level of pathogen within the host and immunological
status of the host. When the host is susceptible, it indicates that no pathogen is present and
only a low level of non-specific immunity exists within the host. As soon as the susceptible
encounters an infectious individual, he becomes infected. The pathogen increases in number
and the infected host may not show any signs of infection and thus he enters the Exposed
compartment. As soon as the pathogen burden is sufficiently high, the Exposed host becomes
Infectious and disease is transmitted to another susceptible individual. When the Infectious
individual can no longer transmit infection as the pathogen is cleared from his immunity
system, he belongs to the Recovered category. The class distinction between Exposed-
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Infectious and Infectious-Recovered is not very distinct because of variability in responses
between different individuals and variability in pathogen levels over the infectious period [7].
5.4. SI model
This modeling approach is unrealistic in case of animal or human infections because here it is
assumed that an infected individual remains in this state forever. Hence, the ultimate conse‐
quence of the presence of one infected individual in the population is the infection of the entire
population. In the early stages of an infection, when the count of infected cases is low, the SI
and SIR models behave in a similar fashion as there is limited number of recovered individuals.
5.5. SIS model
In this model, individuals run stochastically through the cycle of Susceptible-Infected –
Susceptible. Thus, here exist only two states because the infected individual, after recovery,
again becomes susceptible to infection. Removal due to death or acquired immunization is not
considered. Therefore, the number of infected individuals increases up to a stationary non-
zero constant value as observed in case of sexually transmitted diseases [10]. The renewed
susceptibility of an individual is due to vast antigenic variation associated with gonorrhea and
other similar sexually transmitted diseases [7]. This model is based on assumptions like,
different contagion probabilities between different pairs of people, probabilistic recovery from
the disease and multiple stages of infection, with varying disease properties [9].
6. Deterministic and Stochastic approach to mathematical modeling
If the objective of the study is to model disease propagation in a large population, with
continuous variations of population sizes, deterministic model is the most appropriate one.
Such model indicates same output or same fate of individuals subjected to same possible events
with identical probabilities [6]. For a given set of parameter values, the deterministic model
has one solution which can be fitted to data using various methods. The most common method
minimizes the sum of squares of differences between observed data and model prediction.
Natural and biological discrete events of random occurrence in a small population cannot be
explained by deterministic and continuous modeling and here comes the utility of stochastic
modeling. Stochastic models capture the randomness of birth and death rates associated with
disease dynamics and also the variability among disease strains. The earliest stages of an
infection are stochastic. This occurs because encounter with a pathogen may either lead to an
infection or elimination from the system. Stochasticity decreases as the number of cases
increases. Emergent behaviors that have neither been defined nor expected are simulated in
this modeling approach. Probability distributions associated with such systems are typically
memory-less. If the objective of modeling of disease dynamics is to establish the conditions for
disease eradication, or if irregular epidemics are to be modeled, stochastic model is the choice.
Stochasticity can induce chance extinctions of the disease and it introduces variances and co-
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variances that can influence the deterministic behavior. Stochastic simulations are computa‐
tionally intensive.
In stochastic modeling of HIV dynamics, it is assumed that the viral population is governed
by the availability of target cells that can be infected and does not take into account the
contribution of the immune responses in the control of virus load.
Stochastic extinction or disease eradication by chance occurs when an infected individual fails
to reproduce and transmit the infection and ultimately the pathogen dies out.
An interesting thing to note at this juncture is that deterministic model can be transformed to
the corresponding stochastic model by conversion of deterministic rates into the probabilistic
ones on the basis of a fixed reference volume of the model. This has been done in the analysis
of dynamics of HIV and the opportunistic co-infection TB by incorporation of the response of
cytotoxic T-lymphocytes in absence and presence of HAART therapy by altering the model’s
parameters. Evolution of drug resistant strains can also be assumed to exhibit a stochastic
pattern.
A combination of deterministic and stochastic approaches will be the most effective one
because of their complementary features, although it may be time-consuming and may exploit
more resources [1], [7], 12, [16-18].
As no element of chance or uncertainty is involved in the development of deterministic models,
they account for the mean trend of a process only. However in addition to the above feature,
stochastic model also accounts for the variance component around the process. Initial epidemic
growth of an infection cannot be properly approximated by deterministic SIR model. This
occurs because at this stage only a seed of infection is introduced in contrast to the large
population at later stages. Probability that an infection will occur is governed by demographic
stochasticity. In case of stochastic models, some parameters are characterized by a probability
distribution, instead of a fixed constant value, as observed with the deterministic models [6].
Given a stochastic transmission model, most inferential methods rely on likelihood. Given a
likelihood, inference can proceed along conventional lines, using tools such as maximum
likelihood estimation, expectation maximization algorithm, rejection sampling and Markov
chain Monte Carlo methods.
7. Insights into conceptual results from mathematical model
Two approaches can be used to determine the time-scale of disease transmission by utilizing
data on individual-to-individual chains of transmission. Estimation of disease generation time
(T) is one approach. It may be defined as the expected length of time between infection of an
index case and infection of his or her secondary cases. It is the duration of latency plus
infectiousness. The generation time of measles is approximately 14 days. A short generation
time indicates rapid transmission whereas a longer T suggests slower spread but longer
carriage. The duration of carriage of pathogens represents an upper limit on T and it can be
concluded that directly transmitted acute infections have T < 1 month and chronic infections
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have T values in the order of months or years [19]. But, determination of generation time
becomes complicated if the disease possesses asymptomatic periods of infection of variable or
unknown duration. Another quantity that is estimated is the serial interval. It is the time
between clinical onset of symptoms in the index case and the clinical onset of symptoms in the
average secondary case [2].
In a system of differential equations, an equilibrium point is a point at which all the equations
equal zero. This indicates that the state of the system is not changing. In a mathematical model,
a disease-free equilibrium (DFE) and one or more endemic equilibria are present. The DFE
indicates that the entire population is susceptible since not a single infective exists in the
population. Endemic equilibrium is steady-state equilibrium produced by spread of infection.
If the solutions of the equations near the equilibrium points tend toward the points with time,
they are said to be locally stable. An equilibrium point is referred to as globally asymptotically
stable if the behavior of the system at any point tends toward the equilibrium point as time
tends toward infinity.
The stability of DFE and existence of other nontrivial equilibria can be determined from a ratio,
known as basic reproduction ratio [20]. A very brief description of the essential conceptual
results from mathematical modeling has been given in Table 1.
Parameters Description
Disease generation time Time from the moment one person becomes infected until
that person infects another person
Equilibrium point Can be categorized as a. disease-free equilibrium point
when there is no infection in either the host or the vector
or there is no pathogen and b. endemic equilibrium where
the disease persists in the population. Both are steady
state solutions.
Basic reproduction number Number of secondary cases caused by one primary case
introduced into a population that is wholly susceptible
Table 1. Glossary of important parameters associated with mathematical modeling of infectious diseases
8. Basic reproduction ratio
A key concept or parameter in epidemiology, the basic reproduction ratio, R0 is being exten‐
sively studied during deterministic, non-spatial, unstructured modeling of in-host population
dynamics of microparasitic infectious diseases, once they have been established. It is defined
as the expected number of secondary individuals infected by an individual during his or her
entire tenure of infectious period. Its derivation is applicable even when non-constant
transmission probabilities between classes (i.e., non-exponential lifetime distributions) are
assumed. If its value is greater than 1, the infection spreads across a non-zero fraction of
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ones on the basis of a fixed reference volume of the model. This has been done in the analysis
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cytotoxic T-lymphocytes in absence and presence of HAART therapy by altering the model’s
parameters. Evolution of drug resistant strains can also be assumed to exhibit a stochastic
pattern.
A combination of deterministic and stochastic approaches will be the most effective one
because of their complementary features, although it may be time-consuming and may exploit
more resources [1], [7], 12, [16-18].
As no element of chance or uncertainty is involved in the development of deterministic models,
they account for the mean trend of a process only. However in addition to the above feature,
stochastic model also accounts for the variance component around the process. Initial epidemic
growth of an infection cannot be properly approximated by deterministic SIR model. This
occurs because at this stage only a seed of infection is introduced in contrast to the large
population at later stages. Probability that an infection will occur is governed by demographic
stochasticity. In case of stochastic models, some parameters are characterized by a probability
distribution, instead of a fixed constant value, as observed with the deterministic models [6].
Given a stochastic transmission model, most inferential methods rely on likelihood. Given a
likelihood, inference can proceed along conventional lines, using tools such as maximum
likelihood estimation, expectation maximization algorithm, rejection sampling and Markov
chain Monte Carlo methods.
7. Insights into conceptual results from mathematical model
Two approaches can be used to determine the time-scale of disease transmission by utilizing
data on individual-to-individual chains of transmission. Estimation of disease generation time
(T) is one approach. It may be defined as the expected length of time between infection of an
index case and infection of his or her secondary cases. It is the duration of latency plus
infectiousness. The generation time of measles is approximately 14 days. A short generation
time indicates rapid transmission whereas a longer T suggests slower spread but longer
carriage. The duration of carriage of pathogens represents an upper limit on T and it can be
concluded that directly transmitted acute infections have T < 1 month and chronic infections
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have T values in the order of months or years [19]. But, determination of generation time
becomes complicated if the disease possesses asymptomatic periods of infection of variable or
unknown duration. Another quantity that is estimated is the serial interval. It is the time
between clinical onset of symptoms in the index case and the clinical onset of symptoms in the
average secondary case [2].
In a system of differential equations, an equilibrium point is a point at which all the equations
equal zero. This indicates that the state of the system is not changing. In a mathematical model,
a disease-free equilibrium (DFE) and one or more endemic equilibria are present. The DFE
indicates that the entire population is susceptible since not a single infective exists in the
population. Endemic equilibrium is steady-state equilibrium produced by spread of infection.
If the solutions of the equations near the equilibrium points tend toward the points with time,
they are said to be locally stable. An equilibrium point is referred to as globally asymptotically
stable if the behavior of the system at any point tends toward the equilibrium point as time
tends toward infinity.
The stability of DFE and existence of other nontrivial equilibria can be determined from a ratio,
known as basic reproduction ratio [20]. A very brief description of the essential conceptual
results from mathematical modeling has been given in Table 1.
Parameters Description
Disease generation time Time from the moment one person becomes infected until
that person infects another person
Equilibrium point Can be categorized as a. disease-free equilibrium point
when there is no infection in either the host or the vector
or there is no pathogen and b. endemic equilibrium where
the disease persists in the population. Both are steady
state solutions.
Basic reproduction number Number of secondary cases caused by one primary case
introduced into a population that is wholly susceptible
Table 1. Glossary of important parameters associated with mathematical modeling of infectious diseases
8. Basic reproduction ratio
A key concept or parameter in epidemiology, the basic reproduction ratio, R0 is being exten‐
sively studied during deterministic, non-spatial, unstructured modeling of in-host population
dynamics of microparasitic infectious diseases, once they have been established. It is defined
as the expected number of secondary individuals infected by an individual during his or her
entire tenure of infectious period. Its derivation is applicable even when non-constant
transmission probabilities between classes (i.e., non-exponential lifetime distributions) are
assumed. If its value is greater than 1, the infection spreads across a non-zero fraction of
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susceptible population. If the spreading rate is too low and R0 cannot cross beyond the
threshold level, it is not feasible to affect a finite proportion of population and disease dies out
in a finite time. In a contact network model, the disease cannot replenish itself and ultimately
dies out after a finite number of waves, if R0< 1 with probability 1. Disease persists with positive
probability, at least by infecting one person in each wave, if R0 > 1. Keeping and maintaining
the value of R0 < 1 reflects the stability of the disease-free equilibrium and creates a condition
for clearing of pathogen from the population and thus it is the goal of any public health
initiative designed for containment or control of infection. Moreover, the estimation of R0 plays
a crucial role in understanding the outbreak and potential danger from emerging infectious
disease. The concept of R0 has also been developed for complex models like stochastic and
finite systems, models with spatial structure and also macroparasite infections. Comparison
of R0 values, based either on their numerical values or area under the infectiousness curve,
helps in estimation of relative intrinsic transmissibility of the pathogens [9], [10], [21], [22].
There are also alternative approaches of estimating R0 from available incidence or epidemio‐
logical data which require simplifying assumptions for numerical estimation of some un‐
known parameters. It is assumed that the host population is homogeneous, mixes uniformly
and is of constant size in a constant state. The number of contacts per infective is independent
of the number of infectives. Infectivity and mortality do not depend on age, genetic make-up,
geography. Moreover, it is assumed that all individuals are born susceptible and as soon as
disease is acquired, they are no longer considered susceptible. Spreading pattern of the
epidemics is controlled by the generation time-scale. All these assumptions may never be fully
realized in a practical clinical setting. R0 can be expressed as the ratio of the life expectancy and
mean age of acquiring the infection. Thus, higher the R0, lower is the mean age at infection.
Another important relationship that can be derived is that the mean age at infection is the
reciprocal of the force of infection. A key parameter, the coefficient of transmission for airborne
diseases, can be determined from the value of the force of infection. Alternatively, R0 can be
estimated from the intrinsic growth rate of the infected class, which is highly dependent on
collecting accurate data. Stochastic fluctuations can affect the value of growth rate. In case of
vector-borne disease like dengue, R0 was calculated from the survival function, assuming
spatial compartments of varying vector density. For multiple classes of infectives, R0 can be
defined per infection cycle [6], [10], [21].
From sensitivity analysis, it has been found that different infection-and population-related
factors may affect R0 like, transmission rate, vector mortality, incubation period of the vector,
the relative infectiousness after isolation [21].
For both measles and whooping cough in England and Wales from 1945 to 1965, R0 has
been found to be nearly 17. For the H1N1 epidemic in UK, R0 has been estimated to be 1.4.
Estimation of R0 for SARS by different groups have mostly given the values in the range
of 2-4, although a wide range of 1-7 has also been found in the literature. For smallpox,
the R0 was found to be in the range of 4< R0 <10. Though an upper bound has been found
for pandemic influenza, no lower bound could be obtained. For AIDS, R0 is always greater
than 1, especially in African countries and it depends highly on the sexual behavior. For
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homosexual population in the United Kingdom, R0 is close to 4 and approximately 11 for
female prostitutes in Kenya [7], [13], [22].
8.1. Significance of basic reproduction ratio
The magnitude of R0, along with the disease generation time, help in assessing the time scale
of infection, implementing sustainable control measures at the most appropriate time and
justifying implementation of costly approaches in management of infectious diseases. Low
value of R0 for any infection suggests that the epidemic can be controlled, either by adopting
single or combined putative containment procedures [21], [22].
Condition for endemicity can be deduced from an idea of R0. Disease is said to exist in an
endemic state when it persists in the population at a low and constant level of prevalence, for
which there should be a continuous supply of susceptibles. This happens if deaths and births
occur at equal constant rates keeping the population turnover rate at a fixed value. An outcome
of this assumption is the negative exponential distribution of age. At endemic equilibrium, the
relationship between the proportion of susceptible in the population and the basic reproduc‐
tion ratio is inverse [6].
Though R0 is the widely accepted and used indicator of control measure, it has been observed
that different control approaches may produce same degree of reduction of R0 but not same
effect on the growth rate. Factors such as timing of secondary infections, negative impact of
control measures on the population are not considered while implementing public health
initiatives based on the basic reproduction ratio [21].
8.2. Alternatives to R0
R0 is a highly pathogen-centered parameter and recently, a host-centered parameter has been
evolved, the basic depression ratio, D0. An alternative parameter for heterogeneous population
has been developed, type reproduction number, T which indicates the efficacy of the control
measure against a particular subtype of host population, from which if infection is eradicated,
the disease will not sustain at all [21].
In case of a population which is susceptible after acquiring immunity from a previous epidemic
or due to vaccination, instead of R0, Reff or effective value of R0 is used. Reff is a time-dependent
quantity that accounts for the population’s reduced susceptibility. If Reff is greater than one,
the number of infected individuals grows and decreases if Reff is less than one. Therefore, the
critical proportion of susceptible is given by Reff equal to one [11]. The parameter can be
determined by fitting deterministic epidemiological model employing a generalized least
squares estimation scheme [23].
In case of seasonally driven epidemics as with different childhood microparasitic infections,
it is necessary to determine the number of susceptible left after a major epidemic (S0). If S0 goes
above a critical threshold value, epidemic outbreak may recur in the next year or there will be
a skip i.e., a year when epidemic fails to initiate [14].
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susceptible population. If the spreading rate is too low and R0 cannot cross beyond the
threshold level, it is not feasible to affect a finite proportion of population and disease dies out
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dies out after a finite number of waves, if R0< 1 with probability 1. Disease persists with positive
probability, at least by infecting one person in each wave, if R0 > 1. Keeping and maintaining
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for clearing of pathogen from the population and thus it is the goal of any public health
initiative designed for containment or control of infection. Moreover, the estimation of R0 plays
a crucial role in understanding the outbreak and potential danger from emerging infectious
disease. The concept of R0 has also been developed for complex models like stochastic and
finite systems, models with spatial structure and also macroparasite infections. Comparison
of R0 values, based either on their numerical values or area under the infectiousness curve,
helps in estimation of relative intrinsic transmissibility of the pathogens [9], [10], [21], [22].
There are also alternative approaches of estimating R0 from available incidence or epidemio‐
logical data which require simplifying assumptions for numerical estimation of some un‐
known parameters. It is assumed that the host population is homogeneous, mixes uniformly
and is of constant size in a constant state. The number of contacts per infective is independent
of the number of infectives. Infectivity and mortality do not depend on age, genetic make-up,
geography. Moreover, it is assumed that all individuals are born susceptible and as soon as
disease is acquired, they are no longer considered susceptible. Spreading pattern of the
epidemics is controlled by the generation time-scale. All these assumptions may never be fully
realized in a practical clinical setting. R0 can be expressed as the ratio of the life expectancy and
mean age of acquiring the infection. Thus, higher the R0, lower is the mean age at infection.
Another important relationship that can be derived is that the mean age at infection is the
reciprocal of the force of infection. A key parameter, the coefficient of transmission for airborne
diseases, can be determined from the value of the force of infection. Alternatively, R0 can be
estimated from the intrinsic growth rate of the infected class, which is highly dependent on
collecting accurate data. Stochastic fluctuations can affect the value of growth rate. In case of
vector-borne disease like dengue, R0 was calculated from the survival function, assuming
spatial compartments of varying vector density. For multiple classes of infectives, R0 can be
defined per infection cycle [6], [10], [21].
From sensitivity analysis, it has been found that different infection-and population-related
factors may affect R0 like, transmission rate, vector mortality, incubation period of the vector,
the relative infectiousness after isolation [21].
For both measles and whooping cough in England and Wales from 1945 to 1965, R0 has
been found to be nearly 17. For the H1N1 epidemic in UK, R0 has been estimated to be 1.4.
Estimation of R0 for SARS by different groups have mostly given the values in the range
of 2-4, although a wide range of 1-7 has also been found in the literature. For smallpox,
the R0 was found to be in the range of 4< R0 <10. Though an upper bound has been found
for pandemic influenza, no lower bound could be obtained. For AIDS, R0 is always greater
than 1, especially in African countries and it depends highly on the sexual behavior. For
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homosexual population in the United Kingdom, R0 is close to 4 and approximately 11 for
female prostitutes in Kenya [7], [13], [22].
8.1. Significance of basic reproduction ratio
The magnitude of R0, along with the disease generation time, help in assessing the time scale
of infection, implementing sustainable control measures at the most appropriate time and
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a skip i.e., a year when epidemic fails to initiate [14].
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9. Strategies for containment of an infectious disease
Barlett postulated that any infectious disease cannot be maintained if the population size is
below the critical community size unless there is supply of susceptible or regular migration of
the infected class from the adjoining places. This will ultimately lead to disease extinction.
Disease is said to fade-out if the duration of disease extinction is more than the disease
generation length [6]. Although, theoretically, it may be possible to estimate and predict the
time for disease eradication from the population, practically it is not feasible. Therefore, in
practice, attempts are made to prevent spreading of the infection.
Once the epidemiological data have been modeled into a reliable mathematical model, they
can be used to identify population subgroups at high risk of disease and develop preventive
interventions or measures according to time, place and person. These measures include
education, immunization, quarantine regulations or social distancing to restrict interaction
with others and treatment options. Mathematical modeling of intervention strategies can be
done in two ways. In the first method, the goal is to assess the effect on the disease dynamics
by changing the value of a constant parameter associated with the disease. This indicates the
best parameter value for a given performance measure. In the second method, intervention
measures are varied as a function of time and the objective is to determine the best parameter
value for a given performance measure. Pontryagin’s Maximum Principle (PMP) is applied
for comparison of a wide range of time varying functions. The best strategy for mitigation of
spreading of a contagious disease would be the one which evolves with time during different
phases of infection and thus focuses on progressively changing classes of populations. Optimal
control theory suggests the most effective mitigation strategy to minimize the risk of individ‐
uals being infected by applying and balancing vaccination and administering drug in a cost-
effective manner. Based on this, vaccination has been found to be the most common strategy
in reversing the epidemic growth of an infection within the population in the initial stages of
an outbreak. But in absence of the strategy, due to some reason or other, medical practitioners
either isolate symptomatic individuals or trace and quarantine contacts of symptomatic cases.
These strategies require proper diagnosis of the symptoms of the disease in each and every
individual. Efficacy of any implementation strategy is decided by the efficacy at which the
infected person is isolated and the efficacy at which the persons with whom the infectious
person came in contact can be quarantined. An infection can be sufficiently controlled if the
values of basic reproduction ratio and the proportion of transmission occurring asymptotically
can be reduced below a critical line. Since SARS is characterized by low R0 and low infectious‐
ness prior to clinical symptoms, effective isolation of symptomatic patients can sufficiently
control an epidemic outbreak. For those diseases where the proportion of asymptomatic
transmission is more than 1/ R0, contact tracing should be added to the set of control measures
used. This proportion can be determined from the longitudinal data on clinical symptoms and
pathogen load within the patient. Mathematically, it has been deduced that influenza is more
difficult to control than small pox. Moreover, quarantining and contact tracing would not
provide any extra benefit in case of influenza because of very short incubation and infectious
periods. AIDS has taken an alarming proportion because of high risk of pre-symptomatic
transmission and under such circumstance, self-isolation and contact tracing would provide
little respite [10], [22], [24], [25].
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10. Vaccination
Implementation of proper and effective vaccination protocol is of primary concern to the
epidemiologists and public health decision makers. Vaccination program is usually a govern‐
ment initiative applied on large spatial and temporal scales to reduce the level of complexity
of disease. The ultimate goal of any vaccination program is to keep the value of basic repro‐
duction ratio below unity by altering the various control parameters. Mathematical modeling
of vaccination recognizes that linear transfer occurs between the susceptible and the removed
compartments. For modeling purpose, important variables related to vaccination that should
be included are vaccination rate, i.e. the rate at which the susceptible individuals are vaccinated
and efficacy or the proportion of susceptible left unprotected even, after immunization [26].
Two schemes  are  being  widely  employed worldwide  for  prevention  and eradication  of
vaccine-preventable infections-mass vaccination and pulse vaccination. Mass vaccination is
usually carried out in infants before the mean age at infection. But, it may not always be
practically the most effective approach for global disease eradication. Pulse vaccination, on
the other hand, is a cheaper and a better alternative where periodic vaccination of a certain
proportion of the population renders sufficient and enough protection against further spread
of the disease as the percentage of susceptible is always maintained below the threshold
level required for an epidemic to start. But, pulse vaccination suffers from the side effect
of resonance.  Impact of single- and multiple-dose vaccination on rubella eradication has
been studied extensively in an age-structured model with constant transmission rate using
Floquet  analysis.  It  has  been  established  that  eradication  likelihood  is  governed  by  the
effective  duration  of  immunity.  Booster  vaccination  has  also  been  studied,  but,  in  less
details. Permanent immunity is conferred by booster dose in contrast to partial immunity
imparted by primary vaccines.  A new threshold quantity,  known as re-infection thresh‐
old in case of vaccination-induced partial immunity, indicates the condition when vaccina‐
tion will not succeed thereby producing high levels of infection. Prevention or reduction
in epidemicity is more readily achievable by booster vaccination, depending on the level
of  primary vaccination program,  because  it  has  the  capacity  to  increase  the  vaccination
coverage and herd immunity of  the population as  a  whole.  Outcome of  a  booster  dose
depends highly on precise timing of the additional vaccine doses as well as the propor‐
tion of individuals receiving the second-dose. During vaccination, decision of the individu‐
al or mass to undergo program greatly affects the efficacy of the program. Therefore, human
behavior plays a significant role in ensuring success of the strategy [3], [6], [27].
An interesting thing to note while conducting mass scale immunization is that it is possible to
protect the whole population from an outbreak even if there are some susceptibles in the
population, at less than 100% immunization. This effect is called herd immunity. When R0 < 1,
the DFE is globally asymptotically stable resulting in disease eradication as observed in case
of measles. Vaccination reduces the force of infection and increases the mean age at infection
when the infection may be acquired. Vaccination desynchronizes local dynamics which will
prevent migration of susceptible population from neighboring places and thus can facilitate
extinction of the disease. However, vaccination of each and every individual in the susceptible
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class is practically not feasible and more so, in economically backward countries. Therefore,
the critical fraction or proportion of population that needs to be vaccinated is to be determined.
Moreover, desired degree of success may not be always obtained due to vaccination because
of less than optimum coverage, irregularities in the supply of vaccines, use of low-efficiency
vaccines or waning rate of vaccines. All these may lead to re-emergence of disease outbreak,
sometimes with increased intensity, owing to the resurgence of the susceptible class finally
resulting in serious side effects.
Vaccination coverage depends on the characteristics of the endemic equilibrium. At equilibri‐
um, the replacement number, R is equal to the product of basic reproduction ratio and the
proportion of susceptibles i.e. R=R0s*. The replacement number is defined as the average
number of secondary infections produced by a typical infective during its entire course of
infectiousness. Vaccination coverage of p reduces the proportion of susceptible to 1-p. Higher
the magnitude of R0, higher is the vaccination coverage and is complicated by parameter such
as vaccine efficacy. Therefore, for disease eradication to occur, R=R0s*(1-p) < 1 or p > 1-1/ R0.
The critical vaccination coverage is expressed by the formula, pc=1-1/ R0 and the value has been
found to be 0.94 and 0.86 respectively for measles and rubella. An increase in the value results
in a decrease of the spatial synchrony of disease dynamics. Smallpox has been successfully
removed from the face of the earth because it possesses the least critical vaccination coverage.
Vaccine efficacy of 0.97 represents that 3% of those vaccinated do not become immune.
Optimal vaccination coverage and frequency of pulse vaccination has been studied with the
help of Pythagore theorem [6]. The important terminologies associated with vaccination has
been presented in Table 2.
Parameters Description
Herd immunity Immunity and protection of the entire community
achievable by vaccinating a proportion of the population
and creating immune individuals
Basic reproduction number under vaccination Number of secondary cases caused by one primary case
introduced into a population in which a proportion has
been vaccinated
Critical vaccination proportion Proportion of population to be vaccinated to achieve
eradication by maintaining Basic reproduction number
under vaccination equal to one
Vaccine efficacy Effectiveness of the vaccine to induce immunity
Eradication likelihood Determined by effective period of immunity
Re-infection threshold Occurs during transmission induced by partial immunity. It
is a threshold quantity above which levels of infection will
be high and vaccination fails
Table 2. Glossary of important parameters related to vaccination
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11. Quarantine
Quarantine refers to intentional or forceful isolation of individuals suffering from diseas‐
es like leprosy, plague, cholera, typhus, yellow fever, smallpox, diphtheria, tuberculosis etc.
The ultimate objective of the process is to reduce the average infectious period by isolat‐
ing  some  infectives,  so  that  they  do  not  transmit  the  infection.  To  study  the  effect  of
quarantine, a new class Q of quarantined individuals has been included in standard SIS
and SIR endemic models. They include those who have been removed and isolated either
voluntarily or coercively from the Infectious class. The quarantine reproduction number,
R0  depends  on  the  quarantine  rate  constant  which  governs  the  transfer  rate  out  of  the
Infectious class into the Quarantine class [28].
12. Evolution of mathematical modeling
Epidemiological modeling has undergone numerous revisions and improvements to cope up
with emerging new infections and discovery of new concepts and basis of existing infections.
It is well-known that increase in model complexity by including more relevant biological
details improves the accuracy. But it is practically not feasible to construct a fully accurate
model. There will always be some factors related to host, pathogen, environment or population
which cannot be estimated or predicted. Processes of random occurrence affect the degree of
accuracy of model. Predictability of the model depends highly on a strong interplay between
statistics and models for estimation of parameters from epidemiological data.
The key assumption of deterministic mathematical model is the existence of homogeneous and
constant population, where it is assumed that, the death of a susceptible, infectious or
recovered individual is immediately compensated by the birth of a new susceptible. In actual
practice, heterogeneity is observed where the population can be divided into several homo‐
geneous subpopulations or groups on the basis of mode of transmission, contact patterns,
latent period, infectious period, genetic susceptibility or resistance as well as socio-economic,
cultural, demographic and geographic factors. All these complexities can be suitably incorpo‐
rated in a multi-group model and can prove effective in explaining the dynamics of sexually
transmitted diseases such as gonorrhea or AIDS [29]. Population-level heterogeneities that, if
included can improve the model’s accuracy and predictive ability, include age, gender,
behavior, genetic susceptibility [7]. Influenza infection is well-studied and well-modeled. But,
there are still several aspects of the infection which have not been included in model construc‐
tion like, the contribution of strain-specific cell tropism, pre-existing immunity, effect of host
genetic factors on virulence and transmissibility of a particular strain. The model may be
modified to determine the severity, duration and outcome of infection progression within an
individual [30]. Moreover, drug resistance may develop. Therefore, a model with an immune
response can be generated for better insight into the disease dynamics and the predictions from
the model are different from those of a model formulated without an immune response. Two-
phase solution can be used to study different viral infections. Study of models, specific for
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influenza or H1N1 require careful parameterization to match available data and it should
reflect both statistical uncertainty and uncertainty in data itself [13].
A new rule, known as 20-80 rule has been proposed by researchers for certain infectious
diseases which show unique features. According to the rule, 20% of the individuals are
responsible for 80% of onward transmission and they are known as super-spreaders. This gives
rise to variation in the number of secondary infections per infected individual which is denoted
by Z. It is described by two parameters-mean R0 among infections and dispersion parameter,
K. A small K (<0.1) indicates that a small proportion of infected individuals actively transmit
the pathogens whereas, a large K (>4) indicates that all infected individuals are equally
responsible for onward transmission [19].
In multiple-host diseases, different hosts or reservoirs are involved. Dynamics of the disease
itself may vary in the different hosts and the mode of transmission from one host to another
is quite complex. All these factors should be borne in mind during study of these diseases [6].
In viral disease like Hepatitis B, there is a carrier state where the individual is not fully
recovered and is able to transmit low level of infection throughout his life. Some diseases like
chlamydial infection is characterized by infected individual who is asymptomatic but is able
to transmit disease. Again, meningitis may remain benign for long within population but may
exhibit sporadic symptomatic outbreaks [7]. Infectious diseases which are characterized by
multi-factorial pathologies or where concurrent infections prevail in immune-compromised
hosts usher in complexities in mathematical modeling [1]. A common feature of certain
childhood infections is the periodical occurrence of high levels of infection of school-going
children which necessitates the inclusion of a time-varying contact rate between susceptible
and infected classes of individuals in the model, which is then known as seasonally-forced
model and is recognized by a sinusoidal function. The concept of seasonality in the coefficient
of transmission and temporal heterogeneity was introduced by Soper to account for the high
amplitude outbreaks of measles in Glasgow. These types of diseases are characterized by
strong annual, biennial and sometimes irregular oscillations. In India, polio has been found to
occur annually. Measles is known to exhibit biennial occurrence for extended periods in
London. It has been noticed that the same disease can have different temporal patterns during
different epochs which may be attributed to changes in epidemiological factors, e.g. population
birth rate, magnitude of disease transmission, and strength of seasonality [14]. Modeling of
measles dynamics is best achieved by incorporation of an epidemic oscillator, which takes into
account the birth rate variations and can analyze chaotic behavior of epidemic outbreaks. It
has been observed that high birth rates drive measles dynamics to annual cycles and dimin‐
ishing birth rates result in biennial patterns. Vaccination causes irregular cycles. Complex
oscillations arise due to interactions between the externally imposed annual seasonality and
intrinsic oscillatory dynamics of the infection itself [26]. The approach of “term-time forcing”
should also be employed for temporally forced models of another childhood bacterial
infection, pertussis or whooping cough. Though both measles and pertussis possess identical
values for basic reproduction ratio, yet they exhibit different dynamics because the infectious
period in whooping cough is longer than that of measles. School holidays during Christmas
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does not affect severely the transmission of the disease [11], [27]. For better understanding of
the model with periodic perturbations, bifurcation diagram proves beneficial [7].
Assumptions that have been discussed in a previous section hold true for developing countries
where all individuals are exposed to similar death pressure, irrespective of age, due to the
environmental conditions and lack of medical facilities. But the situation differs in developed
countries where square shape age distribution is manifested. This can be attributed to
availability of proper medical care. Modeling becomes somewhat complicated in analysis of
macroparasitic infections owing to their inherent differences from the infections caused due
to microparasites. In case of microparasitic infections, the internal dynamics of the pathogen
within the host is not as crucial as the host’s infection status. But, the complex life cycle of the
macroparasite within the host necessitates inclusion of this parameter in modeling of macro‐
parasitic infections. Moreover, disease transmission and pathogenicity are highly related to
the load of the causative organisms within the host system [6], [7].
Furthermore, complex dynamics may be followed by the infections, where the causative agent
can undergo mutation and can create a class of population, susceptible to the new strains.
Previous infections in those cases confer only partial cross-immunity and thus, history of
infection is important. Number of parameters in the model therefore, increases exponentially
with the number of strains. In these circumstances, either reduced transmission approach or
polarized immunity concept is applied [11]. Emergence of drug resistant strains is an issue of
great concern which should be included in modeling disease dynamics. Sexually transmitted
diseases unfold a different picture because of high risk of exposure of sexually active individ‐
uals, belonging to a particular age group.
Complexities  may  also  arise  in  modeling  of  diseases  in  presence  of  an  optimal  control
measure where there is a delay element between implementation of isolation and quaran‐
tining.  Inclusion  of  delay  increases  the  proportion  of  transmission  occurring  with  an
asymptomatic or pre-symptomatic infector and hence, necessitating adoption of stringent
measure including contact tracing. Oversimplification may fail to estimate the efficacy of
contact tracing in reducing the transmission. However, in this delay period, the patient may
practice self-isolation depending on the nature and severity of the symptoms and the time
scales involved [22].
In a modified SIR model with “skipping” dynamics for diseases like influenza, it has been
shown that the immunity of hosts depends on previous exposure to the disease and immune
memory. Due to mutational changes in influenza virus or antigenic evolution, hosts may be
re-infected with the disease every few years, with years of ‘skips’ or gaps in between [31].
The simple SIR model has been extended to include the effects of saturation where the
incidence rate is not bilinear in S and I but a general function f(S,I). It is assumed that in presence
of large number of infectives in the population, the number of contacts per time diminishes [3].
The simplistic SIR model has evolved into biphasic SIR model (B-SIR) to explain the key
features of multi-ennial epidemic cycle. In this model, the SIR dynamics alternates between
a relatively fast epidemic phase in which there is a significant increase in the number of
infected as well as a rapid decline in the count of the susceptible and a slow build-up phase
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influenza or H1N1 require careful parameterization to match available data and it should
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the pathogens whereas, a large K (>4) indicates that all infected individuals are equally
responsible for onward transmission [19].
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itself may vary in the different hosts and the mode of transmission from one host to another
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recovered and is able to transmit low level of infection throughout his life. Some diseases like
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of transmission and temporal heterogeneity was introduced by Soper to account for the high
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birth rate, magnitude of disease transmission, and strength of seasonality [14]. Modeling of
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should also be employed for temporally forced models of another childhood bacterial
infection, pertussis or whooping cough. Though both measles and pertussis possess identical
values for basic reproduction ratio, yet they exhibit different dynamics because the infectious
period in whooping cough is longer than that of measles. School holidays during Christmas
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does not affect severely the transmission of the disease [11], [27]. For better understanding of
the model with periodic perturbations, bifurcation diagram proves beneficial [7].
Assumptions that have been discussed in a previous section hold true for developing countries
where all individuals are exposed to similar death pressure, irrespective of age, due to the
environmental conditions and lack of medical facilities. But the situation differs in developed
countries where square shape age distribution is manifested. This can be attributed to
availability of proper medical care. Modeling becomes somewhat complicated in analysis of
macroparasitic infections owing to their inherent differences from the infections caused due
to microparasites. In case of microparasitic infections, the internal dynamics of the pathogen
within the host is not as crucial as the host’s infection status. But, the complex life cycle of the
macroparasite within the host necessitates inclusion of this parameter in modeling of macro‐
parasitic infections. Moreover, disease transmission and pathogenicity are highly related to
the load of the causative organisms within the host system [6], [7].
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polarized immunity concept is applied [11]. Emergence of drug resistant strains is an issue of
great concern which should be included in modeling disease dynamics. Sexually transmitted
diseases unfold a different picture because of high risk of exposure of sexually active individ‐
uals, belonging to a particular age group.
Complexities  may  also  arise  in  modeling  of  diseases  in  presence  of  an  optimal  control
measure where there is a delay element between implementation of isolation and quaran‐
tining.  Inclusion  of  delay  increases  the  proportion  of  transmission  occurring  with  an
asymptomatic or pre-symptomatic infector and hence, necessitating adoption of stringent
measure including contact tracing. Oversimplification may fail to estimate the efficacy of
contact tracing in reducing the transmission. However, in this delay period, the patient may
practice self-isolation depending on the nature and severity of the symptoms and the time
scales involved [22].
In a modified SIR model with “skipping” dynamics for diseases like influenza, it has been
shown that the immunity of hosts depends on previous exposure to the disease and immune
memory. Due to mutational changes in influenza virus or antigenic evolution, hosts may be
re-infected with the disease every few years, with years of ‘skips’ or gaps in between [31].
The simple SIR model has been extended to include the effects of saturation where the
incidence rate is not bilinear in S and I but a general function f(S,I). It is assumed that in presence
of large number of infectives in the population, the number of contacts per time diminishes [3].
The simplistic SIR model has evolved into biphasic SIR model (B-SIR) to explain the key
features of multi-ennial epidemic cycle. In this model, the SIR dynamics alternates between
a relatively fast epidemic phase in which there is a significant increase in the number of
infected as well as a rapid decline in the count of the susceptible and a slow build-up phase
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characterized  by  continuous  replenishment  of  susceptible.  This  enables  estimation  of
threshold(bifurcation) values at  which there will  be a switching from biennial  to annual
epidemic dynamics [14].
A likelihood-based methodology has been developed which assumes the generation interval
to follow Weibull distribution and a specific infection network underlies the observed
epidemic curve [23].
An agent-based model in the study of tuberculosis has revealed that recruitment of increased
number of resting macrophages to the infection site in tuberculosis increases bacterial load.
This suggests that the inflammatory response may be detrimental to the host [32].
Since, application of mathematical modeling approach shows that vaccination decreases the
mean age at infection, it deduces that implementation of vaccination programs can actually
increase the incidences of absolute number of serious cases, if the probability of disease
complications increases with age. This is an interesting paradigm of mathematical modeling.
In case of imperfect or ineffective vaccination, a backward transfer between the susceptible
and recovered compartments must be considered because the vaccinated individuals may
come back to the susceptible category or may become directly infected through nonlinear
transmission. This behavior gives rise to bi-stability and backward bifurcation [26].
Exponentially growing population and incidences of mortality due to childhood infections in
developing countries are not considered in modeling of infections where the host population
is assumed to be of constant size. The component of heterogeneity also exists in cases of
sexually transmitted diseases. This is further complicated by the fact that, unlike other
infections, recovery from STD does not guarantee development of acquired immunity. The
currently existing rationale of mathematical modeling may need to be modified while
investigating mother-to-child diseases and diseases transmitted by multiple users of syringe
as in AIDS [6].
A hierarchical dynamics has been observed in epidemic outbreaks of complex heterogene‐
ous networks. Propagation of infection occurs via a cascade from higher to lower degree
classes [10].
In most of the cases, epidemiological processes within the population and immunological
processes involved within the individual host are considered separately, with no explicit
interaction between the two. Infectious diseases, caused by RNA viruses are characterized by
high mutation rate and short generation time of the viruses indicating that evolutionary
processes occur rapidly and evolutionary outcomes depend on the fitness of viral mutants at
different stages of viral lifecycles and interactions between viral variants. Moreover, ecological
and epidemiological factors, such as host contact patterns, transmission routes, host move‐
ments also govern the success of viral transmission in a population. In this approach, three
different time scales are considered-a fast time scale for within-host dynamics, an intermediate
time scale for epidemiological process and a slow time scale for the environmental contami‐
nation [5]. Link between the evolutionary process at the pathogen level and the ecological
processes at the host population level can be established by phylodynamics [11]. The phylo‐
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dynamic approach can be successfully utilized in mathematical modeling of such viruses like
dengue, human respiratory synctial virus, Hepatitis C, Toxoplasma etc. [19], [33], [34].
Several new modeling concepts are being explored for detailed description of diseases like
AIDS, tuberculosis. These include differential infectivity (DI) and staged progression (SP)
model [29]. For modeling of infectious diseases with long infectious period and where there
are multiple alternative disease progression pathways and branching, or where there is
considerable difference in virulence or when only a part of the infected population undergoes
a treatment whereas the rest remains untreated, staged progression models seem to be the
most suitable [35]. Individuals infected with HIV sequentially pass through a series of stages,
being highly infectious in first few weeks after their own infection, then having low infectivity
for many years, and finally becoming more infectious as their immune system breaks down
and they progress to full-blown AIDS. Investigation of the influence of imperfect vaccine on
HIV transmission by individuals in AIDS stage with the help of SP model revealed that the
imperfect vaccine can eliminate HIV in a given community at vaccination reproduction
number less than unity, but the disease will persist otherwise [36], [37]. Since, tuberculosis is
characterized by presence of very long latent period and infectious period, time is not
considered to be constant in modeling of the disease. The latent period and infectious period
are divided into n-stages and stage progression model with bilinear incidence was formulated
[39]. Characteristic features of DI and SP models have been given in a tabular form (Table 3).
DI model SP model
Suitable for diseases where viral levels differ between
individuals as in sexually transmitted diseases and also
diseases where infectivity depends on parasite or viral
loads in infected hosts or vectors e.g. malaria, dengue
fever.
Suitable for modeling of diseases exhibiting variability of
infectiousness with time as in AIDS or where time-scale of
disease transmission is too long.
Infectives are divided into a number of a
groups according to their infectivities. Total population
size is assumed constant.
Total host population is partitioned into the following
compartments: the susceptible compartment, the
infectious compartment , whose members are in the i-th
stage of the disease progression, and the terminal
compartment. It is assumed that there is no recovery from
the disease, and thus the only exit from the terminal
compartment is death.
Infection-free equilibrium is globally stable and there exists
a unique endemic equilibrium for these models
Disease-free equilibrium and unique endemic equilibrium
have also been established with these models
Table 3. Characteristic features of DI and SP model
Healthcare-associated infections (HCAI) or nosocomial infections or hospital acquired
infections are source of great concern in developed as well as developing countries. Such
infections can be modeled using either deterministic or stochastic approach for evaluation of
control policies. This requires sound model parameterization and sensitivity analyses [40].
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infections are source of great concern in developed as well as developing countries. Such
infections can be modeled using either deterministic or stochastic approach for evaluation of
control policies. This requires sound model parameterization and sensitivity analyses [40].
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Influenza control is a challenge since it is difficult to predict the predominant strain that will
be circulating each season. Successful vaccination program can be designed from a model
which includes the drift process (via the emergence of new strains), the co-circulation of
existing strains and pre-existing immunity in the population. A good model is able to repro‐
duce the herald wave phenomenon of strain persistence from one influenza season to the next
in temperate regions [41].
Recently, multi-scale models are being developed which will help in predicting virulence,
transmissibility, at the population level, susceptibility or resistance to drugs without conduct‐
ing tough and time-consuming laboratory experiments. For development of these types of
models, complete genome sequence of the pathogen should be made available, which will
allow mapping from genotype to complex phenotypes.
Numerous modeling approaches contain data estimated from the literature and for such cases
extensive sensitivity analysis may prove beneficial. In uni-variate sensitivity analysis, impact
of variation of one parameter by a certain percent on the outcome of the model is measured
while all other parameters are held constant. Such analysis can be graphically represented on
a tornado plot. In multivariate analysis, impact of multiple parameters is studied through
Monte Carlo simulations [38]. Other multilevel fitting schemes and Bayesian/Markov chain
Monte Carlo frameworks may also be useful [30].
13. Conclusions
Infectious diseases pose a great threat to human civilization and world economy. Therefore,
constant efforts are being made to prevent their occurrence, recurrence and spread. There are
certain infections which do not manifest themselves as definite symptoms in the infected host
for a long period of time but can be highly lethal at the end. Research is focused on development
of economically viable new intervention strategies for any type of infectious disease with the
aid of mathematical modeling. Symbiotic and synergistic relationship should exist between
mathematicians and biologists for detailed analysis of the biological processes involved in
host-pathogen interactions. Mathematical models involve assumption, abstraction, simplifi‐
cation and description of the most complex system of infectious disease, by the use of language
of mathematics. Each element of host and pathogen can be monitored and varied simultane‐
ously without actually performing any experiment to ascertain the role of the element in
disease dynamics. Epidemiological modeling enables extrapolation of population behavior
from individual behavior and long-term behavior from dynamics of early stage of infection
following consideration of different epidemiological factors. Surveillance data, physicians’
reports and data acquired from the hospitals are the sources for individual-to-individual
chains of transmission. Despite the fact that mass human behavior becomes unpredictable at
times, especially during a disaster, concerted rigorous approach adopted during model
development can build up a strong framework for future planning. Extensive long-term data
and refined mechanistic understanding of evolutionary and transmission dynamics has
enriched the field of mathematical modeling and provided insights in shaping the global public
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health response to a pandemic. The foremost important contribution of mathematical epi‐
demiology to healthcare professionals is the concept of basic reproduction ratio and epidemic
threshold. From a medical or public health perspective, models are instrumental in policy-
making, service planning, risk assessment and monitoring performance of infection control
programs. Decision of whom, how and when to quarantine, vaccinate and initiate therapy can
be planned and implemented successfully from the outcomes of a model of high quality. The
source of complexity in models is the occurrence of huge variability in infection profiles,
parameter values and time scales. However, complexity ensures model accuracy. Selection of
type of model and its degree of complexity depends on the purpose of modeling and questions
to be addressed. Failure to understand, forecast and control an epidemic outbreak in a
particular locality can indicate that some of the key disease parameters and elements of
biological complexity might have been overlooked while developing the model. One under‐
lying reason for this may be traced to a key fundamental feature of mathematical model. Unless
the model is tightly fitted to the experimental data, there remains a doubt on the reliability of
the parameter estimates obtained from the model. At the end, it can be said that mathematical
model helps in integrating several disease-related facts and factors into a cohesive structure,
better visualization of a complex system, determining the plausibility of epidemiological
explanations, prediction of unexpected interrelationships among empirical observations and
prediction of impact of changes in the system.
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